,id,ticker,title,category,content,date,provider,url,article_id
178591,400107,WBA,Can Walgreens Continue to Grow in 2020 ,news,"Walgreens Boots Alliance  NASDAQ WBA  released fiscal 2020 first quarter results at the beginning of January  Missing both revenue and earnings per share estimates  the company disappointed investors  decreasing the share price by 7   
The company continues to predict flat growth for 2020 even after the soft quarter  which is due to three factors that have been weighing the company down over the past year and will continue to plague the company in 2020  

Competitive pressures
Amazon com  NASDAQ AMZN  and CVS Health  NYSE CVS   in addition to local pharmacies  are turning up the pressure on Walgreens    specifically surrounding the U S  and international retail pharmacy business segments  which make up 84 6  of Walgreens  revenue  
Amazon s 2018 acquisition of PillPack for  753 million is an industry disrupter  The company focuses on convenience by providing an at home prescription delivery  eliminating the need to wait in line for prescriptions and refills  This free service the massive 100 million Amazon Prime customers aside from the co payment is a threat to every pharmacy  
Walgreens has partnered with Microsoft for seven years to integrate the cloud and provide customers with instant access to healthcare records  offering convenience and increasing efficiency at each location  This cloud adoption will allow healthcare providers  insurers  and pharmacies to access a customer s data  putting Walgreens closer to PillPack s business model and serving 88 million active Walgreens Balance Rewards members  
Providing next day prescription delivery for  4 99 by partnering with FedEx  Walgreens is slowly heading in the right direction  However  the IT infrastructure  customer adoption  and competition from a behemoth company like Amazon will put pressure on Walgreens in 2020  
Lower reimbursement rates from insurers
The pressure is increasing for the Walgreens pharmacy segment as the company is receiving lower payments from insurers for drugs sold in U S  based pharmacies  Reimbursement rates from generic drugs have been historically high  enabling Walgreens to benefit from the spread between the cost of the drugs and the price charged to insurers  This has been changing  though  as insurers have been putting increased costs on pharmacy chains    increasing reimbursement pressure and lowering revenue for Walgreens  
Political changes have increased pressure on drug prices as well  The Trump administration has made a priority of reducing the red tape in drug pricing  increasing generic offerings  and eliminating the rebate policy that allowed drug companies and benefit managers to charge higher prices on drugs  In addition  Democrats have added proposals that will allow the government to negotiate drug prices for all Medicare related prescriptions  
Increased pressure on the U S  healthcare system is directly affecting Walgreens and will continue to do so under the current administration  The fall in generic drug prices has slowed  however  the lower prices on branded drugs in addition to the government oversight on insurers will continue to plague pharmacies  profitability in the coming months    hampering growth and increasing risk for shareholders 
Increasing the buying age of tobacco
In September  Walgreens announced that the company will require customers to be 21 years old to purchase tobacco products  This decision was based on the Food and Drug Administration s  FDA  increased oversight on Walgreens and other retailers that sell tobacco products to adults under age 18  
Walgreens was one of the heaviest violators among the several the FDA investigated  According to the FDA  22  of the Walgreens locations that were inspected were found to be illegally selling products to minors 
Pressure from the FDA and Congress forced Walgreens to increase the selling age of tobacco to 21  Walgreens enacted a  Card All  policy in 2019  This decision has put a damper on tobacco sales  decreasing retail sales during the recent quarter by 2 2  year over year  attributing a 0 5  decrease in comparable sales to the  continued de emphasis of tobacco   
A decent dividend with a shaky future
Given the increased competition and rising political influence within the healthcare industry  Walgreens  growth is stalled in the near term  Walgreens  management during the recent quarter pointed to a  1 8 billion cost savings by 2022 from a combination of store closures  inventory optimization  and the adoption of information technology within business operations  However  these are the only levers Walgreens management has to pull at the moment  
Overall  Walgreens  forward dividend yield of 3 38  is a saving grace for income investors in combination with a 31 23  payout ratio  leaving plenty of room to continue the 6 58  five year dividend compound annual growth rate  As revenue continues to flatline  investors will be looking at the costs of doing business  paying close attention to the  1 8 billion cost cutting initiative and the gross profit margin    which is at 21 61  per the recent quarter 
Purchasing shares of Walgreens at the current valuation isn t outlandish as Walgreens  forward price to earnings of 9 25 leaves shares at a discount in comparison to CVS s 10 25  But investors need to be careful as increased political pressure on the healthcare industry may provide enough systemic risk to affect the financial performance of the entire industry    leaving shareholders a nice dividend but a substandard stock price performance for 2020 ",2020-01-18,The Motley Fool,https://invst.ly/pjomv,2062597
178592,400108,WBA,Where Will Walgreens Boots Alliance Be in 5 Years ,news,"Walgreens Boots Alliance  NASDAQ WBA  has been around in some form or another for 119 years  growing to become the second largest pharmacy chain in the country  There s little doubt it will be around for another five    and beyond  Even so  the retailer is grappling with dramatic shifts in the retail and healthcare sectors and will have to continue to evolve to remain healthy  So what will Walgreens look like in five years  and will it be a good investment 

Present struggles
Walgreens endured a difficult 2019  The stock was down 13 7  last year  marking the fourth straight year of negative annual returns  It was the one of the worst performers among Dow Jones stocks  And it s beginning 2020 in much the same way  down almost 10  year to date through Jan  23  In contrast  Walgreens  larger rival  CVS Health  was up 13 4  last year and is currently down less than 1  in 2020  
There are several reasons why Walgreens has struggled  particularly competition from Amazon com and Walmart  lower prices for generic drugs  declining store traffic  and a steady decline in reimbursement rates  
The company recently missed first quarter 2020 earnings estimates as earnings per share dropped 19 8  year over year to  0 95  Sales were up 1 6  to  34 3 billion  but net operating income dropped 27 6  to  1 billion 
Future plans
Despite the rough quarter  CEO Stefano Pessina maintains a flat growth outlook for 2020  The company is undergoing a turnaround plan that starts with cutting expenses by  1 8 billion by 2022  including the closure of about 200 stores  
In the first quarter earnings report  Pessina said 

We are maintaining our outlook for the year despite a soft first quarter  We are confident our strategic plans are the right ones to drive long term sustainable growth going forward  In addition  during the quarter we were very satisfied with the progress made in our Transformational Cost Management Program and with the strong cash flow we delivered  

Operating cash flow was  1 1 billion in the quarter  up  601 million year over year  Free cash flow    net cash provided by operating activities minus capital expenditures    was  674 million  up  684 million  This strong cash flow created by the cost management plan will fund several new initiatives designed to drive growth  One is a partnership with German healthcare company McKesson to create a joint venture for the European market  Walgreens also partnered with supermarket chain Kroger to form a group purchasing organization to save costs  The company also has a plan to co locate Jenny Craig weight loss centers at various Walgreens stores and create VillageMD primary care clinics in some stores  It s part of an effort to give customers experiences and services they can t get online to drive more traffic 
While it seeks to increase offerings for in store customers  Walgreens is also trying to emulate Amazon and other online retailers by boosting its delivery capabilities  The company is testing a drone delivery service  becoming the first retailer in the country to do so  Given that an estimated 7  of the population lives within five miles of a Walgreens  this would significantly speed up delivery times  It s still testing and may be a few years off  but it shows where they are headed  
The outlook
So where will the company be in five years  It s probably safe to say that a Walgreens will still be there on the corner in your community like it has been for the past 119 years  But will it be good for investors  That s complicated  The first question is  Will it still be a public company  In November  Bloomberg reported that KKR  a private equity investor  had approached Walgreens about taking it private in a leveraged buyout deal  Then in December  The Wall Street Journal reported the deal fell through  Walgreens has not commented on any of the reports  but it s a potential development that investors should be aware of  
On the plus side  the stock price is near a six year low and has a price to earnings ratio that s less than 14 times earnings  Also  it has a very low debt ratio   These factors make it a stock to consider  But given the uncertainties  investors may want to take and wait and see approach before jumping in  While investors may not see positive results this year  the cost cutting measures and strategic initiatives put in place over the next few years should begin to bear fruit for investors inside five years ",2020-01-23,The Motley Fool,https://invst.ly/pm3hq,2066613
178600,400116,WBA,Walgreens Boots Alliance Is Near Its 52 Week Low  Is Now the Time to Buy ,news,"Walgreens Boots Alliance  NASDAQ WBA  isn t off to a good start in 2020  Although last year wasn t great  with the stock down 14  and coming nowhere near the S P 500 s gains of 30   the stock has continued to fall this year and it s now getting close to its low for the past 12 months  At around  53 a share  the stock is near its 52 week low of  49 03  The last time the stock dipped like this was back in August 
That said  it s a good time for investors to evaluate whether Walgreens is a good buy or if it s likely to continue falling lower  Let s take a closer look 
Earnings are dragging down the company s performance thus far
The reason the company s been off to a poor start this year is that its first quarter 2020 report wasn t as impressive as investors were hoping for    with sales of  34 34 billion narrowly missing analyst expectations of  34 6 billion  It should be even less concerning given that a key part of the reason for the decline is that the company has been de emphasizing tobacco products  Otherwise  the pharmacy retailer may have easily surpassed estimates 
Although it s a narrow miss that s easily explainable  the stock has struggled to post gains since then as investors have been quick to push the sell button on the stock  Part of the reason is likely due to the company s results last year when Walgreens underwhelmed investors as well  When the bears are out and looking for a reason to sell shares of a company  it doesn t take much to sink a stock 

Why there s reason for optimism
Despite the bearishness  it s not all doom and gloom for Walgreens as the company can turn things around  For one thing  the company is making significant changes at its locations  including offering more services in store that give customers a reason to visit the store themselves and buy products there  as opposed to buying online from a competitor  The company is also looking at launching a drone delivery service that could make it very competitive with those very same online retailers 
These are just a couple of the ways that Walgreens can inject some life into its quarterly numbers  And a small boost may be all the company needs  The good news is that Walgreens didn t miss estimates by a lot in Q1  meaning that there may not be a lot for the company to do to bridge that gap and get investors excited about the stock again 
Is the stock too cheap to ignore 
One of the benefits of a stock that s dipped in value is that shares become cheap and it s an excellent opportunity to buy low and potentially sell higher later on when it recovers  At just 13 times earnings and two times its book value  Walgreens  stock is trading at a very attractive valuation  making it an appealing option for value investors to consider  Even growth investors may see a bargain given the stock s forward price to earnings ratio  which is less than nine 
As an added bonus  the stock also pays a dividend  which now  as a result of the decline  is yielding 3 6  per year  That s well above the S P 500 average of 1 85  and it can be a great way to pad the stock s returns  or at the very least  offset its losses should it continue to fall 
Overall  Walgreens is a top healthcare stock for investors to own that is not very volatile  pays a great dividend  still has many growth opportunities and is also not an expensive buy  It may only be a matter of time before the stock rallies  Investors may want to buy Walgreens before that happens ",2020-02-08,The Motley Fool,https://invst.ly/pssi1,2079855
178611,400127,WBA,CVS  Walgreens  And Rite Aid Sue Doctors In Latest Move In Federal Opioid Case,news,"The opioid epidemic in the United States is a massive mess  Over 200 000 people have died from overdoses of prescription narcotics over the last 20 years  according to The Washington Post  Federal  state  and local governments have spent a lot of money dealing with opioid addiction  All these governments    and private plaintiffs    are now suing various pharmaceutical companies and drugstores for large sums of money 
But today  it was reported that drugstores including CVS Health  NYSE CVS  Walgreens Boots Alliance  NASDAQ WBA   Rite Aid  NYSE RAD   and Walmart  NYSE WMT  are attempting to shift the culpability to the doctors who prescribed the pain killers that the drug stores filled 

In October  several companies agreed to pay two counties in Ohio  260 million in federal court opioid litigation  The companies involved included opioid distributors McKesson  NYSE MCK   AmerisourceBergen  NYSE ABC  and Cardinal Health  NYSE CAH   and opioid manufacturer Teva Pharmaceuticals  NYSE TEVA    Johnson   Johnson refused to settle  Last August  Johnson   Johnson  NYSE JNJ  was ordered to pay  572 million to the state of Oklahoma in an opioid lawsuit  The company is appealing the ruling   
By admitting liability to the two counties in Ohio  the four above companies are in a weak position to negotiate in the multitude of lawsuits against them in other cities  counties  and states across the land  Plaintiff s attorneys are claiming the companies have admitted culpability  
A bipartisan group of state attorney generals attempted to negotiate a nationwide settlement with the above five companies  The five companies all agreed to pay out  48 billion dollars over a period of 18 years  That settlement was instantly rejected by other litigants   
Drugstores are also being sued in a separate opioid litigation  This October  a federal lawsuit begins against CVS  Walgreens Boots Alliance  and Rite Aid and other major pharmacy chains  This litigation is in the same two counties in Ohio  Summit and Cuyahoga  
What s news
On Monday  the drugstores turned around and filed suit against physicians across northeast Ohio  The claim is that the doctors who made the opioid prescriptions are just as much  perhaps more  to blame for the opioid crisis as the drugstores who fulfilled the prescriptions  
Of course  drugstores have much deeper pockets than individual doctors  many of whom would be bankrupted by a verdict against them in this litigation  The threat to put Ohio s doctors out of business shows just how high the stakes are  What is taking place in these two counties can and likely will be repeated in multiple lawsuits nationwide  The pressure is on for a nationwide settlement    and  48 billion is probably just a drop in the bucket ",2020-01-08,The Motley Fool,https://invst.ly/pfi8u,2055183
178612,400128,WBA,Walgreens Boots Alliance Inc  WBA  Q1 2020 Earnings Call Transcript,news,"Walgreens Boots Alliance Inc  NASDAQ WBA Q1 2020 Earnings CallJan 8  2020  8 30 a m  ETContents 

Prepared Remarks
Questions and Answers
Call Participants

Prepared Remarks 
OperatorLadies and gentlemen  thank you for standing by and welcome to the Walgreens Boots Alliance Inc  First Quarter 2020 Earnings Conference Call  At this time  all participants are in a listen only mode  After the speakers  presentation  there will be a question and answer session   Operator Instructions  I would now like to hand the conference over to your speaker today Gerald Gradwell  Senior Vice President of Special Projects and Investor Relations  Please go ahead Gerald Gradwell    Senior Vice President of Special Projects and Investor RelationsGood morning  ladies and gentlemen and welcome to our first quarter earnings call  I am here today with Stefano Pessina  our Executive Vice Chairman and Chief Executive Officer of Walgreens Boots Alliance  James Kehoe  our Global Chief Financial Officer and Alex Gourlay  Co Chief Operating Officer of Walgreens Boots Alliance and President of Walgreens Before I hand you over to Stefano to make some opening comments  I will  as usual  take you through the legal safe harbor and cautionary declarations  Certain statements and projections of future results made in this presentation constitute forward looking statements that are based on our current market s competitive  and regulatory expectations and are subject to risks and uncertainties that could cause actual results to vary materially  Except to the extent required by the law  we undertake no obligation to update publicly any forward looking statement after this presentation whether as a result of new information  future events  changes in assumptions or otherwise Please see our latest Form 10 K for a discussion of risk factors as they relate to forward looking statements  In today s presentation  we will use certain non GAAP financial measures  We refer you to the appendix in the presentation materials available on our Investor Relations website for reconciliations to the most directly comparable GAAP financial measures and related information You will find a link to the webcast on our Investor Relations website at investor walgreensbootsalliance com  After the call  this presentation and webcast will be archived on the website for 12 months I will now hand you over to Stefano Stefano Pessina    Executive Vice Chairman and Chief Executive OfficerThank you  Gerald and hello everyone  As you will see from our figures  it has been a slow start to the financial year with a competitive US pharmacy environment and soft trading conditions in the UK  That said  as you will hear  there are a number of items affecting the year on year comparisons and given the initiatives that we have under way  we are maintaining our full year guidance In the quarter  we continued to make progress against all four of our core strategic priorities  We are making progress in moving our data resources to a new and more flexible cloud based infrastructure with a significant benefits that brings  We have also made a good progress with the development of new services to build on this new infrastructure to announce our customer experiences  make our teams more efficient and effective and open new opportunities for our businesses  Clearly  this work on the digitalization of our company must and are closely tie in with our work to modernize our retail offering and the shape and structure of our retail footprint  At the same time  we are working with partners to redefine the delivery of healthcare in the community and the important role of pharmacy in the immediate and longer term future  And all of these is of course supported and fueled by our Transformational Cost Management Program  which have made substantive progress during the quarter Finally  we have also continued to make progress on a number of significant partnerships  both established a new to enhance our offering and efficiency and toward the value growth in our businesses  In the quarter  we entered into a procurement joint venture with Kroger  building on the already strong relationship that has been formed between Kroger and Walgreens  And we announced a joint venture with McKesson to bring together our two businesses in Germany  improving our reach and scale with a focus on enhancing the efficiency and performance of whole  Phonetic  combined wholesale operation in the significant German pharmaceutical wholesale market I will come back to make a few comments on the future at the end of our presentation  But now  I will ask James and Alex to take us through the results in a little more detail  James James Kehoe    Executive Vice President and Global Chief Financial OfficerThank you  Stefano and good morning  Adjusted EPS was  1 37  5 7  lower than prior year on a constant currency basis  The year on year comparison was impacted by around 5 percentage points of adverse items including the year on year bonus impact  In Retail Pharmacy USA  strong cost management and improved retail comp sales were offset by lower gross margin  Retail Pharmacy International continued to be negatively impacted by a challenging UK market and we saw continued strong performance from Pharmaceutical Wholesale  Our Transformational Cost Management Program is very much on track and we expect to achieve annual cost savings in excess of  1 8 billion by 2022  Cash generation was very strong in the quarter with free cash flow of  674 million   684 million better than prior year And finally  we are maintaining our guidance for fiscal year  20 of flat adjusted earnings per share on a constant currency basis with a range of plus or minus 3   Looking forward  we see improved core business trends with however some noise in the second quarter as we cycle through the timing of reimbursement payments and year on year bonus impacts  In total  these result in an expected EPS headwind of around 13   but both of these items were budgeted in fiscal year  20 and have no impact on full year guidance Let s now look in more detail on the results  First quarter sales were up 1 6  including a currency headwind of 0 7   On a constant currency basis  sales were up 2 3   Adjusted operating income declined 15 4  on a constant currency basis  reflecting lower gross margin in the US and a difficult UK market  Adjusted EPS was  1 37  a constant currency decline of 5 7   Our share repurchase program contributed 4 percentage points of growth and an additional 5 7 percentage points came from a favorable tax rate as we benefited from a number of discrete items  The result included adverse items of over 5 percentage points  including the year on year bonus impact  mark to market adjustments and lapping prior year supplier funding  GAAP EPS declined 19 8  to  0 95 and also reflected costs relating to the Rite Aid transaction and the implementation of the Transformational Cost Management Program Now let s move to Retail Pharmacy USA  Sales increased 1 6  in the quarter with 2 9  growth in pharmacy  partially offset by lower retail sales  Note that the sales growth includes a negative impact of 50 basis points due to our store optimization programs  Adjusted gross profit declined 4 9  due to lower pharmacy and retail gross profit  Adjusted SG A spend decreased 1 6  in the quarter and was 17 6  of sales  an improvement of 0 6 percentage points versus prior year  The decline in SG A clearly shows our strong execution against our Transformational Cost Management Program with savings more than offsetting incremental investments  the impact of inflation and the year on year bonus impact  Adjusted operating income declined 16 2  as the SG A savings were not enough to offset the decline in gross profit and the adverse items I mentioned earlier  In total  these adverse items accounted for over 6 percentage points of the decline in operating income Now let s look in more detail at Pharmacy  Total Pharmacy sales increased 2 9  versus prior year  reflecting continued brand inflation and script volume growth  Central specialty sales continue to grow nicely  up 9 3  versus prior year  Comp pharmacy sales were up 2 5  and comp scripts grew 2 8   While this was weaker than expected  we have seen improved growth in recent weeks  Market share for the quarter was 20 9   down 55 basis points versus prior year including the impact from our store optimization program  Adjusted gross profit decreased mid single digit  as the impact of procurement savings and script growth was more than offset by reimbursement pressure Turning next to our US Retail business  Total Retail sales declined 2 2  in the quarter  impacted by store optimization  Comp retail sales declined 0 5  and continued to show an improving trend  Excluding tobacco and e cigarettes  comp sales were up 0 8   As you know  we are exiting the sale of e cigarettes  While this did not have a significant impact on comps this quarter  it will have a bigger impact from the next quarter onwards and we continue to anticipate a full year EPS impact of around  0 06  We saw a solid comp growth in our core categories with health and wellness up 3 3  and beauty up 2 5   We estimate a tailwind of around 80 basis points from cough  cold  flu  Retail adjusted gross profit declined low single digits due to lower sales including the impact of store optimization programs  higher shrink and the timing of prior year supplier funding  Adjusted gross margin declined slightly  however  excluding the higher shrink and supplier funding timing underlying category margins were in line with prior year Turning next to Retail Pharmacy International  And as usual  I will talk to constant currency numbers  Sales decreased 2 7   mainly due to the UK and Chile  Boots UK comp pharmacy sales increased 0 9  in the quarter  reflecting relatively higher NHS reimbursement levels and increased sales from services  partly offset by lower script volume  Boots UK comp retail sales declined 2 9   as the UK High Street continued to be very challenging  However  overall  we held market share  Adjusted operating income was down 39 1   mainly due to lower UK retail sales volume and margin  The results include an adverse impact of 13 percentage points from the year on year bonus impact and higher technology investments Turning now to the Pharmaceutical Wholesale division  which I ll also discuss in constant currency  The Pharmaceutical Wholesale division delivered another strong quarter with sales up 8 3   led by emerging markets and the UK  The change in the customer contract  which I ve mentioned before  helped our UK performance contributing 1 4  to the overall sales growth  We have now lapped the impact of this contract change  Adjusted operating income increased 4 9   reflecting strong revenue performance and a higher contribution from AmerisourceBergen  This strategic joint venture with McKesson aims to drive sustainable profitable growth in the largest pharmaceutical drug market in Europe by leveraging scale and improving efficiency  Mid term  we expect the JV to be EPS accretive and to accelerate our Pharmaceutical Wholesale profit growth Turning next to cash flow  Operating cash flow was  1 1 billion  up  601 million versus prior year  Free cash flow was strong at  674 million  up  684 million on prior year  Our key working capital initiatives are on track  We are removing excess inventory from the system and we have started to extend payment terms to industry leading levels and we have a strong pipeline of initiatives to fuel our cash flow generation over a multiyear period Let s turn now to our Transformational Cost Management Program  In October  we raised our annual cost savings target to in excess of  1 8 billion by fiscal 2022  We now have a very robust pipeline and our savings initiatives are gaining momentum  This gives us a much higher level of confidence that we can exceed  1 8 billion target  Importantly  these savings will allow us to fund the investments needed to create new and innovative business models Let me now give you some detail on our activities in the quarter  On smart spend  we are accelerating our energy management efficiency program and we see opportunities to ramp up our procurement activities in goods not for resale  The Energy Management Program is interesting  ULED lighting saves money  is environmentally friendly and improves the store experience for consumers  This is a perfect example of save to invest to grow  On smart organization  we re undertaking an end to end process review in Boots UK  covering all major business processes with the aim of transforming how we operate  ultimately leading to a lean and effective operating model  We are now actively planning the implementation of global business services and we have implemented the second wave of headquarter cost reductions in Mexico  Chile  and Thailand On divisional optimization  we have completed 114 of the 200 Walgreens store closures and 28 of the 200 Boots UK closures  We continue to test new store formats in the US and we re now operating 23 small stores with encouraging results  On IT  we have started implementation of a new operating model and our vendor optimization work is progressing well  For example  we recently selected Tata Consulting Services as our new partner to accelerate the work on our critical pharmacy operating system  On digitalization  we have prioritized investments in mass personalization and reinventing the pharmacy prescription journey Now  I ll hand over to Alex Alex Gourlay    Co Chief Operating OfficerThank you  James  I ll now update you in some of the actions we ve taken in the US during the quarter  starting with a retail offering  Our strategic partnership with Kroger is progressing well  The initial Kroger Express pilot in Northern Kentucky has been running for just over one year and the pilot in Knoxville  Tennessee for five months  We ve seen very positive results so far with a strong sales list  Phonetic   Building on the success of these pilots  we formed the group procurement office  retail procurement alliance with Kroger in December to purchase both of our private label goods  We expect this joint venture to deliver cost savings  encourage sourcing innovation and generate efficiencies across the supply chain  Our strategy of focusing on the higher margin health and wellness and beauty categories is delivering benefits and both delivered solid performances in the quarter  Our flagship No7 beauty brand performed well with sales up in the mid teens  reflecting nationwide advertising campaign in our new e commerce site and we have introduced an enhanced skincare offering in over 900 stores  which we expect to drive future performance Moving on to healthcare  We have opened the second of five VillageMD primary care locations in Houston  Our wellness partnership with Jenny Craig is progressing well and we are on track to open approximately 100 locations by the end of January  We re also in the process of converting our optical pilots to the  Indecipherable  brand  which offers improved insurance coverage and stronger consumer brands In specialty  I m delighted to see that all 300 community based specialty pharmacies have received URAC accreditation and we continue to believe that our strong community based presence alongside our central fill capability provides the best access for these important medications to our patients in the marketplace  In partnership with UnitedHealthcare  we continue to create new opportunities for growth in Medicare Advantage  We are very pleased with customer adoption of the new core branded Medicare Advantage product  we started selling from October 15th 2019  And finally  we are also opening 14 UnitedHealthcare patient resource centers  designed to help our customers navigate their insurance and healthcare needs within Walgreens stores Turning next to digitalization  Our Find Care platform now has 32 healthcare service providers  spanning over 46 services  We continue to develop our patient medication adherence programs to deliver better clinical outcomes  Our Save A Trip Refills program now has 3 million patients signed up  an increase of over 25  since last quarter  Our consumers continue to demand the convenient omni channel retail shopping experience  I m pleased to say we had record breaking sales on walgreens com on the Black Friday weekend  up over 45  versus the prior year and particularly strong performance in retail products  Indecipherable   Overall  our omnichannel business continues to grow  Our Walgreens app has now been downloaded 60 million times  up 12  since last year  Around 33  of Walgreens retail refill scripts eligible for digital refill were entered via digital channels in the quarter  up almost 18  since last year  And we have increased our Balance Rewards members to 89 9 million  Finally  Walgreens digitally initiated sales reached over  3 7 billion in the quarter  up around 9  year over year Next I will update you on initiatives we ve undertaken in Retail Pharmacy International  starting with the retail  In Boots UK  as you know  we ve introduced our beauty reinvention program to 26 of our flagship beauty hauls in the second half of last year  I m pleased to report that we ve seen an improved performance in these stores in line with our expectations  Building on this  we rebalanced the retail space in 200 of our largest stores and have introduced 20 new beauty brands  Since the quarter end  we have signed an exclusive UK franchise agreement with Mothercare  a British retailer and brand  specializing in products for mothers  babies  and children  We will be selling Mothercare branded goods across the UK and online Moving on to healthcare  Our purpose built pharmacy operating system has been rolled out to over 1 400 Boots to UK stores  allowing our pharmacists to provide a greater level of customer service  even more efficiency and over time a wider range of new pharmacy offerings  And we continue to develop new healthcare services with diagnostics where our pharmacists now have the ability to write prescriptions for certain conditions  I mentioned last quarter that we are developing new initiatives in digital healthcare with plans for expanding pharmacy services  to improve the customer journey and broaden access to healthcare  We launched our online pharmacy in May 2019  which has made solid progress in the markets  We have made further good progress on digitalization  Our online business  boots com delivered strong growth with sales up 12  versus prior year in the quarter  We also saw a record breaking Black Friday weekend with result in online sales  up around 25   And finally  we have agreed an exclusive partnership to offer omnichannel photo and personalized gifting services in the UK and Ireland I ll now hand you back to Stefano for his closing comments Stefano Pessina    Executive Vice Chairman and Chief Executive OfficerThank you  Alex  As you have heard  this year has opened with a number of challenges  The main changes that are impacting the global healthcare sector are generating some difficult conditions for our businesses  As said  change always brings opportunity  We must act to meet the challenges and ensure we make the most of the opportunities we see  Seeing these opportunities and mindful of the challenges side  we are maintaining our full year guidance for the year  We continuously review our Group to ensure we have the right mix of businesses  to maximize our performance in a dynamic sector  Pursuing our strategic priorities is having a real impact in driving our businesses  The changes in our markets are obscuring some of the positive impacts we are having  but these will not be the case forever I have said before and I will say again  I strongly believe in an expanded role for pharmacy and in our company s ability to play a significant part in shaping how healthcare is delivered in the community going forward  I believe these as much today as I ever have  I believe we have true financial strength as a business  As we have demonstrated this quarter  we have an extraordinary ability to generate strong and sustainable cash flow and we have many opportunities to deploy this cash flow to create real value  I remain convinced that we have in our company through our partnership an extraordinary foundation on which to build  The work that we are doing today is creating a strong and flexible engine of our growth in our businesses for many years to come Thank you  Now we will take your questions Questions and Answers Operator Operator Instructions  Your first question comes from the line of Robert Jones from Goldman Sachs  Your line is open Robert Jones    Goldman Sachs   Co     AnalystGreat  thanks  Thanks for taking the question  I know there s a lot of moving pieces and it s only the first quarter  but if I just take a step back  clear EPS was down around 6  in the quarter  below the full fiscal year guidance  it sounds like  James  if I m hearing you correctly next quarter given some of the moving pieces  it could see an even steeper decline in EPS  I guess if we think about the back half  could you maybe just give us the building blocks or the things that you guys have visibility into that gives you confidence that the back half can get you into that flat plus or minus 3  EPS for the year James Kehoe    Executive Vice President and Global Chief Financial OfficerYeah  That s an expected question  obviously  Let me just give you a little bit of context on the first quarter  However  first  I think the only real surprise we had in the first quarter was on the script volume  it did come in weaker than we expected  We were thinking of a number of around 4  and we come in at 2 8   that s the piece that    and I want to be clear  Our internal budget was  1 37 and we came in over budget  What we had was a favorability on tax  offsetting script growth in Q1  So that was the one thing we were disappointed on We had a lot of stuff we re very happy about  so free cash flow was off the charts  we beat our internal budget by hundreds of millions  largely driven by programs we re implementing in the US  As Stefano said in his comments  Transformational cost management program and that s key to the answer to your question is  I will classify it right now is well ahead of track  particularly due to actions in the US and the U K  Another items I d highlight that shouldn t be lost on you  we finally we have nailed one of the first steps in the Kroger relationship  We think it s extremely positive that we have started up a GPO  And I think it will lead to many good things in the future  And then finally a strategic deal in a problematic German wholesale market  which we think will drive tremendous value longer term  So we think there was a lot of good things that happened and script growth was the one that was more challenging Let me give you a prospect of looking forward is    and actually we re a little bit surprised as well  We re seeing quite a strong momentum in the current month of December  So we believe when we call out 5 percentage points of items in the first quarter  we re probably under calling that  that were clear shifts between call at the Thanksgiving period  Christmas periods and I don t want to give the precise number  but our script growth is in solid mid single digit growth in the month of December  So we re clearly feeling that we re not really reading why the shifts are happening that well  We know cough  cold  flu is driving some of the buoyancy in December  So we are seeing signals  but we are counting on to hit our full year guidance  We do need or script growth to be in the 3 5  to 4  kind of  maybe 4 5  depending on the quarter  But right now in December  we re seeing numbers in excess of that  So script growth is the key one  The other key one is that will drive increasing performance as we exit the year  Obviously  as you take out costs  the cost take out is over the course of the year  So the savings roughly in the first quarter are around 15   So of the total goal of    we haven t given the numbers  a large number were less than 15  in Q1  As we exit the year  we will be up double the run rate of savings  So overheads will become a much more significant driver in the second half  And I do want to point out for that  for a company of our size with the amount of overheads we have  the total overheads were down 1 6  in the quarter  In the context    and I think it s important to have the context  we did say that the combination of inflation and volume impacts is about  400 million  you have the bonus year on year that s in the region of  350 million   400 million and we have incremental investments of  100 million to  150 million  So it will give you some indication of the size of the cost management initiatives  And I think we ll come back next quarter with probably more visibility on the potential further opportunity on the cost program  but I just finished answering your question  I think if you were to do your model again for the full year  we will probably have a slight favorability in taxes  So call it somewhat 0 6   0 7  on the full year and we will have more coming from overheads and probably slightly less coming from gross profit because we had a miss in the first quarter on scripts  So that s why we feel it s basically the overheads and some tax opportunity that we feel we can offset the call of the script under delivery in Q1 Does that cover what you were looking for Robert Jones    Goldman Sachs   Co     AnalystThat s tremendously helpful  And I guess just one other probably anticipated question again  Just around the prime relationship in the wake of the Prime Express Cigna announcement  Just wanted to get any update on how you guys are viewing the Prime relationship  any impact of the Alliance or ex JV just as we think about how that relationship played out for you this past year relative to your expectations or how it would contribute in 2020 would be helpful  Thank you Alex Gourlay    Co Chief Operating OfficerHi Bob  it s Alex here  Yeah  We have recontacted with Prime in a direct relationship  So Prime is now working with Express Scripts as a PBM working with us in a direct relationship  so we anticipate to hold our market share with Prime and potentially grow as a Prime model will be more competitive in a marketplace  So our relationship with Prime continues to be a very strong one and we continue to walk you very well with independent blues  Phonetic   So we are happy with the situation  In terms of the impact  obviously we ve readjusted the margin of debts  but it really was in forecast in budget  So we had expected this impact and had planned for it On AllianceRx side  AllianceRx actually is doing OK at the moment  But again  we have a great relationship with Prime  We are speaking to them  how do we adopt to an ever changing specialty marketplace  which is becoming even more important for both of us  We expect to have conversations next year along these lines to improve that model further  So all is good from our point of view and we wish Prime success with their new model and in that work we feel very confident that we will benefit from that relationship in the future Robert Jones    Goldman Sachs   Co     AnalystThank you OperatorYour next question comes from the line of Eric Percher from Nephron Research  Your line is open Eric Percher    Nephron Research LLC    AnalystThank you and thanks for the commentary on the cadence with respect to volume and cost  Maybe to hit on one other item  reimbursement and the impact on 1 1 20  I know you gave us a 13  number  I think was reimbursement and bonus  but can you provide a little bit more context on what the outlook is as we move from Q1 into Q2 on 1 1 20 James Kehoe    Executive Vice President and Global Chief Financial OfficerYeah  The 13  reference was to Q2 and we re specifically highlighting two things in the quarter  And I would say it s like 7  due to reimbursement timing and the other  Phonetic  is 6  is due to bonus year on year  And the reason we called out the Q2 reimbursement is  it really is a timing item  it s a true up of prior year contracts that occurs typically in the April  May  June timeline of the year  And as it happened in the prior year  there was no true up  So it s not really a reimbursement impact year on year in terms of increase in contract prices  it s a contractual true up of the contract for prior year and it s quite a large number because it impacts 7 percentage points  We didn t actually call out anything on Q1  What we said about Q1 is reimbursement was actually broadly in line with the plans we ve put together  because if you recall when we gave guidance  we said at the time that    I think 58  or 60  of all of our contracts were already defined when we gave guidance  so we had fairly decent line of sight to the full year reimbursement  And we came within  20 million of the reimbursement estimate for the first quarter  So we were actually quite pleased with that because it s quite difficult to forecast reimbursement  And you know we have looked back on some of our prior guidance on the quarters and the reason for giving something on Q2 just to highlight this exceptional reimbursement of timing true up  Right now as we sit  we have no reason to call any different outlook on reimbursement for the full year  We should presume that means plus or minus  50 million  So it s    we were pleasantly surprised with the Q1 on that side  And I reiterate our issue on pharmacy in Q1  nothing to do with procurement  nothing to do with reimbursement  they were actually net  probably slightly positive  it was probably  it was all script volume  So it was just lighter than we would have planned it to be Eric Percher    Nephron Research LLC    AnalystThat s really helpful  And reimbursement in the UK  it sounds like NHS funding did improve  but we didn t see it in the revenue line  Was this simply the new contract or have you seen any makeover for the debt and the lack of payment last year Alex Gourlay    Co Chief Operating OfficerSo again there is really two stories here  Hi  it s Alex here  One is  as you say there has been a stabilization of payment  which is in the marketplace can be seen on the NHS site  And secondly  we have taken some actions to reduce loss making services that we have in the UK and to make them more profitable  As a result of that we ve lost some volume  not as much volume as we had expected to be honest  but some volume  And we re quite pleased that with the retention of customers with these actions and that s what s caused a slight further decrease in terms of our revenue in the UK  it s not reimbursement  it s actions we ve taken to reduce loss making services that we were offering Eric Percher    Nephron Research LLC    AnalystThank you OperatorYour next question comes from the line of Elizabeth Anderson from Evercore  Your line is open Elizabeth Anderson    Evercore ISI    AnalystHi  good morning guys  A couple of times you mentioned or should have alluded to potentially a little bit of a change in competitive environment in the US Pharmacy or perhaps some pressure on or versus your expectations in the quarter in terms of script growth  Could you comment more broadly on sort of what you re seeing there and sort of your thoughts on how that s progressing Alex Gourlay    Co Chief Operating OfficerHi Elizabeth  it s Alex here  I think as the consolidation in the market has really accelerated both vertically and horizontally  and as for example  the Prime Express deal is a good example of this  The PBMs are working more closely together  That s clearly putting more pressure on the marketplace for better pricing and that s really what we are alluding to  So we are working hard as James has said  as we always have done to mitigate that pressure through cost programs and through driving volume  As James is going to say very clearly  we were disappointed with the volume growth in Q1  Part of that was timing as James has said and part of that is because the fact that we lost some access to some particular  some Medicaid networks during the summer  that is rolling into this year  And  as we spoke to    I think it was the last quarter  we re working    investigating obviously with Advanced Rx  Indecipherable  the opportunity for us to to become more efficient together and offer a new model in the Medicaid business  We recognize that we are under share there and we have to operate differently in that marketplace In Medicare  we continue to do very well with UnitedHealthcare  We re really pleased with the relationship and the new MA plan as we ve spoke to in the prepared comments has done well and we expect that will come through in the changes in January 1  Obviously  we are doing less  well  with the other a strong performer  which is Aetna Insurance  We have done really well and we are doing less  well  with them for maybe obvious reasons  But in the whole  we feel we are going to be there or thereabouts in Medicare Then in commercial  already said and replied previously  they will be very pleased to have renewed the contract with Prime  which again is a very important book of business for us in the commercial network  So I think that s the picture from my point of view  And I don t know if  Indecipherable  question Elizabeth that s how we see it and all underpins the 3 5  to 4  volume growth that we expect to see in the full year Elizabeth Anderson    Evercore ISI    AnalystOkay  perfect  That s very helpful  Thank you OperatorYour next question comes from the line of Lisa Gill from JPMorgan  Your line is open Lisa Gill    JP Morgan    AnalystThanks very much  Good morning  I wanted to start with just some thoughts around branded inflation as well as generic procurement in the current market  As we think about the gross margins and how this will impact it  I m just wondering  James  first  can you just talk about what s in your current expectation and guidance James Kehoe    Executive Vice President and Global Chief Financial OfficerWhat we saw in    I ll tell you what we ve seen in Q1  We saw branded inflation of around 4  and we    most of the market read seem to be the inflation and this is on a constant mix basis  so like for like SKUs  deflation of around 4   We would say that internally    on generics  sorry  And maybe I ll ask Alex to weigh in  And then two is we would be outperforming versus that 4  will probably be in mid to high single digit and we generally are projecting that kind of number going forward  somewhere in the mid to high single digit deflation mix adjustment  which is    it s probably quarters will change versus market  but generally that s what we re seeing in the market and we re delivering slightly better in terms of cost reduction in the P L I don t know Alex  if you want to add Alex Gourlay    Co Chief Operating OfficerYeah  I think the  Indecipherable  and we continue to feel very good about our global operation and we via attack  Phonetic  delivering just slightly beyond  Indecipherable  reductions in COGS  cost of goods  So that s exactly what we are seeing James Kehoe    Executive Vice President and Global Chief Financial OfficerYeah Alex Gourlay    Co Chief Operating OfficerYeah Lisa Gill    JP Morgan    AnalystAnd then Alex  you talked about a number of healthcare initiatives and updates  a few of that you didn t touched on today would be LabCorp  and Humana  One  on the LabCorp side  can you just talk about where you are today  are you on track  On the Humana side  any plans to expand  Can you talk about United on the Medicare Advantage side  I m curious what you re doing with Humana  And then just more broadly speaking  the strategic priority for expanding the role of pharmacy  as you know I m a big believer in that as well  But with the reimbursement pressure  do you ever see that subsiding in any way where you can actually get ahead of that where you can start to change the paradigm and I know I ve asked this for multiple years  but do you finally think that you can start to see that on the horizon as you start to have bigger and bigger relationships like north of 100 million lives now in the combination of Prime and Express  you think about large relationships like United Alex Gourlay    Co Chief Operating OfficerSo I think maybe start with the Humana questions  So we ve opened up preferred partners in primary care  It looks very good and is operating really well and the relationship between the pharmacist and doctors is really close  So we continue to feel really good about that  very small  but important test joint venture and of course  we ve opened up two also with the clinical VillageMD which I m sure you know  down in Houston will be five in total by the end of February  And again  we are very  very pleased with how that s operating already  We ve taken a small stake in that company  VillageMD as well  which we re pleased to do and we see that partnership of the doctor and the pharmacist been fundamental to the future of community healthcare delivery going forward in core to our model on the lending lots about how we can do two things  take cost out the system together and get customers to understand and do the medications better and change the lifestyles  And so it s really interesting walk and it points to maybe your last question  So that s on the Humana On LabCorp  we re bang on track in terms of number of service centers opened  I think we ll have well over 100 in the ground by the end of this quarter  I think that s really bang on track and they are performing well  We are seeing NPS scores and the usage of the centers all in or above our expectations  so we are very pleased with our program and we expect 600 and maybe more  we don t know yet in the ground within the four years as we promised  And role of pharmacist  we are working really hard to get our new system in  As James spoke to in prepared remarks  we re going to be accelerating that system from the current pace  That will be fundamental to be in the cloud  the date will be in the cloud  it will be fundamental to taking the work code out and freeing up our pharmacists to really drive that in future We re seeing increased payments from certain insurers and PBMs  particularly in Medicare D  We really like working with United because they are stretching to this in terms of getting the payment  but the very clear on the goalposts that we have to hit to get the payment and we ve been successful in achieving that  I do believe other insurance companies will follow their leads and the government eventually will also make sure that we have clear KPIs going forward as well  So  yeah  it s a longer play for sure  but we are really committed to and we re making more progress and appears right now than our numbers on and we continue to keep on pushing this to fundamental to pharmacy and fundamental we believe to a more efficient healthcare system in the US Lisa Gill    JP Morgan    AnalystAnd then just for understanding that none of that is in your expectation for 2020  So I heard you say longer term a couple of times in this conversation  so should we anticipate that this could potentially impact fiscal 2021 or 2022  How do we just think about it from a timing perspective Alex Gourlay    Co Chief Operating OfficerYeah  We are already earning some money back  as you know the famous  Indecipherable  well  So we are earning more money back than we did previously and the amount of money available to us is growing and our ability to get that money grows as we get our systems in and of course  we re also deploying pharmacy specific of pharmacists  I think we have about 150 Internet work who are specifically working to achieve these performance outcomes  So I think this will start to affect  21 and  22  It s already given us some relief in  20 as well  There is improved money in our forecast for performance networks Lisa Gill    JP Morgan    AnalystOkay  great  Thank you for the comments OperatorYour next question comes from the line of Soo Romanoff from Morningstar  Your line is open Soo Romanoff    Morningstar    AnalystThank you for taking the question  The background you ve given on a lot of initiatives have been great  perhaps maybe specialties become such a big component of your business  I mean is that  is that mix also impacting the margins as well James Kehoe    Executive Vice President and Global Chief Financial OfficerYeah  We called that out in the quarter  It impact by about 50 basis points because it s growing at high single digit versus the pharmacy scripts of 2 8   so it s driving adverse mix of 50 basis points Soo Romanoff    Morningstar    AnalystAnd I guess that makes sense  I mean  do the initiatives that you re kind of putting in place help expand those margins or also provide kind of that long term wellness and part of the healthcare transformation Alex Gourlay    Co Chief Operating OfficerYeah  Absolutely  Soo  I mean  we strongly believe in having a community presence and as you know  we have two models  We have one  which of course to the doctors who are practicing and specialty for example in oncology and then we have pharmacies inside of their hospitals and sort of healthcare systems  We have 300 plus of these and we ve now got URAC accreditation for them all  So every single pharmacy that we run in the community  which is very unusual I believe will be fast to achieve this has got that accreditation  That means more attractive to the manufacturers  because they know that we will take full care of the patient and more and more patients are living longer with diseases in communities  So we believe the local model that will become important to the future of healthcare delivery and always be a central fill model  I m sure  but we believe the local model will become more and more important Also  we announced our relationship with Shields  Shields as a variance  I think platform that s working with healthcare systems and we have a lot of relationships with healthcare systems as you know to make sure as patients leave hospitals  they maintain themselves on the drugs  being dispensed primarily by the hospital pharmacy  So again  we are investing both in technology with Shields and also  Indecipherable  as well in terms of data and tracking customers and low community pharmacies to make sure pharmacist can actually take care of these customers as it lifts and more often a home and we re also of course working closely with Prime as we said already to make sure that we have a really efficient and effective central model And most importantly of all we have  outstanding relationships with the manufacturers  it s really driven  both through our relationship with AmerisourceBergen and also the Ornella with her team at global level to make sure that we have the very best relationships  So while these manufacturers are bringing these new and unique products to the markets and we feel as a global partner we can apply our capabilities for them in the US market through our relationship OperatorYour next question comes from the line of Eric Coldwell from Baird  Your line is open Eric Coldwell    Robert W  Baird   Co     AnalystThank you very much  I know it s difficult to parse this out with the store closings in the UK as well as the shift to more services from volume perhaps  but could you give us a clear sense on the impact of the NHS reimbursement scheme change either quarter over quarter or year over year  And then how did that really stack up compared to your expectations  It sounds OK  but I d like to get a little more detail on that in terms of not only the quarter over quarter  but also how that progresses through the next few quarters  Thank you Alex Gourlay    Co Chief Operating OfficerSure  Yeah  I know  It s Alex here  No  it was exactly as we expected  So the quarter for pharmacy both in volume as I said already were slightly below or on the market in terms of underlying business  but we gave up some scripts because of some unprofitable services  In terms of margin  exactly as we had expected  This tracking too as we expected  So it s relatively easy to track this because the government resigned the five year contract with the industry through what s called the PSNC  which represents all pharmacies in the UK as a one contract  So we can track this quite carefully  It does vary sometimes from from quarter to quarter  but it s trued up in a way which is transparent  So we feel very confident that we ve got a good line of sight to this  We feel very confident that we are working operationally very well in the UK and we have additional piece of work there  which is called pharmacy of the future  an idea really is to transform the operating model for pharmacy in the UK  This will take some time of course  We ve already marked that investment  we are investing strongly in a new farm system  we ve rolled out 1 400 which is well over half of the  Indecipherable  state and it s now present all the home countries including Scotland most recently  So again we are feeling pretty good about the visibility  We re not feeling as good about the profitability of pharmacy  We believe that that needs to improved further  so that we can reinvest back in community pharmacy properly in the years ahead  But we are very committed to getting that operating model understood and changed over time James Kehoe    Executive Vice President and Global Chief Financial OfficerYeah  If you want to characterize the euro of prior year  it was a tough year for pharmacy where there were a lot of untime impacts coming from NHS funding  and there will be a general euro recovery from that  It was surprising  We were within  500 000 of the gross profit targets for pharmacy in the UK  it was bang on target  We are looking at a fairly sizable improvement in gross profit in the business this year  So as Alex mentioned earlier in his comments  we have some marginal profitability businesses on the sidelines and we re aggressively driving the improvement of those  So don t be surprised if you see script volumes and market share going down slightly  We re addressing the profitability of sub categories that we don t think are strategic to the company and we definitely don t want to be in marginal profitability positions  So a bit of a shift in the orientation in the business  slightly more to profitability  So as your modeling is out  don t get fixated by script declines because the core business is actually quite solid and solid in the quarter Eric Coldwell    Robert W  Baird   Co     AnalystYeah  Got it  Thank you very much James Kehoe    Executive Vice President and Global Chief Financial OfficerAnd just one point on the UK though as we go through it  We did have a rough quarter in retail and it really does come down to the market and our share of the    whole share overall quite interestingly though we ve seen in the last couple of weeks and it s maybe a little bit important as you think through your modeling  We had a rough quarter  not 40  decline  now there was a lot of one time items in there  probably half of that was one time adverse items just generally  but as you think through this  we saw a very  very strong Christmas period  There are huge phasing on  mainly of our primary markets  The whole December month started out extremely slow  The second last week of the month was extremely strong with high single digit revenue growth  And in the last week of the year  we again have mid to high single digit growth across our key categories and we re still getting in on bisecting just what happened  but December performance is quite a bit more positive than the quarter we just came out of  And the double surprise was it was achieved with higher margins than the prior year  So we re rebalancing the commercial approach in the UK and we re not chasing volume at any cost and surprisingly we re seeing better volumes and we re seeing better margins  Now it s only two weeks  so it s too early to churn success  but we ve seen a better performance across December across the entire the main two markets  actually both businesses have done quite well in the Christmas period  very well actually OperatorYour next question comes from the line of Kevin Caliendo from UBS  Your line is open Kevin Caliendo    UBS Investment Bank    AnalystHi  thanks for taking my call  You mentioned you had 60  of your PBM contract set when you gave guidance and now you ve renewed Prime  What remains outstanding and how much variance is there really at this point  Could there be an reimbursements as we look out over the rest of the year Alex Gourlay    Co Chief Operating OfficerHi Kevin  it s Alex here  Firstly  I mean there ll be some small net works which can change mid year for sure  but the vast majority now is contracted  the vast majority  I can t give a precise number  but I will always give you an estimate  it will over 90  because the consolidation market is very clear  And yeah  so that s where we are  But so we feel we have good line of state in this fiscal year and again we will start negotiating the majority of the Med D contracts as we move through the summer months  but that will be before starting January 1st 2021 Kevin Caliendo    UBS Investment Bank    AnalystAnd the renewal Prime that takes you through  is it more than a one year contract  meaning like the Express relationship won t have any impact on that at all going forward Alex Gourlay    Co Chief Operating OfficerThat s right  I mean  we don t disclose the length of the contracts  but this is a multi year deal  typical of a longish commercial contract Kevin Caliendo    UBS Investment Bank    AnalystGot it  And one last one  Have you guys looked at the OECD proposals around multinational corporation tax rules  They are obviously still just proposals  but wondering if they were implemented  but will it any way impact Walgreens or WBAD or anything like that Stefano Pessina    Executive Vice Chairman and Chief Executive OfficerWe have I would say quite expert tax group and they are extremely active  they are all over this think you have to wait till dust settles on these things  but we would obviously realign the corporate structure according to new legislation as it comes along  We think that we    that s in a    it s in the right location  It delivers attractive tax positions  but it s all vetted and approved by all jurisdictions globally and it s in line with current policy  As policies change globally  we will adapt to the policies  but we have an attractive tax rate compared to our peer set by quite a number of percentage points and we ll try and maintain that as much as possible  but you can be sure the team is all over this and we don t see any short term risks Kevin Caliendo    UBS Investment Bank    AnalystGreat  Thanks so much  That s really helpful OperatorOur last question comes from Michael Cherny from Bank of America  Your line is open Michael Cherny    Bank of America Merrill Lynch    AnalystThanks for squeezing me in here  So I want to tie back I guess a big picture question  At the beginning you talked about the broader strategy you re taking  I know you mentioned the role of pharmacy going forward  you ve highlighted a number of the various different partnerships  I guess as you think about the next call or rest of this fiscal year two  three years  what are some of the checkpoints you re looking for relative to the partnership model  relative to the strategy  relative to the EBIT contribution from all of these to essentially declare success or if some of them are going to kind of cut bait  And how does that play into the broader on thought process around the organization and the role and where you sit in the market on a go forward basis given as well but you re also going through a pretty broad restructuring about the cost base and the store footprint Alex Gourlay    Co Chief Operating OfficerThanks  Michael  Yeah  It s Alex here  So I think if we start with our key  Phonetic  priorities and they know that they start with managing of the drug store and new retail offerings  But probably more advanced with the Kroger relationship and the reason why that s quite important is because it allows us to do two things  allows us to walk with them on the convenience model  which is really important to drive footfall into our physical stores and also really important from a consumer point of view  the definition of convenience is such a big change in the marketplace  So we are feeling really good about that  I said in my prepared remarks  we are seeing substantial sales growth both in the box itself and also in the categories that we are supporting  We ve also launched our own products  I think we ve got    we re going to have them in the  Indecipherable  just over 15  16  17 Kroger stores so that for this gives us an opportunity to put our health and beauty composition and private label on brands into their customers views as well And then lastly  when you put together the two customer sets  we serve together around about 20 million customers a day between us  So we have a strong  strong presence in American households and our ability therefore to work with them being the the genuine  Indecipherable  part of America and those being very  very competent  we believe in pharmacy health and to some extent beauty category as it relates to healthcare and wellness  We believe that s going to be a strong opportunity  The procurement structure allows us to earn money in the short to medium term  And of course we will be working together on other issues in the supply chain and also in other issues on procurement we believe as well in the future  So that s one area where I think we have made good progress both tactically and strategically With healthcare  we are well into testing quality brands and quality offers in partnership with others  sort of the acceleration of our lessons learned and optical is one example of it  We are working with GrandVision who are renowned as a quality optical retailer with access to insurance and the very best brands  We really are delighted to get more opportunities to be doctors into our stores alongside pharmacists and we believe that  well  that will be a longer term model  We know from experience in Europe that that model can be really effective in delivering end to end primary care in communities And last but not least into the Find Care platform that we have built very quietly with an internal team has really grown and we believe that will be a digital marketplace that will become very important to us into the market in the future  but will take time to grow  So that s really where we are in terms of that measure  So we expect some contribution over time in the retail side faster than the contribution maybe in the healthcare side but the healthcare side will come through the hill  Phonetic  of scripts over time and the access to more James Kehoe    Executive Vice President and Global Chief Financial OfficerAnd maybe one we didn t get this question  but progress on digitalization in the quarter  We ve just launched two major initiatives launched and funded  I want to kind of go back to the previous guidance we gave  We ve got  500 million of capital expenditures behind digital and development plus about  100 million to  150 million of expense this year and we launched two big initiatives in the last account  One is on mass personalization  And that s how do you use your marketing dollars more effectively to target a better connection with the consumer  We believe we will significantly underpin particularly the retail revenue profile for a multi year period  And these are not small investments  they are in the  50 million to  100 million range  And the second one is the  the prescription journey and I use that one very generically  but again it s a similar size of investment and it s on a two speed  we re not waiting for the core systems to be upgraded  it s on a parallel process and this is a 2 ish journey and what s it going to do what s going to connect the consumer much more closely with the prescription  how they want to deliver  how they want to pay for it  the transparency of the cost of it and the options we give consumers and getting closer to consumers  And the second thing it will do it will take friction out of the system  which means it will reduce the cost to fill a prescription  So we re working on initiatives that don t just boost    take out costs  but they actually boost revenue and the connectivity to patients and consumers longer term and some of that will be lost  these investments are large and they re multi year and they will also drive long term revenue and sustainable growth Michael Cherny    Bank of America Merrill Lynch    AnalystAnd I guess just quickly  how do you balance all of those investments in long term initiatives against some of the quarterly volatility and reimbursement risks and the moving pieces on the transformational cost program that you see Stefano Pessina    Executive Vice Chairman and Chief Executive OfficerIt s tough Alex Gourlay    Co Chief Operating OfficerIt s not easy  But we have our program management approach  We have got a lot of cable people but it s not easy in every    but we are paying a lot of attention to the future and to today as you can tell by the comments that James have made James Kehoe    Executive Vice President and Global Chief Financial OfficerA lot of these funds go through the Transformational Cost Management Program and Alex  myself and Ornella and Head of HR sit on it  We are the four people on it  So it s a small team  takes decisions quickly and frankly some of these are tough trade offs and in some quarters you theoretically can t afford it  but you have to do it or otherwise you re going to damage the long term future of the company Stefano Pessina    Executive Vice Chairman and Chief Executive OfficerAnd this is the problem  It s Stefano  Yes  Every strategy    our strategy is as it has always been a medium long term strategy  And we believe in the pharmacy  We believe in the hold that the pharmacies will have in future  Of course  the pharmacy will have to be able to satisfy the needs of the patients and the needs of the customers and we are working in that direction  Not all the pharmacies will provide in future  not all the pharmacies will be important in the local economy of the city or the villages  We try to be in pharmacy that can have a whole and of course we have to invest  We had to invest now for the future  If we work just for the next quarter maybe we will have a little better results  but at the end  we will probably create a problem over the long survival of our stores of our pharmacies  And now you have to take a decision  Either you believe in the strategy  which is focused on the long term or you just try to look at the next quarters and maybe you try to do deals just to let s say make easier over less evidence the problems that you have  We have decided to work for the long term  And I hope that at the end  we would be right OperatorThere are no further questions at this time  I turn the call back over to the presenters Gerald Gradwell    Senior Vice President of Special Projects and Investor RelationsThank you very much indeed  Thank you  I know that Not everyone that want to ask question got to ask the question but as ever the IR team are here and we ll take your calls during the course tomorrow and the rest of the week and we look forward to speaking to you all again next quarter  Thank you very much indeed Operator Operator Closing Remarks Duration  70 minutesCall participants Gerald Gradwell    Senior Vice President of Special Projects and Investor RelationsStefano Pessina    Executive Vice Chairman and Chief Executive OfficerJames Kehoe    Executive Vice President and Global Chief Financial OfficerAlex Gourlay    Co Chief Operating OfficerRobert Jones    Goldman Sachs   Co     AnalystEric Percher    Nephron Research LLC    AnalystElizabeth Anderson    Evercore ISI    AnalystLisa Gill    JP Morgan    AnalystSoo Romanoff    Morningstar    AnalystEric Coldwell    Robert W  Baird   Co     AnalystKevin Caliendo    UBS Investment Bank    AnalystMichael Cherny    Bank of America Merrill Lynch    Analyst
More WBA analysis
All earnings call transcripts",2020-01-08,The Motley Fool,https://invst.ly/pfjhh,2055263
178616,400132,WBA,Why Walgreens Boots Alliance Isn t the Value Stock You re Looking For   Yet,news,"With a horrid 14  negative return in 2019  Walgreens Boots Alliance  NASDAQ WBA  earned itself a spot on the Dogs of the Dow list  The global retail pharmacist has been struggling with shifting consumer trends toward e commerce  a competitive pharmacy industry  and consolidating insurance companies that are paying out less for prescriptions  leading to flat revenue and falling profits the last couple of years    even as healthcare and wellness spending overall continues to rise  
In response  Walgreens has been investing in digital operations and cutting costs  There isn t a ton to be excited about here  except that shares are beginning to look cheap  The stock fell again    more than 5  the day it reported on results from its fiscal 2020 first quarter 
A quick recap of Q1
After putting up a 4  increase in sales but a 0 5  decrease in adjusted earnings per share  Walgreens started the new year sluggishly  missing average Wall Street sales expectations and seeing its adjusted earnings fall 6   Management had issued adjusted earnings guidance for 2020 to be flat with last year  so the quick fall left many investors feeling glum    although that guidance for a flat bottom line remained unchanged after the report  

Pp   percentage point  Data source  Walgreens Boots Alliance   
Walgreens credited the top line growth to rising drug prices and sales volume  but that obviously didn t help the all important bottom line  And that s been the problem for a while now at the retail pharmacist  Management did say it s making progress on its cost savings plan by updating its computing systems to cloud based ones and introducing a new drug procurement joint venture with grocery retailer Kroger  NYSE KR   It also started another joint venture with healthcare and pharmacy company McKesson  NYSE MCK  to handle operations in Germany  All told  savings are now expected to be in excess of  1 8 billion a year by 2022  

One cheap dividend stock 
However  paltry growth that leads to contracting profits doesn t exactly make for a high conviction stock purchase  Nevertheless  buying well established names on weakness  like what was exhibited in 2019 and so far in 2020  can be a winning strategy  And while there are obvious flaws with Walgreens  business  at some point the stock will be too cheap to ignore  Shares trade for just 13 1 times last years  free cash flow  what s left after operating and capital expenses  and only nine times one year forward expected earnings  The dividend is currently a respectable 3 1  yield as well  
However  with Walgreens continuing to forecast another flat year for the bottom line and little headway being made to differentiate itself from the other retail healthcare options out there  this stock is cheap for a reason  After a weaker than expected Q1 2020  shares could continue to tumble for the next few weeks  I m not quite ready to say the time is right to make a purchase  but I do think it s getting close  If shares continue to fall and deepen the discount post report  I ll be ready to pick up a few shares ",2020-01-11,The Motley Fool,https://invst.ly/pgu91,2057451
178629,400145,WBA,Walgreens Boots Stock Falls 5 ,news,"Investing com   Walgreens Boots  NASDAQ WBA  Stock fell by 5 26  to trade at  56 15 by 09 30  14 30 GMT  on Wednesday on the NASDAQ exchange 
The volume of Walgreens Boots shares traded since the start of the session was 888 75K  Walgreens Boots has traded in a range of  56 00 to  56 32 on the day 
The stock has traded at  59 7800 at its highest and  56 0100 at its lowest during the past seven days ",2020-01-08,Investing.com,https://www.investing.com/news/stock-market-news/walgreens-boots-stock-falls-5-2054983,2054983
178630,400146,WBA,Why Walgreens Q1 Is Underwhelming,news,"Walgreens Boots Alliance Inc   NASDAQ  WBA  reported its fiscal first quarter financial results before the markets opened on Wednesday  The retailer said that it had  1 37 in earnings per share  EPS  and  34 3 billion in revenue  which compared with consensus estimates of  1 41 in EPS and  34 6 billion in revenue  The same period of last year reportedly had  1 46 in EPS and  33 79 billion in revenue Overall  net sales saw an increase of 1 6  from the year ago quarter and an increase of 2 3  on a constant currency basis The Retail Pharmacy USA segment had fourth quarter sales of  26 1 billion  an increase of 1 6  year over year  At the same time  Retail Pharmacy International saw sales of  2 7 billion  a decrease of 5 4  div connatix margin bottom  1 5em   div connatix img  margin  unset  Pharmaceutical Wholesale had fourth quarter sales of  6 0 billion  an increase of 5 2   On a constant currency basis  comparable sales increased 8 3   led by emerging markets and the United Kingdom The company maintained guidance of roughly flat growth in fiscal 2020 adjusted EPS at constant currency rates  with a range of plus or minus 3   Consensus estimates are calling for  5 93 in EPS and  139 91 billion in revenue for the full year Stefano Pessina  executive vice chair and chief executive  commented We are maintaining our outlook for the year despite a soft first quarter  We are confident our strategic plans are the right ones to drive long term sustainable growth going forward  In addition  during the quarter we were very satisfied with the progress made in our Transformational Cost Management Program and with the strong cash flow we delivered Shares of Walgreens traded down nearly 6  at  55 99 on Wednesday  in a 52 week range of  49 03 to  74 94  The consensus price target is  57 21  


				ALSO READ  Jefferies Adds New Stocks to Buy for 2020 to Top Performing Franchise Picks List				


By Chris Lange",2020-01-08,247wallst,https://invst.ly/pfgd6,2055033
178631,400147,WBA,Walgreens Q1 Fiscal 2020 Results Fall Short of Expectations,news,"Walgreens Boots Alliances  NASDAQ WBA  released its first quarter results of fiscal 2020 on Wednesday  and things aren t off to a good start for the pharmacy retailer 
For the quarter ending Nov  30  2019  the company s adjusted earnings per share  EPS  of  1 37 fell short of the  1 41 analysts expected  Sales of  34 34 billion rose 1 6  from last year but were also just shy of expectations of  34 6 billion  Retail sales were down 2 2  from a year ago but the company notes that was mainly a result of tobacco products  which Walgreens has de emphasized  Comparable retail sales excluding tobacco products and e cigarettes were up 0 8   
The company did have a strong performance over the Black Friday weekend with online sales in its U S  retail division seeing 45  growth from the prior year while revenue in its international segment rose by 25  
Although it wasn t a strong quarter for Walgreens  the company left its guidance unchanged for fiscal 2020 as it still expects to see flat growth and these latest results don t change that 

Still on the right track
The company s Executive Vice Chairman and CEO Stefano Pessina believes the company is still on the right path despite the less than stellar results   We are confident our strategic plans are the right ones to drive long term sustainable growth going forward   The company is optimistic about its Transformational Cost Management Program as it continues to make progress with Walgreens still expecting to achieve annual cost savings of at least  1 8 billion by fiscal 2022  
Shares of the healthcare stock were down more than 6  Wednesday morning as a result of the earnings release ",2020-01-08,The Motley Fool,https://invst.ly/pfhfp,2055116
178632,400148,WBA,Walgreens misses profit estimates on pharmacy weakness  shares fall 7 ,news,"By Manas Mishra and Trisha Roy  Reuters    Walgreens Boots Alliance Inc s  O WBA  quarterly profit missed Wall Street estimates on Wednesday  hit by lower payments from insurers on drugs sold at its U S  pharmacies  knocking back its shares and those of rival CVS Health Corp  N CVS    The company sought to reassure investors  saying it would meet its adjusted full year profit forecast of roughly flat growth  betting on cost cuts and a harsh flu season   But shares fell nearly 7  to  55  dragging down those of CVS 2   as investors worried that the pressure on reimbursement rates from insurers was likely to hurt profits further   Walgreens has also been struggling with disappointing performance in its Boots UK unit and intense competition from the arrival of Amazon com Inc  O AMZN  in the pharmacy market in the past year   To cushion the impact  Walgreens has closed stores and launched cross selling partnerships with companies including grocer  Kroger Co   N KR  and weight loss clinic operator Jenny Craig   The changes in our markets are obscuring some of the positive impact we are having   said Chief Executive Officer Stefano Pessina   This will not be the case forever   Insurers and pharmacy benefit managers in the United States have been seeking to push more of the cost of the drugs they pay for   and reimburse   to the pharmacy chains that actually deliver them to insured consumers   In recent years  the Deerfield  Illinois based company had benefited from steep falls in generic drug prices that helped it offset the pressure from lower reimbursement rates  but such declines have slowed in the past year    Profitability and sales growth may be hard to come by for the foreseeable future in this era of reimbursement pressure and a rapidly changing health care environment   said Edward Jones analyst John Boylan  Walgreens said on Wednesday it had completed 114 of the 200 planned namesake store closures in the United States and 28 of a scheduled 200 Boots UK closures  The company s cost cutting program  launched in 2018  aims to save more than  1 8 billion annually by 2022   Boots  acquired in 2014  has struggled with competition from online retailers  as well as a broader decline of the UK high street  which has seen dozens of major retailers collapse in recent years   Excluding items  Walgreens earned  1 37 per share  short of estimates of  1 41   Revenue rose 1 6  to  34 34 billion  but missed analysts  estimate of  34 60 billion   
Shares have fallen 15 3  in the past 12 months  making them the worst performer on the Dow Jones Industrials Average index  DJI  ",2020-01-08,Reuters,https://www.investing.com/news/stock-market-news/walgreens-firstquarter-profit-falls-nearly-25-on-higher-costs-2054809,2054809
178634,400150,WBA,Why Walgreens Boots Alliance Shares Are Sinking Today,news,"What happened
Shares of Walgreens Boots Alliance  NASDAQ WBA  were sinking 6  lower as of 11 27 a m  EST on Wednesday  The decline came after the pharmacy retailer and wholesaler announced disappointing fiscal year 2020 first quarter results before the market opened 
Walgreens reported Q1 revenue of  34 3 billion  up 1 6  year over year  The consensus analysts  estimate projected that the company would generate revenue of  34 6 billion  Adjusted earnings per share were  1 37  down 6  year over year and below the average analysts  estimate of  1 41 

So what
One disappointing quarter isn t all that important in the big scheme of things  But Walgreens  Q1 performance underscores the continued challenges for the company 
It especially faces headwinds with its international retail pharmacy business  Sales fell for its Boots UK business  Unrest in Chile also weighed on Q1 results  The company s biggest segment  retail pharmacy USA  continues to experience the negative financial impact of Walgreens  decision to de emphasize sales of tobacco products 
But its U S  retail business is growing overall  as is its pharmaceutical wholesale business  And while CEO Stefano Pessina acknowledged that it was  a soft first quarter   he said that the company remains  confident our strategic plans are the right ones to drive long term sustainable growth going forward  
Now what
Despite the weaker than expected Q1 results  Walgreens didn t lower its full year fiscal 2020 outlook  The company still expects roughly flat growth in adjusted EPS on a constant currency basis 
Investors will want to watch how two new partnerships for Walgreens unfold  The company is forming a wholesale joint venture in Germany with McKesson  and it has created a group purchasing organization with Kroger  
Even with these initiatives  Walgreens doesn t appear on track to deliver much growth in the foreseeable future  It remains a reasonably solid dividend stock  though  with a yield of 3 1  and a track record of 44 consecutive years of dividend increases ",2020-01-08,The Motley Fool,https://invst.ly/pfi92,2055186
178649,400165,WBA,Company News For Jan 9  2020,opinion,Shares of Applied Therapeutics  Inc    NASDAQ APLT   gained 34 5  after the company announced positive top line results from the pivotal Phase 2 portion of the ACTION Galactosemia in adult Galactosemia patients Shares of Newater Technology  Inc    NASDAQ NEWA   surged 17 3  after disclosing a contract of the company s wholly owned subsidiary Yantai Jinzheng Eco Technology for a coal mine wastewater treatment project Shares of Walgreens Boots Alliance  Inc    NASDAQ WBA   lost 5 8  after the company s adjusted earnings per share of  1 37 for first quarter fiscal 2020 missed the Zacks Consensus Estimate by 2 1  Shares of Livent Corporation   NYSE LTHM   declined 11 3  after the company s Q3 2019 earnings of  0 12 per share missed the Zacks Consensus Estimate of  0 14 ,2020-01-08,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-jan-9-2020-200497558,200497558
178650,400166,WBA,Rite Aid  RAD  Up 6 4  Since Last Earnings Report  Can It Continue ,opinion,"It has been about a month since the last earnings report for Rite Aid  RAD   Shares have added about 6 4  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Rite Aid due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Rite Aid Beats Q3 Earnings Estimates  Updates ViewRite Aid reported better than expected earnings and sales in third quarter fiscal 2020 results  The company delivered adjusted earnings from continuing operations of 54 cents per share  which significantly beat the Zacks Consensus Estimate of 3 cents  Also  the bottom line increased from the year ago quarter s adjusted figure of 28 cents  Further  it revised view for the current fiscal Notably  the bottom line benefited from higher adjusted EBITDA  courtesy of tight expense control and higher prescription count at retail pharmacies  Improved pharmacy network management at EnvisionRxOptions also aided performance  Further  the company has been investing in the expansion of EnvisionRxOptions  especially its services  technologies and clinical offerings   Management stated that it will announce a comprehensive strategy for revitalizing the retail pharmacies as well as training pharmacists to cater to health and wellness needs Q3 in DetailRevenues inched up 0 2  to  5 462 3 million and surpassed the Zacks Consensus Estimate of  5 428 million  During the fiscal third quarter  the Retail Pharmacy segment revenues slipped 1 7  due to lower store count  In the Pharmacy Services segment  revenues rose 5 7  owing to rise in Medicare Part D membership Retail Pharmacy same store sales slipped 0 1   thanks to 0 5  decline in front end sales  The downside was partly offset by 0 1  rise in pharmacy sales  Excluding cigarettes and tobacco products  front end same store sales inched up 1   Pharmacy sales included an adverse impact of nearly 331 basis points  bps  from the introduction of new generic drugs  Further  prescription count at same store sales  adjusted to 30 day equivalents  rose 2 8   Prescription sales contributed 67 7  to total drugstore sales Rite Aid s adjusted EBITDA increased 10 7  year over year to  158 1 million and adjusted EBITDA margin expanded 30 bps to 2 9   The upside can be attributed to higher adjusted EBITDA in the Retail Pharmacy and Pharmacy Services segments Moreover  the Retail Pharmacy s adjusted EBITDA benefited from robust labor and expense control  somewhat offset by lower gross profit and decline in the Transition Service Agreement fee income from Walgreens Boots Alliance  NASDAQ WBA   The Pharmacy Services segment gained from improved pharmacy network performance Financial StatusRite Aid ended the quarter with cash and cash equivalents of approximately  289 5 million  long term debt  net of current maturities  of  3 566 3 million and total shareholders  equity of  1 015 9 million Further  the company used cash from operating activities of  423 7 million in the fiscal third quarter OutlookRite Aid updated its outlook for fiscal 2020  The view includes the assumption of higher prescription count as well as improvements in drug costs and SG A expenses  compensated with lower prescription reimbursement rates  Moreover  EnvisionRxOptions are likely to witness consistent improvements in pharmacy network as well as initial results of SG A decline and gains from integration and restructuring efforts It continues to project sales in the range of  21 5  21 9 billion for fiscal 2020  The company projects same store sales growth in the band of 0 1  over fiscal 2019  Moreover  Rite Aid now anticipates adjusted EBITDA to be between  515 million and  545 million compared with the earlier projection of  510  550 million for fiscal 2020 Further  the company estimates net loss in the band of  174  204 million compared with the prior expectation of  235  275 million  The company now envisions adjusted earnings in the band of 13 55 cents per share compared with the earlier guidance of flat to 56 cents  Meanwhile  capital expenditures are expected to be nearly  230 million 
How Have Estimates Been Moving Since Then 
It turns out  estimates revision have trended downward during the past month  The consensus estimate has shifted  1000  due to these changes 
VGM Scores
At this time  Rite Aid has a strong Growth Score of A  though it is lagging a lot on the Momentum Score front with a D  However  the stock was allocated a grade of A on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Rite Aid has a Zacks Rank  1  Strong Buy   We expect an above average return from the stock in the next few months ",2020-01-17,Zacks Investment Research,https://www.investing.com/analysis/rite-aid-rad-up-64-since-last-earnings-report-can-it-continue-200499806,200499806
178651,400167,WBA,Walgreens  WBA  Down 2 2  Since Last Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for Walgreens Boots Alliance  NASDAQ WBA   Shares have lost about 2 2  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Walgreens due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Walgreens Boots Q1 Earnings Lag Estimates  Margins FallWalgreens Boots Alliance  Inc   reported adjusted earnings per share of  1 37 for first quarter fiscal 2020  down 6 2  year over year  down 5 7  at constant exchange rate or CER   Also  the figure missed the Zacks Consensus Estimate by 2 1  Reported earnings per share of 95 cents declined 19 5  on a year over year basis Sluggishness in Retail Pharmacy International and margin contraction built pressure on the bottom line Total SalesWalgreens Boots recorded total sales of  34 34 billion in the fiscal first quarter  up 1 6  year over year and 2 3  at constant exchange rate or CER  The top line  however  missed the Zacks Consensus by 0 8   The year over year growth was led by improvement within the Retail Pharmacy USA and Pharmaceutical Wholesale divisions  partially offset by a dull performance by Retail Pharmacy International Segments in DetailWalgreens Boots reports through three segments  Retail Pharmacy USA  Retail Pharmacy International and Pharmaceutical Wholesale Retail Pharmacy USAThe segment s sales totaled  26 1 billion in the first quarter  highlighting an improvement of 1 6  year over year Pharmacy sales increased 2 9  from the year ago quarter on higher brand inflation  prescription volume and growth in central specialty  Pharmacy sales at comparable stores improved 2 5  year over year  while prescriptions filled in comparable stores  adjusted to 30 day equivalents  rose 2 8  in the quarter  Retail sales dipped 2 2  while comparable retail sales slid 0 5  year over year on continued de emphasis of tobacco Retail Pharmacy InternationalRevenues at the Retail Pharmacy International division declined 5 4  on a year over year basis to  2 7 billion in the fiscal first quarter  Sales were down 2 7  at CER due to lower Boots UK sales and lower sales in Chile Comparable pharmacy sales increased 0 6  at CER and comparable retail sales declined 3  at CER in the reported quarter Pharmaceutical WholesaleThe Pharmaceutical Wholesale division s quarterly sales were  6 billion  up 5 2  year over year  comparable sales were up 8 3  at CER on growth in the emerging markets and the United Kingdom  MarginsGross profit in the reported quarter fell 4 9  year over year to  7 26 billion  Gross margin contracted 146 basis points  bps  to 21 1  Selling  general and administrative  SG A  expenses were down 26 5  year over year to  6 26 billion  Operating income deteriorated 39  to  1 billion  Overall  operating margin contracted 111 bps to 2 9  Financial ConditionWalgreens Boots exited the first quarter of fiscal 2020 with cash and cash equivalents of  811 million compared with  1 02 billion at the end of fiscal 2019  Long term debt was  10 63 billion at the end of the first quarter of fiscal 2020 compared with  11 09 billion at the end of the fiscal 2019  Net cash provided by operating activities was  1 1 billion  up from  460 million from year ago period Fiscal 2020 GuidanceThe company reaffirmed its guidance at roughly flat growth in fiscal 2020 adjusted EPS  on a constant currency basis  with a range of plus or minus 3   The Zacks Consensus Estimate for fiscal 2020 adjusted earnings per share is currently pegged at  5 93 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in estimates revision  The consensus estimate has shifted  8 12  due to these changes 
VGM Scores
At this time  Walgreens has a nice Growth Score of B  though it is lagging a bit on the Momentum Score front with a C  Charting a somewhat similar path  the stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  It s no surprise Walgreens has a Zacks Rank  4  Sell   We expect a below average return from the stock in the next few months ",2020-02-06,Zacks Investment Research,https://www.investing.com/analysis/walgreens-wba-down-22-since-last-earnings-report-can-it-rebound-200505790,200505790
178652,400168,WBA,Walgreens  shares fall after company misses earnings expectations,news,Walgreens Boots Alliance reported earnings before the bell on Wednesday that missed expectations Shares of the company were down in midday trading Walgreens also maintained its full year adjusted earnings per share outlook of  roughly flat  growth ,2020-01-08,CNBC,https://invst.ly/pfdpo,2054816
178672,400188,WBA,Walgreens Boots Alliance  WBA  Lags Q1 Earnings And Revenue Estimates,opinion,"Walgreens Boots Alliance  NASDAQ WBA  came out with quarterly earnings of  1 37 per share  missing the Zacks Consensus Estimate of  1 40 per share  This compares to earnings of  1 46 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of  2 14   A quarter ago  it was expected that this largest U S  drugstore chain would post earnings of  1 41 per share when it actually produced earnings of  1 43  delivering a surprise of 1 42  
Over the last four quarters  the company has surpassed consensus EPS estimates two times 
Walgreens  which belongs to the Zacks Retail   Pharmacies and Drug Stores industry  posted revenues of  34 34 billion for the quarter ended November 2019  missing the Zacks Consensus Estimate by 0 84   This compares to year ago revenues of  33 79 billion  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Walgreens shares have added about 0 6  since the beginning of the year versus the S P 500 s gain of 0 2  
What s Next for Walgreens 
While Walgreens has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Walgreens was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 60 on  35 22 billion in revenues for the coming quarter and  5 93 on  139 76 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Retail   Pharmacies and Drug Stores is currently in the top 12  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2020-01-07,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-alliance-wba-lags-q1-earnings-and-revenue-estimates-200497195,200497195
178673,400189,WBA,Can Value Investors Choose Walgreens Boots  WBA  Stock ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value  One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Walgreens Boots Alliance  Inc    NASDAQ WBA   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Walgreens Boots has a trailing twelve months PE ratio of 9 88  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 20 23  If we focus on the long term PE trend  Walgreens Boots s current PE level puts it below its midpoint of 16 64 over the past five years  Moreover  the current level stands well below the highs for the stock  suggesting that it can be a solid entry point Further  the stock s PE also compares favorably with the Zacks Retail Wholesale sector s trailing twelve months PE ratio  which stands at 28 86  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that Walgreens Boots has a forward PE ratio  price relative to this year s earnings  of just 10 04  so it is fair to say that a slightly more value oriented path may be ahead for Walgreens Boots stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings  Right now  Walgreens Boots has a P S ratio of about 0 39  This is a bit lower than the S P 500 average  which comes in at 3 5x right now  Also  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years If anything  this suggests some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  Walgreens Boots currently has a Value Score of A  putting it into the top 20  of all stocks we cover from this look  This makes Walgreens Boots a solid choice for value investors  and some of its other key metrics make this pretty clear too  What About the Stock Overall Though Walgreens Boots might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth Score of B and a Momentum Score of D  This gives WBA a Zacks VGM score   or its overarching fundamental grade   of A   You can read more about the Zacks Style Scores  The consensus estimate in the current year did not witness any changes in the past two months  while the next year estimate has inched higher by 0 3   You can see the consensus estimate trend and recent price action for the stock in the chart below Walgreens Boots Alliance  Inc  Price and Consensus   This somewhat mixed trend is why the stock has just a Zacks Rank  3  Hold  and why we are looking for in line performance from the company in the near term  Bottom LineWalgreens Boots is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Further  a strong industry rank  among Top 12  of more than 250 industries  instills our confidence  However  over the past two years  the Zacks Retail   Pharmacies And Drug Stores industry has clearly underperformed the broader market  as you can see below So  value investors might want to wait for estimates and analyst sentiment to turn around in this name first  but once that happens  this stock could be a compelling pick  The Hottest Tech Mega Trend of All Last year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2020-01-07,Zacks Investment Research,https://www.investing.com/analysis/can-value-investors-choose-walgreens-boots-wba-stock-200497233,200497233
178675,400191,WBA,Mothercare rescues UK presence with Boots supply deal,news," Reuters    Mothercare Plc  L MTC  said on Friday it had agreed to supply baby care and other products exclusively to Boots UK stores  keeping its goods on British shelves after the collapse of its retail network in its home market   Shares in the company  which called in administrators for its UK business last month and is set to close all of its British stores with the loss of at least 2 500 jobs  jumped 10 4  to 14 9 pence in response to the news   Boots  owned by U S  based Walgreens Boots Alliance  O WBA   will sell Mothercare branded clothing  home and travel products  pushchairs and car seats  in larger Boots stores across the UK as well as online  Mothercare said the deal was  great news  after a grim year for the company  The baby products retailer that operates 1 010 overseas franchise stores has fallen victim to extremely difficult conditions in Britain because of stiff competition from online retailers and rising costs  The company has said it will now focus abroad as it sets out to return the rest of the group to profitability  But it warned earlier this week that volatility in markets including India  Indonesia and Russia  and supply disruptions from the UK closures could see trading performance worsen further  
A limited range of Mothercare products will be available to buy online at Boots from mid 2020  and a wider range will be available from late summer 2020 ",2019-12-13,Reuters,https://www.investing.com/news/stock-market-news/boots-uk-to-stock-mothercare-products-2040867,2040867
178676,400192,WBA,Breaking  Justice Dept  Sues CVS Over Medicare Prescriptions,news,"Investing com   The U S  federal government filed a lawsuit against CVS Health  NYSE CVS  and the company s Omnicare unit Tuesday for fraudulently billing Medicare  sending shares lower 
The Justice Department accused CVS of continuing to issue prescriptions after they had expired or the amount of refills had ended to elderly or disabled people 
CVS  NYSE CVS  fell 1 4  after the news  while Dow component Walgreens Boots Alliance  NASDAQ WBA  dropped 1 1  ",2019-12-17,Investing.com,https://www.investing.com/news/stock-market-news/breaking-justice-dept-sues-cvs-over-medicare-prescriptions-2043120,2043120
178677,400193,WBA,What to Expect When Walgreens Reports Wednesday,news,"Walgreens Boots Alliance Inc   NASDAQ  WBA  is scheduled to release its fiscal first quarter financial results before the markets open on Wednesday  The consensus estimates are calling for  1 41 in earnings per share  EPS  and  34 58 billion in revenue  The same period of last year reportedly had  1 46 in EPS and  33 79 billion in revenue Merrill Lynch s Michael Cherny and Allen Lutz recently issued a report noting that are still many hurdles to a potential buyout  go private or merger deal for Walgreens  The Merrill Lynch team noted  many  hurdles to completing this hypothetical deal  Walgreens continues to have a number of operational issues  These come with questions about potential exit values and returns assumed for the deal  Other issues come from general reimbursement pressure  deflation in the pharmaceutical segment from generic competition and even slower sales from the retail portion of the drug store chain due to e commerce  The team even said that a number of operating expense reductions are already factored into the firm s own financial estimates As for a standalone value  Merrill Lynch maintained its Underperform rating and  50 price objective  The firm did caution that headlines could create ongoing volatility  implying that deal talk reports could move the shares up or down depending on the implications div connatix margin bottom  1 5em   div connatix img  margin  unset  AmerisourceBergen comes into play on this because there have been press reports in the past that the drug wholesaler potentially could be acquired by the pharmacy giant  After all  Walgreens already owns about 27  of AmerisourceBergen  Merrill Lynch also pointed out that there are problems with considering that for M A  Merrill Lynch has only an  83 price objective  and it remains handily under the average target price from other analysts  Its report said With or without a potential WBA deal  we think the premium in AmerisourceBergen shares for a hypothetical sale to WBA is unwarranted  The other corollary is CVS  which is WBA s biggest competitor and is heavily investing in its new service model  If WBA were going to go even further into cost rationalization efforts  it could provide share gain opportunities for CVS going forward Overall  Walgreens has underperformed the broad markets  with its stock down 12  in the past 52 weeks  In the past quarter  shares are actually up 12  A few other analysts weighed in on Walgreens ahead of the report 
Wells Fargo has an Equal Weight rating 
SunTrust Banks has a Hold rating and a  60 price target 
Pivotal Research has a Hold rating with a  55 price target 
JPMorgan s Neutral rating comes with a  63 target price 
Shares of Walgreens traded down less than 1  Monday at  58 65  in a 52 week range of  49 03 to  74 94  The consensus price target is  57 11 


				ALSO READ  Is SmileDirectClub s Walmart Partnership the Beginning of Something Big 				


By Chris Lange",2020-01-06,247wallst,https://invst.ly/pebc1,2053232
178696,400212,WBA,United Natural To Cut Retail Presence Via Shoppers Store Sale,opinion,United Natural Foods  Inc    NYSE UNFI   is on track to downsize its retail presence and emerge as North America s leading food wholesaler  In this regard  the company inked deals to divest 13 of its 43 Shoppers Food   Pharmacy  or  Shoppers   stores to three distinct grocery operators  Apart from this  the company stated that it will cease four Shoppers stores  which are anticipated to discontinue operations by the end of January 2020 The news seems to have boosted investors  sentiments as shares of this Zacks Rank  3  Hold  stock rose 2 9  on Dec 6 Shoppers  Deals in DetailPertaining to the sale of these stores  each of the three agreements is anticipated to conclude between mid December and February  2020  end  This includes plans to shut down operations at all these locations  including selling the remaining inventory and concluding the store closure process before it reopens under other banners   As for the other four store closures  United Natural decided not to renew the lease for three stores  and cancel the fourth one  Following these actions  the company will be left with 26 operational Shoppers stores  for which it is still looking for buyers  Notably  United Natural shuttered down 30 Shoppers in store pharmacies earlier this year  Also  the company sold prescriptions and pharmacy inventories of these stores to Walgreens   NASDAQ WBA   and CVS Efforts Likely to Aid GrowthUnited Natural has long been keen on shedding retail assets of SUPERVALU to focus on profitable areas  Management stated that it will continue focusing on exiting its retail operations strategically  which will help speed up the business transformation  Additionally  this will help the company focus its resources on areas with better growth potential Well  United Natural acquired SUPERVALU in October 2018  The enhanced scale of the combined entities has provided a radical boost to the company s performance  In fact  the buyout has been driving the top line  as witnessed in the fourth quarter of fiscal 2019 Moreover  the merger lent a competitive edge to United Natural in the grocery space by augmenting offerings We note that management is on track with the integration of the SUPERVALU conventional business  In this respect  the company is refurbishing the supply chain network to better consolidate SUPERVALU s distribution centers  Management earlier stated that it expects net run rate cost synergies worth more than  185 million from this buyout in the fourth year of the deal We expect such moves to uplift the stock that has otherwise declined 8 4  year to date against the  s growth of 19 9  Don t Miss These Solid Consumer Staple StocksBoston Beer   NYSE SAM    with a Zacks Rank  1  Strong Buy   has a long term earnings per share growth rate of 10   You can see Beyond Meat   NASDAQ BYND    with a Zacks Rank  2  Buy   has an impressive earnings surprise record The Hottest Tech Mega Trend of All  Last year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2019-12-08,Zacks Investment Research,https://www.investing.com/analysis/united-natural-to-cut-retail-presence-via-shoppers-store-sale-200491157,200491157
178699,400215,WBA,Tesco shares jump on possible sale of Asian business,news,"By James Davey
LONDON  Reuters    Shares in  Tesco   L TSCO  rose more than 5  on Monday after Britain s biggest retailer said it might sell its Asian businesses  in Thailand and Malaysia  which analysts valued at up to  9 billion 
Tesco said on Sunday it had begun a review of its Asian operations after receiving approaches for the businesses 
It said the review was at an early stage and gave no details of the interest received in the businesses  which generate about 8  of the supermarket group s total annual revenue and 10  of its profit 
Pulling out of Asia would mark a further retreat toward Tesco s core domestic market and a shift in strategy as the group had identified Thailand  where it is the market leader  as a key growth area at its Capital Markets Day in June 
 Hence  to us  for any approach to be accepted by the Tesco board for Thailand then it needs to be highly attractive if not a knock out price   said Shore Capital analyst Clive Black 
Shares in Tesco were up 5 5  at 1122 GMT  valuing the retailer at 24 billion pounds   31 billion   as analysts said rival retailers and private equity investors could be interested 
If Tesco does exit Asia the decision could be made by its new CEO  Ken Murphy  rather than incumbent Dave Lewis who is stepping down next year 
Analysts at Bernstein valued the Asian business at 6 5 billion pounds to 7 2 billion pounds   8 3 billion to  9 2 billion  
Tesco trades from 1 967 stores in Thailand and 74 in Malaysia  In the six months to Aug  24 the businesses generated sales of 2 56 billion pounds  up 1  at constant exchange rates from a year earlier  and operating profit of 171 million pounds  up 42 3  
Bernstein analyst Bruno Monteyne said Tesco s Thai operation was a  high quality business   with 50  of its earnings coming from a mall rental business and 50  from a food retail market that is much less competitive than the UK  He said the Thai business still had significant growth opportunities 
In 2016 France s Casino sold its majority stake in Thai hypermarket operator Big C Supercenter  Tesco s main competitor in Thailand  to TCC Group for 3 1 billion euros  Rival  Carrefour   PA CARR  quit Thailand in 2010 
Monteyne noted the Big C deal was at 16 times enterprise value earnings before interest  tax  depreciation and amortization  EBITDA   while Tesco itself trades at 6 8 times 
 That leaves the Thai business hugely undervalued as part of the group  That in itself provides ample justification to consider a disposal  especially if there is unsolicited interest   he said 
GROWTH AVENUE
While selling Thailand could mean a material distribution to Tesco s shareholders it would remove a growth avenue from the group  which said in June that it saw an opportunity for 750 new convenience stores in Thailand over the  medium term  
Celebrating its 100th anniversary  Tesco is five years into a UK focused recovery plan launched by Lewis after an accounting scandal capped a dramatic downturn in trading  In October Lewis declared Tesco s turnaround complete and said he would step down next summer  Murphy  a former executive at healthcare group Walgreens Boots Alliance  O WBA   has not yet confirmed his start date 
In 2015 Tesco sold its South Korean arm to a group led by private equity firm MBK Partners for  6 1 billion  A year later it sold its Kipa business in Turkey to Migros  the country s largest supermarket chain 
Under its previous management Tesco made costly exits from Japan  the United States and China  starting a retreat from its once lofty global ambitions 
If Tesco does quit Thailand and Malaysia  it will inevitably raise questions over the future of its remaining overseas operations   its central European division  consisting of stores in Czech Republic  Hungary  Poland and Slovakia ",2019-12-09,Reuters,https://www.investing.com/news/stock-market-news/tesco-shares-jump-on-possible-sale-of-asian-business-2036847,2036847
178712,400228,WBA,Company News For Nov 12  2019,opinion,Qurate Retail Inc  s   NASDAQ QRTEA   shares jumped 11 4  after the company reported third quarter 2019 adjusted earnings per share of  0 42  beating the Zacks Consensual Estimate of  034 Amicus Therapeutics Inc    NASDAQ FOLD   surged 3 8  after the company posted third quarter 2019 total revenue of  48 8 million  surpassing the Zacks Consensus Estimate of  48 1 million Shares of Nektar Therapeutics   NASDAQ NKTR   soared 4 7  following positive clinical trial data of its drug NKTR 358 to treat autoimmune and inflammatory diseases Walgreens Boots Alliance Inc    NASDAQ WBA   shares climbed 5 1  following news that KKR   Co  Inc    NYSE KKR   has decided to acquire the drugstore giant ,2019-11-11,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-nov-12-2019-200484632,200484632
178713,400229,WBA,Walgreens  Did The Market Foresee The KKR Offer ,opinion,"Anyone who s been in Elliott Wave analysis long enough has noticed how often some external factor  makes the price move  in the direction the analysis had identified much earlier  We ve seen it happening in crypto  we ve seen in happening in stock indices  Now  it happened with Walgreens stock 

Walgreens  NASDAQ WBA  jumped on November 5th after CNBC reported the company was exploring a go private deal  The rumor turned out to be true on November 11th  when the drug store chain was officially approached by private equity firm KKR  NYSE KKR  




Walgreens was down to a multi year low of  49 03 in late August but spiked to  64 50 after the rumor first came out  What is more interesting is the fact that there was a bullish Elliott Wave setup in place two months earlier  Take a look at it below 
This chart was published on September 5th in an article titled  Walgreens Stock Can Add Roughly 30    It revealed that the decline between  86 and  49 was a complete five wave impulse pattern  To every Elliott Wave analyst this meant that a move in the opposite direction can be expected 
Elliott Wave Analysis ahead of the Walgreens Buyout Rumor
The anticipated rally had to be of respectable size in relation to the preceding impulse  So  we thought  we can expect a notable recovery to roughly  65 a share for a total gain of nearly 30    In addition  there was a strong bullish MACD divergence supporting the positive outlook 




The next chart shows Walgreens stock as it is today  over two months after the September 5th analysis 
One  KKR takes Walgreens private at a price not much higher than the current market price  And two  the companies fail to reach a deal and Walgreens remains a public entity  That second possibility is probably keeping arbitrageurs up at night 
If a deal is not reached  WBA stock will be at the mercy of pure market forces again  The problem is that with a complete bearish 5 3 wave cycle already in place  another selloff is going to be very likely  In other words  if KKR fails to pull off the largest leveraged buyout in history  Walgreens stock may revisit the sub  50 area once more ",2019-11-12,EWM Interactive,https://www.investing.com/analysis/walgreens-did-the-market-foresee-the-kkr-offer-200484440,200484440
178714,400230,WBA,Walgreens Could Go Private  What Does This Say About The Market ,opinion,"Technically Speaking For November 12
Summary
Early indications are that corporate investment will be weak again in 4Q19 Walgreens may be going private The markets are probably consolidating gains from the last two weeks 
It looks like corporate investment will continue to be weak  A story in the Financial Times indicates corporate investment will grow a paltry 1 8  in 4Q19  One of the reasons given is continued uncertainty due to the lack of trade policy clarity  which has also weakened corporate sentiment  This is in line with recent data 




The equipment investment component of the GDP report has been stable for the last three quarters  left chart  while declining on a Y Y basis  right chart  




New orders for nondefense goods ex aircraft have been stable for the last year  left chart  and are now declining on a Y Y basis  right chart   This poses potential problems for GDP growth  Last quarter  consumer spending was the primary driver of top line growth  With a weak reading for investment probable  weak fourth quarter growth is likely 

Is  Walgreens going private  News reports indicate the company is at least thinking about it  emphasis added  

Shares of Walgreens  NASDAQ WBA  gained as much as 7 7  in early trading Monday  that KKR  a private equity firm  formally approached the drugstore about a deal that could be the largest ever leveraged buyout 

A spokesperson for Walgreens declined to comment 

KKR has been working on a proposal to take Walgreens private  and is one of a group of private equity firms that s had    
This is big news for a number of reasons  First  it would be the largest buy out in history  Second  it would remove a dividend aristocrat from the pool  WBA has increased its dividend for 43 consecutive years   Third  it would continue the trend of   emphasis added  

The American stock market has been shrinking  It s been happening in slow motion   so slow you may not even have noticed  But by now the change is unmistakable  The market is half the size of its mid 1990s peak  and 25 percent smaller than it was in 1976 
Going public    with its increased reporting requirements  short term orientation  and increased public scrutiny    is simply not as attractive as it once was 
Industrial production is weaker across the globe 




From the Dallas Fed
Over at Econbrowser    who will pick up the industrial production slack during this slowdown  In 2016  a drop in oil prices slowed the US energy sector  which then slowed US industrial production  But then  the rest of the world s production remained sufficiently strong to sustain global economic momentum  Now  everybody is dropping 

Let s turn to the performance tables 





Yesterday was an odd day for the markets  The long end of the Treasury market led the way higher  gaining 0 46   That was followed by micro caps and the QQQs  The 10 20 year section of the curve followed in fourth place  Other equity indexes were up modestly  On the downside are the transports and mid caps  Overall  this table is inconclusive 




The sector performance is mixed as well  The top four spots are split between conservative and aggressive sectors  the rest of the table is mixed as well 
Let s turn to some charts  starting with the TLTs 




I ve stripped out the price bars  leaving only the EMAs to allow us to look at the underlying trends  The shorter EMAs are still above the 200 day EMA  But the shorter averages are all moving lower with the shorter EMAs below the longer ones    a bearish alignment  This also shows that the weight of the short term movement is down  




The 30 day SPY chart shows a clear uptrend in place  as does    




    the 30 day IWM chart 
But there s still weakness in the small cap indexes 




Mid caps broke through the lower 198 area  which was the main area of resistance over the last six months  But the chart has stalled  It s possible to argue prices are consolidating gains  But the lack of meaningful follow through    especially when the larger cap indexes are rallying    is modestly concerning  




Although the IWMs are in a 30 day uptrend  see above   prices are still caught in the 6 month highs 
It could simply be that the markets are cooling off a bit  This would make sense  given the strength of the last two weeks  But  we could also be seeing the lack of participation from the smaller caps  which was pronounced during the Spring rally    which also signaled the underlying problems with the broader market ",2019-11-13,Hale Stewart,https://www.investing.com/analysis/walgreens-could-go-private-what-does-this-say-about-the-market-200484820,200484820
178715,400231,WBA,Walgreens  UnitedHealthcare Team Up To Boost Medicare Services ,opinion,Walgreens Boots Alliance   NASDAQ WBA    in collaboration with UnitedHealthcare  recently announced plans to open Medicare services centers at Walgreensstore locations  Per Walgreens  this latest move is part of a multi year partnership with UnitedHealthcare  Financial terms of the deal have been kept under wraps The plan is expected to be executed starting from January 2020  with 14 centers at Walgreens stores across five metropolitan areas namely  Cleveland  Denver  Las Vegas  Phoenix  and Memphis UnitedHealthcare  a unit of UnitedHealth Group Inc     NYSE UNH    is known for offering Medicare Advantage and Medicare Part D plans This partnership should further strengthen Walgreens  Medicare coverage for its customers More About the PartnershipFollowing the deal  UnitedHealthcare will be expanding the access of its Medicare resources to a larger number of Walgreens customers  offering key facilities they expect from their UnitedHealthcare Medicare Advantage plans  Walgreens customers will also be provided better customer service and information that they want locally within Walgreens  Furthermore  Walgreens announced its partnership deal with UnitedHealthcare on Medicare plans   AARP Medicare Advantage Walgreens Plans  Those plans will offer easy access to medications through Walgreens  cheaper drugs as well as features like  0 premiums and  0 copays on benefits like primary care visits and generic drugs Recent Collaborations With UnitedHealthcareIn the past few years  Walgreens has been investing in a few crucial partnerships with UnitedHealthcare In February 2018  Walgreens had signed an agreement with UnitedHealth Group s MedExpress urgent care centers to offer primary healthcare across 15 locations of the drugstore chain in the United States In 2017  Deerfield  an Ill  based chain  had collaborated with Optum  another UnitedHealth Group subisidiary  to initiate urgent care centers at some of Walgreens  9 000 plus drugstores across all 50 states and territories in the United States Price PerformanceIn the past six months  Walgreens has rallied 17 2  compared with  the  s 30 1  growth Zacks Rank   Stocks Worth a LookWalgreens currently has a Zacks Rank  3  Hold  A few better ranked stocks from the broader medical space are Haemonetics Corporation   NYSE HAE   and NuVasive  Inc   NASDAQ NUVA    While Haemonetics sports a Zacks Rank  1  Strong Buy   NuVasive carries a Zacks Rank  2  Buy   You can see Haemonetics has a projected long term earnings growth rate of 13 5  NuVasive has an expected long term earnings growth rate of 10 9  5 Stocks Set to Double Each was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth  Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-11-25,Zacks Investment Research,https://www.investing.com/analysis/walgreens-unitedhealthcare-team-up-to-boost-medicare-services-200488119,200488119
178716,400232,WBA,Why Is Walgreens  WBA  Up 6  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Walgreens Boots Alliance  NASDAQ WBA   Shares have added about 6  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Walgreens due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Walgreens Boots Q4 Earnings Surpass EstimatesWalgreens Boots Alliance  Inc reported adjusted earnings per share  EPS  of  1 43 for fourth quarter fiscal 2019  down 3 4  year over year  down 2 9  at constant exchange rate or CER   However  the figure exceeded the Zacks Consensus Estimate by 1 4  Meanwhile  reported EPS came in at 75 cents  down 51 4  on a year over year basis Sluggishness in Retail Pharmacy International and margin contractions put pressure on the bottom line during the quarter For the full year  adjusted EPS was  5 99  reflecting a 0 5  decline from the year ago period  This  however  outpaced the Zacks Consensus Estimate by 0 3  Total SalesWalgreens Boots recorded total sales of  33 95 billion in the fiscal fourth quarter  up 1 5  year over year and 2 6  at constant exchange rate or CER  The top line edged past the Zacks Consensus Estimate of  33 86 billion  Year over year growth was led by improvements within the Retail Pharmacy USA and Pharmaceutical Wholesale divisions  partially offset by a dull performance within Retail Pharmacy International For the full year  total revenues were  136 87 billion  accounting for a 4 1  improvement from the year ago period  This too beat the Zacks Consensus Estimate of  136 79 billion by a slight margin Segments in DetailWalgreens Boots reports through three segments  Retail Pharmacy USA  Retail Pharmacy International and Pharmaceutical Wholesale Retail Pharmacy USAThe segment s sales came in at  26 04 billion in the fourth quarter  highlighting an improvement of 2 1  year over year  Excluding the impact of store optimization following the acquisition of Rite Aid stores  organic sales growth was 2 9  year over year Pharmacy sales  accounting for 75 1  of the Retail Pharmacy USA division s sales in the quarter  increased 4 2  from the year ago quarter on higher brand inflation  prescription volume and growth in central specialty  Pharmacy sales at comparable stores improved 5 4  while prescriptions filled in comparable stores  adjusted to 30 day equivalents  rose 3 3  year over year in the quarter  The impact of store optimization following the acquisition of Rite Aid stores caused a 3 9  dip in retail sales  Comparable retail sales slid 1 2  year over year Retail Pharmacy InternationalRevenues at the Retail Pharmacy International division decreased 6 3  on a year over year basis to  2 7 billion in the fiscal fourth quarter  Sales were down 1 8  at CER considering a 2 1  slip in Boots UK Comparable pharmacy sales slipped 1  at CER and comparable retail sales declined 2 7  in the reported quarter Pharmaceutical WholesaleThe Pharmaceutical Wholesale division s quarterly sales were  5 74 billion  up 3 1  year over year  comparable sales were up 7 9  at CER  banking on growth in the emerging markets and the United Kingdom  MarginsGross profit in the reported quarter fell 4 6  year over year to  7 23 billion  Gross margin contracted 137 basis points  bps  to 21 3  Selling  general and administrative  SG A  expenses were up 2 9  year over year to  6 4 billion  Adjusted operating income deteriorated 39  to  819 million  Overall  operating margin contracted 162 bps to 2 4  Financial ConditionWalgreens Boots exited the fiscal 2019 with cash and cash equivalents of  1 02 billion compared with  785 million at the end of fiscal 2018  Long term debt was  11 09 billion at the end of the current fiscal compared with  12 43 billion at the end of the last fiscal  For the full year  the company generated operating cash flow of  5 59 billion compared with  8 26 billion in the year ago period Fiscal 2020 Guidance InitiatedWalgreens Boots announced its fiscal 2020 adjusted EPS guidance to roughly be flat with the year ago period s figure at CER with a range of plus or minus 3  from the same  The company noted that without considering the impact of lower fiscal 2019 bonus payout  this expected performance represents a year over year increase in the mid single digits  The Zacks Consensus estimate of fiscal 2020 adjusted earnings is currently pegged at  5 92 per share 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates 
VGM Scores
At this time  Walgreens has a nice Growth Score of B  however its Momentum Score is doing a bit better with an A  Following the exact same course  the stock was allocated a grade of A on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of these revisions has been net zero  Notably  Walgreens has a Zacks Rank  4  Sell   We expect a below average return from the stock in the next few months ",2019-11-26,Zacks Investment Research,https://www.investing.com/analysis/why-is-walgreens-wba-up-6-since-last-earnings-report-200488418,200488418
178717,400233,WBA,Walgreens Boots Alliance  WBA  Stock Moves  0 55   What You Should Know,opinion,"In the latest trading session  Walgreens Boots Alliance  NASDAQ WBA  closed at  59 27  marking a  0 55  move from the previous day  This move was narrower than the S P 500 s daily loss of 0 86   Meanwhile  the Dow lost 0 96   and the Nasdaq  a tech heavy index  lost 1 13  
Coming into today  shares of the largest U S  drugstore chain had gained 8 8  in the past month  In that same time  the Retail Wholesale sector gained 2 75   while the S P 500 gained 3 66  
WBA will be looking to display strength as it nears its next earnings release  On that day  WBA is projected to report earnings of  1 39 per share  which would represent a year over year decline of 4 79   Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  34 59 billion  up 2 36  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  5 93 per share and revenue of  139 86 billion  These totals would mark changes of  1  and  2 19   respectively  from last year 
Any recent changes to analyst estimates for WBA should also be noted by investors  Recent revisions tend to reflect the latest near term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  The Zacks Consensus EPS estimate has moved 0 1  lower within the past month  WBA currently has a Zacks Rank of  4  Sell  
Looking at its valuation  WBA is holding a Forward P E ratio of 10 04  For comparison  its industry has an average Forward P E of 10 72  which means WBA is trading at a discount to the group 
We can also see that WBA currently has a PEG ratio of 1 49  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  Retail   Pharmacies and Drug Stores stocks are  on average  holding a PEG ratio of 1 49 based on yesterday s closing prices 
The Retail   Pharmacies and Drug Stores industry is part of the Retail Wholesale sector  This group has a Zacks Industry Rank of 165  putting it in the bottom 36  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-12-02,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-alliance-wba-stock-moves-055-what-you-should-know-200489420,200489420
178720,400236,WBA,Walgreens Boots Falls 4 ,news,"Investing com   Walgreens Boots  NASDAQ WBA  fell by 4 02  to trade at  58 74 by 10 14  15 14 GMT  on Wednesday on the NASDAQ exchange 
The volume of Walgreens Boots shares traded since the start of the session was 3 54M  Walgreens Boots has traded in a range of  58 72 to  61 56 on the day 
The stock has traded at  64 4600 at its highest and  53 9900 at its lowest during the past seven days ",2019-11-06,Investing.com,https://www.investing.com/news/stock-market-news/walgreens-boots-falls-4-2013510,2013510
178721,400237,WBA,Walgreens Boots Rises 4 ,news,"Investing com   Walgreens Boots  NASDAQ WBA  rose by 4 25  to trade at  61 75 by 09 32  14 32 GMT  on Monday on the NASDAQ exchange 
The volume of Walgreens Boots shares traded since the start of the session was 2 71M  Walgreens Boots has traded in a range of  61 22 to  62 66 on the day 
The stock has traded at  64 5000 at its highest and  55 0100 at its lowest during the past seven days ",2019-11-11,Investing.com,https://www.investing.com/news/stock-market-news/walgreens-boots-rises-4-2017844,2017844
178722,400238,WBA,Walgreens Boots Alliance Jumps on KKR Buyout Offer,news,"Investing com   Shares of Walgreens Boots Alliance  NASDAQ WBA  surged in midday trade on Monday after confirmation that KKR has approached the company about a potential takeover bid  
Private equity firm KKR made a formal offer to take the company private in a deal that could be worth up to  70 billion  Bloomberg reported 
Walgreens has been debating about going private in one of the biggest buyouts in history  according to various reports  
Shares of Walgreens jumped 6 4  on the news ",2019-11-11,Investing.com,https://www.investing.com/news/stock-market-news/walgreens-boots-alliance-jumps-on-kkr-buyout-offer-2017943,2017943
178742,400258,WBA,Walgreens Boots Alliance  WBA  Tops Q4 Earnings And Revenue Estimates,opinion,"Walgreens Boots Alliance  NASDAQ WBA  came out with quarterly earnings of  1 43 per share  beating the Zacks Consensus Estimate of  1 41 per share  This compares to earnings of  1 48 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 1 42   A quarter ago  it was expected that this largest U S  drugstore chain would post earnings of  1 42 per share when it actually produced earnings of  1 47  delivering a surprise of 3 52  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
Walgreens  which belongs to the Zacks Retail   Pharmacies and Drug Stores industry  posted revenues of  33 95 billion for the quarter ended August 2019  surpassing the Zacks Consensus Estimate by 0 28   This compares to year ago revenues of  33 44 billion  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Walgreens shares have lost about 18 9  since the beginning of the year versus the S P 500 s gain of 20 6  
What s Next for Walgreens 
While Walgreens has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Walgreens was unfavorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  4  Sell  for the stock  So  the shares are expected to underperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 39 on  34 47 billion in revenues for the coming quarter and  5 92 on  139 66 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Retail   Pharmacies and Drug Stores is currently in the top 41  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-10-28,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-alliance-wba-tops-q4-earnings-and-revenue-estimates-200478926,200478926
178743,400259,WBA,Walgreens  WBA  Buyout Gets Closer,opinion,Monday  November 11  2019 There will be no economic data released by the U S  government today  in honor of this nation s Veterans Day  This is what s referred to as a  bank holiday   though the stock markets will keep regular trading hours today  There will also be earnings releases both ahead of the open and after the close  though Q3 earnings season has seen most of its  marquee  names already having reported  This will be a week of extensive speeches by members of the Federal Open Market Committee  FOMC   which just a couple weeks ago lowered interest rates to 1 75    the first time we ve been sub 2  since June 2018  a year and a half ago  This morning  we anticipate an address from Boston Fed President Eric Rosengren  followed by Fed VP Richard Clarida  Philadelphia s Patrick Harker and Neel Kashkari from Minneapolis tomorrow  Fed Chair Jerome Powell will add his testimony on Wednesday  and Chicago Fed President Charles Evans  St  Louis  James Bullard and New York s John Williams  NYSE WMB  will speak Thursday  The next meeting for the FOMC will address a summary of economic projections for calendar year 2020  and is scheduled for December 10 11  Walgreens Going Private  Getting Closer Elsewhere  private equity giant KKR   Co    NYSE KKR   has announced it has made a formal leveraged buyout  LBO  bid to take Walgreens Boots Alliance   NASDAQ WBA   off the NYSE and into private ownership  This  53 billion market cap Consumer Staples retailer would be the largest such LBO in history  Details were not immediately forthcoming  but shares of WBA are up 7  on the news  Futures are in the red this morning  following record closings for the major indexes on Friday afternoon  We are looking at five straight weeks of growth on the S P 500  However  the S P is down 13 points a half hour ahead of the opening bell  the Nasdaq is down 38 and the Dow  125 points  We expect lower than normal volume as many observe the holiday to honor our veterans  Mark VickerySenior Editor  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-11-10,Zacks Investment Research,https://www.investing.com/analysis/walgreens-wba-buyout-gets-closer-200484353,200484353
178744,400260,WBA,Walgreens Is Heading Toward Private ,opinion,There will be no economic data released by the U S  government today  in honor of this nation s Veterans Day  This is what s referred to as a  bank holiday   though the stock markets will keep regular trading hours today  There will also be earnings releases both ahead of the open and after the close  though Q3 earnings season has seen most of its  marquee  names already having reported This will be a week of extensive speeches by members of the Federal Open Market Committee  FOMC   which just a couple weeks ago lowered interest rates to 1 75    the first time we ve been sub 2  since June 2018  a year and a half ago  This morning  we anticipate an address from Boston Fed President Eric Rosengren  followed by Fed VP Richard Clarida  Philadelphia s Patrick Harker and Neel Kashkari from Minneapolis tomorrow Fed Chair Jerome Powell will add his testimony on Wednesday  and Chicago Fed President Charles Evans  St  Louis  James Bullard and New York s John Williams  NYSE WMB  will speak Thursday  The next meeting for the FOMC will address a summary of economic projections for calendar year 2020  and is scheduled for December 10 11 Walgreens Going Private  Getting CloserElsewhere  private equity giant KKR   Co    NYSE KKR   has announced it has made a formal leveraged buyout  LBO  bid to take Walgreens Boots Alliance   NASDAQ WBA   off the NYSE and into private ownership  This  53 billion market cap Consumer Staples retailer would be the largest such LBO in history  Details were not immediately forthcoming  but shares of WBA are up 7  on the news Futures are in the red this morning  following record closings for the major indexes on Friday afternoon  We are looking at five straight weeks of growth on the S P 500  However  the S P is down 13 points a half hour ahead of the opening bell  the Nasdaq is down 38 and the Dow  125 points  We expect lower than normal volume as many observe the holiday to honor our veterans ,2019-11-10,Zacks Investment Research,https://www.investing.com/analysis/walgreens-is-heading-toward-private-200484345,200484345
178748,400264,WBA,Walgreens Boots Rises 6 ,news,"Investing com   Walgreens Boots  NASDAQ WBA  rose by 6 40  to trade at  63 48 by 13 32  18 32 GMT  on Tuesday on the NASDAQ exchange 
The volume of Walgreens Boots shares traded since the start of the session was 5 11M  Walgreens Boots has traded in a range of  59 14 to  63 48 on the day 
The stock has traded at  63 4800 at its highest and  53 9900 at its lowest during the past seven days ",2019-11-05,Investing.com,https://www.investing.com/news/stock-market-news/walgreens-boots-rises-6-2012567,2012567
178766,400282,WBA,Walgreens Boots Alliance  WBA  Stock Moves  0 91   What You Should Know,opinion,"Walgreens Boots Alliance  NASDAQ WBA  closed the most recent trading day at  52 28  moving  0 91  from the previous trading session  This move was narrower than the S P 500 s daily loss of 1 56   Meanwhile  the Dow lost 1 19   and the Nasdaq  a tech heavy index  lost 1 67  
Prior to today s trading  shares of the largest U S  drugstore chain had lost 5 09  over the past month  This has lagged the Retail Wholesale sector s loss of 3 42  and the S P 500 s loss of 1 22  in that time 
WBA will be looking to display strength as it nears its next earnings release  which is expected to be October 28  2019  On that day  WBA is projected to report earnings of  1 41 per share  which would represent a year over year decline of 4 73   Our most recent consensus estimate is calling for quarterly revenue of  33 90 billion  up 1 38  from the year ago period 
Investors should also note any recent changes to analyst estimates for WBA  These revisions help to show the ever changing nature of near term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 1 08  lower  WBA is holding a Zacks Rank of  4  Sell  right now 
Digging into valuation  WBA currently has a Forward P E ratio of 8 9  Its industry sports an average Forward P E of 8 9  so we one might conclude that WBA is trading at a no noticeable deviation comparatively 
Investors should also note that WBA has a PEG ratio of 1 34 right now  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  WBA s industry had an average PEG ratio of 1 34 as of yesterday s close 
The Retail   Pharmacies and Drug Stores industry is part of the Retail Wholesale sector  This group has a Zacks Industry Rank of 177  putting it in the bottom 31  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
You can find more information on all of these metrics  and much more  on Zacks com ",2019-10-08,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-alliance-wba-stock-moves-091-what-you-should-know-200471636,200471636
178767,400283,WBA,Rite Aid  RAD  Up 8 9  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Rite Aid  RAD   Shares have added about 8 9  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Rite Aid due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  Rite Aid Beats Q2 Earnings Estimates  Updates ViewRite Aid reported second quarter fiscal 2020 results  wherein adjusted earnings from continuing operations of 12 cents per share outshined the Zacks Consensus Estimate of 8 cents  Moreover  the bottom line compared favorably with the year ago quarter s adjusted loss of 15 cents per share Notably  the bottom line benefited from lower impairment charges in the reported quarter  somewhat offset by a decrease in adjusted EBITDA  Moreover  operating efficiency in the Retail Pharmacy Segment along with higher Medicare Part D revenues and prescription count sales growth remains impressive  Management is also optimistic about the company  courtesy of EnvisionRxOptions PBM as well as health and wellness offerings Q2 in DetailRevenues dipped nearly 1  to  5 366 3 million and also lagged the Zacks Consensus Estimate of  5 415 million  During the second quarter  the Retail Pharmacy segment revenues slipped 1 6  owing to lower store count  somewhat offset by higher same store sales  At the Pharmacy Services segment  revenues edged up 1 1  owing to higher Medicare Part D revenues Retail Pharmacy same store sales inched up 0 4  owing to a 1 5  rise in pharmacy sales  partly offset by a 1 8  decline in front end sales  Excluding cigarettes and tobacco products  front end same store sales fell 0 6   Pharmacy sales included an adverse impact of nearly 276 basis points  bps  from the introduction of new generic drugs  Further  prescription count at same store sales rose 2 7   Prescription sales constituted 67 2  of total drugstore sales  Notably  the company delivered the fifth straight quarter of same store pharmacy sales and prescription count improvement Rite Aid s adjusted EBITDA fell 9 7  year over year to  134 2 million  with adjusted EBITDA margin contracting 20 bps to 2 5   This downturn was due to a lower adjusted EBITDA at the Retail Pharmacy and Pharmacy Services segments Moreover  the Retail Pharmacy s adjusted EBITDA was hurt due to weaker front end gross profit on account of lower front end same store sales and decrease in the Transition Services Agreement   TSA   fee income from Walgreens Boots Alliance  NASDAQ WBA   The Pharmacy Services segment was hurt by to higher cost of investments toward growth  partly compensated with improvements in pharmacy network performance Store UpdateRite Aid remodeled 24 stores while relocated one outlet in the fiscal second quarter  bringing the company s total wellness store count to 1 805  Moreover  it shuttered two stores  taking the total store count to 2 464 as of Aug 31  2019 Financial StatusRite Aid ended the quarter with cash and cash equivalents of approximately  142 2 million  long term debt  net of current maturities  of  3 834 6 million and total shareholders  equity of  960 6 million Further  the company used cash from operating activities of  278 8 million in the fiscal second quarter OutlookRite Aid updated its outlook for fiscal 2020  This view includes the assumption of higher prescription count coupled with improvements in drug costs and SG A expenses  Also  management expects to witness strength in pharmacy network performance in the Pharmacy Services division  However  it expects to witness a decrease in prescription reimbursement rates It continues to project sales of  21 5  21 9 billion for fiscal 2020  The company projects same store sales growth of 0 1  over fiscal 2019  Moreover  Rite Aid now anticipates adjusted EBITDA to be between  510 million and  550 million compared with the earlier projection of  500  560 million for fiscal 2020 Further  it now estimates a net loss of  235  275 million  wider than the prior expectation of  170  220 million  The company now envisions adjusted earnings in the range of flat to 56 cents per share  Earlier  it projected the bottom line between adjusted loss of 14 cents and earnings of 72 cents per share  Meanwhile  capital expenditures are likely to be roughly  250 million 
How Have Estimates Been Moving Since Then 
Fresh estimates followed a downward path over the past two months  The consensus estimate has shifted  72 22  due to these changes 
VGM Scores
Currently  Rite Aid has a subpar Growth Score of D  however its Momentum Score is doing a lot better with a B  However  the stock was allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Rite Aid has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-10-25,Zacks Investment Research,https://www.investing.com/analysis/rite-aid-rad-up-89-since-last-earnings-report-can-it-continue-200478732,200478732
178785,400301,WBA,Rite Aid  RAD  Beats Q2 Earnings Estimates  Updates View,opinion,Rite Aid Corporation   NYSE RAD   reported second quarter fiscal 2020 results  wherein adjusted earnings from continuing operations of 12 cents per share outshined the Zacks Consensus Estimate of 8 cents  Moreover  the bottom line compared favorably with the year ago quarter s adjusted loss of 15 cents per share Notably  the bottom line benefited from lower impairment charges in the reported quarter  somewhat offset by a decrease in adjusted EBITDA  Moreover  operating efficiency in the Retail Pharmacy Segment along with higher Medicare Part D revenues and prescription count sales growth remains impressive  Management is also optimistic about the company  courtesy of EnvisionRxOptions PBM as well as health and wellness offerings Backed by these positives  shares of this Zacks Rank  3  Hold  gained 1 8  yesterday  You can see  Rite Aid Corporation Price  Consensus and EPS Surprise    Q2 in DetailRevenues dipped nearly 1  to  5 366 3 million and also lagged the Zacks Consensus Estimate of  5 415 million  During the second quarter  the Retail Pharmacy segment revenues slipped 1 6  owing to lower store count  somewhat offset by higher same store sales  At the Pharmacy Services segment  revenues edged up 1 1  owing to higher Medicare Part D revenues Retail Pharmacy same store sales inched up 0 4  owing to a 1 5  rise in pharmacy sales  partly offset by a 1 8  decline in front end sales  Excluding cigarettes and tobacco products  front end same store sales fell 0 6   Pharmacy sales included an adverse impact of nearly 276 basis points  bps  from the introduction of new generic drugs  Further  prescription count at same store sales rose 2 7   Prescription sales constituted 67 2  of total drugstore sales  Notably  the company delivered the fifth straight quarter of same store pharmacy sales and prescription count improvement Rite Aid s adjusted EBITDA fell 9 7  year over year to  134 2 million  with adjusted EBITDA margin contracting 20 bps to 2 5   This downturn was due to lower adjusted EBITDA at the Retail Pharmacy and Pharmacy Services segments Moreover  the Retail Pharmacy s adjusted EBITDA was hurt due to weaker front end gross profit on account of lower front end same store sales and decrease in the Transition Services Agreement   TSA   fee income from Walgreens Boots Alliance   NASDAQ WBA    The Pharmacy Services segment was hurt by to higher cost of investments toward growth  partly compensated with improvements in pharmacy network performance Store UpdateRite Aid remodeled 24 stores while relocated one outlet in the fiscal second quarter  bringing the company s total wellness store count to 1 805  Moreover  it shuttered two stores  taking the total store count to 2 464 as of Aug 31  2019 Financial StatusRite Aid ended the quarter with cash and cash equivalents of approximately  142 2 million  long term debt  net of current maturities  of  3 834 6 million and total shareholders  equity of  960 6 million Further  the company used cash from operating activities of  278 8 million in the fiscal second quarter OutlookRite Aid  which shares space with Herbalife Nutrition Ltd    NYSE HLF   and CVS Health Corporation   NYSE CVS    updated its outlook for fiscal 2020  This view includes the assumption of higher prescription count coupled with improvements in drug costs and SG A expenses  Also  management expects to witness strength in pharmacy network performance in the Pharmacy Services division  However  it expects to witness decrease in prescription reimbursement rates It continues to project sales of  21 5  21 9 billion for fiscal 2020  The company projects same store sales growth of 0 1  over fiscal 2019  Moreover  Rite Aid now anticipates adjusted EBITDA to be between  510 million and  550 million compared with the earlier projection of  500  560 million for fiscal 2020 Further  it now estimates a net loss of  235  275 million  wider than the prior expectation of  170  220 million  The company now envisions adjusted earnings in the range of flat to 56 cents per share  Earlier  it projected bottom line between adjusted loss of 14 cents and earnings of 72 cents per share  Meanwhile  capital expenditures are likely to be roughly  250 million Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-09-26,Zacks Investment Research,https://www.investing.com/analysis/rite-aid-rad-beats-q2-earnings-estimates-updates-view-200468811,200468811
178786,400302,WBA,Walgreens  WBA  Becomes Latest Retailer To Suspend Zantac Sales ,opinion,"Walgreens   NASDAQ WBA   announced today that they would be suspending the sales of Sanofi s   NASDAQ SNY   heartburn medication Zantac  Zantac  which is sold generically under the name ranitidine  is currently under investigation by the US Food and Drug Administration after they found that it contained a carcinogen known as NDMA which can lead to cancer  The FDA started an investigation after Valisure  an online pharmacy company  alerted the FDA earlier this month that Zantac includes an impurity that could cause cancer  Walgreens  decision to suspend the drug while the FDA continues its investigation comes after CVS   NYSE CVS   announced on Saturday that they were discontinuing their sales of Zantac 
CVS stated that they were taking action out of an  abundance of caution  and that there is no current recall of the product  but customers who purchased these products can bring them into their stores for a refund  Ranitidine  which was originally thought of as an ulcer drug  is approved for treatment and prevention of stomach and intestine ulcers and heartburn  Ranitidine is considered an H2 blocker  which reduces stomach acid by blocking acids that produce it  CVS announced that it would continue to sell its other over the counter H2 blocker products such as Pepcid and Tagamet 
Sanofi  PA SASY  has said that Zantac has been around for over a decade and meets all the specified safety requirements for use  The large cap pharmaceutical company also went on to comment that they  are working closely with the FDA and are conducting their own robust investigations to ensure they continue to meet the highest quality standards  
The FDA has said that NDMA can cause harm in large doses  but their preliminary tests have found that NDMA levels in Zantac barely exceed what might be found in common foods  NDMA is part of a class of compounds called nitrosamines that are found in water and foods like dairy  meats  and vegetables  The federal administration is investigating whether exposure to small amounts of the carcinogen can potentially pose serious health risks to patients and that it would reveal their conclusions publicly as soon as possible 
Moving Forward
Many generic drugs for high blood pressure have already been found to contain low levels of NDMA and other related carcinogenic chemicals  The FDA has grappled with the NDMA issue for more than a year  and Zantac is the latest drug that they have brought into question 
The administration acknowledged that more than 2 million people have been exposed to the carcinogen through high blood pressure drugs  Generic drugs have been in the hot seat over the past year as a series of recalls have been issued for hypertension drugs  which has raised questions about the safety of generic drugs 
On Monday  Sanofi shares closed up 0 15   Walgreens shares ended the day in the green by 1 65   and CVS closed up 1 59   The FDA s probe into Sanofi s heartburn relief drug spells potential bad news for the pharmaceutical company if they find evidence that small doses of NDMA can cause harm to consumers  Sanofi shareholders should monitor the progression of the probe and if other drug retailers choose to follow in CVS and Walgreens  footsteps 
Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-09-30,Zacks Investment Research,https://www.investing.com/analysis/walgreens-wba-becomes-latest-retailer-to-suspend-zantac-sales-200469339,200469339
178787,400303,WBA,Walgreens Boots Alliance  WBA  Stock Moves  1 1   What You Should Know,opinion,"Walgreens Boots Alliance  NASDAQ WBA  closed at  54 70 in the latest trading session  marking a  1 1  move from the prior day  This move was narrower than the S P 500 s daily loss of 1 23   Meanwhile  the Dow lost 1 28   and the Nasdaq  a tech heavy index  lost 1 13  
Heading into today  shares of the largest U S  drugstore chain had gained 8 05  over the past month  outpacing the Retail Wholesale sector s loss of 0 49  and the S P 500 s gain of 1 95  in that time 
Wall Street will be looking for positivity from WBA as it approaches its next earnings report date  This is expected to be October 28  2019  The company is expected to report EPS of  1 42  down 4 05  from the prior year quarter  Our most recent consensus estimate is calling for quarterly revenue of  33 83 billion  up 1 16  from the year ago period 
Investors should also note any recent changes to analyst estimates for WBA  These revisions help to show the ever changing nature of near term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection remained stagnant  WBA currently has a Zacks Rank of  2  Buy  
Valuation is also important  so investors should note that WBA has a Forward P E ratio of 9 23 right now  Its industry sports an average Forward P E of 9 23  so we one might conclude that WBA is trading at a no noticeable deviation comparatively 
We can also see that WBA currently has a PEG ratio of 1 38  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  WBA s industry had an average PEG ratio of 1 38 as of yesterday s close 
The Retail   Pharmacies and Drug Stores industry is part of the Retail Wholesale sector  This industry currently has a Zacks Industry Rank of 77  which puts it in the top 31  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow WBA in the coming trading sessions  be sure to utilize Zacks com ",2019-10-01,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-alliance-wba-stock-moves-11-what-you-should-know-200469698,200469698
178792,400308,WBA,Walgreens Boots Rises 4 ,news,"Investing com   Walgreens Boots  NASDAQ WBA  rose by 4 03  to trade at  57 00 by 12 42  16 42 GMT  on Friday on the NASDAQ exchange 
The volume of Walgreens Boots shares traded since the start of the session was 3 44M  Walgreens Boots has traded in a range of  55 13 to  57 00 on the day 
The stock has traded at  57 0000 at its highest and  53 8300 at its lowest during the past seven days ",2019-11-01,Investing.com,https://www.investing.com/news/stock-market-news/walgreens-boots-rises-4-2010166,2010166
178793,400309,WBA,Walgreens Boots Rises 4 ,news,"Investing com   Walgreens Boots  NASDAQ WBA  rose by 4 18  to trade at  59 77 by 11 08  16 08 GMT  on Monday on the NASDAQ exchange 
The volume of Walgreens Boots shares traded since the start of the session was 3 55M  Walgreens Boots has traded in a range of  57 92 to  59 77 on the day 
The stock has traded at  59 7700 at its highest and  53 9900 at its lowest during the past seven days ",2019-11-04,Investing.com,https://www.investing.com/news/stock-market-news/walgreens-boots-rises-4-2011383,2011383
178802,400318,WBA,Why Is Walgreens  WBA  Up 1  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Walgreens Boots Alliance  NASDAQ WBA   Shares have added about 1  in that time frame  underperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Walgreens due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Walgreens Boots Tops Q3 Earnings  Revenues  Margins DeclineWalgreens Boots reported adjusted earnings per share  EPS  of  1 47 for third quarter fiscal 2019  down 3 9  year over year  down 2 4  at constant exchange rate or CER   However  the figure exceeded the Zacks Consensus Estimate by 3 5  On a reported basis  net earnings came in at  1 billion  reflecting a 23 6  decline from the prior year quarter  Reported EPS came in at  1 13  down 16 2  on a year over year basis Sluggishness in Retail Pharmacy International and margin contractions put pressure on the bottom line during the quarter Total SalesWalgreens Boots recorded total sales of  34 59 billion in the fiscal third quarter  up 0 7  year over year and 2 9  at constant exchange rate or CER  The top line edged pastthe Zacks Consensus Estimate of  34 53 billion  Year over year growth was led by improvements within the Retail Pharmacy USA and Pharmaceutical Wholesale divisions  partially offset by a dull performance within Retail Pharmacy International Segments in DetailWalgreens Boots reports through three segments  Retail Pharmacy USA  Retail Pharmacy International and Pharmaceutical Wholesale Retail Pharmacy USAThe segment s sales came in at  26 5 billion in the third quarter  highlighting an improvement of 2 3  year over year  Excluding the impact of store optimization following the acquisition of Rite Aid stores  organic sales growth was 2 9  year over year Pharmacy sales  accounting for 73 9  of the Retail Pharmacy USA division s sales in the quarter  increased 4 3  from the year ago quarter on higher brand inflation  prescription volume and growth in central specialty  Pharmacy sales at comparable stores improved 6  while prescriptions filled in comparable stores rose 4 7  year over year in the quarter  The impact of store optimization following the acquisition of Rite Aid stores caused a 2 9  dip in retail sales  Comparable retail sales slid 1 1  year over year Retail Pharmacy InternationalRevenues at the Retail Pharmacy International division decreased 7 3  on a year over year basis to  2 8 billion in the fiscal third quarter  Sales were down 1 6  at CER considering a 1  slip in Boots UK In the United Kingdom  comparable pharmacy sales inched up 0 8  and comparable retail sales declined 2 6  in the reported quarter Pharmaceutical WholesaleThe Pharmaceutical Wholesale division s quarterly sales were  5 9 billion  down 1 7  year over year  up 8 3  at CER  banking on growth in the emerging markets  MarginsGross profit in the reported quarter fell 4 2  year over year to  7 45 billion  However  gross margin contracted 111 basis points  bps  to 21 5  Selling  general and administrative  SG A  expenses remained relatively flat year over year at  6 24 billion  Adjusted operating income deteriorated 21 2  to  1 21 billion  Overall  operating margin shrank 98 bps to 3 5  Financial ConditionWalgreens Boots exited the fiscal third quarter with cash and cash equivalents of  839 million compared with  818 million at the end of second quarter fiscal 2019  Long term debt was  12 13 billion compared with  12 69 billion at the end of the fiscal second quarter  Year to date  the company generated operating cash flow of  3 22 billion compared with  5 45 billion in the year ago period Guidance IntactWalgreens Boots maintained its earlier provided adjusted EPS guidance for fiscal 2019  flat with the year ago period s figure at CER The Zacks Consensus Estimate for this metric is pegged at  5 99 
How Have Estimates Been Moving Since Then 
Estimates revision followed a downward path over the past two months 
VGM Scores
At this time  Walgreens has a nice Growth Score of B  though it is lagging a lot on the Momentum Score front with an F  However  the stock was allocated a grade of A on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Walgreens has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-07-26,Zacks Investment Research,https://www.investing.com/analysis/why-is-walgreens-wba-up-1-since-last-earnings-report-200446050,200446050
178803,400319,WBA,Is Walgreens Boots Alliance  WBA  A Great Value Stock Right Now ,opinion,"The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks  Nevertheless  we know that our readers all have their own perspectives  so we are always looking at the latest trends in value  growth  and momentum to find strong picks 
Of these  value investing is easily one of the most popular ways to find great stocks in any market environment  Value investors use tried and true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels 
Luckily  Zacks has developed its own Style Scores system in an effort to find stocks with specific traits  Value investors will be interested in the system s  Value  category  Stocks with both  A  grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now 
Walgreens Boots Alliance  NASDAQ WBA  is a stock many investors are watching right now  WBA is currently sporting a Zacks Rank of  2  Buy   as well as a Value grade of A  The stock holds a P E ratio of 8 31  while its industry has an average P E of 8 36  Over the last 12 months  WBA s Forward P E has been as high as 12 86 and as low as 8 17  with a median of 10 06 
Finally  we should also recognize that WBA has a P CF ratio of 6 70  This metric takes into account a company s operating cash flow and can be used to find stocks that are undervalued based on their solid cash outlook  WBA s P CF compares to its industry s average P CF of 6 78  Within the past 12 months  WBA s P CF has been as high as 12 21 and as low as 6 61  with a median of 8 92 
These are just a handful of the figures considered in Walgreens Boots Alliance s great Value grade  Still  they help show that the stock is likely being undervalued at the moment  Add this to the strength of its earnings outlook  and we can clearly see that WBA is an impressive value stock right now ",2019-09-03,Zacks Investment Research,https://www.investing.com/analysis/is-walgreens-boots-alliance-wba-a-great-value-stock-right-now-200461407,200461407
178804,400320,WBA,Walgreens Stock Can Add Roughly 30 ,opinion,"On December 4th  2018  Walgreens Boots Alliance Inc  NASDAQ WBA  stock was trading north of  86 30 a share  Yesterday  it closed at  51 43 for a total loss of 40 4  in nine months  Nine months in which the general stock market has been rallying 
Walgreens Boots Alliance  NASDAQ WBA  is a pharmacy retailer with over 18 500 stores in 11 countries  Walgreens is considered a    company  because people get sick and need medicine regardless of the economic conditions  Well  losing 40  of the investment in less than a year is not exactly our idea of  defensive  
However  Walgreens  business remains solid and at some point the stock is going to stop falling and head north again  Is WBA ready to start recovering  Let s see if  can help us find out 




The 4 hour chart of Walgreens stock reveals that the decline from over  86 to  49 is   According to the theory  a three wave correction in the other direction follows every impulse 
If this count is correct  WBA stock is already searching for a bottom  We can expect a notable recovery to roughly  65 a share for a total gain of nearly 30   The MACD indicator also supports the positive outlook  It shows a strong bullish  between waves 1  3 and 5 
No trend lasts forever and Walgreens  downtrend is not going to either ",2019-09-05,EWM Interactive,https://www.investing.com/analysis/walgreens-stock-can-add-roughly-30-200461730,200461730
178823,400339,WBA,Tesco CEO Dave Lewis to step down in 2020,news,"By James Davey
LONDON  Reuters     Tesco   L TSCO  boss Dave Lewis will step down next summer after completing the turnaround of Britain s biggest retailer and hand the baton to Ken Murphy  a former executive at Walgreens Boots Alliance  O WBA  
Celebrating its 100th anniversary  Tesco  which has a 27 4  share of Britain s grocery market  is in the final stages of a recovery plan that Lewis instigated after a 2014 accounting scandal capped a dramatic downturn in its fortunes 
 With the turnaround complete and as we begin to implement the next steps of our sustainable growth strategy  now is the right time to plan a smooth and orderly succession   Lewis  who joined Tesco from  Unilever   LON ULVR  in 2014  said on Wednesday 
 As such  I will step down as group CEO next summer and pass the baton to Ken Murphy  
The group has met the majority of its turnaround goals  including a key margin target of earning between 3 5 pence and 4 pence of operating profit for every pound customers spend 
Lewis has overhauled Tesco s relationship with suppliers  lowered prices versus competitors  simplified product ranges and improved store standards since taking charge  Jobs have also been cut  including 4 500 announced in August 
The 54 year old has also pursued growth by buying wholesaler Booker  forming a global purchasing alliance with  Carrefour   PA CARR  and launching a new discount format called Jack s 
The announcement of Lewis s departure came as Tesco reported a better than expected first half operating profit before one of items of 1 41 billion pounds  a rise of 25 4  
The retailer said it had a  strong start  to the year and was well positioned to be highly competitive in a challenging market 
Lewis s successor Murphy was joint chief operating officer at Boots UK   Ireland before rising to executive vice president  chief commercial officer and president global brands at Walgreens Boots Alliance 




He left his executive position at the U S  retailer at the end of 2018 but retained a consultancy role  Tesco said ",2019-10-02,Reuters,https://www.investing.com/news/stock-market-news/tesco-ceo-dave-lewis-to-step-down-in-2020-1990630,1990630
178824,400340,WBA,StockBeat   Tesco Savior Dave Lewis Bows Out   With Perfect Timing,news,"By Geoffrey Smith
Investing com    The man who saved   Tesco    LON TSCO  is leaving 
Dave Lewis said Wednesday he ll step down in summer next year  nearly six years after taking over as chief executive when the U K  s largest food retailer was reeling from a false accounting scandal 
He called the decision  a personal one   in a statement accompanying the supermarket chain s latest earnings which   true to form   revealed a 3 7  increase in currency adjusted profits in the first half of its fiscal year  along with a sharp dividend hike  a doubling of cash flow from retail activities and a further reduction in net debt 
Lewis took over with Tesco s share price languishing at the lowest in decades  its foreign operations a hot mess and its U K  market share under pressure from pushy German discounters and online startups such as Ocado  LON OCDO  
He never quite stopped the bleeding   Tesco s market share of 26 9  in the 12 weeks through Sept  8 is still down a couple of points from when he took over  and there is no sign of Aldi and Lidl going ex growth yet  But there is no exaggeration in his statement Wednesday that    Our turnaround is complete  we have delivered all the metrics we set for ourselves   The leadership team is very strong  our strategy is clear and it is delivering  The  Tesco   LON TSCO  brand is stronger and customer satisfaction is the highest it has been for many years  
While the 31  increase in the share price during his reign may not seem extreme  the wonder is that it happened it all  given the competitive environment and the relentless squeeze on U K  consumer finances from Brexit  which has caused the U K  to go from the top of the G7 growth league in 2015 to the bottom in 2018   No wonder that chairman John Allen said in the same statement that he accepted the resignation  with regret  
Another aspect of the departure is the relatively smooth succession planning  Lewis is staying around until summer 2020  giving his designated successor Ken Murphy  a veteran of Walgreens Boots Alliance  NASDAQ WBA   plenty of time to acclimatize 
That  along with the results and the dividend hike  helps to explain the stock s 1 8  rise on a day when the FTSE 100 is down 1 5  and the rest of Europe is also in the red  The Stoxx 600 was down 1 2  and the German DAX down 1 1  by 5 AM ET  0900 GMT  
It also means that Lewis will still be at the helm over what is set to be a tumultuous few months for  Tesco   LON TSCO   given the risk of a disorderly  No Deal Brexit  at the end of the month or  perhaps  a couple of months later after a General Election   The erection of new border checks at U K  ports is set to cause acute disruption to supplies of fresh food in particular  according to the British Retail Consortium  which said last month that government claims to the contrary are  categorically untrue  
 Retailers will be preparing for Christmas  stretching already limited warehousing capacity  and the U K  will be importing the majority of its fresh food from the EU  magnifying the impact of border delays   the BRC said at the time  The Food and Drink Federation also predicts  significant and adverse changes to product availability  and random shortages  after a No Deal Brexit 
 I will give the job everything I have until my very last day   Lewis said  and  Tesco   LON TSCO  shareholders can be thankful for that  For Lewis  there s the consolation that  whatever chaos Brexit brings  it will all be someone else s problem before too long ",2019-10-02,Investing.com,https://www.investing.com/news/stock-market-news/stockbeat--tesco-savior-dave-lewis-bows-out--with-perfect-timing-1990693,1990693
178825,400341,WBA,In turbulent times  Tesco s new boss has something to build on,news,"By James Davey
LONDON  Reuters    When the little known Ken Murphy takes over next year as CEO of  Tesco   L TSCO   Britain s biggest retailer  he will inherit something current boss Dave Lewis did not have the luxury of when he joined in 2014   a strategy and a stable business 
But the 52 year old veteran of healthcare retailing will still have to work hard for his  1 7 million a year salary  with Britain facing a potentially disruptive exit from the European Union and German discounters Aldi and Lidl grabbing market share from the country s top supermarket chains 
When former  Unilever   LON ULVR  executive Lewis became CEO of Tesco on Sept  1  2014  the supermarket group was already reeling from a dramatic downturn in trading  Three weeks later  an accounting scandal plunged it into the biggest crisis in its history 
Fast forward five years and Lewis  54  has declared Tesco s turnaround complete  He will hand over to Murphy  a former executive at healthcare group Walgreens Boots Alliance  O WBA   next summer 
 I don t think we had a strategy in September 2014   Lewis told reporters when reflecting on his arrival at Tesco 
Jason Tarry  now Tesco s UK and Ireland CEO  said the strategy then was  survival  
Lewis said Murphy  an Irish national  would be in a much better place because he would inherit a  super clear strategy  that he could evolve 
Lewis  strategy has focused on differentiating the Tesco brand from competitors  reducing costs and generating cash  improving profit margins  maximizing value from property and driving innovation 
He has also pursued growth by buying wholesaler Booker  forming a global purchasing alliance with  Carrefour   PA CARR  and launching discount format Jack s 
 The good thing is   all the heavy lifting of the turnaround and getting us back financially secure and stable again has been done and so now it s much more in terms of investment choices that he ll have to make   said Lewis 
CHOICES
Analysts say those choices revolve around taking the fight on prices to Aldi and Lidl who have been gobbling up market share  as well as investment in technology  online grocery capacity  convenience stores  Booker and overseas ventures 
Murphy  a qualified accountant who has studied at Harvard  will also have to decide if excess cash should be returned to shareholders 
Alasdair McKinnon  lead fund manager of Tesco shareholder  the Scottish Investment Trust  said Murphy was  potentially well placed to deliver the next stage of Tesco s transformation  
HSBC analyst Andrew Porteous said Murphy was  a strong choice  whose key challenge was to drive sales growth 
But Murphy s appointment has left others puzzled 
 Walgreens Boots has material strategic challenges in the U S  and the UK  What is it about Ken s track record there that impressed the board   asked Bernstein analyst Bruno Monteyne 
Murphy led the turnaround of drugs wholesale and retail group Alliance UniChem in Italy  then shared the top operations job at health and beauty business Boots UK   Ireland before becoming executive vice president  chief commercial officer and president of global brands at Walgreens Boots Alliance 
His appointment came in a big week for UK grocery sector moves  On Tuesday  John Rogers  the boss of Sainsbury s  L SBRY  Argos business who was seen as the favorite to succeed Mike Coupe as Sainsbury s CEO  quit to become finance chief of advertising group WPP  LON WPP   while Waitrose  JLPLC UL  boss Rob Collins said he would step down next year 
Lewis has no doubt Murphy  who began his retail career helping in his father s shop at the age of 15  will succeed  dismissing his lack of major UK grocery retailing experience as an irrelevance 
 What Ken needs to have and I do know him and I do believe he has it is   have you got a strategic perspective  Do you understand brand  do you understand the customer  Have you got the interpersonal skills to engage with 450 000 people  
His advice to Murphy    use his ears more than his mouth  ",2019-10-03,Reuters,https://www.investing.com/news/stock-market-news/in-turbulent-times-tescos-new-boss-has-something-to-build-on-1991534,1991534
178844,400360,WBA,Analysts Estimate Walgreens Boots Alliance  WBA  To Report A Decline In Earnings  What To Look Out For,opinion,"The market expects Walgreens Boots Alliance  NASDAQ WBA  to deliver a year over year decline in earnings on higher revenues when it reports results for the quarter ended May 2019  This widely known consensus outlook is important in assessing the company s earnings picture  but a powerful factor that might influence its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on June 27  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This largest U S  drugstore chain is expected to post quarterly earnings of  1 43 per share in its upcoming report  which represents a year over year change of  6 5  
Revenues are expected to be  34 53 billion  up 0 6  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Walgreens 
For Walgreens  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  1 40  
On the other hand  the stock currently carries a Zacks Rank of  4 
So  this combination makes it difficult to conclusively predict that Walgreens will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Walgreens would post earnings of  1 70 per share when it actually produced earnings of  1 64  delivering a surprise of  3 53  
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Walgreens doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-06-19,Zacks Investment Research,https://www.investing.com/analysis/analysts-estimate-walgreens-boots-alliance-wba-to-report-a-decline-in-earnings-what-to-look-out-for-200433312,200433312
178845,400361,WBA,Walgreens Boots Alliance  WBA  Q3 Earnings And Revenues Surpass Estimates,opinion,"Walgreens Boots Alliance  NASDAQ WBA  came out with quarterly earnings of  1 47 per share  beating the Zacks Consensus Estimate of  1 42 per share  This compares to earnings of  1 53 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 3 52   A quarter ago  it was expected that this largest U S  drugstore chain would post earnings of  1 70 per share when it actually produced earnings of  1 64  delivering a surprise of  3 53  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
Walgreens  which belongs to the Zacks Retail   Pharmacies and Drug Stores industry  posted revenues of  34 59 billion for the quarter ended May 2019  surpassing the Zacks Consensus Estimate by 0 16   This compares to year ago revenues of  34 33 billion  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Walgreens shares have lost about 23 3  since the beginning of the year versus the S P 500 s gain of 16 2  
What s Next for Walgreens 
While Walgreens has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Walgreens was unfavorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  4  Sell  for the stock  So  the shares are expected to underperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 46 on  33 81 billion in revenues for the coming quarter and  5 99 on  136 74 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Retail   Pharmacies and Drug Stores is currently in the bottom 7  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-06-27,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-alliance-wba-q3-earnings-and-revenues-surpass-estimates-200435221,200435221
178846,400362,WBA,Walgreens Boots Falls 4 ,news,"Investing com   Walgreens Boots  NASDAQ WBA  fell by 4 17  to trade at  55 64 by 10 34  14 34 GMT  on Thursday on the NASDAQ exchange 
The volume of Walgreens Boots shares traded since the start of the session was 1 84M  Walgreens Boots has traded in a range of  55 56 to  58 00 on the day 
The stock has traded at  58 1000 at its highest and  50 7300 at its lowest during the past seven days ",2019-09-12,Investing.com,https://www.investing.com/news/stock-market-news/walgreens-boots-falls-4-1976679,1976679
178847,400363,WBA,U S  consumer watchdog hires new enforcement chief  fills other vacancies,news,"By Katanga Johnson
WASHINGTON  Reuters    The U S  Consumer Financial Protection Bureau on Wednesday announced new hires at the agency  including a former state regulator to serve as new permanent chief of its enforcement office 
Bryan Schneider  former head of the Illinois Department of Financial and Professional Regulation  will serve as the associate director of the agency s Division of Supervision  Enforcement and Fair Lending 
According to his LinkedIn  NYSE LNKD  profile  Schneider has also previously been employed at pharmaceutical giant  the Walgreens Boots Alliance  NASDAQ WBA  Inc  for nearly 15 years in various roles  including as vice president 
The consumer watchdog began looking to fill vacant roles in August  after a two year hiring freeze and budget cuts by the administration of U S  President Donald Trump left the agency with several openings in senior positions 
Created in the wake of the 2008 financial crisis to crack down on predatory lenders  the CFPB is charged with protecting consumers and policing financial products 
Current CFPB Director Kathy Kraninger succeeded interim director and current White House chief of staff  Mick Mulvaney  who instituted the freeze and budget reductions  Kraninger was sworn in in December 
Republicans  who long argued the agency was too powerful  set about overhauling it after gaining control in November 2017  including rolling back rules and reducing enforcement actions 
Democratic lawmakers have accused the administration of bowing to industry lobbyists and warned efforts to shrink the agency could lead to a lack of industry oversight 
Overall  CFPB enforcement actions have fallen by around half under the Trump administration  a Reuters analysis found last month 
On Wednesday  other key roles  including the assistant director of research  the chief data officer and a deputy chief of staff were also named ",2019-09-25,Reuters,https://www.investing.com/news/economy/us-consumer-watchdog-hires-new-enforcement-chief-fills-other-vacancies-1986153,1986153
178866,400382,WBA,Walgreens Boots Rises 4 ,news,"Investing com   Walgreens Boots  NASDAQ WBA  rose by 4 07  to trade at  54 69 by 10 58  14 58 GMT  on Monday on the NASDAQ exchange 
The volume of Walgreens Boots shares traded since the start of the session was 1 51M  Walgreens Boots has traded in a range of  52 65 to  54 74 on the day 
The stock has traded at  54 7300 at its highest and  50 0400 at its lowest during the past seven days ",2019-09-09,Investing.com,https://www.investing.com/news/stock-market-news/walgreens-boots-rises-4-1973538,1973538
178883,400399,WBA,Walgreens Boots Alliance  WBA  Gains As Market Dips  What You Should Know,opinion,"Walgreens Boots Alliance  NASDAQ WBA  closed the most recent trading day at  53 56  moving  0 11  from the previous trading session  This change outpaced the S P 500 s 0 3  loss on the day  Meanwhile  the Dow lost 0 54   and the Nasdaq  a tech heavy index  lost 0 41  
Coming into today  shares of the largest U S  drugstore chain had lost 1 85  in the past month  In that same time  the Retail Wholesale sector lost 0 26   while the S P 500 lost 0 43  
Investors will be hoping for strength from WBA as it approaches its next earnings release  The company is expected to report EPS of  1 43  down 6 54  from the prior year quarter  Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  34 54 billion  up 0 61  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  5 99 per share and revenue of  136 77 billion  These totals would mark changes of  0 5  and  3 98   respectively  from last year 
Investors should also note any recent changes to analyst estimates for WBA  Recent revisions tend to reflect the latest near term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Our research shows that these estimate changes are directly correlated with near term stock prices  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  The Zacks Consensus EPS estimate remained stagnant within the past month  WBA is currently a Zacks Rank  4  Sell  
Investors should also note WBA s current valuation metrics  including its Forward P E ratio of 8 93  Its industry sports an average Forward P E of 11 97  so we one might conclude that WBA is trading at a discount comparatively 
Meanwhile  WBA s PEG ratio is currently 1 09  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  The Retail   Pharmacies and Drug Stores was holding an average PEG ratio of 1 09 at yesterday s closing price 
The Retail   Pharmacies and Drug Stores industry is part of the Retail Wholesale sector  This industry currently has a Zacks Industry Rank of 231  which puts it in the bottom 10  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
You can find more information on all of these metrics  and much more  on Zacks com ",2019-05-09,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-alliance-wba-gains-as-market-dips-what-you-should-know-200419835,200419835
178884,400400,WBA,Rite Aid  RAD  Down 22 3  Since Last Earnings Report  Can It Rebound ,opinion,"A month has gone by since the last earnings report for Rite Aid  RAD   Shares have lost about 22 3  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Rite Aid due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Rite Aid Posts Narrower Than Expected Q4 Loss  Revenues LagRite Aid reported narrower than expected loss in fourth quarter fiscal 2019  The company s sales also lagged Zacks Consensus Estimate and fell year over year Q4 in DetailIn the reported quarter  Rite Aid s adjusted loss from continuing operations was 1 cent per share  Though quarterly loss was in line with the prior year period  it was narrower than the Zacks Consensus Estimate of loss of 3 cents Revenues declined 0 3  to  5 379 6 million and missed the Zacks Consensus Estimate of  5 557 million  At the Retail Pharmacy segment  revenues for the fiscal fourth quarter remained flat year over year  At the Pharmacy Services segment  revenues inched up 1 2   owing to increased Medicare Part D membership Retail Pharmacy same store sales improved 0 7   including 2 1  rise in pharmacy sales and a 1 9  decline in front end sales  Notably  Pharmacy sales included a negative impact of nearly 100 basis points  bps  from the introduction of generic drugs  Further  prescription count at comparable stores advanced 0 8   Prescription sales constituted 65 9  of total drugstore sales Notably  the company delivered the third straight quarter of same store pharmacy sales and prescription growth despite a mild flu season  This was backed by a record number of immunizations as well as other script growth strategies Driven by lower pharmacy gross profit  Rite Aid s adjusted EBITDA fell 13 4  year over year to  134 1 million  In addition  lower front end same store sales coupled with higher distribution costs  partly stemming from the realignment of stores across the company s distribution network  hurt EBITDA  The downside was somewhat offset by reduction in salaries and benefits  lower advertising expenses  and higher Transition Services Agreement   TSA   fee income from Walgreens Boots Alliance  NASDAQ WBA   Meanwhile  adjusted EBITDA margin declined 40 bps to 2 5  Further  adjusted EBITDA at the Retail Pharmacy Segment totaled  96 2 million  depicting a 20 8  decline from the prior year quarter s figure  At the Pharmacy Services segment  the metric amounted to  37 8 million  reflecting rise of almost 13 5  Store UpdateRite Aid remodeled 30 stores in the fiscal fourth quarter  bringing the total wellness store count to 1 765  Further  it shuttered 56 stores during the reported quarter  consequently taking the store count to 2 469 as of Mar 2  2019 Other DevelopmentsRite Aid completed the refinancing of a new senior secured credit agreement  This includes  2 7 billion senior secured asset based revolving credit facility and  450 million  first in  last out  senior secured term loan facility  Furthermore  the company s present  2 7 billion senior secured asset based revolving credit facility was refinanced by the latest  3 15 billion credit facility  This facility was slated to mature in January next year  Impressively  Rite Aid boasts no debt maturing till 2023  It also raised liquidity by  450 million Furthermore  the company will start selling CBD creams  lotions  and lip balms at stores in Oregon and Washington  beginning from this month Financial StatusRite Aid ended the fiscal fourth quarter with cash and cash equivalents of approximately  144 4 million  long term debt  net of current maturities  of  3 454 6 million  and total shareholders  equity of  1 186 7 million Further  the company used cash of  215 9 million from operating activities as of Mar 2  2019 OutlookRite Aid provided guidance for fiscal 2020  Management anticipates lower reimbursement rates  in line with the decline witnessed in fiscal 2019  This view also includes an assumption of a decrease of roughly  40 million in TSA fee income  The company is likely to offset the reduction in fee income by lowering corporate SG A costs  Further  it expects rise of  11 million in rent charges  stemming from the adoption of the new lease accounting standard Depending on conditions in the generic drug space  the company is not able to largely compensate declines with generic drug purchasing savings in comparison to the last fiscal year Consequently  Rite Aid projects revenues of  21 5  21 9 billion for fiscal 2020  with same store sales growth of 0 1  for fiscal 2019 Moreover  the company anticipates adjusted EBITDA to be between  500 million and  560 million  For fiscal 2020  management estimates net loss of  170  220 million  Further  adjusted net  loss  income per share is now envisioned to be between loss of 1 cent and earnings of 4 cents Capital expenditure is anticipated to be roughly  250 million 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates ",2019-05-10,Zacks Investment Research,https://www.investing.com/analysis/rite-aid-rad-down-223-since-last-earnings-report-can-it-rebound-200420432,200420432
178885,400401,WBA,Walgreens to close about 200 stores in United States,news," Reuters    Walgreens Boots Alliance Inc  O WBA  said on Tuesday it plans to close about 200 U S  stores and expects to record related pre tax charges of between  1 9 billion and  2 4 billion 
The Deerfield  Illinois based company in June said it would close about 200 stores in the United Kingdom as performance in its UK Boots business continued to lag in the latest reported quarter 
The store closures are part of the company s cost management program that is aimed at mitigating the pressure related to generic drug prices  the company had said in June 




The program is expected to deliver annual cost savings in excess of  1 5 billion by 2022  the company said in a regulatory filing https    on Tuesday ",2019-08-06,Reuters,https://www.investing.com/news/stock-market-news/walgreens-to-close-about-200-stores-in-united-states-1946915,1946915
178886,400402,WBA,Walgreens Boots Falls 4 ,news,"Investing com   Walgreens Boots  NASDAQ WBA  fell by 4 13  to trade at  50 89 by 12 02  16 02 GMT  on Wednesday on the NASDAQ exchange 
The volume of Walgreens Boots shares traded since the start of the session was 1 63M  Walgreens Boots has traded in a range of  50 88 to  52 44 on the day 
The stock has traded at  53 9000 at its highest and  50 0900 at its lowest during the past seven days ",2019-08-14,Investing.com,https://www.investing.com/news/stock-market-news/walgreens-boots-falls-4-1955098,1955098
178901,400417,WBA,Walgreens Longer Term Outlook Remains Bearish,opinion,"Whilst many US stocks have mirrored the price action on the primary indices over the last few months  falling and then recovering  this has not been the case for Walgreens Boots Alliance  NASDAQ WBA  which has continued lower under the weight of a bearish technical picture and poor earnings  with a big miss in April adding to an already bearish picture  This fundamental driver is clearly in evidence on the weekly chart for the stock with the widespread down candle on ultra high volume injecting further downside momentum in April  that has continued to weigh heavily as the stock sinks further  and with no signs yet of any market maker buying  the longer term outlook remains very bearish 
What is interesting about the chart is the appearance of the volatility indicator which is unusual on a slow timeframe such as this  and yet as always reveals what to expect following its appearance  The volatility indicator is triggered when price action moves outside the average true range and the expectation is for price action to either consolidate or reverse as a result  The reason for this is simple  Volatility and insider participation go hand in hand and as such  fast moves in any market provide the ideal opportunity to trap trade investors and traders into weak positions on the reversal  And on the weekly chart  we have two examples  the first signalling a reversal  the second consolidation before there is a continuation of the primary bearish trend 

The pattern for this stock now seems to be set  with minor rallies higher punctuating the move lower  and until we see major accumulation  a move through  50 now seems likely  Indeed the monthly chart is interesting here  with rising volumes and falling prices confirming this sentiment  and with the trend monitor now in transitional phase  and with a low volume node ahead   45 now seems to be the next possible pause point  Thereafter a return to the volume point of control at  35 longer term may be achieved ",2019-05-01,Anna Coulling,https://www.investing.com/analysis/walgreens-boots-are-red-200413540,200413540
178902,400418,WBA,Walgreens Boots Rises 4 ,news,"Investing com   Walgreens Boots  NASDAQ WBA  rose by 4 19  to trade at  54 58 by 09 35  13 35 GMT  on Thursday on the NASDAQ exchange 
The volume of Walgreens Boots shares traded since the start of the session was 939 68K  Walgreens Boots has traded in a range of  53 60 to  54 69 on the day 
The stock has traded at  54 8200 at its highest and  51 4600 at its lowest during the past seven days ",2019-06-27,Investing.com,https://www.investing.com/news/stock-market-news/walgreens-boots-rises-4-1909440,1909440
178913,400429,WBA,Opening Bell  Trade Hopes Revive Global Stock Rally  Pound Rewards Brexit Shift,opinion,"U S  futures climb on reported trade deal progress  STOXX 600 triggers golden cross
Asian and U S  stocks complete bullish patterns
Treasurys  yen  dollar drop  Oil hits 4 month high

Pound rallies as U K  PM May meets opposition leader to break Brexit impasse


Key Events
Global equities and futures on the S P 500  Dow and NASDAQ 100 resumed a risk on rally this morning  as U S  Treasurys and the yen extended a selloff  China s Vice Premier Liu He s visit to Washington to continue trade talks swayed the sentiment pendulum back to the hopeful side a shift that was also helped by upbeat service sector readings from both Europe and China 
The STOXX Europe 600 climbed for a fourth day  after the eurozone services PMI hit its highest level since December  Automobiles and miners outperforming once again  Technically  the price posted a fresh short term peak  extending the uptrend since the late December bottom  to reach the highest level since early August  Through the rally  the gauge s 50 DMA crossed above the 200 DMA  triggering a golden cross 
In the earlier Asian session  regional indices closed higher  after the Financial Times reported that U S  and China negotiators were close to reaching an agreement  having resolved  most of the issues standing in the way of a deal  
China s Shanghai Composite sealed a 1 24  advance after the country s services PMI beat expectations  further feeding a rally in iron ore  Hong Kong s Hang Seng came in second with a 1 22  gain  followed by South Korea s KOSPI  which climbed 1 2   Japan s Nikkei added 0 97  and Australia s S P ASX 200 rallied 0 68  
Global Financial Affairs
In yesterday s U S  session  all four major indices ended off their lows  The NASDAQ Composite was the only index to build on previous gains  edging 0 25  higher 
The S P 500 closed flat  with strength in Real Estate   0 86   and Communication Services   0 53   offsetting a selloff in Consumer Staples   0 82   and Energy   0 69    Technically  the price paused after an upside breakout of a bullish pattern 

The Dow Jones Industrial Average gave back 0 3   falling for the first time in four days  weighed down by a plunge in Walgreens Boots Alliance  NASDAQ WBA  shares after reduced pharmacy reimbursement hit the drugstore chain s earnings 
Technically  the index pared gains after finally joining the rally  making new highs for the post Christmas uptrend and beating the Nov  8 peak  to reach the highest close since Oct  8  The fresh short term uptrend high coincided with an upside breakout of a symmetrical triangle  bullish in an uptrend  and therefore suggests a continued rally to retest the October peak 
The Russell 2000 slipped 0 17  

Yields on 10 year Treasurys jumped for the fifth day out of six  bouncing from the lowest level since December 2017  We consider the rally to be short term  as it is an upward correction within a downtrend 
The Treasury slide lead to a dollar selloff  wiping out almost three days of gains  It s interesting that despite the USD weakness and the broader risk on mood  gold clung on to profits 

The pound strengthened for a third day as markets seemed to reward U K  Prime Minister Theresa May s move to favor a cross party approach with Labour Party leader Jeremy Corbyn to break a long standing Brexit deadlock  Technically  the currency bounced off its uptrend line 

The price of WTI climbed for the fourth consecutive day  hitting a four month high inches away the  63 mark  after OPEC  oil producers signalled further supply tightening  Technically  the rally proves our calls over four small bullish pattern within a massive bottom 
Up Ahead

India s central bank will set policy on Thursday 
The monthly U S  jobs report on Friday is projected to show nonfarm payrolls were up 175 000 in March  Economists think the jobless rate held at 3 8   with hourly earnings growing at a strong rate 


Market Moves
Stocks

The MSCI Asia Pacific Index rose 0 7  
The Euro Stoxx 50 Volatility Index slid less than 0 05  

Currencies

The Dollar Index fell 0 1  
The euro advanced 0 1  to  1 1217 and the largest gain in two weeks 
The Japanese yen slipped 0 2  to 111 54 per dollar 
The MSCI Emerging Markets Currency Index rose 0 3  
The Australian dollar advanced 0 6  to the strongest level in more than a week on the biggest rise in two months 

Bonds

The yield on 10 year Treasurys rose four basis points to 2 52  
The yield on 2 year Treasurys climbed three basis points to 2 33  
Germany s 10 year yield gained four basis points to  0 01  
France s 10 year yield edged three basis points higher 

Commodities

Brent crude rose 0 6  to  69 79 a barrel 
Iron ore rallied 3  to  90 42 per metric ton ",2019-04-03,Pinchas Cohen/Investing.com,https://www.investing.com/analysis/opening-bell-200403424,200403424
178914,400430,WBA,Walgreens Tanks On Weak Earnings And Guidance,opinion,"Summary 

Walgreens Boots Alliance Inc  NASDAQ WBA  fell 12  on Tuesday after the company posted earnings that missed Wall Street expectations 
Our outlooks remain negative into the summer months  with a target of  50 

Walgreens  WBA  Stock Weekly Chart 
The company reported earnings per share of  1 64 and total revenue of  34 53 billion  compared to analyst estimates of  1 72 and  34 56 billion  For the fiscal year  the company reduced its guidance from 7 12  growth to flat 
CEO Stefano Pessina provided a clear explanation   The market challenges and macro trends we have been discussing for some time accelerated  However  our response was not rapid enough given market conditions  resulting in a disappointing quarter that did not meet our expectations  
Our analysis has had this stock as negative  expecting lower prices into June July  As it has broken cycle support  our target now is near  50 ",2019-04-03,Steve Miller,https://www.investing.com/analysis/walgreens-tanks-on-weak-earnings-and-guidance--more-pain-to-come-200403438,200403438
178920,400436,WBA,Oil Nears Tipping Point As OPEC Tightens Market  U S  Squeezes Iran,opinion,"Crude Oil is flirting with the 200 day moving average as OPEC tightens the market and the U S  squeezes Iran  The U S  ADP employment report  and ISM non manufacturing index are both due up next  All currencies are up against the U S  dollar except for the yen  AUD leads the way  Our long US crude oil Premium trade entered at 51 54 remains in progress 

Year to date  U S  crude oil is the 2nd highest performing commodity up 38   behind gasoline s 46   Crude is now flirting with several key technical levels that will be pivotal in the days ahead  The main one is the 200 day moving average  It was broken in WTI on Tuesday but sits just above the Brent high of  69 57  Next is psychological resistance at  70 00 and just behind that is the August 2018 low  now resistance  at  70 30  If those break  watch the 61 8  retracement of the Q4 plunge at  72 68 
It s increasingly clear that Saudi Arabia is determined to tighten global supplies  They ve nearly halted exports to the U S  and OPEC is pumping at four year lows  Saudi officials were frustrated in September when the U S  granted sanctions waivers to Iran s biggest customers but news on that front may also be bullish with the U S  s envoy to Iran saying Tuesday that with crude prices still relatively low  they were on the  fast track  to curbing exports to zero 
Investment in oil is low this year and speculators remain deeply skeptical of crude  Even with the jump so far this year  there is little enthusiasm in the market  A rise to Brent  at  70 will likely trigger some producers to hedge but that may just stretch out a rally towards later in the year 
Another spot we have been watching closely is Bitcoin  Ashraf has been touting longs for weeks  see below  and the 15  rally added to the upside  What s unclear is what was behind the rip in cryptocurrencies  There has been non stop speculation but the only coherent thing we ve seen is talk of a  100m order but that still doesn t explain why someone would flood the market with bids 
Click To Enlarge
Looking ahead  the ISM non manufacturing index is a key report to watch in the day ahead  The U S  economy has sent out confusing signals including on Tuesday when core durable goods orders were soft once again  Also note that U S  drugstore giant Walgreens  NASDAQ WBA  reported same store sales down 3 8  y y in Q1 as earnings  get underway  The consensus for ISM is a dip to 58 0 from 59 7  The ADP employment report is expected at 175K from 183K ",2019-04-03,Ashraf Laidi,https://www.investing.com/analysis/oil-nears-tipping-point-200403448,200403448
178921,400437,WBA,Marijuana Banking  IPOs   Weed Votes  Will Hemp Grow Higher   Revised  ,opinion,The much awaited Cannabis Banking Bill was finally passed by the House Financial Services Committee on Mar 28  This opens up avenues for legal and effective financing for marijuana companies in the United States  Meanwhile  Walgreens   NASDAQ WBA   announced plans to sell weed based products through its drug retail stores Interestingly  a number of marijuana companies are expected to go public this year  With both Canada and the United States becoming increasingly weed liberal  a bump in weed stocks is widely expected Cannabis Banking Bill to Boost Gains for Marijuana CompaniesOn Thursday  the House Financial Services Committee voted 45 15 in favor of passing the Secure and Fair Enforcement Banking Act of 2019 or the SAFE Banking Act The bill seeks to safeguard the process of financial lending to cannabis companies in the country  This would not only protect the industry s credit lines but also aid cannabis ancillary industries in the country  The ancillary sector has been suffering from financial uncertainties associated with the legal status of marijuana in the past Notably  47 U S  states with a population of 319 million people offer some form of legalized marijuana for sale  In 2018 alone  buyers in Colorado bought  1 55 billion worth of legal weed products  Moreover  the cannabis industry in California is expected to reach  5 1 billion by 2020  Therefore  offering secure financing to such a burgeoning industry would result in stunning gains for major players in the space Weed IPO Wave to Continue in 2019Experts are of the view that the marijuana industry would generate as much as  5 billion in annual revenues over the next two years  With a host of marijuana companies listing themselves in 2018  the trend is likely to continue this year  courtesy of the favorable conditions  The marijuana heavy exchange traded fund ETFMG Alternative Harvest ETF  MJ  has rallied 45 8  year to date It is largely expected that Pax Labs  the cannabis focused vaporizer company  will soon go public  The company raised  20 million last October  Next on the list might be Harborside  in business as FLRish IP LLC  The California based operator of a chain of retail pot shops  CEO Andrew Berman said the company plans to go public soon Current players in the marijuana industry like Cronos Group   NASDAQ CRON    Aurora Cannabis Inc    TO ACB    Innovative Industrial Properties  Inc    NYSE IIPR   and Canopy Growth   NYSE CGC   have posted excellent year to date returns of 77 4   82 7   80  and 61 4   respectively  Aurora  Innovative Industrial and Canopy possess a Zacks Rank  3  Hold   You can see To ConcludePer a CNBC report  Walgreens has announced plans to sell CBD creams  patches and sprays in nearly 1 500 of its stores in the country  The drugstore chain will be offering these cannabis based products in Oregon  Colorado  New Mexico  Kentucky  Tennessee  Vermont  South Carolina  Illinois and Indiana Guam s lawmakers voted in favor of a bill to legalize marijuana on Mar 27  making it the first U S  territory to legalize weed this year  The bill allows adults who are 21 and above to possess  consume  cultivate as well as purchase marijuana from licensed retailers Increasing tolerance  financial protection  credit availability and legal votes have shaped America s hemp industry lately  Such a development has more to do with growing awareness of its commercial and medicinal values  Establishment of stores  which sell recreational weed in the east coast  would go a long way in establishing a firm footing for the space  We are reissuing this article to correct a mistake  The original article  issued on April1  2019  should no longer be relied upon  ,2019-04-03,Zacks Investment Research,https://www.investing.com/analysis/marijuana-banking-ipos--weed-votes-will-hemp-grow-higher-revised-200403989,200403989
178924,400440,WBA,Kroger to start selling cannabis based products,news, Reuters    Kroger  NYSE KR  Co said on Tuesday it would start selling cannabis based products in 945 stores  joining the growing number of retailers that are trying to tap the demand for cannabidiol  CBD  products  The Ohio  Cincinnati based company will sell products containing hemp derived CBD such as creams  balms and oils at its stores spread across 17 states  the company said  CBD is the non psychoactive chemical found in marijuana and does not cause intoxication  Kroger joins retailers like Walgreens Boots Alliance  NASDAQ WBA  Inc  CVS Health Corp  NYSE CVS  and Vitamin Shoppe Inc in selling CBD products in some of their stores ,2019-06-11,Reuters,https://www.investing.com/news/stock-market-news/kroger-to-start-selling-cannabisbased-products-1894933,1894933
178932,400448,WBA,Marijuana Banking  IPOs   Weed Votes  Will Hemp Grow Higher  ,opinion,The much awaited Cannabis Banking Bill was finally passed by the House Financial Services Committee on Mar 28  This opens up avenues for legal and effective financing for marijuana companies in the United States  Meanwhile  Walgreens   NASDAQ WBA   announced plans to sell weed based products through its drug retail stores Interestingly  a number of marijuana companies are expected to go public this year  With both Canada and the United States becoming increasingly weed liberal  a bump in weed stocks is widely expected Cannabis Banking Bill to Boost Gains for Marijuana CompaniesOn Thursday  the House Financial Services Committee voted 45 15 in favor of passing the Secure and Fair Enforcement Banking Act of 2019 or the SAFE Banking Act The bill seeks to safeguard the process of financial lending to cannabis companies in the country  This would not only protect the industry s credit lines but also aid cannabis ancillary industries in the country  The ancillary sector has been suffering from financial uncertainties associated with the legal status of marijuana in the past Notably  47 U S  states with a population of 319 million people offer some form of legalized marijuana for sale  In 2018 alone  buyers in Colorado bought  1 55 billion worth of legal weed products  Moreover  the cannabis industry in California is expected to reach  5 1 billion by 2020  Therefore  offering secure financing to such a burgeoning industry would result in stunning gains for major players in the space Weed IPO Wave to Continue in 2019Experts are of the view that the marijuana industry would generate as much as  5 billion in annual revenues over the next two years  With a host of marijuana companies listing themselves in 2018  the trend is likely to continue this year  courtesy of the favorable conditions  The marijuana heavy exchange traded fund ETFMG Alternative Harvest ETF  MJ  has rallied 45 8  year to date It is largely expected that Pax Labs  the cannabis focused vaporizer company  will soon go public  The company  which raised  20 million last October  is currently valued at  15 billion  Next on the list might be Harborside  in business as FLRish IP LLC  The California based operator of a chain of retail pot shops  CEO Andrew Berman said the company plans to go public soon Current players in the marijuana industry like Cronos Group   NASDAQ CRON    Aurora Cannabis Inc    TO ACB    Innovative Industrial Properties  Inc    NYSE IIPR   and Canopy Growth   NYSE CGC   have posted excellent year to date returns of 77 4   82 7   80  and 61 4   respectively  Aurora  Innovative Industrial and Canopy possess a Zacks Rank  3  Hold   You can see To ConcludePer a CNBC report  Walgreens has announced plans to sell CBD creams  patches and sprays in nearly 1 500 of its stores in the country  The drugstore chain will be offering these cannabis based products in Oregon  Colorado  New Mexico  Kentucky  Tennessee  Vermont  South Carolina  Illinois and Indiana Guam s lawmakers voted in favor of a bill to legalize marijuana on Mar 27  making it the first U S  territory to legalize weed this year  The bill allows adults who are 21 and above to possess  consume  cultivate as well as purchase marijuana from licensed retailers Increasing tolerance  financial protection  credit availability and legal votes have shaped America s hemp industry lately  Such a development has more to do with growing awareness of its commercial and medicinal values  Establishment of stores  which sell recreational weed in the east coast  would go a long way in establishing a firm footing for the space Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ,2019-03-31,Zacks Investment Research,https://www.investing.com/analysis/marijuana-banking-ipos--weed-votes-will-hemp-grow-higher-200402715,200402715
178933,400449,WBA,Durable Goods Mixed  Walgreen s  WBA  Disappoints,opinion,"Tuesday  April 2  2019Another delayed economic read has crossed into pre market headlines this morning  February s Durable Goods Orders have been released  Even those these figures are lagging indicators  due to the government shutdown in December January   the good news is that we are catching up with more or less  real time  data The preliminary view on February Durable Goods Orders was better than expected   1 6  as compared with  2 1  expected  The revision to January s headline lost 20 basis points to  0 1  The key to this sort of data is to consider the volatility of large goods orders   particularly new airplanes  While they bring volatility to these monthly numbers depending on how many plane orders are made  they make a significant contribution to the U S  economy  Thus we pay close attention to these figures month by month  then do the math over the longer term Ex transportation  Durable Goods swings to a positive  at  0 1   This represents a swing from  0 2  in the last read  However  ex Defense spending  we see  1 9   pulling the overall durables reads deeper into negative territory in February Non Defense  ex aircraft spending   sort of the bottom line of all these figures   also swung from a negative to a positive   0 2  to  0 1   We take this as an overall positive on Durable Goods data  albeit a month in arrears  We look forward to more current Durable Goods data coming out later this month Jobs Data Tomorrow  FridaySpeaking of up to date economic data  tomorrow we see private sector payroll totals for March from Automatic Data Processing   NASDAQ ADP    followed on Friday by the government s employment report from the Bureau of Labor Statistics  BLS   February numbers on the BLS side were disappointing  with only 20K new jobs reported  ADP put up 183K for the month  in line with estimates Walgreens Boots  WBA  DisappointsShares of Walgreens Boots Alliance   NASDAQ WBA   are down 9 5  in today s pre market following a very disappointing fiscal Q2 earnings report  Not only did earnings of  1 64 per share miss the Zacks consensus by 6 cents  on  34 5 billion in revenues than came in slightly below estimates Looking under the hood  comps for the quarter fell 3 8   which puts it in the bottom range of retail earnings releases for the quarter  And guidance has been slashed for full year 2019 from  7 12  previously to flat this morning  The company had carried a Zacks Rank  4  Sell  rating ahead of this Q2 report  Mark VickerySenior Editor
Zacks  Top 10 Stocks for 2019
In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year 
From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  
This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-04-01,Zacks Investment Research,https://www.investing.com/analysis/durable-goods-mixed-walgreens-wba-disappoints-200403176,200403176
178934,400450,WBA,Walgreens  Earnings   Economic Data In Focus,opinion,Another delayed economic read has crossed into pre market headlines this morning  February s Durable Goods Orders have been released  Even those these figures are lagging indicators  due to the government shutdown in December January   the good news is that we are catching up with more or less  real time  data The preliminary view on February Durable Goods Orders was better than expected   1 6  as compared with  2 1  expected  The revision to January s headline lost 20 basis points to  0 1  The key to this sort of data is to consider the volatility of large goods orders   particularly new airplanes  While they bring volatility to these monthly numbers depending on how many plane orders are made  they make a significant contribution to the U S  economy  Thus we pay close attention to these figures month by month  then do the math over the longer term Ex transportation  Durable Goods swings to a positive  at  0 1   This represents a swing from  0 2  in the last read  However  ex Defense spending  we see  1 9   pulling the overall durables reads deeper into negative territory in February Non Defense  ex aircraft spending   sort of the bottom line of all these figures   also swung from a negative to a positive   0 2  to  0 1   We take this as an overall positive on Durable Goods data  albeit a month in arrears  We look forward to more current Durable Goods data coming out later this month Jobs Data Tomorrow  FridaySpeaking of up to date economic data  tomorrow we see private sector payroll totals for March from Automatic Data Processing   NASDAQ ADP    followed on Friday by the government s employment report from the Bureau of Labor Statistics  BLS   February numbers on the BLS side were disappointing  with only 20K new jobs reported  ADP put up 183K for the month  in line with estimates Walgreens Boots  WBA  DisappointsShares of Walgreens Boots Alliance   NASDAQ WBA   are down 9 5  in today s pre market following a very disappointing fiscal Q2 earnings report  Not only did earnings of  1 64 per share miss the Zacks consensus by 6 cents  on  34 5 billion in revenues than came in slightly below estimates Looking under the hood  comps for the quarter fell 3 8   which puts it in the bottom range of retail earnings releases for the quarter  And guidance has been slashed for full year 2019 from  7 12  previously to flat this morning  The company had carried a Zacks Rank  4  Sell  rating ahead of this Q2 report ,2019-04-01,Zacks Investment Research,https://www.investing.com/analysis/walgreens-earnings--economic-data-in-focus-200403162,200403162
178935,400451,WBA,Discount retailer Fred s to close nearly 30 percent of stores,news, Reuters    Fred s Inc said on Thursday it would close at least 159 underperforming and unprofitable stores  or nearly 30 percent of its total number of outlets  as the discount retailer works to turnaround its struggling business  Fred s said it had retained financial adviser PJ Solomon to evaluate other options for its business  which has been making losses since 2015  Liquidation sales at 159 of Fred s 557 stores will begin on Thursday  The stores are expected to close by the end of May  The company also said it is continuing to pursue the sale of its remaining pharmacy assets following the sale of patient prescription files and related pharmacy inventory from 179 Fred s stores to drugstore chain Walgreens Boots Alliance  NASDAQ WBA  Inc   Fred s shares  which have lost nearly 80 percent of their value since the company was forced to scrap its bid for 1 200 Rite Aid Corp stores in June 2017  rose 2 9 percent to  2 15 in early trading on Thursday ,2019-04-11,Reuters,https://www.investing.com/news/stock-market-news/discount-retailer-freds-to-close-nearly-30-percent-of-stores-1833689,1833689
178936,400452,WBA,Walgreens to restrict tobacco product sales to customers under 21 years,news," Reuters    Walgreens Boots Alliance  NASDAQ WBA  Inc said on Tuesday its drugstores will sell tobacco products to customers who are at least 21 years old under a new policy  effective September  In the face of an  epidemic  rise in tobacco products use among middle and high school students  the U S  health regulator has been introducing new policies to restrict teen access to such products  Last week  U S  Senate Majority leader Mitch McConnell disclosed plans to introduce a legislation to raise the minimum age for buying tobacco products  including vaping devices  to 21 from 18  
Walgreens  which operates 9 560 drugstores across the country  has in the past been pulled up by the U S  Food and Drug Administration for flouting tobacco sale rules by selling tobacco products to minors ",2019-04-23,Reuters,https://www.investing.com/news/stock-market-news/walgreens-to-restrict-tobacco-product-sales-to-customers-under-21-years-1843053,1843053
178937,400453,WBA,Walmart raises U S  tobacco purchase age to 21 starting in July,news,"By Nandita Bose WASHINGTON  Reuters    Walmart  NYSE WMT  Inc said on Wednesday it will raise the minimum age to purchase tobacco products to 21 across its U S  stores starting July 1  responding to growing regulatory and political pressure to curb a surge in teenage use of e cigarettes   It also pushed the world s largest retailer to say it discontinue the sale of fruit and dessert flavored electronic nicotine delivery systems  In March  the U S  Food   Drug Administration  FDA  put 15 national retailers  including Walmart  Kroger  NYSE KR   Walgreens Boots Alliance  NASDAQ WBA  and Family Dollar Stores  on notice for allegedly selling tobacco products such as e cigarettes to minors  In April  Walgreens and Rite Aid said they would raise the minimum age to buy tobacco products to 21  Last month  U S  Senate Majority leader Mitch McConnell said he plans to introduce legislation to raise the minimum age for buying tobacco products  including vaping devices  to 21 from 18  E cigarettes have been a bone of contention in the public health community  Some focus on the potential for the products to shift lifelong smokers onto less harmful nicotine products  while others fear they risk drawing a new generation into nicotine addiction  The increased pressure on retailers comes at a time when states and cities across the United States have moved to raise the legal age for purchasing tobacco in an effort to prevent addiction at young ages  A 2015 study from the National Academy of Medicine found that among adults who became daily smokers  about 90 percent started using cigarettes before they were 19  The study found that raising the minimum legal age to 21 would prevent 223 000 premature deaths  So far 12 states have enacted laws to raise the minimum age to 21  including New Jersey and California  Lawmakers in New York state and Maryland have also approved legislation  Walmart said the FDA had conducted approximately 12 800 compliance checks involving minors at Walmart stores and Sam s Club locations around the country since 2010  Over that period  Walmart stores passed 93 percent and Sam s Club cleared 99 percent of those checks   In 2018  the Walmart stores cleared 94 percent of the 2 400 FDA checks and Sam s Club passed 100 percent of its 15 checks   While we have implemented a robust compliance program  we are not satisfied with falling short of our companywide goal of 100 percent compliance   John Scudder  U S  chief ethics and compliance officer  said in a letter to the FDA   Even a single sale to a minor is one too many   he said  In the letter  Walmart also assured the regulator that it would remained focused on improving its compliance rates and any sale to minor violation would be dealt with promptly  Walmart said it had increased disciplinary action against store workers who failed to check ID s for shoppers who appeared to be under 40  It will also use internal and external data  including FDA data  to implement alerts  controls  training and monitoring to reduce the risk of a sale to an underage customer  In 2019  the retailer said it would conduct 8 000 secret shopper visits  and stores and that workers who fail the checks would be required to complete a  corrective action plan   
 Going forward     a cashier who fails a secret shopper check will be subjected to disciplinary action  up to and including termination   Scudder said in the letter ",2019-05-08,Reuters,https://www.investing.com/news/stock-market-news/walmart-raises-us-tobacco-purchase-age-to-21-starting-in-july-1861013,1861013
178942,400458,WBA,Walgreens Boots Alliance  WBA  Lags Q2 Earnings And Revenue Estimates,opinion,"Walgreens Boots Alliance  NASDAQ WBA  came out with quarterly earnings of  1 64 per share  missing the Zacks Consensus Estimate of  1 70 per share  This compares to earnings of  1 73 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of  3 53   A quarter ago  it was expected that this largest U S  drugstore chain would post earnings of  1 43 per share when it actually produced earnings of  1 46  delivering a surprise of 2 10  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
Walgreens  which belongs to the Zacks Retail   Pharmacies and Drug Stores industry  posted revenues of  34 53 billion for the quarter ended February 2019  missing the Zacks Consensus Estimate by 0 89   This compares to year ago revenues of  33 02 billion  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Walgreens shares have lost about 7 1  since the beginning of the year versus the S P 500 s gain of 14 4  
What s Next for Walgreens 
While Walgreens has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Walgreens was unfavorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  4  Sell  for the stock  So  the shares are expected to underperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 60 on  34 66 billion in revenues for the coming quarter and  6 39 on  137 09 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Retail   Pharmacies and Drug Stores is currently in the bottom 13  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-04-02,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-alliance-wba-lags-q2-earnings-and-revenue-estimates-200403126,200403126
178943,400459,WBA,Walgreens Tumbles After Earnings  Here s The Trade,opinion,"Pharmacy and well being retail store operator Walgreens Boots Alliance  NASDAQ WBA  fell sharply after reporting earnings  The stock traded lower by more than 12 0 percent to  55 71 a share  Traders should note that WBA has been in a down trend since December 2018  trading below all of its major weekly moving averages 
Support
The next important support level on the chart is around  50  That s where the stock should have some solid support  This support area would be where the stock broke out of a sideways base in September 2013  There is also a major retrace level and other important major moving averages around this key area  This level should be defended by the institutional crowd when retested ",2019-04-02,Nicholas Santiago,https://www.investing.com/analysis/walgreens-tumbles-after-earnings-heres-the-trade-200403276,200403276
178950,400466,WBA,Stock Market News For Apr 3  2019,opinion,Wall Street closed mixed on Tuesday as investors digest weak earnings result and not so impressive economic data  Continuation of Brexit issue also dented investors  confidence  The Dow ended in the red while both the S P 500 and Nasdaq Composite managed to advance The Dow Jones Industrial Average  DJI  closed at 26 179 13  declining 0 3   The S P 500 Index  INX  rose 0 1  to close at 2 867 24  Meanwhile  the Nasdaq Composite Index  IXIC  closed at 7 832  gaining 0 3   A total of 6 45 billion shares were traded on Tuesday  lower than the last 20 session average of 7 46 billion shares  Decliners outnumbered advancers on the NYSE by 1 13 to 1 ratio  On the Nasdaq  advancers had an edge over decliners by 1 04 to 1 ratio   The CBOE VIX decreased 0 3  to close at 13 36  How Did the Benchmarks Perform The Dow ended in negative territory with 21 stocks of the 30 stocks blue chip index finishing in the red while nine ended in the green  The tech heavy Nasdaq Composite finished in the green due to strong performance by large cap tech stocks The S P 500 also closed in the green  The Real Estate Select Sector SPDR  XLRE  gained 0 9  while Consumer Staples Select Sector SPDR  XLP  lost 0 8    Notably  five out of eleven sectors of the benchmark index closed in the green and six finished in the red Walgreens Boots Pull Down Dow Pharmacies and Drug Stores giant Walgreens Boots Alliance Inc    NASDAQ WBA   reported disappointing earnings results for the second quarter of fiscal 2019  Reported adjusted earnings per share  EPS  of  1 64 were down 5 4  year over year  The figure missed the Zacks Consensus Estimate of  1 70 Walgreens Boots recorded total sales of  34 53 billion missing the Zacks Consensus Estimate of  34 87 billion Gross margin contracted 210 basis points  bps  to 22 4  Walgreens Boots lowered its fiscal 2019 adjusted EPS guidance from 7 12  growth at constant exchange rate to roughly flat Consequently  shares of Walgreens Boots plunged 12 8   marking its worst single day drop since Aug  6  2014  You can see  Weak Economic Data The Department of Commerce reported that U S  durable goods orders for the month of February declined 1 6   higher than the consensus estimate of a decline of 1 5   Durable goods orders for January were revised downward from a gain of 0 4  reported earlier to just 0 1  Orders for non defense core capital goods  excluding aircrafts  fell 0 1  in February However  core capital goods orders increased 2 6  on a year on year basis Major decliners were machinery  computers and electronic products  This metric is closed watched by economists as an indicator for business spending plans  January s core capital goods orders revised upward to 0 9  from 0 8  reported earlier Brexit Problems ContinueThe British parliament is in a state of deadlock as it failed for the second time to vote for an alternative option to Prime Minister Theresa May s Brexit agreement which was rejected by the parliament  If no deal finally gets the approval of the parliament  then Britain may head for a no deal Brexit by Apr 12 Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-04-02,Zacks Investment Research,https://www.investing.com/analysis/stock-market-news-for-apr-3-2019-200403654,200403654
178954,400470,WBA,Walgreen s Plunges 12  Midday After Disappointing Earnings,news,"Investing com   Walgreens Boots Alliance  NASDAQ WBA  fell more than 12  in midday trading Tuesday as the company s earnings failed to beat estimates 
The Dow component guided flat earnings for the year and reported earnings per share of  1 64 on  34 53 billion in revenue  compared to the consensus forecast of  1 72 EPS on  34 56 billion in revenue 
The stock was the worst first quarter performer among 30 Dow stocks 
U S  same store volume was below trend  the company said on its earnings call  according to Briefing com  while uncertainty in the U K  over Brexit has weighed on consumers 
The company also faced reimbursement and inflationary pressures 
Elsewhere  rival CVS Health  NYSE CVS  was down 3 4   while Rite Aid  NYSE RAD  sank 7 3  ",2019-04-02,Investing.com,https://www.investing.com/news/stock-market-news/walgreens-plunges-12-midday-after-disappointing-earnings-1825235,1825235
178955,400471,WBA,Wall Street pauses after recent surge  Walgreens slides on profit warning,news,"By Sruthi Shankar  Reuters    A three day surge in U S  stocks stalled on Tuesday  as a downbeat forecast from drugstore chain Walgreens Boots hit the pharma sector and economic data did little to ease growth concerns  The Dow Jones Industrial Average was dragged down by a 12 2  slump in Walgreens Boots Alliance  NASDAQ WBA  Inc after the company cut its 2019 profit growth forecast and reported a quarterly profit that missed analysts  estimates  The S P consumer staples index was down 0 7   leading declines among nine of the 11 major S P sectors that were down  Rival CVS Health Corp  NYSE CVS  fell 3   while shares of several drug wholesalers also took a hit  Data showed new orders for key U S  made capital goods slipped in February and shipments were flat  Orders for non defense capital goods excluding aircraft  or core capital goods orders  a closely watched proxy for business spending plans  fell 0 1   Economists polled by Reuters had forecast it to remain unchanged  The data comes on the heels of a survey showing a surprise rebound in China s manufacturing activity and better than expected U S  numbers  which drove the S P 500 to near six month highs on Monday   We ve gotten to a place and time where we are going to need new evidence to move this market higher   said Art Hogan  chief market strategist at National Securities in New York   Incrementally better than expected data might move this market higher  which was not the case in today s durable goods number   At 12 43 p m  ET  the Dow was down 106 92 points  or 0 41   at 26 151 50 and the S P 500 was down 3 47 points  or 0 12   at 2 863 72  The Nasdaq Composite was up 4 89 points  or 0 06   at 7 833 80  boosted by a 2 8  jump in  Facebook Inc   NASDAQ FB   Despite coming under pressure  the S P 500 is 2 4  away from a record closing high hit in late September  held back by trade uncertainties  the Federal Reserve s plans to end monetary policy tightening  Britain s chaotic exit from the European Union and concerns about corporate profit growth  With the first quarter corporate earnings reporting season about two weeks away  investors are bracing for what may be the first U S  profit decline since 2016  Analysts expect quarterly earnings to fall 2   according to Refinitiv data  Airline stocks got a lift from Delta Air Lines  NYSE DAL  Inc s better than expected first quarter profit forecast  Its shares jumped 6 5   while the Dow Jones US Airlines index was up 3 2   Dow Inc was up 4 7  in its stock market debut following the spin off from DowDuPont  Declining issues outnumbered advancers for a 1 71 to 1 ratio on the NYSE and a 1 30 to 1 ratio on the Nasdaq  
The S P index recorded 31 new 52 week highs and two new lows  while the Nasdaq recorded 44 new highs and 33 new lows ",2019-04-02,Reuters,https://www.investing.com/news/stock-market-news/futures-take-a-breather-more-data-awaited-1824888,1824888
178956,400472,WBA,While Dividend Seems Safe  Walgreens Faces Big Challenges,news,"By Charley Blaine
Investing com   The best you can say about Walgreens Boots Alliance  NASDAQ WBA  now is that the dividend of  1 76 a year is safe 
Everything else is uncertain  especially after Walgreens  earnings on Tuesday  which even CEO Stefano Pissena called  very disappointing  during the company s analyst call  The prospects are ugly enough that the company cut its fiscal 2019 guidance for 7  to 12  earnings growth on a constant currency basis to flat 
The stock fell 13  on Tuesday and fell below  55 on Wednesday for the first time since 2013  It is the worst performing stock in the Dow Jones Industrial Average this year  down more than 19   and off more than 35  from its 52 week high reached last fall 
After the call  a number of analysts cut price targets on the stock into the low  60s  Technical indicators on Investing com rate the stock a strong sell 
Sales are getting pressured just about everywhere  but the biggest issue is the U S  pharmacy business  Insurance companies and government agencies are driving down reimbursement levels  So  while Walgreens is filling more prescriptions  and will be as the population ages   its profit from each sale is shrinking 
Business in the front of its pharmacies is getting hurt  too  in part because old reliables aren t so reliable  This year s flu season wasn t nearly as bad as 2018  cutting into sales of cough  flu and cold medicine  Plus  tobacco sales are lower  in part because Walgreens is getting out of the business 
Its Boots business  which operates pharmacies across of much of Europe  is showing poor results  at least in dollars  as the dollar rises and the pound and euro slip  Plus  European economies aren t doing all that well 
Competitors are doing wild and crazy things  CVS Health  NYSE CVS  went out and bought health insurance company Aetna  NYSE AET  for  68 billion 
The analyst call was more notable for what wasn t really addressed 
First  no analyst raised the issue of whether Medicare for all might actually happen  CFO James Kehoe noted that the company is implementing  1 5 billion in annual cost cuts and a massive move into digitizing everything  Then  he said   Over the long term  we are comfortable that our growth model can deliver mid  to high single digit adjusted EPS growth in constant currencies  
So  for Walgreens the issue is dealing with what appear to be incremental issues posed by any changes to healthcare laws 
This second issue is larger 
Walgreens Boots Alliance  formed in 2014 when Walgreens bought the 45  of Alliance Boots it didn t own  is now a sprawling operation  It has a presence in more than 25 countries  either wholly or through investments or franchises  and counts more than 415 000 employees  While the U S  is the largest piece portion of that business  it s still hard to juggle when things don t match up country to country 
At least the dividend is not really pressuring operations  It represents about 28  of cash flow  And there s enough cash flowing through the business that the company expects to buy back  1 7 billion in shares each year over the next three  which helps boost reported earnings per share 
Its consistency suggests that the company has the financial strength to fix the business  at least for now ",2019-04-03,Investing.com,https://www.investing.com/news/stock-market-news/while-dividend-seems-safe-walgreens-faces-big-challenges-1826639,1826639
178971,400487,WBA,Earnings Preview  Walgreens Boots Alliance  WBA  Q2 Earnings Expected To Decline,opinion,"Walgreens Boots Alliance  NASDAQ WBA  is expected to deliver a year over year decline in earnings on higher revenues when it reports results for the quarter ended February 2019  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on April 2  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This largest U S  drugstore chain is expected to post quarterly earnings of  1 70 per share in its upcoming report  which represents a year over year change of  1 7  
Revenues are expected to be  34 87 billion  up 5 6  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 3 09  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Walgreens 
For Walgreens  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  2 35  
On the other hand  the stock currently carries a Zacks Rank of  4 
So  this combination makes it difficult to conclusively predict that Walgreens will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Walgreens would post earnings of  1 43 per share when it actually produced earnings of  1 46  delivering a surprise of  2 10  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Walgreens doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-03-25,Zacks Investment Research,https://www.investing.com/analysis/earnings-preview-walgreens-boots-alliance-wba-q2-earnings-expected-to-decline-200401067,200401067
178975,400491,WBA,Rite Aid shakes up top management  to cut about 400 U S  jobs,news, Reuters    Rite Aid Corp said on Tuesday its chief executive officer would exit as part of a revamp of its leadership  and that it would slash about 400 corporate positions  Camp Hill  Pennsylvania based Rite Aid said the layoffs will affect more than 20 percent of corporate positions located at the company s headquarters and across field operations  The company expects annual savings of about  55 million from the restructuring  of which about  42 million will be realized within fiscal year 2020   It also expects to incur a one time charge of about  38 million related to the restructuring  John Standley  CEO since 2010  will remain in the post until the appointment of his successor  the company said  It also said Chief Financial Officer Darren Karst and Chief Operating Officer Kermit Crawford would also leave the company  The company named Chief Accounting Officer Matt Schroeder as the new CFO and Bryan Everett as the COO  Everett is currently the COO of Rite Aid Stores  Almost the entire executive management team is moving on leaving the company in the hands of Rite Aid veterans who created the challenges and making it tough to recruit a new CEO  Evercore ISI analyst Ross Muken said in a note  Rite Aid  which sold more than 1 900 stores to Walgreens Boots Alliance  NASDAQ WBA  Inc in 2017  has reported losses in three out of last four quarters   The company and U S  grocer Albertsons Companies Inc had terminated a  24 billion merger in August last year after Rite Aid s shareholders opposed the deal    All in given the elevated leverage levels and likely declining profit line we think the outlook here is pretty dire  We see no real scenario long term whereby  the company  plays a meaningful role in the  drug  Supply Chain   Muken said   Rite Aid s shares  which closed down about 2 percent on Tuesday  were up about 18 percent at 80 cents in extended trade ,2019-03-12,Reuters,https://www.investing.com/news/stock-market-news/rite-aid-shakes-up-top-management-to-cut-about-400-jobs-in-restructuring-1805542,1805542
178976,400492,WBA,Day Ahead  Top 3 Things to Watch,news,"1  Durable Goods Orders Seen Falling
The latest measure of spending on long lasting goods leads the economic calendar tomorrow 
The Commerce Department will release February durable goods orders 8 30 AM ET  12 30 GMT  
Orders for goods that last thee or more years are expected to have fallen 1 1  in February  according to economists  forecasts compiled by Briefing com 
Core durable goods orders  which exclude transportation  are expected to be up 0 3  for the month  Orders for non defense items  excluding aircraft  are forecast to rise 0 1  
2  Walgreen s Leads Earnings Calendar
The biggest company on the earnings calendar tomorrow is Walgreens Boots Alliance  NASDAQ WBA   which joined the Dow Jones Industrial Average last fall 
The pharmacy  retail and distribution giant is expected to report  1 72 a share in the second fiscal quarter  according to analysts polled by Investing com  That would be down slightly from a year ago s  1 73  Revenue is expected to rise 4 7  to  34 56 billion 
The stock was the worst first quarter performer among the 30 Dow stocks  falling 7 4  
Dave   Buster s Entertainment  NASDAQ PLAY   which operates high volume restaurants and bars  is expected to report 63 cents in the fiscal fourth quarter  up 2 cents from a year ago  Revenue is seen growing 6 5  to  324 5 million 
And GameStop  NYSE GME   the big video game retailer  is expected to earn  1 58 a share in the fiscal fourth quarter  down from  2 02 a share a year ago  Revenue is projected at  3 28 billion  up very slightly from a year ago 
The company announced Monday it will add two directors to its board from investor groups unhappy with the company s performance  The stock has been struggling for the last year 
3  Crude Prices to Extend Rally 
A fresh batch of petroleum data from the American Petroleum Institute due Tuesday is expected to be closely watched to gauge whether U S  crude supplies continue to increase  threatening the rally in oil prices 
The API last week reported crude oil stockpiles rose by 1 93 million barrels for the week ended March 22 
Crude oil futures gained 2 4  to settle at  61 59 a barrel today on improved China and U S  manufacturing data  and risk on sentiment  Oil prices were also boosted by positive remarks from Iranian oil minister Bijan Namdar Zanganeh  who touted the prospect of extending the production cut agreement 
 My understanding is  there is no difficulty extending the cooperation  It should be easy  to prolong the deal beyond the first half of the year  Zanganeh told reporters in Moscow following a meeting with his Russian counterpart Alexander Novak 
Oil prices soared 33  in the first quarter  driven by OPEC  output cuts and sanctions on Iran and  more recently  Venezuela ",2019-04-01,Investing.com,https://www.investing.com/news/stock-market-news/day-ahead-top-3-things-to-watch-1824343,1824343
178977,400493,WBA,Walgreens Boots Falls 12 ,news,"Investing com   Walgreens Boots  NASDAQ WBA  fell by 12 11  to trade at  55 81 by 09 30  13 30 GMT  on Tuesday on the NASDAQ exchange 
The volume of Walgreens Boots shares traded since the start of the session was 2 57M  Walgreens Boots has traded in a range of  55 55 to  55 96 on the day 
The stock has traded at  64 1200 at its highest and  55 5500 at its lowest during the past seven days ",2019-04-02,Investing.com,https://www.investing.com/news/stock-market-news/walgreens-boots-falls-12-1825073,1825073
178986,400502,WBA,Walgreens Boots Falls 4 ,news,"Investing com   Walgreens Boots  NASDAQ WBA  fell by 4 17  to trade at  68 22 by 09 31  14 31 GMT  on Friday on the NASDAQ exchange 
The volume of Walgreens Boots shares traded since the start of the session was 582 82K  Walgreens Boots has traded in a range of  68 05 to  71 18 on the day 
The stock has traded at  71 8900 at its highest and  68 0500 at its lowest during the past seven days ",2019-03-01,Investing.com,https://www.investing.com/news/stock-market-news/walgreens-boots-falls-4-1795460,1795460
178998,400514,WBA,Walgreens  WBA  Up 4 1  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Walgreens Boots Alliance  NASDAQ WBA   Shares have added about 4 1  in that time frame  underperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Walgreens due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Walgreens Boots Beats on Q1 Earnings  Margins DeclineWalgreens Boots reported adjusted earnings per share  EPS  of  1 46 for first quarter fiscal 2019  up 14 1  year over year  same at constant exchange rate or CER   The figure surpassed the Zacks Consensus Estimate of  1 43 On a reported basis  net earnings came in at  1 12 billion  reflecting an 36 8  surge from the prior year quarter  Reported EPS came in at  1 18  up 45 7  on a year over year basis Total SalesWalgreens Boots recorded total sales of  33 79 billion in the fiscal first quarter  up 9 9  year over year and up 11 4  at constant exchange rate or CER  The top line exceeded the Zacks Consensus Estimate of  33 58 billion Segments in DetailWalgreens Boots reports under three operating segments  Retail Pharmacy USA  Retail Pharmacy International and Pharmaceutical Wholesale Retail Pharmacy USAThe segment recorded sales of  25 7 billion in the first quarter  highlighting an improvement of 14 4  year over year  Excluding the benefit from acquired Rite Aid stores  organic sales growth was 4 6  year over year Pharmacy sales  which accounted for 74 4  of the Retail Pharmacy USA division s sales in the quarter  increased 17 5  from the year ago quarter on higher prescription volume from the acquisition of Rite Aid stores and central specialty  Pharmacy sales at comparable stores improved 2 8  while prescriptions filled in comparable stores increased 2  year over year in the quarter  With the addition of Rite Aid stores  retail sales increased 8 3  year over year  However  comparable retail sales dropped 3 2  Retail Pharmacy InternationalRevenues at the Retail Pharmacy International division dropped 5 9  on a year over year basis to  2 9 billion in the first quarter  Sales were down 3 6  at CER considering the negative impacts of the divestiture of Boots Contract Manufacturing in the prior year quarter and a change in loyalty accounting  In the United Kingdom  comparable pharmacy sales dropped 3 5  and comparable retail sales decreased 2 6  in the reported quarter Pharmaceutical WholesaleThe Pharmaceutical Wholesale division recorded quarterly sales of  5 7 billion  down 0 2  year over year  up 6 6  at CER banking on continued strong growth in emerging markets  MarginsGross profit in the reported quarter increased 4 1  year over year to  7 64 billion  However  gross margin contracted 127 basis points  bps  to 22 6  Selling  general and administrative  SG A  expenses increased 6 3  year over year to  6 3 billion  Adjusted operating income declined 4 9  to  1 4 billion  Overall  operating margin contracted 63 bps to 4  Financial ConditionWalgreens Boots exited the fiscal first quarter with cash and cash equivalents of  980 million  compared with  785 million at the end of fiscal 2018  Long term debt was  11 64 billion  compared with  12 43 billion at the end of fiscal 2018  In the first quarter  the company generated operating cash flow of  460 million compared with  1 billion a year ago GuidanceWalgreens Boots maintained its fiscal 2019 adjusted EPS guidance in the range of  6 40 to  6 70  a 7  to 12  growth at CER   The Zacks Consensus Estimate of  6 53 per share is within the guided range The company has also announced the launch of a new transformational cost management program  which is targeting annual cost savings of more than  1 billion by the end of the third year 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates 
VGM Scores
Currently  Walgreens has an average Growth Score of C  though it is lagging a bit on the Momentum Score front with a D  However  the stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision indicates a downward shift  Notably  Walgreens has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-01-18,Zacks Investment Research,https://www.investing.com/analysis/walgreens-wba-up-41-since-last-earnings-report-can-it-continue-200377332,200377332
179003,400519,WBA,Walgreens to pay  269M to settle civil fraud lawsuits  DoJ says,news,Walgreens Boots Alliance  NASDAQ WBA  agrees to pay  269 2M to settle whistleblower lawsuits accusing it of civil fraud for overbilling federal healthcare programs  the U S  Department of Justice says WBA will pay  209 2M to resolve claims it improperly billed Medicare  Medicaid and other federal programs during 2006 17 for hundreds of thousands of insulin pens it dispensed to patients it knew did not need them  and  60M to resolve claims it overcharged Medicaid during 2008 17 by failing to disclose and charge the discount drug prices it offered the public through its Prescription Savings Club program WBA  which  admits  acknowledges  and accepts responsibility  for the alleged conduct  says it set aside enough money for the settlements as of Nov  30  2018 Now read ,2019-01-22,Seeking Alpha,https://www.investing.com/news/stock-market-news/walgreens-to-pay-269m-to-settle-civil-fraud-lawsuits-doj-says-1754366,1754366
179004,400520,WBA,Loose money era leaves trail of U S  corporate debt junkies,news,"By Jessica DiNapoli  Kate Duguid and Joshua Franklin NEW YORK  Reuters    Many U S  companies that gorged on cheap debt with forgiving terms over the last decade now find themselves shackled by it  spending much of their earnings paying off lenders rather than investing in their businesses or hiring  As small firms  which together account for half of U S  employment  begin to feel the squeeze  this could have a chilling effect on hiring  wages and consumption  adding to headwinds from wobbly financial markets and ebbing global growth  economists and corporate finance professionals say  The number of companies struggling with their debt obligations is hovering near record highs  Some 17 percent of publicly traded U S  companies had trouble making debt interest payments at the end of last year  up from less than 10 percent in 2010 and off from a high of over 20 percent in 2016  according to the Institute of International Finance Inc  a trade group for financial institutions  In value terms  such firms account for a fraction of companies the IIF monitors  But they exemplify the struggles of a bigger universe of private firms which have loaded up on so called leveraged debt  typically variable rate loans offered on generous terms by banks and non bank lenders  With Federal Reserve rate increases pushing up interest expenses and the U S  economy facing a slowdown as it nears a cyclical downturn  more and more of those borrowers may scramble just to stay afloat   It could reduce capital expenditures  capital deployment and lock up the economy  because companies could be so focused on making debt payments that they may not be hiring   said Christopher Zook  chief investment officer of family office CAZ Investments LLC  Take CPI Card Group Inc  which makes credit and debit cards for banks and retailers  The card maker was among firms that tapped the leveraged loan market  when it borrowed  435 million for general purposes before it went public in 2015   CPI repaid some of the loan with proceeds from its public offering  but as its profits have deteriorated  the company has nearly lost its ability to service the remaining debt  Its earnings for 2018 roughly matched its debt expenses  according to Moody s Investors Service  down from nearly five times the size in 2014  The company cut its headcount by 13 percent between 2015 and 2017 to 1 200 workers  Last year  it shut a plant in Littleton  Colorado  where it is headquartered  according to the state s Department of Labor and Employment  As Americans complete the shift to chip enabled credit cards  CPI forecasts revenue will rise in 2019  But the forces that have held it back will persist  the credit card maker is losing market share to competitors  and high inventories help big banks keep prices low  says Stephen Morrison  analyst at Moody s  CPI Card declined to comment  EASY CREDIT Investors  hunt for higher returns in an era of record low interest rates has given debt laden companies access to cheap  easy credit  encouraging them to take on more debt than would be possible in less forgiving conditions  As a result  the median debt levels of non financial companies relative to their earnings already exceed levels before the last financial crisis  according to Standard   Poor s rating agency   Graphic     While U S  policymakers assure that credit conditions remain broadly healthy  the volume of leveraged loans  which are rated as junk or near junk  has doubled to a record  1 4 trillion over the last five years    The leveraged loan market can be considered a canary in the coal mine for the U S  economy   said Jeremy Swan  managing principal for financial sponsors at accounting firm CohnReznick LLP  Drug store chain Rite Aid Corp is another example of how initial relief offered by such loans turned  over time  into a burden  The Pennsylvania based company borrowed over  1 billion on loose terms in 2013 to refinance old debt  according to Refinitiv data  Credit ratings agencies welcomed the financing at the time because it would help the chain  though still heavily indebted and facing uneven sales  lower its interest costs   Yet the debt burden proved too much in the years to come    They couldn t grow because they had so much debt   said Mickey Chadha  a senior credit officer at Moody s Investors Service   They didn t have the cash flow and the capital to invest in their stores    Last year  the retailer  after two failed attempts to sell itself  sold about 1 900 stores to competitor Walgreens Boots Alliance  NASDAQ WBA  Inc to reduce its leverage at a time when the rise of e commerce has challenged its business   The number of associates Rite Aid employed slowly declined to 87 000 from 89 000 as it worked toward paying off the debt  according to the company s annual reports  Its store count fell to 4 536 from 4 623  After the sale to Walgreens Boot Alliance  Rite Aid had 2 550 stores and 59 000 employees  Its shares are trading below  1  though it recently announced plans for a reverse stock split   Rite Aid has made significant progress in reducing the company s debt and simplifying and strengthening its capital structure over the last several years   the retailer said in a statement  The company said it recently refinanced  pushing out maturities until 2023 and winning improved interest rates  It also has about  1 9 billion in liquidity   providing strong flexibility to operate and invest in  its  business   Economists say generous lending terms allow highly leveraged companies that otherwise might be pushed into bankruptcy to carry on  but the firms  pullback from investment and hiring can exacerbate an anticipated slowdown and hurt thinly capitalized non bank lenders  
 It s a fault line in the ecosystem that threatens the broader economy   said Mark Zandi  chief economist at Moody s Analytics   I don t know if we should send off the red flares  but  definitely  the yellow flares  ",2019-02-05,Reuters,https://www.investing.com/news/economy-news/loose-money-era-leaves-trail-of-us-corporate-debt-junkies-1769193,1769193
179017,400533,WBA,Walgreens Boots Alliance  WBA  Dips More Than Broader Markets  What You Should Know,opinion,"Walgreens Boots Alliance  NASDAQ WBA  closed the most recent trading day at  71 71  moving  1 06  from the previous trading session  This change lagged the S P 500 s daily loss of 0 02   At the same time  the Dow lost 0 03   and the tech heavy Nasdaq lost 0 21  
Prior to today s trading  shares of the largest U S  drugstore chain had lost 11 95  over the past month  This has lagged the Retail Wholesale sector s loss of 0 15  and the S P 500 s loss of 1 4  in that time 
WBA will be looking to display strength as it nears its next earnings release  which is expected to be March 27  2019  In that report  analysts expect WBA to post earnings of  1 74 per share  This would mark year over year growth of 0 58   Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  34 72 billion  up 5 16  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  6 52 per share and revenue of  136 85 billion  These totals would mark changes of  8 31  and  4 04   respectively  from last year 
Any recent changes to analyst estimates for WBA should also be noted by investors  These revisions typically reflect the latest short term business trends  which can change frequently  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Our research shows that these estimate changes are directly correlated with near term stock prices  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 0 21  lower  WBA is currently sporting a Zacks Rank of  3  Hold  
Digging into valuation  WBA currently has a Forward P E ratio of 11 11  This valuation marks a no noticeable deviation compared to its industry s average Forward P E of 11 11 
Also  we should mention that WBA has a PEG ratio of 1 13  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  WBA s industry had an average PEG ratio of 1 01 as of yesterday s close 
The Retail   Pharmacies and Drug Stores industry is part of the Retail Wholesale sector  This industry currently has a Zacks Industry Rank of 73  which puts it in the top 29  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2019-01-11,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-alliance-wba-dips-more-than-broader-markets-what-you-should-know-200374917,200374917
179039,400555,WBA,Company News For Dec 21  2018,opinion,Walgreens Boots Alliance Inc    NASDAQ WBA   shares tumbled 5  after the company reported that first quarter fiscal 2019 gross profit margin and operating margin declined year over year by 127 bps and 63 bps  respectivelyShares of BlackBerry Ltd    NYSE BB   climbed 2 7  after the company posted third quarter fiscal 2019 adjusted earnings per share of  0 03 beating the Zacks Consensus Estimate of  0 02Carnival Corp    NYSE CCL   shares plunged 9 5  after posting fourth quarter fiscal 2018 revenues of  4 456 million  lagging the Zacks Consensus Estimate of  4 459 millionShares of Tilray Inc    NASDAQ TLRY   jumped 10 3  after announcing that it will form a partnership with Anheuser Busch InBev SA NV   NYSE BUD   to research marijuana laced beverages,2018-12-20,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-dec-21-2018-200370244,200370244
179040,400556,WBA,Walgreens Counts On International Progress  Strategic Deals,opinion,On Dec 27  we issued an updated research report on Walgreens Boots Alliance  Inc    NASDAQ WBA    The company s series of strategic deals is expected to benefit it more over the long run  Its strong cash balance and progress in cost cutting initiatives further boost investor confidence in the stock  The stock carries a Zacks Rank  3  Hold  Over the past six months  shares of Walgreens Boots have outperformed its   The stock has rallied 11 3  compared with the industry s 6 9  rise In the last reported quarter  Retail Pharmacy USA division witnessed comparable prescription growth and benefited from a strong retail prescription market  Within this segment  Walgreens Boots has been making a good improvement on account of expanding prescription volume  Solid pharmacy sales growth encourages us through synergies drawn from Rite Aid store addition and organic growth  Within Retail Pharmacy USA  the company is currently launching a phase of transformational cost management to counteract margin pressure  Walgreens Boots Alliance  Inc  Price   The company has been gaining traction from calculated tie ups as well  We are looking forward to Walgreens Boots  recent alliance with Alphabet s life sciences and healthcare segment  Verily  to collaborate on multiple projects regarding chronic ailments  In the beginning  both companies are going to initiate a medication adherence pilot project that will install devices and other approaches designed to improve adherence Moreover  Walgreens Boots with Onduo   Verily s joint venture with Sanofi  PA SASY    will unveil a virtual diabetes solution  This in turn  will cater to Walgreens Boots  employees and family members with Type 2 diabetes via the Walgreens Boots employee health plan We are also looking forward to Walgreens Boots  agreement with Express Scripts  NASDAQ ESRX  and Kroger  NYSE KR   aimed at extending its existing group purchasing efforts and product offerings  respectively Per the company s partnership with Kroger  a pilot program will be introduced at 13 selected Walgreens Boots outlets in Northern Kentucky  According to the deal  customers ordering Kroger grocery items online can pick the same up from Walgreens Boots  outlets Walgreens Boots  association with Express Scripts is expected to strengthen its existing group purchasing efforts  Since biosimilars have potential to lower production costs  the move is considered a prudent and timely one However  over the recent quarters  Walgreens Boots Retail Pharmacy International division remained soft  In the last reported quarter too  sales decreased 5 9   In the United Kingdom  comparable pharmacy sales dipped 3 5  and comparable retail sales declined 2 6  in the reported quarter Walgreens Boots faces headwinds in the form of fierce competition and tough industry conditions  Even though the company continues to reap benefits from its growth initiatives  major business tycoons are already advancing in pharmacy businesses  flaunting a fair market share Notably  a slowdown in generic introduction over the last few years has been affecting Walgreens Boots  margins  Also  an escalated reimbursement pressure and a generic drug cost inflation have been denting Walgreens Boots  margins significantly Key PicksSome better ranked stocks in the broader medical space are Integer Holdings Corporation   NYSE ITGR    Surmodics  Inc    NASDAQ SRDX   and Veeva Systems   NYSE VEEV   Integer Holdings has an earnings growth rate of 31 2  for the first quarter of 2019  The stock has a Zacks Rank  2  Buy  Surmodics  long term earnings growth rate is projected at 10   The stock carries a Zacks Rank of 2 currently Veeva Systems  long term earnings growth rate is estimated at 19 5   The stock sports a Zacks Rank  1  Strong Buy  at present  You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-12-30,Zacks Investment Research,https://www.investing.com/analysis/walgreens-counts-on-international-progress-strategic-deals-200371908,200371908
179041,400557,WBA,Walgreens Boots Alliance  WBA  Stock Moves  1 04   What You Should Know,opinion,"In the latest trading session  Walgreens Boots Alliance  NASDAQ WBA  closed at  67 33  marking a  1 04  move from the previous day  This change was narrower than the S P 500 s 2 48  loss on the day  At the same time  the Dow lost 2 83   and the tech heavy Nasdaq lost 3 04  
Heading into today  shares of the largest U S  drugstore chain had lost 17 85  over the past month  lagging the Retail Wholesale sector s loss of 8 8  and the S P 500 s loss of 8 82  in that time 
Investors will be hoping for strength from WBA as it approaches its next earnings release  which is expected to be March 27  2019  On that day  WBA is projected to report earnings of  1 74 per share  which would represent year over year growth of 0 58   Meanwhile  our latest consensus estimate is calling for revenue of  34 63 billion  up 4 88  from the prior year quarter 
WBA s full year Zacks Consensus Estimates are calling for earnings of  6 52 per share and revenue of  137 billion  These results would represent year over year changes of  8 31  and  4 15   respectively 
Any recent changes to analyst estimates for WBA should also be noted by investors  These revisions help to show the ever changing nature of near term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Our research shows that these estimate changes are directly correlated with near term stock prices  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  Within the past 30 days  our consensus EPS projection has moved 0 27  lower  WBA is holding a Zacks Rank of  3  Hold  right now 
Investors should also note WBA s current valuation metrics  including its Forward P E ratio of 10 43  Its industry sports an average Forward P E of 10 43  so we one might conclude that WBA is trading at a no noticeable deviation comparatively 
We can also see that WBA currently has a PEG ratio of 1 06  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  The Retail   Pharmacies and Drug Stores industry currently had an average PEG ratio of 1 04 as of yesterday s close 
The Retail   Pharmacies and Drug Stores industry is part of the Retail Wholesale sector  This group has a Zacks Industry Rank of 181  putting it in the bottom 29  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-01-03,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-alliance-wba-stock-moves-104-what-you-should-know-200372712,200372712
179053,400569,WBA,Walgreens Boots Earnings beat  Revenue misses In Q1,news,"Investing com   Walgreens Boots  NASDAQ WBA  reported first quarter earnings  that beat analysts  expectations on Thursday and revenue that fell short of forecasts 
The firm reported earnings per share of  1 46 on revenue of  33 79B  Analysts polled by Investing com forecast EPS of  1 43 on revenue of  33 82B  That compared to EPS of  0 81 on revenue of  30 74B in the same period a year earlier  The company had reported EPS of  1 48 on revenue of  33 44B in the previous quarter 
For the year  Walgreens Boots shares are up 0 92   outperforming the S P 500 which is down 6 59  year to date 
Walgreens Boots follows other major Services sector earnings this month
 On December 13  Costco reported first quarter EPS of  1 61 on revenue of  35 07B  compared to forecasts of EPS of  1 62 on revenue of  37 57B 
Alimentation Couchen A earnings beat analyst s expectations on November 27  with second quarter EPS of  0 84 on revenue of  14 70B  Investing com analysts expected EPS of  0 83 on revenue of  11 498M
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2018-12-20,Investing.com,https://www.investing.com/news/stock-market-news/walgreens-boots-earnings-beat-revenue-misses-in-q1-1727377,1727377
179054,400570,WBA,Walgreens  cost cut plans aim to save more than  1 billion annually,news,"By Manas Mishra and Manojna Maddipatla  Reuters    Walgreens Boots Alliance Inc  O WBA  said on Thursday it would consolidate warehouses and shut some stores as part of a cost cutting plan aimed at saving more than  1 billion annually  Shares of the company  however  fell nearly 3 percent as the company s international business suffered mainly due to weak demand in Britain  where its market share gains were offset by a weak retail environment  The company operates nearly 2 500 stores in the UK  roughly half its non U S  stores  making it vulnerable to Brexit related uncertainties   Walgreens  overall profitability was not as strong as we would have liked  This  in our view  was due to lower demand in the United Kingdom   Edward Jones analyst John Boylan said  The cost cutting program  which is expected to save more than  1 billion by the end of the third year  comes as the company consolidates 1 932 stores acquired from  Rite Aid Corp   N RAD  last year for  4 38 billion  The company said its pharmaceutical wholesale division and retail businesses in Chile and Mexico were part of its cost saving plan  which is expected to result in significant restructuring and other special charges  International retail sales fell 5 9 percent to  2 9 billion  while same store sales at its U S  retail stores  where it sells over the counter drugs and personal care products  fell 3 2 percent   We were facing a tough year ago comp number that was boosted by the impact of hurricanes and a very strong cough cold flu season   Chief Financial Officer James Kehoe said on a conference call  U S  retail sales also took a hit as the company scaled back sales of certain products including tobacco  However  its U S  pharmacy business posted a strong quarter  helping Walgreens beat profit estimates  Same store sales at its U S  pharmacies rose 2 8 percent  beating analysts  estimates of a 2 6 percent increase  according to IBES data from Refinitiv   Net income attributable to the company rose to  1 12 billion  or  1 18 per share  in the first quarter ended Nov  30 from  821 million  or 81 cents per share  a year earlier  Excluding items  Walgreens earned  1 46 per share  Sales rose 9 9 percent to  33 79 billion  
Analysts on average had expected a profit of  1 43 per share and revenue of  33 78 billion ",2018-12-20,Reuters,https://www.investing.com/news/stock-market-news/walgreens-costcut-plans-aim-to-save-more-than-1-billion-annually-1727785,1727785
179066,400582,WBA,Walgreens Boots Alliance  WBA  Earnings Expected To Grow  Should You Buy ,opinion,"Wall Street expects a year over year increase in earnings on higher revenues when Walgreens Boots Alliance  NASDAQ WBA  reports results for the quarter ended November 2018  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on December 20  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This largest U S  drugstore chain is expected to post quarterly earnings of  1 43 per share in its upcoming report  which represents a year over year change of  11 7  
Revenues are expected to be  33 58 billion  up 9 3  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 17  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is subject to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Walgreens 
For Walgreens  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 50  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that Walgreens will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Walgreens would post earnings of  1 44 per share when it actually produced earnings of  1 48  delivering a surprise of  2 78  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Walgreens doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2018-12-12,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-alliance-wba-earnings-expected-to-grow-should-you-buy-200367842,200367842
179067,400583,WBA,Walgreens Boots Alliance  WBA  Beats Q1 Earnings And Revenue Estimates,opinion,"Walgreens Boots Alliance  NASDAQ WBA  came out with quarterly earnings of  1 46 per share  beating the Zacks Consensus Estimate of  1 43 per share  This compares to earnings of  1 28 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 2 10   A quarter ago  it was expected that this largest U S  drugstore chain would post earnings of  1 44 per share when it actually produced earnings of  1 48  delivering a surprise of 2 78  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Walgreens  which belongs to the Zacks Retail   Pharmacies and Drug Stores industry  posted revenues of  33 79 billion for the quarter ended November 2018  surpassing the Zacks Consensus Estimate by 0 62   This compares to year ago revenues of  30 74 billion  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Walgreens shares have added about 0 9  since the beginning of the year versus the S P 500 s decline of  6 2  
What s Next for Walgreens 
While Walgreens has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Walgreens was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 78 on  34 69 billion in revenues for the coming quarter and  6 53 on  137 38 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Retail   Pharmacies and Drug Stores is currently in the top 41  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2018-12-19,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-alliance-wba-beats-q1-earnings-and-revenue-estimates-200369848,200369848
179068,400584,WBA,Walgreens  WBA  Q1 Earnings Top Estimates  Margins Down,opinion,"Walgreens Boots Alliance  Inc    NASDAQ WBA   reported adjusted earnings per share  EPS  of  1 46 for first quarter fiscal 2019  up 14 1  year over year  same at constant exchange rate or CER   The figure surpassed the Zacks Consensus Estimate of  1 43 
On a reported basis  net earnings came in at  1 12 billion  reflecting an 36 8  surge from the prior year quarter  Reported EPS came in at  1 18  up 45 7  on a year over year basis 
Total Sales
Walgreens Boots recorded total sales of  33 79 billion in the fiscal first quarter  up 9 9  year over year and up 11 4  at constant exchange rate or CER  The top line exceeded the Zacks Consensus Estimate of  33 58 billion 
Segments in Detail
Walgreens Boots reports under three operating segments  Retail Pharmacy USA  Retail Pharmacy International and Pharmaceutical Wholesale 
Retail Pharmacy USA
The segment recorded sales of  25 7 billion in the first quarter  highlighting an improvement of 14 4  year over year  Excluding the benefit from acquired Rite Aid stores  organic sales growth was 4 6  year over year Walgreens Boots Alliance  Inc  Price  Consensus and EPS Surprise

   Pharmacy sales  which accounted for 74 4  of the Retail Pharmacy USA division s sales in the quarter  increased 17 5  from the year ago quarter on higher prescription volume from the acquisition of Rite Aid stores and central specialty  Pharmacy sales at comparable stores improved 2 8  while prescriptions filled in comparable stores increased 2  year over year in the quarter  With the addition of Rite Aid stores  retail sales increased 8 3  year over year  However  comparable retail sales dropped 3 2  
Retail Pharmacy International
Revenues at the Retail Pharmacy International division dropped 5 9  on a year over year basis to  2 9 billion in the first quarter  Sales were down 3 6  at CER considering the negative impacts of the divestiture of Boots Contract Manufacturing in the prior year quarter and a change in loyalty accounting  In the United Kingdom  comparable pharmacy sales dropped 3 5  and comparable retail sales decreased 2 6  in the reported quarter 
Pharmaceutical Wholesale
The Pharmaceutical Wholesale division recorded quarterly sales of  5 7 billion  down 0 2  year over year  up 6 6  at CER banking on continued strong growth in emerging markets  
Margins
Gross profit in the reported quarter increased 4 1  year over year to  7 64 billion  However  gross margin contracted 127 basis points  bps  to 22 6  
Selling  general and administrative  SG A  expenses increased 6 3  year over year to  6 3 billion  Adjusted operating income declined 4 9  to  1 4 billion  Overall  operating margin contracted 63 bps to 4  
Financial Condition
Walgreens Boots exited the fiscal first quarter with cash and cash equivalents of  980 million  compared with  785 million at the end of fiscal 2018  Long term debt was  11 64 billion  compared with  12 43 billion at the end of fiscal 2018  In the first quarter  the company generated operating cash flow of  460 million compared with  1 billion a year ago 
Guidance 
Walgreens Boots maintained its fiscal 2019 adjusted EPS guidance in the range of  6 40 to  6 70  a 7  to 12  growth at CER   The Zacks Consensus Estimate of  6 53 per share is within the guided range 
The company has also announced the launch of a new transformational cost management program  which is targeting annual cost savings of more than  1 billion by the end of the third year 
Our Take
Walgreens Boots reported better than expected first quarter results  The year over year strong increase in both earnings and revenues were encouraging 
Overall  Retail Pharmacy USA division witnessed comparable prescription growth and benefited from a strong retail prescription market  Within this segment  Walgreens Boots has been making good progress on account of increasing prescription volume  Meanwhile  tough market conditions  particularly in retail  have been leading to sluggishness in Retail Pharmacy International division 
Meanwhile  the guidance for fiscal 2019 looks promising 
Zacks Rank   Key Picks
Walgreens currently carries a Zacks Rank  3  Hold  
Some better ranked stocks in the broader medical space are Integer Holdings Corp    NYSE ITGR    Surmodics  Inc    NASDAQ SRDX   and Veeva Systems   NYSE VEEV   
Veeva Systems  long term earnings growth rate is estimated at 19 5   The stock carries a Zacks Rank  1  Strong Buy  at present  You can see  
Integer Holdings  with a Zacks Rank  2  has an earnings growth rate of 31 2  for the first quarter of fiscal 2019 
Surmodics  long term earnings growth rate is projected at 10   The stock carries a Zacks Rank of 2 currently 
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6  and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-12-20,Zacks Investment Research,https://www.investing.com/analysis/walgreens-wba-q1-earnings-top-estimates-margins-down-200370023,200370023
179089,400605,WBA,Walgreens Gains From New Alliances  International Expansion,opinion,"On Nov 28  we issued an updated research report on Walgreens Boots Alliance  Inc    NASDAQ WBA    We are currently looking forward to the company s Rite Aid store purchase  which is expected to benefit the company in the long run  The stock carries a Zacks Rank  2  Buy  
Over the past three months  Walgreens Boots has been outperforming its   The stock has gained 24 8  in comparison to the industry s 13 9  rise 
In the last reported quarter  Retail Pharmacy USA division witnessed comparable prescription growth and benefited from a strong retail prescription market  Within this segment  Walgreens Boots has been making good progress on account of increasing prescription volume  Solid pharmacy sales growth encourages us  reflecting synergies from Rite Aid store addition and organic growth 
The company has been gaining on account of strategic tie ups  We are looking forward to Walgreens Boots  alliance with Express Scripts  NASDAQ ESRX  and Kroger  NYSE KR   aimed at expanding its existing group purchasing efforts and product offerings  respectively 

 
Per the company s partnership with Kroger  a pilot program will be launched at selected 13 Walgreens outlets in Northern Kentucky  According to the deal  customers ordering Kroger grocery items online can pick them up at Walgreens  outlets 
Walgreens Boots  tie up with Express Scripts is expected to expand its existing group purchasing efforts  Since biosimilars have the potential to lower production costs  the move is considered to be a prudent and timely one 
This apart  the Rite Aid deal seems to benefit Walgreens Boots in more ways than one  Accordingly  the collaboration allowed Rite Aid to buy generic drugs sourced through a Walgreens Boots  affiliate at a cost equivalent to the company s for about 10 years  which raises optimism 
We are also hopeful about Walgreen Boots  global footprint expansion with its decision to acquire a 40  stake in Sinopharm Holding Guoda Drugstores  a subsidiary of China National Accord Medicines Corporation Ltd 
However  Walgreens Boots faces headwinds in the form of fierce competition and tough industry conditions  Even though the company continues to reap benefits from its growth initiatives  major business tycoons are already advancing in pharmacy businesses  flaunting a fair market share 
Notably  a slowdown in generic introduction over the last few years has been affecting Walgreens Boots  margins  Also  an escalated reimbursement pressure and generic drug cost inflation have been denting Walgreens Boots  margins significantly 
Other Key Picks
Other top ranked stocks in the broader medical space are Integer Holdings Corp    NYSE ITGR    Surmodics  Inc    NASDAQ SRDX   and Veeva Systems   NYSE VEEV   
Veeva Systems  long term earnings growth rate is estimated at 19 3   The stock carries a Zacks Rank  1  Strong Buy   You can see  
Integer Holdings has an expected earnings growth rate of 30 3  for the current year and a Zacks Rank  2 
Surmodics  long term earnings growth rate is projected at 10   The stock carries a Zacks Rank of 2 currently 
The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-29,Zacks Investment Research,https://www.investing.com/analysis/walgreens-gains-from-new-alliances-international-expansion-200363716,200363716
179090,400606,WBA,Is Walgreens Boots Alliance  WBA  Outperforming Other Retail Wholesale Stocks This Year ,opinion,"Investors focused on the Retail Wholesale space have likely heard of Walgreens Boots Alliance  NASDAQ WBA   but is the stock performing well in comparison to the rest of its sector peers  By taking a look at the stock s year to date performance in comparison to its Retail Wholesale peers  we might be able to answer that question 
Walgreens Boots Alliance is one of 227 individual stocks in the Retail Wholesale sector  Collectively  these companies sit at  9 in the Zacks Sector Rank  The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors 
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks  This system has a long record of success  and these stocks tend to be on track to beat the market over the next one to three months  WBA is currently sporting a Zacks Rank of  2  Buy  
Over the past 90 days  the Zacks Consensus Estimate for WBA s full year earnings has moved 1 42  higher  This signals that analyst sentiment is improving and the stock s earnings outlook is more positive 
Based on the most recent data  WBA has returned 18  so far this year  At the same time  Retail Wholesale stocks have gained an average of 10 33   This means that Walgreens Boots Alliance is outperforming the sector as a whole this year 
Looking more specifically  WBA belongs to the Retail   Pharmacies and Drug Stores industry  a group that includes 6 individual stocks and currently sits at  68 in the Zacks Industry Rank  On average  stocks in this group have gained 15 20  this year  meaning that WBA is performing better in terms of year to date returns 
Investors in the Retail Wholesale sector will want to keep a close eye on WBA as it attempts to continue its solid performance ",2018-12-04,Zacks Investment Research,https://www.investing.com/analysis/is-walgreens-boots-alliance-wba-outperforming-other-retailwholesale-stocks-this-year-200364958,200364958
179091,400607,WBA,Walgreens Boots Alliance  WBA  Outpaces Stock Market Gains  What You Should Know,opinion,"In the latest trading session  Walgreens Boots Alliance  NASDAQ WBA  closed at  82 44  marking a  0 77  move from the previous day  This move outpaced the S P 500 s daily gain of 0 54   Elsewhere  the Dow gained 0 64   while the tech heavy Nasdaq added 0 95  
Coming into today  shares of the largest U S  drugstore chain had lost 0 13  in the past month  In that same time  the Retail Wholesale sector lost 5   while the S P 500 lost 4 97  
Investors will be hoping for strength from WBA as it approaches its next earnings release  which is expected to be January 3  2019  The company is expected to report EPS of  1 43  up 11 72  from the prior year quarter  Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  33 61 billion  up 9 32  from the year ago period 
WBA s full year Zacks Consensus Estimates are calling for earnings of  6 54 per share and revenue of  137 49 billion  These results would represent year over year changes of  8 64  and  4 52   respectively 
It is also important to note the recent changes to analyst estimates for WBA  These revisions typically reflect the latest short term business trends  which can change frequently  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Our research shows that these estimate changes are directly correlated with near term stock prices  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  Within the past 30 days  our consensus EPS projection has moved 0 13  lower  WBA currently has a Zacks Rank of  3  Hold  
Digging into valuation  WBA currently has a Forward P E ratio of 12 52  This valuation marks a no noticeable deviation compared to its industry s average Forward P E of 12 52 
Also  we should mention that WBA has a PEG ratio of 1 28  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  WBA s industry had an average PEG ratio of 1 15 as of yesterday s close 
The Retail   Pharmacies and Drug Stores industry is part of the Retail Wholesale sector  This industry currently has a Zacks Industry Rank of 109  which puts it in the top 42  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
You can find more information on all of these metrics  and much more  on Zacks com ",2018-12-12,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-alliance-wba-outpaces-stock-market-gains-what-you-should-know-200367549,200367549
179118,400634,WBA,Walgreens Boots Alliance  WBA  Is A Great Momentum Stock  Should You Buy ,opinion,"Momentum investing is all about the idea of following a stock s recent trend  which can be in either direction  In the  long  context  investors will essentially be  buying high  but hoping to sell even higher   And for investors following this methodology  taking advantage of trends in a stock s price is key  once a stock establishes a course  it is more than likely to continue moving in that direction  The goal is that once a stock heads down a fixed path  it will lead to timely and profitable trades 
Even though momentum is a popular stock characteristic  it can be tough to define  Debate surrounding which are the best and worst metrics to focus on is lengthy  but the Zacks Momentum Style Score  part of the Zacks Style Scores  helps address this issue for us 
Below  we take a look at Walgreens Boots Alliance  NASDAQ WBA   which currently has a Momentum Style Score of A  We also discuss some of the main drivers of the Momentum Style Score  like price change and earnings estimate revisions 
It s also important to note that Style Scores work as a complement to the Zacks Rank  our stock rating system that has an impressive track record of outperformance  Walgreens Boots Alliance currently has a Zacks Rank of  2  Buy   Our research shows that stocks rated Zacks Rank  1  Strong Buy  and  2  Buy  and Style Scores of A or B outperform the market over the following one month period 
You can see the current list of Zacks  1 Rank Stocks here    
Set to Beat the Market 
In order to see if WBA is a promising momentum pick  let s examine some Momentum Style elements to see if this largest U S  drugstore chain holds up 
Looking at a stock s short term price activity is a great way to gauge if it has momentum  since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment  It is also useful to compare a security to its industry  as this can help investors pinpoint the top companies in a particular area 
For WBA  shares are up 4 03  over the past week while the Zacks Retail   Pharmacies and Drug Stores industry is up 4 34  over the same time period  Shares are looking quite well from a longer time frame too  as the monthly price change of 9 57  compares favorably with the industry s 5 05  performance as well 
While any stock can see its price increase  it takes a real winner to consistently beat the market  That is why looking at longer term price metrics    such as performance over the past three months or year    can be useful as well  Over the past quarter  shares of Walgreens Boots Alliance have risen 17 39   and are up 18 67  in the last year  On the other hand  the S P 500 has only moved  2 87  and 8 29   respectively 
Investors should also pay attention to WBA s average 20 day trading volume  Volume is a useful item in many ways  and the 20 day average establishes a good price to volume baseline  a rising stock with above average volume is generally a bullish sign  whereas a declining stock on above average volume is typically bearish  WBA is currently averaging 7 898 199 shares for the last 20 days 
Earnings Outlook
The Zacks Momentum Style Score also takes into account trends in estimate revisions  in addition to price changes  Please note that estimate revision trends remain at the core of Zacks Rank as well  A nice path here can help show promise  and we have recently been seeing that with WBA 
Over the past two months  8 earnings estimates moved higher compared to none lower for the full year  These revisions helped boost WBA s consensus estimate  increasing from  6 45 to  6 54 in the past 60 days  Looking at the next fiscal year  4 estimates have moved upwards while there have been no downward revisions in the same time period 
Bottom Line
Given these factors  it shouldn t be surprising that WBA is a  2  Buy  stock and boasts a Momentum Score of A  If you re looking for a fresh pick that s set to soar in the near term  make sure to keep Walgreens Boots Alliance on your short list ",2018-11-06,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-alliance-wba-is-a-great-momentum-stock-should-you-buy-200356146,200356146
179119,400635,WBA,Is Walgreens Boots Alliance  WBA  Stock Outpacing Its Retail Wholesale Peers This Year ,opinion,"Investors focused on the Retail Wholesale space have likely heard of Walgreens Boots Alliance  NASDAQ WBA   but is the stock performing well in comparison to the rest of its sector peers  By taking a look at the stock s year to date performance in comparison to its Retail Wholesale peers  we might be able to answer that question 
Walgreens Boots Alliance is a member of the Retail Wholesale sector  This group includes 228 individual stocks and currently holds a Zacks Sector Rank of  5  The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups 
The Zacks Rank is a successful stock picking model that emphasizes earnings estimates and estimate revisions  The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months  WBA is currently sporting a Zacks Rank of  2  Buy  
The Zacks Consensus Estimate for WBA s full year earnings has moved 1 55  higher within the past quarter  This signals that analyst sentiment is improving and the stock s earnings outlook is more positive 
Our latest available data shows that WBA has returned about 12 79  since the start of the calendar year  Meanwhile  stocks in the Retail Wholesale group have gained about 10 04  on average  This shows that Walgreens Boots Alliance is outperforming its peers so far this year 
Looking more specifically  WBA belongs to the Retail   Pharmacies and Drug Stores industry  which includes 6 individual stocks and currently sits at  16 in the Zacks Industry Rank  On average  stocks in this group have gained 12 88  this year  meaning that WBA is slightly underperforming its industry in terms of year to date returns 
Investors in the Retail Wholesale sector will want to keep a close eye on WBA as it attempts to continue its solid performance ",2018-11-07,Zacks Investment Research,https://www.investing.com/analysis/is-walgreens-boots-alliance-wba-stock-outpacing-its-retailwholesale-peers-this-year-200356954,200356954
179120,400636,WBA,Company News For Nov 20  2018	,opinion,Cimarex Energy Co  s   NYSE XEC   shares declined 0 8  following reports that the oil and gas company would be acquiring Resolute Energy Corporation   NYSE REN   for  35 per share in cash and stockShares of Spectrum Brands Holdings  Inc    NYSE SPB   plummeted 19  after the company reported fourth quarter fiscal 2018 earnings of  0 79 per share  missing the Zacks Consensus Estimate of  1 13 per shareWalgreens Boots Alliance  Inc  s   NASDAQ WBA   shares fell 0 7  after the state of Florida sued the company accusing it of not taking precautionary measures to stop illegal sales of opioidsShares of Colfax Corporation   NYSE CFX   declined 15 2  after the company shared plans of acquiring DJO Global for  3 15 billion in cash,2018-11-19,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-nov-20-2018-200361089,200361089
179121,400637,WBA,Walgreens Boots Alliance  WBA  Stock Sinks As Market Gains  What You Should Know,opinion,"In the latest trading session  Walgreens Boots Alliance  NASDAQ WBA  closed at  79 76  marking a  0 04  move from the previous day  This move lagged the S P 500 s daily gain of 0 3   At the same time  the Dow 0   and the tech heavy Nasdaq gained 0 92  
Coming into today  shares of the largest U S  drugstore chain had gained 7 49  in the past month  In that same time  the Retail Wholesale sector lost 3 96   while the S P 500 lost 4 06  
Investors will be hoping for strength from WBA as it approaches its next earnings release  which is expected to be January 3  2019  On that day  WBA is projected to report earnings of  1 43 per share  which would represent year over year growth of 11 72   Meanwhile  our latest consensus estimate is calling for revenue of  33 64 billion  up 9 44  from the prior year quarter 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  6 54 per share and revenue of  137 65 billion  These totals would mark changes of  8 64  and  4 65   respectively  from last year 
Any recent changes to analyst estimates for WBA should also be noted by investors  Recent revisions tend to reflect the latest near term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection has moved 0 29  higher  WBA is currently a Zacks Rank  2  Buy  
Valuation is also important  so investors should note that WBA has a Forward P E ratio of 12 19 right now  Its industry sports an average Forward P E of 12 19  so we one might conclude that WBA is trading at a no noticeable deviation comparatively 
Investors should also note that WBA has a PEG ratio of 1 27 right now  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  Retail   Pharmacies and Drug Stores stocks are  on average  holding a PEG ratio of 1 09 based on yesterday s closing prices 
The Retail   Pharmacies and Drug Stores industry is part of the Retail Wholesale sector  This group has a Zacks Industry Rank of 10  putting it in the top 4  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2018-11-22,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-alliance-wba-stock-sinks-as-market-gains-what-you-should-know-200361853,200361853
179122,400638,WBA,Walgreens  WBA  Hits 52 Week High  Can The Run Continue ,opinion,"Have you been paying attention to shares of Walgreens Boots Alliance  NASDAQ WBA   Shares have been on the move with the stock up 6  over the past month  The stock hit a new 52 week high of  83 53 in the previous session  Walgreens Boots Alliance has gained 15  since the start of the year compared to the 4 8  move for the Zacks Retail Wholesale sector and the 14 5  return for the Zacks Retail   Pharmacies and Drug Stores industry 
What s Driving the Outperformance 
The stock has an impressive record of positive earnings surprises  as it hasn t missed our earnings consensus estimate in any of the last four quarters  In its last earnings report on October 11  2018  Walgreens reported EPS of  1 48 versus consensus estimate of  1 44 
For the current fiscal year  Walgreens is expected to post earnings of  6 54 per share on  137 49 billion in revenues  This represents an 8 64  change in EPS on a 4 52  change in revenues  For the next fiscal year  the company is expected to earn  7 04 per share on  141 73 billion in revenues  This represents a year over year change of 7 71  and 3 09   respectively 
Valuation Metrics
Walgreens may be at a 52 week high right now  but what might the future hold for the stock  A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself 
On this front  we can look at the Zacks Style Scores  as they provide investors with an additional way to sort through stocks  beyond looking at the Zacks Rank of a security   These styles are represented by grades running from A to F in the categories of Value  Growth  and Momentum  while there is a combined VGM Score as well  The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style 
Walgreens has a Value Score of B  The stock s Growth and Momentum Scores are B and F  respectively  giving the company a VGM Score of B 
In terms of its value breakdown  the stock currently trades at 12 8X current fiscal year EPS estimates  On a trailing cash flow basis  the stock currently trades at 10 7X versus its peer group s average of 8 3X  Additionally  the stock has a PEG ratio of 1 3  This isn t enough to put the company in the top echelon of all stocks we cover from a value perspective 
Zacks Rank
We also need to look at the Zacks Rank for the stock  as this supersedes any trend on the style score front  Fortunately  Walgreens currently has a Zacks Rank of  2  Buy  thanks to rising earnings estimates 
Since we recommend that investors select stocks carrying Zacks Rank of 1  Strong Buy  or 2  Buy  and Style Scores of A or B  it looks as if Walgreens passes the test  Thus  it seems as though Walgreens shares could have potential in the weeks and months to come ",2018-11-27,Zacks Investment Research,https://www.investing.com/analysis/walgreens-wba-hits-52week-high-can-the-run-continue-200363120,200363120
179149,400665,WBA,Here s How To Invest In A Stock Market That s Due For A Hard Landing,opinion,"I simply don t trust the fundamentals of the global economy right now  The system is built on quicksand 
Debt is growing globally and governments are running huge deficits while interest rates are still incredibly low  Looking at almost any metric  stock markets have been more expensive once in the last 100 years   just before the dot com bubble burst  There is also another risk in a category of its own  China 
A recent Bloomberg report on Chinese real estate noted that from June 2015 through the end of last year  the 100 City Price Index  published by SouFun Holdings Ltd   rose 31  to almost  202 per square foot  That s 38  higher than the median price per square foot in the U S   where per capita income is more than 700  greater than in China 
This China story gets more interesting  Most of these apartments are sitting empty because they are purchased as investments  Rental yields in China are 1 5   while the cost of borrowing  mortgage cost  is around 5  6   Chinese consumer debt to GDP is much greater than it was in the U S  during the 2008 09 financial crisis 
Since household real estate lending is 22  of Chinese banks  assets  if you are the almighty Chinese government  you have a decision to make  Do you let real estate prices normalize  decline  and then suddenly discover that your financial institutions are bankrupt  or do you allow  and actually support  the inflation of housing prices 
Predictably  as the Bloomberg report relates  China is ramping up development  and rather than curtail leverage  banks are jumping into the speculative real estate bubble  mortgage growth is now at 20  
Which brings me to one of my all time favorite books   Margin of Safety   by investing legend Seth Klarman  who writes 

 There is the old story about the market craze in sardine trading when the sardines disappeared from their traditional waters in Monterey  California  The commodity traders bid them up and the price of a can of sardines soared  One day a buyer decided to treat himself to an expensive meal and actually opened a can and started eating  He immediately became ill and told the seller the sardines were no good  The seller said   You don t understand  These are not eating sardines  they are trading sardines  

Applying this to China  when an apartment becomes an unoccupied asset whose sole purpose to be used as a investment or speculation  it turns into a trading sardine  Its price will rise until   nobody knows  but at some point someone will metaphorically open that trading can and Chinese real estate prices will collapse  bringing the banking system and the nation s economy down with them  Simply put  things that cannot go on forever don t   it just feels like they ll go on forever while you re waiting for them to stop 
Today s global investment environment is a game of musical chairs  Investors are up and marching along because the music is playing  hoping they ll be able to grab a chair when the music stops  few will do so   Accordingly  I am investing as if the music might stop any second 
Over the past 10 years it has not paid to be cautious  Low interest rates drove prices of almost all assets higher  Pricier assets made people feel wealthier and thus magically created economic growth  Low interest rates also pushed people into riskier assets  thus creating a mismatch between the assets people hold and their true risk affordability and appetite 
So far  none of this has mattered   the more risk you took  the more money you made  It will matter when risk gets ugly  because investor reaction to it will be more irrational than usual  This is why my firm hedges our portfolios through put options 
The problem with an economy being propped up by artificially appreciated assets is that this pendulum swings both ways  At some point  prices will decline  No one knows what will cause the decline   maybe higher interest rates  maybe a presidential tweet  maybe the implosion of the Chinese economy  or maybe just because stock markets and real estate prices don t grow to the sky  Or it could be triggered by something completely unseen today 
What is clear is that since interest rates are low and global economies are highly leveraged  central banks and governments will not have as much power to help 
This is one reason why my firm s portfolio holds a lot of healthcare stocks  including Walgreens Boots Alliance  NASDAQ WBA   Healthcare companies have great balance sheets  their business is not cyclical  the demand for its products doesn t fluctuate with the whims of the global economy   and there is a huge tailwind behind their backs in the form of the aging global population  Moreover  many of these stocks trade at highly attractive valuations 
Disclosure  Vitaliy Katsenelson is CIO at Investment Management Associates  His investment strategy is spelled out here ",2018-09-26,Vitaliy Katsenelson,https://www.investing.com/analysis/how-to-invest-in-a-stock-market-thats-due-for-a-hard-landing-200345577,200345577
179150,400666,WBA,Walgreens Boots Alliance  WBA  Gains But Lags Market  What You Should Know,opinion,"Walgreens Boots Alliance  NASDAQ WBA  closed the most recent trading day at  79 90  moving  0 16  from the previous trading session  This move lagged the S P 500 s daily gain of 0 65   Elsewhere  the Dow gained 0 79   while the tech heavy Nasdaq added 1 01  
Coming into today  shares of the largest U S  drugstore chain had gained 8 09  in the past month  In that same time  the Retail Wholesale sector lost 12 48   while the S P 500 lost 6 82  
WBA will be looking to display strength as it nears its next earnings release  which is expected to be January 3  2019  On that day  WBA is projected to report earnings of  1 43 per share  which would represent year over year growth of 11 72   Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  33 64 billion  up 9 44  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  6 54 per share and revenue of  137 65 billion  These totals would mark changes of  8 64  and  4 65   respectively  from last year 
It is also important to note the recent changes to analyst estimates for WBA  These revisions typically reflect the latest short term business trends  which can change frequently  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  Within the past 30 days  our consensus EPS projection has moved 1 55  higher  WBA is currently a Zacks Rank  2  Buy  
Digging into valuation  WBA currently has a Forward P E ratio of 12 19  This represents a no noticeable deviation compared to its industry s average Forward P E of 12 19 
Meanwhile  WBA s PEG ratio is currently 1 24  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  Retail   Pharmacies and Drug Stores stocks are  on average  holding a PEG ratio of 1 07 based on yesterday s closing prices 
The Retail   Pharmacies and Drug Stores industry is part of the Retail Wholesale sector  This group has a Zacks Industry Rank of 11  putting it in the top 4  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow WBA in the coming trading sessions  be sure to utilize Zacks com ",2018-11-01,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-alliance-wba-gains-but-lags-market-what-you-should-know-200353587,200353587
179171,400687,WBA,Special Report  Starting in Arkansas  Trump era Medicaid rules alter healthcare landscape,news,By Yasmeen Abutaleb EARLE  Arkansas  Reuters    Gregory Tyrone Bryant left his last stable job at a meatpacking factory to fight a cocaine addiction eight years ago  When he returned to the workforce a year later  his options were limited  mostly temporary jobs without healthcare benefits  Since 2014  he s relied on medical coverage offered under Arkansas  expanded Medicaid program for low income households  It proved essential last June when he needed surgery to replace his right knee  and covers costly prescriptions for acid reflux and high blood pressure medicines  Bryant  48  had been out of work again for more than a year until late last month  when he got hired as a janitor in his local school district  On a 90 day probation period  he hopes the job will turn into full time work  He had been living off a monthly short term disability check from his last job assembling rear axles for Toyota cars  There s not much on offer near his home in Earle  Arkansas  population 2 000  If his job doesn t pan out  his unemployment will pose a new threat to his healthcare coverage  In June  Arkansas became the first U S  state to require that many able bodied Medicaid recipients do some combination of work  volunteer  job training or schooling a minimum of 80 hours each month to keep their benefits  a sweeping shift in healthcare rules that will soon be followed by Indiana and New Hampshire  Another eight states await approval from the Trump administration for similar work requirements that will fundamentally refigure the 50 year old program  Republican governors and lawmakers say the work requirements are vital to help manage their ballooning Medicaid costs  particularly in states like Arkansas that expanded the program under former President Barack Obama s Affordable Care Act  The goal  they say  is to encourage healthier residents to return to the employment track  or seek better jobs that could eventually bring benefits   It s an element of individual responsibility that if you re able bodied   you should be contributing in some fashion   Arkansas Governor Asa Hutchinson said in an interview   You always want people to move up to make more wages and have a higher income so they don t even have to qualify for Medicaid   Yet the new measures have triggered fears that thousands could lose their Medicaid benefits  putting already vulnerable laborers deeper into the hole  The changes are also forcing insurers to hustle to help clients navigate the maze of paperwork they must complete to keep benefits intact  And Kentucky s plan  poised to become the second to take effect  hit an abrupt halt last month when a federal judge blocked the law   deeming the Trump administration s approval  arbitrary and capricious   The U S  Department of Health and Human Services never fully considered whether Kentucky s plan will provide medical assistance to residents  U S  District Judge James Boasberg ruled  The state said it will amend its proposal in hopes of clearing the legal hurdle  In Kentucky alone  nearly 100 000 more people could be eliminated from Medicaid within five years than without the new measures  state estimates say  Kentuckians who do not work 80 hours in any one month or fail to pay new premiums will be locked out for six months  beneficiaries could take a health or financial literacy course to reactivate coverage  In Arkansas  those who fail to meet the work requirements for any three months will be locked out of health insurance for the remainder of the year  In meetings with state legislators  the Arkansas Hospital Association has expressed concern that many affected by the rules will either not be able to find work  or won t be able to meet online filing requirements because they live in rural areas without reliable Internet access   We re worried about people losing coverage who should not be losing their coverage   said Bo Ryall  the group s president  As he visited a local health clinic for severe back pain  Bryant pondered that question   I thought the insurance was to help us  even if you re working  even if you re not working   he said   It was supposed to help us  not pull us down   MEDICAID GIVE AND TAKE The Republican controlled Congress tried several times last year to repeal Obamacare  formally known as the Affordable Care Act  and replace it with new legislation that would have overhauled Medicaid by giving states block grants to run their own Medicaid programs in lieu of the existing federal state partnership  Their proposals would have cut federal spending on the government s health insurance program for the poor and disabled by nearly  800 billion over 10 years  When those efforts failed  the Trump administration put a conservative stamp on health policy  including approving state requests to implement work requirements  Most states that have submitted proposals will require adult beneficiaries who are not disabled  pregnant or elderly to engage in some combination of work  volunteer  job training or school opportunities for at least 80 hours a month   or lose their benefits  Such requirements create new hurdles to healthcare businesses in states that adopt them  Those businesses  including health insurers  hospitals and community clinics  say they re moving to minimize the number of people who could lose their insurance  WellCare  N WCG   one of Kentucky s five Medicaid providers  said it will help connect members with job opportunities and training courses  It will staff a call center for beneficiaries to navigate requirements and services such as child care or access to food  The insurer has been meeting for more than a year with state officials gearing up for the program rollout  said Bill Jones  WellCare s state president in Kentucky  The company  which administers Medicaid plans in 12 states  has grown its business considerably since the Medicaid expansion took effect in 2014  Its stock price has more than tripled in that time   There s always a concern there s going to be business impact  I just want to make sure we re not losing the wrong members   Jones said  referring to beneficiaries who meet the requirements but don t properly log their hours  The insurer could lose members who transition to employer provided coverage  Jones added  calling that the  right reason   Hospital and insurer lobbyists have begun pushing state government and health officials to allow for flexibility in exemptions from work  such as for those who live in areas with high unemployment  and to allow for a grace period before someone is locked out  They also want states to weigh worries that Medicaid members may not have transportation to work   Arkansas Blue Cross and Blue Shield has staffers in its stores to help residents log their hours  The insurer will contact members not complying with work requirements   by  among other steps  tracking whether patients have picked up a pharmacy prescription  The pharmacist would then ensure customers understand the new rules  Arkansas Blue Cross and Blue Shield said it was working with Walmart  N WMT   Walgreens  O WBA   CVS  N CVS   local pharmacies and others  In Arkansas  the work requirements apply to the Medicaid expansion population  which totals about 300 000 people  But many will be exempt from the new rules thanks to exceptions  including for illness  disability  pregnancy or their role as a caregiver  Still  state officials estimate that up to 30 000 40 000 people in the first phase will have to find work to maintain their benefits  in which able bodied adults 30 49 who earn less than  680 a month must submit documents each month showing they have worked or volunteered  In 2019  the program extends to adults 19 29  Ennis Barnes  40  fears he won t make the cut  The new rules coincide with similar requirements for Arkansas food stamp recipients  and Barnes has already received notice his food benefits will be reduced  Barnes lives in rural Lepanto  Arkansas  For several years  he s worked with temp agencies to connect with manufacturing jobs  He worries companies won t hire him permanently because of a drug charge dating back more than a decade  He works as a barber in his house a couple days a week   work that will not count toward his required hours since he doesn t get a pay stub   I ve got a family to take care of  grandbabies and everything   Barnes said   I just don t understand   Kentucky planned to introduce its  community engagement  requirements this month for able bodied adults 19 64 who are not pregnant  medically frail  a single parent  chronically homeless  in substance abuse treatment  enrolled in food stamps or a full time student  The state is phasing in beneficiaries by region  The requirements also impose premium payments based on income  some who fail to make the payment will have to take a financial literacy course  That plan hit a roadblock in federal court  Sixteen Medicaid recipients in Kentucky won a federal lawsuit asking a judge to overturn the state s work requirements  contending the federal HHS went beyond its authority by approving Kentucky s waiver  The lawsuit said the plaintiffs are at risk of losing health benefits because of new eligibility criteria  the highest ever premiums allowed in Medicaid and lockouts for those not meeting the requirements  Kentucky said the judge blocked the program on the  narrow basis  that HHS had not considered the plan s impact on Medicaid coverage  and said it would work with the agency to address the issue  Days after the ruling  Kentucky Governor Matt Bevin cut dental and vision benefits for some 460 000 state Medicaid recipients  saying the benefits were dependent on implementation of the community engagement requirements  Without the new rules   immediate benefit reductions would be required to compensate for the increasing costs of expanded Medicaid   said Doug Hogan  spokesman for the state s Cabinet for Health and Family Services  Some legal experts say the ruling could thwart the Trump administration s Medicaid blueprint  should residents in other states bring similar lawsuits   It points to the failure of the administration to provide a legitimate record to justify the approval   said Allison Hoffman  a professor at the University of Pennsylvania Law School   It s unlikely that they re going to come up with the kind of evidence they need to show that the requirements here actually make poor people healthier   BIG EMPLOYERS  PART TIME WORKERS Major corporations with large numbers of part time workers  such as Walmart  headquartered in Bentonville  Arkansas  are one focal point of concern  The world s largest retailer has shifted to more part time workers over the last decade  according to a May report from the Organization United for Respect  formerly called OUR Walmart  The labor group says it is a network of more than 150 000 people working in low wage retail jobs  An estimated 50 percent of Walmart s U S  workforce in 2018 is part time  compared to 20 percent in 2005  the report said  Daniel Schlademan  OUR s co director of organization  said that means more Walmart workers rely on state Medicaid programs for their healthcare  but did not provide figures   All this is going to do is make more people have less coverage   he said   Walmart said its health plan covers more than one million people in the U S   including spouses and dependents  and has seen the number of associates eligible for health coverage grow as its full time workforce expanded  Its part time employees are eligible for medical benefits if they average 30 hours per week over a 12 month period  the company said  Walmart did not say how many of its employees receive health benefits  and it declined to provide a breakdown of part time and full time workers  The company disputed the OUR report  saying it converts about 150 000 employees a year from part  to full time   We are proud to be one of the few retailers with a majority full time hourly workforce   said Walmart spokesman Justin Rushing   We have more full time jobs than any private business in America and we have seen that percentage go up over the last few years   Part time and temporary workers could be particularly vulnerable with the new changes  Part timers comprised nearly 16 percent of Arkansas  workforce in 2017  or 208 000 people  federal data show  Walmart and poultry producer  Tyson Foods   N TSN   another large Arkansas employer  declined to discuss how the Medicaid measures would affect their workforces  Other large state employers  including propane supplier Ferrellgas  N FGP   chicken producer OK Foods  Cooper Tire   Rubber Co  N CTB  and department store chain Dillards  declined comment  Supporters of the new law say it will push more residents to find full time work  Arkansas  for one  is short on registered nurses  certified nurse assistants  technical health field workers  truck drivers  construction workers and manufacturing laborers  said Arkansas Chamber of Commerce President Randy Zook   It s going to persuade some people to take another look and likely they ll find better opportunities than they thought were available   Zook said  Some Arkansans noted  though  that the new rules could be a challenge for people in rural pockets where full time job openings have historically been thin  Tina Lotts  46  is one case study  She works 40 hours a week as a security guard at a consumer goods and technology warehouse  Yet Lotts is not considered a full time employee and doesn t qualify for healthcare coverage from her employer  A diabetic  Lotts relies on Medicaid for her doctor visits and the four medications needed to control her blood sugar levels and hypertension   I have 11 bills and it s hard to pay them all   Lotts said  Since he lost his short term disability payments  Bryant is applying for long term disability in the hope of receiving an exemption from Arkansas  requirements so that he is not at risk of losing his insurance  His wife  Felicia  has already applied for long term disability due to vertigo  sciatic nerve pain and other issues  Ideally  Bryant said  his new job will turn into full time work and he won t need an exemption   I m trying to find work every day   Indeed  labor advocates challenge the notion that able bodied Americans haven t pushed to find jobs  an underlying tenet of the new rules  The number of Americans actively engaged in the labor force who are looking  but haven t found jobs  has declined to an 18 year low of 3 8 percent  and is considered near or at full employment   These are people who want to work full time but can t get full time work   said William Spriggs  chief economist of the AFL CIO union  To Spriggs  the work requirements are  extremely na ve to assume that simply looking for a job gets someone a job    or  at worst   mean spirited   Hutchinson  governor of the new law s first test case  disagrees   It s not punitive   he said   It s simply that we respect work and we know the people of Arkansas want to work  ,2018-07-10,Reuters,https://www.investing.com/news/politics-news/special-report-starting-in-arkansas-trumpera-medicaid-rules-alter-healthcare-landscape-1523377,1523377
179206,400722,WBA,Prince heirs sue Illinois hospital  Walgreens pharmacy chain over singer s death,news,"By Dan Whitcomb  Reuters    Heirs of Prince have sued an Illinois hospital and pharmacy chain Walgreens  saying they could have prevented the singer s 2016 death if they had properly diagnosed and treated his overdose days earlier  a court document showed on Monday  The wrongful death lawsuit  filed in Cook County Circuit Court in Chicago on Friday  accuses a doctor and pharmacist at Trinity Medical Center in Rock Island  Illinois  of failing to properly investigate the overdose or see that the pop star received appropriate counseling   The six heirs also accuse two Walgreens pharmacists of improperly dispensing prescription medication to Prince  according to the lawsuit  Representatives of the hospital could not be reached by Reuters for comment on Monday evening  A spokesman for the hospital s parent company  UnityPoint Health  told the Minneapolis Star Tribune that the company did not comment on pending litigation  A spokesman for Walgreens  whose parent company is Walgreens Boots Alliance  NASDAQ WBA  Inc  declined to comment to Reuters   Prince  57  was found dead at his Paisley Park home and recording studio complex near Minneapolis on April 21  2016  The official cause of death was a self administered overdose of the painkiller fentanyl  which is 50 times stronger than heroin   A Minnesota prosecutor said last week he could not bring any criminal charges in connection with the  Purple Rain  singer s death after a two year investigation failed to determine where he obtained a counterfeit painkiller laced with fentanyl   Police investigating Prince s death found numerous opioids in the singer s home  according to court documents released in April 2017   The death of the music superstar  who crafted a public image of a clean and healthy vegan lifestyle  shocked the world and set off a protracted battle among his siblings and half siblings over who would inherit his estate  estimated to be worth hundreds of millions of dollars  Prince  known for his androgynous style and sexually charged songs  died a day before he was set to meet a California based doctor who specializes in addiction treatment  
After his death  his longtime collaborator and protege Sheila E  told  Entertainment Tonight  that Prince had been suffering from hip and knee pain from decades of intense performing  much of it in his heels ",2018-04-24,Reuters,https://www.investing.com/news/general-news/prince-heirs-sue-illinois-hospital-walgreen-pharmacy-chain-over-singers-death-report-1409810,1409810
179207,400723,WBA,Theranos founder Holmes  former president indicted for fraud,news,"By Nate Raymond  Reuters    Theranos Inc founder Elizabeth Holmes and the embattled blood testing company s former president were indicted on charges that they engaged in schemes to defraud investors  doctors and patients  the U S  Justice Department announced on Friday  The charges against Holmes  34  and Ramesh  Sunny  Balwani  53  were announced shortly after the privately held company said that she was stepping down as its chief executive  Prosecutors said that Holmes and Balwani used advertising and solicitations to encourage doctors and patients to use its blood testing laboratory services despite knowing the company could not produce accurate and reliable results consistently   This conspiracy misled doctors and patients about the reliability of medical tests that endangered health and lives   FBI Special Agent in Charge John Bennett said in a statement  The indictment also alleged that Holmes and Balwani made numerous misrepresentations about Theranos  financial condition and prospects  Balwani  who worked at Theranos from September of 2009 through 2016  had also served as chief operating officer and was a member of the board  In a statement  Theranos said Holmes would remain chair of the company s board and David Taylor  the firm s general counsel  had been appointed CEO  Each defendant faces two counts of conspiracy to commit wire fraud and nine counts of wire fraud  Prosecutors said both entered pleas of not guilty on Friday during a hearing before a federal magistrate judge in San Jose  California  The criminal charges came after Holmes in March settled civil fraud charges brought by the U S  Securities and Exchange Commission under which she was barred from serving as an officer or director of a public company for 10 years  Lawyers for Holmes did not respond to requests for comment  Jeffrey Coopersmith  Balwani s attorney  said his client had committed no crimes   Mr  Balwani looks forward to trial because he did not defraud anyone  and it will be an honor to defend him vigorously   Coopersmith said in a statement  Holmes  who started Theranos at the age of 19  was celebrated as a rising star of Silicon Valley until it became clear that many of the claims about the company s supposedly revolutionary blood test were bogus  The company reached a  9 billion valuation based on its promise to disrupt the laboratory testing business  In presentations to potential investors  to doctors at medical meetings and to the media  Holmes claimed the Theranos analyzer could perform a full range of clinical tests using tiny blood samples drawn from a finger stick  and that it could produce results that were more accurate  reliable and faster than those from conventional blood tests   The indictment alleges that Holmes and Balwani knew their analyzer had accuracy and reliability problems  performed a limited number of tests  was slower than some competing devices  and  in some respects  could not compete with existing conventional machines  They told investors that Theranos could generate about  1 billion in revenues in 2015 when in fact the company had generated just a few hundred thousand dollars in 2014 and 2015  the indictment said  
In 2015  the Wall Street Journal reported that Theranos  devices were flawed and inaccurate  setting off a downward spiral for the company that had bagged investors including venture capital firm DFJ  Walgreens  O WBA   media mogul Rupert Murdoch and Oracle  N ORCL  co founder Larry Ellison ",2018-06-15,Reuters,https://www.investing.com/news/stock-market-news/theranos-founder-elizabeth-holmes-steps-down-as-ceo-1495490,1495490
179218,400734,WBA,Walgreens Boots  WBA  Down 2 4  Since Last Earnings Report,opinion,"It has been about a month since the last earnings report for Walgreens Boots Alliance  Inc    NASDAQ WBA    Shares have lost about 2 4  in that time frame 
Will the recent negative trend continue leading up to its next earnings release  or is WBA due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers 
Recent EarningsWalgreens Boots reported adjusted earnings per share  EPS  of  1 73 in second quarter fiscal 2018  up 27 2  year over year and 25 7  at constant exchange rate  CER   The figure surpassed the Zacks Consensus Estimate of  1 55 On a reported basis  net earnings came in at  1 3 billion  reflecting an increase of 27 3  from the prior year quarter  Reported EPS came in at  1 36  up 38 8  on a year over year basis Total SalesWalgreens Boots recorded total sales of  33 02 billion in the fiscal second quarter  up 12 1  year over year and 9 4  at CER  The top line outpaced the Zacks Consensus Estimate of  31 99 billion Segments in DetailWalgreens Boots reports under three operating segments  Retail Pharmacy USA  Retail Pharmacy International and Pharmaceutical Wholesale Retail Pharmacy USAThe segment recorded sales of  24 5 billion in the second quarter  highlighting an improvement of 12 2  year over year  Within this segment  total sales at comparable drugstores rose 2 4   while prescriptions filled in comparable stores grew 4  on account of Medicare Part D growth and volume growth from strategic pharmacy collaborations  Comparable retail sales dropped 2 7  Pharmacy sales  which accounted for 70 3  of the Retail Pharmacy USA division s sales in the quarter  increased 18 7  from the year ago quarter  Pharmacy sales at comparable stores rose 5 1  on higher volumes Retail Pharmacy InternationalRevenues at the Retail Pharmacy International division rose 7  on a year over year basis  down 2 6  at CER  to  3 3 billion owing to currency fluctuations  At CER  comparable store sales in the second quarter declined 1 7  year over year along with a 0 6  uptick in comparable pharmacy sales Pharmaceutical WholesaleThe Pharmaceutical Wholesale division recorded quarterly sales of  5 8 billion  up 14 4  year over year  up 3 4  at CER  MarginsGross profit in the reported quarter increased 7 1  year over year to  8 09 billion  However  gross margin contracted 116 basis points  bps  to 24 5  Selling  general and administrative  SG A  expenses were up 3 2  year over year to  6 32 billion  However  adjusted operating income increased 23 7  to  1 78 billion  Adjusted operating margin contracted 50 bps to 5 4  Financial ConditionWalgreens Boots exited the second quarter with cash and cash equivalents of  1 75 billion  compared with  1 83 billion at the end of the first quarter  Long term debt was  12 53 billion  compared with  12 73 billion at the end of the preceding quarter Year to date  the company has generated operating cash flow of  3 18 billion  compared with  3 38 billion a year ago  The resultant free cash flow was  2 51 billion Guidance RaisedWalgreens Boots has raised the low and high ends of its outlook for fiscal 2018 EPS to  5 85 to  6 05 from  5 45 to  5 70  The Zacks Consensus Estimate for earnings is pegged at  5 79  below the company s guided range The company now expects cash tax benefit from U S  tax law changes in excess of  350 million in fiscal 2018  compared with the previously announced estimate of more than  200 million 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  There have been two revisions higher for the current quarter compared to six lower Walgreens Boots Alliance  Inc  Price and Consensus
     
VGM Scores
At this time  WBA has a nice Growth Score of B  however its Momentum is doing a bit better with an A  The stock was also allocated a grade of A on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is more suitable for value and momentum investors than growth investors 
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift  Interestingly  WBA has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-04-26,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-wba-down-24-since-last-earnings-report-200310242,200310242
179219,400735,WBA,Fred s Confirms Sale Of Specialty Pharmacy Unit  Stock Up,opinion,Fred s Inc    NASDAQ FRED   confirmed sale of certain assets of its specialty pharmacy business  EntrustRx  to CVS Health Corporation   NYSE CVS    The company has been considering the divesture of its specialty pharmacy unit for a while  in a bid to monetize non core assets  reduce debt load and induce a turnaround in its operations  Per the terms  Fred s is entitled to receive  40 million along with a sum equivalent to EntrustRx s inventory value  The transaction is expected to close by May end  upon approval of customary closing conditions Further  this latest move by Fred s seems to have perked up investors  optimism in the stock  Evidently  the stock moved up 2 1  in yesterday s trading session  Let s now delve into this development and see how Fred s is expected to benefit from it The Significance of the DivestitureFred s has been grappling with dismal comparable store sales performance since many quarters  due to lower traffic  sale of low productive discontinued inventory and persistent increase in generic dispensing rate  Although the company made investments in sales teams  therapy diversification and technology upgradations to revive its pharmacy business  it failed to uplift performance  To make matters worse  the company s attempt to improve its pharmacy business performance was crushed by the cancelled Rite Aid Corporation   NYSE RAD   and Walgreens Boots Alliance   NASDAQ WBA   merger in June 2017  The deal could not make its way through regulatory hurdles  which marred Fred s store expansion plans    Amid such headwinds  Fred s has long been exploring strategic alternatives for its pharmacy business and revive itself  Indeed  the company seems to have struck the right chords with its latest deal with CVS Health  The divestiture is expected to provide a relief to Fred s ailing business by vending off some of its dismally performing business units and concentrate more on other prospective areas   In fact  management of Fred s also stated that the cash proceeds from this divestiture will enable the company to strengthen its financial position by reducing debt load Apart from this  Fred s has also been exploring opportunities to augment its retail pharmacy operations  The company is committed toward undertaking strategic transactions  improving cost structure and capital allocation  optimizing assortments  undertaking talent acquisition and efforts to drive revenues and margins  Notably  management foresees cost savings opportunities of  30  40 million for fiscal 2018  backed by the aforementioned efforts and initiatives to lower SKU count  We expect that such well chalked strategies will aid the company to uplift its stock performance in the long run that has declined almost 64  over the past six months  compared with the  s rally of 16 4  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana       Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-05-07,Zacks Investment Research,https://www.investing.com/analysis/freds-confirms-sale-of-specialty-pharmacy-unit-stock-up-200314226,200314226
179225,400741,WBA,Walgreens Boots beats by  0 18  beats on revenue,news,Walgreens Boots  NASDAQ WBA   Q2 EPS of  1 73 beats by  0 18 Revenue of  33 02B   12 1  Y Y  beats by  830M Shares  2 03  PM Press ReleaseNow read ,2018-03-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/walgreens-boots-beats-by-018-beats-on-revenue-1366827,1366827
179226,400742,WBA,Rite Aid completes store transfer to Walgreens,news,Rite Aid  NYSE RAD  has completed the transfer of all 1 932 stores and related assets to Walgreens Boots Alliance  NASDAQ WBA  in exchange for cash proceeds of  4 157B The transfer of three distribution centers and related inventory will start after September 1 Rite Aid s board has terminated the tax benefits preservation plan that it adopted in January aimed at protecting its   2 2B in net operating losses  It was originally set to expired on January 3  2019 Now read ,2018-03-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/rite-aid-completes-store-transfer-to-walgreens-1366812,1366812
179227,400743,WBA,Walgreens pharmacy business drives profit  sales beat,news," Reuters    Walgreens Boots Alliance Inc s  O WBA  quarterly profit and sales beat analysts  estimates on Wednesday  as the drugstore chain s partnerships with pharmacy benefit managers over the past year helped it fill more prescriptions and mail orders  Shares of the biggest U S  drugstore chain operator were up 4 percent in premarket trading on Wednesday  Rival CVS Health Corp s  N CVS  stock also rose 1 percent  Walgreens  which has been focusing on its pharmacy business in the face of falling retail sales  added more than 20 million members through its partnership with pharmacy benefit managers such as Minnesota based Prime Therapeutics  This helped fill 9 1 percent more prescriptions in the quarter and drive a 5 1 percent rise in pharmacy same store sales  The higher number of prescriptions also comes as the United States faced its harshest flu season in decades  with flu related doctor visits reaching a 20 year high  Same store sales at its retail business fell 2 7 percent  missing analysts estimates of a flat growth  according to Evercore analyst Ross Muken   The Deerfield  Illinois based company lifted its full year adjusted earnings forecast to between  5 85 and  6 05 per share from between  5 45 and  5 70 per share  Analysts were estimating  5 78 per share for the year   The lift in forecast reflects a  350 million tax benefit for fiscal year 2018  an increase of about  150 million from the company s previous estimate   Net income attributable to the company rose to  1 35 billion  or  1 36 per share  in the quarter ended Feb  28 from  1 06 billion  or 98 cents per share  a year earlier  Excluding items  Walgreens earned  1 73 per share  Net sales rose 12 percent to  33 02 billion  helped in part by Walgreen s ongoing takeover of nearly 2 000 Rite Aid  N RAD  stores  
Analysts on average were expecting a profit of  1 55 per share on revenue of  32 19 billion  according to Thomson Reuters I B E S ",2018-03-28,Reuters,https://www.investing.com/news/stock-market-news/walgreens-pharmacy-business-drives-profit-sales-beat-1367168,1367168
179239,400755,WBA,Should You Buy Walgreens Boots  WBA  Ahead Of Earnings ,opinion,Walgreens Boots Alliance  Inc    NASDAQ WBA   has been gaining investor confidence on consistently positive results  The stock has lost 19 4  over a year  versus the broader  s 22 8  fall Ahead of its second quarter fiscal 2018 earnings scheduled on Mar 28  we note that the company currently has a market cap of  69 68 billion  Its five year historical growth rate is also favorable at 12 5  compared with the industry s 4 3  Considering the solid prospects  this Zacks Rank  2  Buy  stock is an attractive bet for investors at the moment The company s estimate revision trend for the current year has been positive  In the last 60 days  three analysts revised their estimates upward  with no movement in the opposite direction  The estimate revision for earnings increased around 1 2  to  5 79 per share  Per our   Walgreens Boots sports a Growth Score of B  which is reflective of the company s solid prospects Our research shows that stocks with a Growth Style Score of A or B when combined with a Zacks Rank  1  Strong Buy  or 2 offer the best upside potential In this regard  Walgreens Boots has a favorable Net Margin  Net Income Sales  of 3 2  compared with the industry s 0 4   Moreover  the projected sales growth rate of 9 4  surpassed the industry s rate of 4 5  Factors in FavorLet s take a look at the possible growth propellers Solid Q1 PerformanceWalgreens Boots exited the first quarter on a promising note with better than expected earnings and revenues  We are also encouraged by the uptick in sales at the Retail Pharmacy International segment  Moreover  Walgreens Boots has been gaining on strategic tie ups  which brought more patients to its U S  pharmacies Strong Retail Pharmacy USA BusinessOver the recent past  we have observed Walgreens Boots  Retail Pharmacy USA division witnessing comparable prescription growth and benefitting from strength in retail prescription market  Several planned developments  early benefits of new pharmacy contracts as well as an increase in volume owing to previously announced pharmacy partnerships have been driving growth in this space Moreover  rising expenditure on prescription drugs and growing demand for specialty drugs have been boosting the retail pharmacy market Express Scripts Deal Prospects Promising We are encouraged by Walgreens Boots  plans to expand its existing group purchasing efforts with Express Scripts Holding Company   NASDAQ ESRX   to ensure availability of specialty brand drugs  Since biosimilars have the potential to lower production costs  the move is considered a prudent and timely one Guangzhou Pharmaceuticals Investment StrategicWe are upbeat about the company expanding its global footprint with its decision to acquire a 40  stake in Sinopharm Holding Guoda Drugstores Co   Ltd   GuoDa   a subsidiary of China National Accord Medicines Corporation Ltd  On completion  this investment should provide a strong impetus to Walgreens Boots  worldwide retail pharmacy business  Notably  Shanghai based GuoDa is a large national pharmacy chain in China  It is the retail pharmacy platform of China National Pharmaceutical Group Corporation   CNPGC   Moreover  the company s acceptance of the proposal to sell part of its investment in its Chinese wholesale partner Guangzhou Pharmaceuticals Corporation for huge cash returns buoys optimism Other Key PicksOther top ranked stocks in the broader medical sector are Bio Rad Laboratories   NYSE BIO   and athenahealth  Inc    NASDAQ ATHN   Bio Rad Laboratories sports a Zacks Rank of 1  You can see  The company has a long term expected earnings growth rate of 20  athenahealth is a Zacks  1 Ranked player  The company has a long term expected earnings growth rate of 21 5  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-03-26,Zacks Investment Research,https://www.investing.com/analysis/should-you-buy-walgreens-boots-wba-ahead-of-earnings-200301074,200301074
179240,400756,WBA,Company News For Mar 29  2018,opinion,lululemon athletica inc  s   NASDAQ LULU   shares increased 9 2  after reporting fourth quarter fiscal 2017 adjusted earnings of  1 33 per share  surpassing the Zacks Consensus Estimate of  1 27Shares of RH   NYSE RH   rose 22 5  after reporting fourth quarter fiscal 2017 earnings per share of  1 69  surpassing the Zacks Consensus Estimate of  1 56 Walgreens Boots Alliance  Inc  s   NASDAQ WBA   shares increased 2 5  after reporting second quarter fiscal 2018 adjusted earnings per share of  1 73  surpassing the Zacks Consensus Estimate of  1 55Shares of Facebook  Inc    NASDAQ FB   rose 0 5  after the company responded to the recent date misuse scandal by unveiling changes to its data and privacy tools ,2018-03-28,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-mar-29-2018-200301806,200301806
179241,400757,WBA,The Week Ahead  Have Stock Prices Veered From The Fundamentals  ,opinion,"The economic calendar has several of the most important reports  The managerial rosters will be back at full strength  perhaps after an extra day or two off  Investment committees will consider implications from Q1 results  Pundits will try to explain what it all means  They will ask 
Have stock prices diverged from the fundamental outlook 
Last Week Recap
In my last edition of WTWA I asked whether a trade war could be avoided  This was the key question for the week  and progress was more rapid than most  including me  expected  While not resolved  the stimulus to negotiation and delay in full implementation is encouraging 
The Story in One Chart
I always start my personal review of the week by looking at a great chart  I always start my personal review of the week by looking at a great chart of the S P 500  I especially like the version updated each week by Jill Mislinski  She includes a lot of valuable information in a single visual  The full post has even more charts and analysis  so check it out 

The loss this week included a trading range of about 4   This is in line with recent volatility  but not all in one direction  as was the case in several weeks during Q1  I summarize actual and implied volatility each week in the Indicator Snapshot 
The News
Each week I break down events into good and bad  For our purposes   good  has two components  The news must be market friendly and better than expectations  I avoid using my personal preferences in evaluating news   and you should  too 
Feel free to add items that I have missed  Please keep in mind that we are looking for current news  especially from the last week or so  WTWA is not about long term concerns like debt  These are important  of course  but not our weekly subject unless there has been some major change 
The Good

Personal income just met expectations  but the gain of 0 4  is solid 
Initial jobless claims declined to 215K  much better than expectations of 230K and a new cycle low  It is the lowest week since January of 1973  I like  because it shows both a longer term trend as well as a focus on recent results 




Q4 GDP revised higher to an annualized real rate of 2 9   better than the last estimate of 2 5  and expectations for improvement 
Pending home sales increased 3 1   beating expectations and bouncing back from the January results  revised even lower   The index is still down 4 1  year over year    
Bearish sentiment increased  a contrarian indicator    


The Bad

Chicago PMI declined from 61 9 to 57 4  missing expectations for a slight increase  This is often an indication of the ISM index to be released on Monday 
Consumer confidence softened  although the market is not really treating the near record levels as  bad  

Conference Board 127 7 with 130 prior and forecast 
Michigan sentiment 101 4 with 102 preliminary and consensus  Despite missing expectations  this final reading is the highest since 2004    


Home prices still lag historical growth patterns and measured in real terms  remain 11 1  below the bubble peak   the importance of this approach instead of the typical comparison of nominal prices 

The Ugly
Managerial responses  I am struggling to find the right adjective for the delayed Facebook  NASDAQ FB  apology and policy changes  Large organizations are clumsy when there is no plan in place for a particular event  Facebook s personal link to users contributed to setting the bar higher 
Michigan State University continues to struggle with the consequences of an institutional failure to protect its students  Just when it seemed like the Nassar story had played out  we learn of  against former MSU dean William Strampel  These relate not only to his supervision of Nassar  but allegations about his own acts of sexual harassment and assault  How is management handling the problem  Among other steps they  to a consulting firm to monitor social media  including the accounts of victims 
Mrs  OldProf  when consulted on this question  rattled off some better ideas for a university to spend that amount  along with sympathy for the many innocent students and faculty with ties to the university 
We always hope that our institutions will improve on past mistakes  but this is not encouraging 
The Week Ahead
We would all like to know the direction of the market in advance  Good luck with that  Second best is planning what to look for and how to react 
The Calendar
We have a big economic calendar  featuring the employment report for March  the ISM manufacturing and service indexes  both   and auto sales 
There is a bit of FedSpeak  Congress is in recess  Despite this  the Washington circus may well dominate the news   once again 
 has a good U S  economic calendar for the week  and many other good features which I monitor each day   Here are the main U S  releases 

Next Week s Theme
The economic calendar is more important than usual  with key reports on employment  the ISM surveys  and data on auto sales  While there have been some soft spots  the economic story has remained strong and corporate earnings growth has been excellent  Meanwhile  stocks have given up the gains from early in 2018 
As fund managers  investment committees  investors   and of course the punditry   pause to review the quarter  they will see a mixed picture  Brian Gilmartin sets the table for this week  Earnings estimate revisions are strong  but Q1 stock performance was negative  What is the explanation 
Why the divergence between stock prices and the earnings outlook 
This question lies at the heart of investment plans  Here are the popular alternatives  beginning with those that question the fundamental strength to those that dismiss the current market  message  

At last  The market is finally starting to see the wisdom of my valuation measures  You can see AMZN plummet as people finally calculate its Q ratio  And those pesky forward earnings increases will come down rapidly when this  half cycle  is over and CAPE is king again 
Early year gains were built on false optimism  Reality has set in 
The YTD results are quite normal if one looks at history  See the Jill Mislinski drawdown chart below 
Welcome to normal   David Templeton   
The Trump tax rally has met the Trump trade decline  This is the result   the distortions from mixing political viewpoints with investments  He observes how fear has become extreme despite slender evidence 




Earnings prospects remain strong  despite challenges from the trade controversy  This remains true if one focuses on revenue  avoiding the typical arguments about measuring earnings    



Markets eventually reflect reality   but perhaps not right away     

As usual  I ll save my own conclusions for today s Final Thought 
Quant Corner
We follow some regular featured sources and the best other quant news from the week 
Risk Analysis
I have a rule for my investment clients  Think first about your risk  Only then should you consider possible rewards  I monitor many quantitative reports and highlight the best methods in this weekly update 
The Indicator Snapshot

Short term trading conditions worsened this week  In mildly bearish conditions our trading approaches can still be profitable  but that might not be true for everyone  We continue to monitor the technical health measures on a daily basis  If this indicator goes to fullish bearish  we liquidate trading positions  This is not a forecast that the market will decline  It indicates increased difficulty in trading profitably 
The long term fundamentals and outlook are little changed  The FOMC decision flattened the yield curve a bit  and that is one component of the C Score  Based upon historical data for this indicator  I have increased the 9 month recession probability to the 18  range  I am monitoring  but not yet especially worried  Please see James Picerno below 
The Featured Sources 
  Business cycle analysis via the  C Score 
  Strong quantitative indicators for both economic and market analysis 
  All things earnings  for the overall market as well as many individual companies 
  Business cycle indicator and market timing tools  None of Georg s indicators signal recession 
  Regular updating of an array of indicators  Great charts and analysis  With more new reports  it is time for an update of the    indicators  Results  while still solid  are a touch weaker in Q1 than at the end of the year 

Guests 
James Picerno cites another Fed official  Loretta Mester  expressing skepticism about the value of the yield curve as a signal for economic weakness  Last week James noted a comment from the new Fed Chair  Jerome Powell  questioning the usefulness of yield curve inversion as an indicator of the economy  That is something to watch 
 an indicator based upon an aggregate of regional Fed surveys  I am not a fan of the individual components  so I like this idea  Just to provide a taste  he is a combination of the Capex element   especially important for continuing growth 

Insight for Traders
Our discussion of trading ideas has moved to the weekly Stock Exchange post  The coverage is bigger and better than ever  We combine links to trading articles  topical themes  and ideas from our trading models  Each week we explore a topic of current interest  drawing upon trading experts    Do you keep a shopping list ready   We discussed some stock ideas and updated the ratings lists for Felix and Oscar  this week featuring the S P 500   has taken the lead role on this post  using information both from me and from the models  He is doing a great job  presenting a wealth of new ideas and information each week 
While my intent is to focus on traders  long term investors may also benefit  That was especially true in this week s post 
Insight for Investors
Investors should have a long term horizon  They can often exploit trading volatility  I remind investors of this each week  but now is the time to pay attention 
Best of the Week
If I had to pick a single most important source for investors to read this week it would be Morgan Housel s honest and insightful observation about the investment sales process   Using powerful illustrative analogies  he explains how the process should be client focused  not dependent upon the advisor s own ideas  As he so often does  Morgan has put this well 

Claiming your investment product is entertaining is usually the refuge of those who can t point to performance  But it s crazy to assume that many people don t find investing incredibly entertaining   so much so that they rationally do nutty stuff regardless of what it does to their returns 


Everyone giving investing advice   or even just sharing investing opinions   should keep top of mind how emotional money is and how different people are  If the appropriate path of cancer treatments isn t universal  man  don t pretend like your bond strategy is appropriate for everyone  even when it aligns with their time horizon and net worth 


The best way to talk to people about money is keeping the phrases   What do you want to do   or  Whatever works for you   loaded and ready to fire  You can explain to other people the history of what works and what hasn t while acknowledging their preference to sleep well at night over your definition of  winning  

Stock Ideas
 reviews some interesting dividend candidates for the rest of 2018 
 reviews Twitter  NYSE TWTR   including the effect of privacy concerns and Citron Research s announced short position  The conclusion is that Twitter has much less to lose from tighter regulations 
Walgreens  NASDAQ WBA  or CVS  NYSE CVS    analyzes the history of the competition  developments in the business model  and of course  the relevant data 
Some REITs can withstand rising interest rates    
 has a REIT idea that includes a takeover kicker 
Making money from the mistakes of others  The less that is known  the better the chances   a fund based upon irrationality in the Chinese market 
The  whether it is  all over  for artificial intelligence after Uber s Arizona accident  This is an interesting analysis of the worst performing stocks of the last two weeks  I covered a  about market efficiency  using AI as an example  There are some good stock ideas in this sector 
Personal Finance
Seeking Alpha Senior Editor Gil Weinreich continues his excellent about issues affecting financial advisors  It always has many themes of interest for individual investors  His  post is well suited for my own theme this week  I especially enjoyed Douglas Tengdin s analysis of   There are many heartbreaking examples of those who wound up seriously over weighted in a single stock or two  Often  this is their employer  That doubles the danger 
Abnormal Returns has a  for individual investors  There are a variety of ideas  and nearly always something you will find useful  I especially liked the Scientific American article    I read many of the same sources as Tadas  but he regularly unearths something valuable that I have missed 
I especially recommend the section on communication with spouses  Mrs  OldProf  at year 8 or so of our marriage made an admission  She had been under the impression that college professors made a lot of money 
Strategy   Value Investing
Davidson  via Todd Sullivan  offers insights on   and a couple of   I especially like posts with an educational them and clear illustrations  These meet those tests 
Charlie Bilello    explains that any investment factor  including the value approach  will have periods of significant under performance  Most active managers are quick to dump something that has not  worked  for a year or two 


The problem    3 year underperformance is far from atypical for any smart beta strategy  To the contrary  large cap value has actually underperformed large caps in 51  of rolling 3 year periods going back to 1981  
 Jeff  Strategies that work well in the long run usually have lagging periods  The drive for short term performance leaves many active managers chasing what worked last year  Individual investors can choose better 
Watch out for
Pot stocks  according to a   Bill Alpert analyzes the Canadian stocks  comparing valuations to other markets like gold and alcohol  He writes 

As they often do  investors have celebrated this emerging business early by embracing Canadian companies that claim a cannabis connection  Traveling in Canada  cabbies  bankers  and even border guards will tell you their favorites in a bubble that has floated Canadian cannabis stocks to a collective stock market value above  30 billion  That s already about half the market capitalization of Canada s gold mining industry 



But a Canada weed glut is a real risk  At current valuations  marijuana stocks are already too high for an investor tempted to join the party 

Indexed annuities   reports that annual sales were the lowest since the late  90s  apparently because of the fiduciary rule which went into effect in June  If you do not understand what this means  you should get a second opinion before buying an annuity 
Target date funds   the gap between what beneficiaries seek and what the funds provide 
Final Thoughts
What is normal  Analyzing the market depends on what to expect  Intelligent people who follow financial news will see an  explanation  for everything  even when the market moves are below the typical noise level  No one on financial TV discusses signal to noise 
If your experience is limited to recent years  you will face some surprises  The market is returning to normal  It seems unusual only in the perspective of recent experience  Let s take a closer look 
Market efficiency  Markets are efficient eventually  but often not in short time frames  I wrote a  to alert readers to the current action about how to exploit market inefficiencies  I hope you gained from the ideas  which worked well  but opportunity still abounds   that returns are  lumpy  
Risk  An important part of my interview with a potential client is aligning expectations with their personal needs and concerns  The multiple choice tests for risk tolerance may be OK for satisfying regulators  but they do not really reveal much about the investor  An honest balance of needs and risk requires work  That starts with a realistic idea about risk 
Stock programs typically offer the highest potential return  We take several steps  documented regularly in WTWA  to limit the biggest risks  That said  15 20  drawdowns go with the territory  There is usually not a clear cut reason  although speculation abounds  After a period of extremely small drawdowns and hardly any volatility  even a partial return to normal can be upsetting  Volatility also seems greater because the moves reflect near daily surprises out of Washington  The  provides perspective 

Volatility is normal  Despite the breathless TV commentary  daily stock average moves of 1  are normal  Your own holdings  if both attractive and aggressive  may have larger moves   how volatility  as we have been documenting weekly  is gradually returning to normal levels  The point moves seem large with the averages close to all time highs  but the percentage changes are routine 


Long term investment prospects are solid  The three key elements are all in place 

Expected earnings
Low inflation expectations  and therefore bond yields 
Low inflation risk

Since many confuse headlines with fundamental valuation measures  the market remains inefficient  There are many cheap stocks that are even more attractive than the averages  You just need to know how to look for them 
Investment Conclusion
Early last year  there were many skeptical investors  When the tax cuts passed  many stocks celebrated the repatriation of assets and lower future rates  Investors who were out of the market often felt that they had missed a great opportunity   If only     was a popular refrain 
What about a second chance  a reset  Since I stick to the numbers  I see a chance for investors to re establish a basic stock position  You need not  and should not  go all in  You need a plan  Unless you expect to remain forever on the sideline 
Many investors wait for a dip and then are talked out of their plan it when it comes 
I m more worried about 

The investigation spiral  Is there a threat that the various allegations  lawsuits  and investigations will rise beyond the irritation level  I have no good answer  but my concern has increased in recent weeks 
Leadership turnover  While it is not obvious to some  government agencies benefit from stable and experienced leadership  It is important to have loyal  honest  and dependable nominees at the head of agencies  They should also have an able and experience supporting staff  There is a recurring pattern of deviation from long held and valuable historical norms 

I m less worried about 

Finding stock opportunities  Whatever your analysis of the Trump Administration policies  there is a winners list 
Trade issues  There was  apparently and maybe  some progress this week  Certainly with S  Korea  and maybe on other fronts  There seems to be some progress in the Trump deal making strategy 

 Do the economic challenges seem complicated and threatening  You might find help in my paper on getting back in the market  the top investor pitfalls  or my suggestions about managing risk  Just write for our free information on these topics  While they describe what I am doing  the do it yourself investor can apply the same principles  These are available for free from main at newarc dot com  ",2018-04-01,Jeff Miller,https://www.investing.com/analysis/have-stock-prices-veered-from-the-fundamentals-200302158,200302158
179249,400765,WBA,Walgreens quarterly profit falls 22 percent,news," Reuters    Drugstore chain Walgreens Boots Alliance Inc  O WBA  on Thursday reported a 22 1 percent fall in quarterly profit  partly hurt by an impairment charge related to its investment in Chinese wholesale partner Guangzhou Pharmaceuticals  GZPHA UL   Net income attributable to Walgreens fell to  821 million  or 81 cents per share  in the first quarter ended Nov  30  from  1 05 billion  or 97 cents per share  a year earlier   
Net sales rose 7 9 pct to  30 74 billion ",2018-01-04,Reuters,https://www.investing.com/news/stock-market-news/walgreens-quarterly-profit-falls-22-percent-1061291,1061291
179251,400767,WBA,Walgreens Boots declares  0 40 dividend,news,Walgreens Boots  NASDAQ WBA  declares  0 40 share quarterly dividend  in line with previous Forward yield 2 11 Payable March 12  for shareholders of record Feb  15  ex div Feb  14 Now read ,2018-01-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/walgreens-boots-declares-040-dividend-1122694,1122694
179257,400773,WBA,Zacks com Highlights  Huntington Ingalls Industries  Sprouts Farmers Market  Lithia Motors  Dollar General And Walgreens Boots Alliance,opinion,For Immediate ReleaseChicago  IL   March 1  2018   Stocks in this week s article include  Huntington Ingalls Industries  Inc    NYSE HII    Sprouts Farmers Market  Inc    NASDAQ SFM    Lithia Motors  Inc    NYSE LAD    Dollar General Corporation   NYSE DG   and Walgreens Boots Alliance  Inc    NASDAQ WBA   Screen of the Week of Zacks Investment Research 5 Stocks with Impressive Interest Coverage Ratio to Buy NowWe often judge a company on the basis of its sales and earnings numbers  These  however  may not be enough  Sometimes  a stock gets a boost if these numbers climb year over year or surpass estimates in a particular quarter  This will definitely be a great opportunity for an investor with a shorter horizon to cash in on  But if you seek long term returns  investments backed only by sales and earnings numbers may not yield the desired results A critical analysis of a company s financial background is a prerequisite for an informed investment decision  Here  coverage ratios that determine whether a company is sound enough to meet its financial obligations play a crucial role  The higher the ratio  the better it is  The focus of this article is on  Interest Coverage   which is one such ratio Interest Coverage Ratio   Earnings before Interest   Taxes  EBIT  divided by Interest Expense Why Interest Coverage Ratio Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt Debt  which is crucial for most of the companies to finance operations  comes at a cost called interest  Interest expense has a direct bearing on the profitability of a company and its creditworthiness depends on how effectively it meets interest obligations  Therefore  Interest Coverage Ratio is one of the important criteria to factor in before making any investment decision Interest Coverage Ratio suggests the number of times the interest could be paid from earnings and gauges the margin of safety a firm carries for paying interest An interest coverage ratio lower than 1 0 implies that the company is unable to fulfill its interest obligations and could default on repaying debt  A company that is capable of generating earnings well above its interest expense can withstand financial hardships  Definitely  one should also track the company s past performance to determine whether the interest coverage ratio has improved or worsened over a period of time And that s what we re screening for today For the rest of this Screen of the Week article please visit Zacks com at  Get the remaining stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and back testing software The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material About Screen of the WeekZacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine   But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has more than doubled the market from 1988 through 2016  Its average gain has been a stellar  25  per year  Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Contact  Jim GiaquintoCompany  Zacks comPhone  312 265 9268Email  Visit  Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2018-02-28,Zacks Investment Research,https://www.investing.com/analysis/zackscom-highlights-huntington-ingalls-industries-sprouts-farmers-market-lithia-motors-dollar-general-and-walgreens-boots-alliance-200295380,200295380
179258,400774,WBA,Can Strategic Efforts Aid Fred s To Achieve A Turnaround ,opinion,With underperforming stores  cancellation of dividends and continued bottom line loses  Fred s  Inc  s   NASDAQ FRED   troubles have been aggravating and denting its business for a while  However  to cater to consumers  rapidly changing preferences and sustain market competition  the company has been focusing on pharmacy organization for driving scripts into its stores   Additionally  it has been putting much effort to reduce operating expenses Let s take a look into the factors that have been bruising this discount retailer and discuss the growth plans it has put into place for achieving recovery Factors Denting the StockFred s comps have long been ailing from store closures  thanks to receding store traffic   To top it  comps have also been bearing the brunt of continued increase in generic dispensing rate and sale of low productive discontinued inventory  Persistent challenges in the front store business and competitive consumable categories have also affected overall sales figures  Due to these downsides  comps dipped 1 2   0 3  and 0 8  during the first  second and third quarters  respectively  In addition to dismal comps  increased promotional activity to drive store traffic has been denting business  Incidentally  the company has been reporting bottom line losses for six straight quarters Moreover  the company s business expansion plans were eclipsed by the cancelled Walgreens Boots Alliance   NASDAQ WBA   and Rite Aid Corporation   NYSE RAD   merger in June 2017  If the deal were to materialize  it would have positioned Fred s as the third largest drugstore chain in the nation after Walgreens and CVS Health Corporation   NYSE CVS    However  obstacles such as antitrust concerns cancelled the deal and kept Fred s far behind industry leaders To make matters worse  management announced the cancellation of dividend alongside a dismal third quarter results  In combination  all such factors have gravely affected the company s price performance  The stock has lost 80  in the past year  against the  s rally of 15  Can Efforts Revive Performance Fred s strives to improve store traffic and has accordingly shifted focus to pharmacy organization  This is likely to drive scripts into its stores and improve services for patients  Fred s Retail Pharmacy business seems to be stable  benefiting from the company s shift to profitable generic prescriptions  In order to improve retail pharmacy business  the company has been expanding flu shots capacity along with aggressive inventory management and marketing initiatives Further  management continues to build momentum in the Specialty Pharmacy business through investing in sales team  therapy diversification and technology  Owing to such efforts  the company expects its specialty business to gain access to 5 million new patients across different markets in the forthcoming periods  Additionally  such efforts position the company for new drug introductions  improve data flow and thereby increase efficiency in patient care Fred s also initiated several measures for reducing excess inventory and improving technology to better manage product life cycle  During the third quarter  the company witnessed a turnaround in its tobacco business as well as improved sales of its beer and cosmetics businesses  Further  the company expects improved trends in these categories in the forthcoming periods Along with strengthening pharmacy operations  expense reduction is also listed amongst Fred s efforts to achieve profitability  During the third quarter  management successfully reduced selling  general and administrative  SG A  expenses by 7  to  133 4 million  Further  management expects lower SG A costs to help augment free cash flows  The company expects to pass the gains from the reduced cost structure to its customers and drive store traffic  Moreover  management plans to allocate funds derived from the cancelled dividend toward curtailing debt load  buyback shares and undertake other corporate initiatives With such prospective endeavors in place  all is not gloomy for this Zacks Rank   3  Hold  stock and we can still hope for its revival from the shambles  We hope that such dedicated efforts will help the company to uplift investors  confidence in the stock in the long run You can see Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ,2018-03-13,Zacks Investment Research,https://www.investing.com/analysis/can-strategic-efforts-aid-freds-to-achieve-a-turnaround-200298046,200298046
179259,400775,WBA,AstraZeneca s Tudorza Pressair successful in Phase 4 COPD study,news,Results from the Phase 4 ASCENT study showed AstraZeneca s  NYSE AZN  Tudorza Pressair  aclidinium bromide  400  g  administered twice daily as background therapy  produced a statistically significant reduction on the annual rate of moderate or severe exacerbations compared to placebo in patients with moderate to very severe chronic obstructive pulmonary disease  COPD  with significant cardiovascular risk factors The study also met the primary safety endpoint The company is continuing its analysis of the data  Complete results will be shared with the FDA and submitted for presentation at a future medical conference  It also plans to file a U S  marketing application for the expanded indication of Tudorza AstraZeneca is collaborating with Circassia Pharmaceuticals on the development and commercialization of Tudorza and Duaklir  aclidinium bromide formoterol  in the U S Now read ,2017-12-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/astrazenecas-tudorza-pressair-successful-in-phase-4-copd-study-947870,947870
179260,400776,WBA,Asian Shares Mixed With The Nikkei 225 Up Solidly In Rebound,news,"Investing com   Asian shares were mixed on Thursday  with Tokyo recouping some losses from the previous day 
Japan s Nikkei 225 rose 1 27   while Australia s S P ASX 200 gained 0 57   In Australia  the trade balance for October came in at a surplus of A 105 million  down from a surplus of A 1 604 billion posted in September 
The Australian Securities Exchange said in a Thursday statement it intended to replace its existing clearing and settlement system with distributed ledger technology  or blockchain  The new system will be open to market feedback at the end of March 2018  the ASX said 
Elsewhere  Walgreens Boots Alliance  NASDAQ WBA  on Wednesday said it would acquire 40  of Sinopharm Holding Guoda Drugstores  a Chinese retail pharmacy operator  Walgreens said it would buy the stake for CNY 2 77 billion   416 million  from China National Accord Medicines Corporation 
In Greater China  the Shanghai Composite fell 0 59  and the Hang Seng index eased 0 01  
Overnight  US stocks closed mixed on Wednesday as investors awaited an update on the progress of tax reform  while   slump in financials offset strong gains in tech pressuring the main indexes lower 
The Dow Jones Industrial Average closed higher at 24143 04  The S P 500 closed 0 01  lower while the Nasdaq Composite closed at 6776 38  up 0 21  
US stocks continued to come under pressure as financials  mostly banks  underperformed the broader market amid a lack of details on the tax reform progress 
The Senate and House of Representatives are set to get talks underway this week to reconcile their respective bills  Investor expectations  however  remained bullish that a final bill will reach President Donald Trump for approval before year end 
On the economic data front investors  cheered bullish private sector job creation data  stoking expectations for a solid non farm payrolls report due Friday 
Private payrolls grew by 190 000 for the month  according to a report released Wednesday by ADP and Moody s Analytics  That beat economists  forecast of 185 000 ",2017-12-06,Investing.com,https://www.investing.com/news/stock-market-news/asian-shares-mixed-with-the-nikkei-225-up-solidly-in-rebound-963283,963283
179261,400777,WBA,Walgreens Boots Alliance to reduce stake in Guangzhou Pharmaceuticals,news,Walgreens Boots Alliance  NASDAQ WBA  announces that it has       entered into an agreement to reduce its stake in Guangzhou       Pharmaceuticals to 20  by selling a 30  interest to Guangzhou Baiyunshan       Pharmaceutical  WBA will continue to account       for its remaining stake as an equity method investment  Now read ,2017-12-22,Seeking Alpha,https://www.investing.com/news/stock-market-news/walgreens-boots-alliance-to-reduce-stake-in-guangzhou-pharmaceuticals-1023213,1023213
179262,400778,WBA,Rite Aid fiscal Q3 top line down 6   non GAAP EPS down 100   cash flow down 41   shares down 5  after hours on revenue miss,news,Rite Aid  NYSE RAD  fiscal Q3 results   M   Revenues  5 353 2   5 6    Retail Pharmacy  3 959 0   3 0    Pharmacy Services  1 445 1   12 2   Net Income  81 0   440 0    non GAAP Net Income  1 619 0   94 0    EPS  0 08   700 0    non GAAP EPS  0 00   100 0   Cash flow ops  129 0   41 0   1 932 stores and three distribution centers are in the process of being sold to Walgreens Boots Alliance  NASDAQ WBA  Consensus view was a loss share of   0 02  on revenues of  7 45B Now read ,2018-01-03,Seeking Alpha,https://www.investing.com/news/stock-market-news/rite-aid-fiscal-q3-top-line-down-6-nongaap-eps-down-100-cash-flow-down-41-shares-down-5-after-hours-on-revenue-miss-1059551,1059551
179264,400780,WBA,Walgreens Boots beats by  0 02  beats on revenue,news,Walgreens Boots  NASDAQ WBA   Q1 EPS of  1 28 beats by  0 02 Revenue of  30 74B   7 9  Y Y  beats by  390M Press ReleaseNow read ,2018-01-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/walgreens-boots-beats-by-002-beats-on-revenue-1061296,1061296
179286,400802,WBA,Walgreens Boots declares  0 40 dividend,news,Walgreens Boots  NASDAQ WBA  declares  0 40 share quarterly dividend  in line with previous Forward yield 2 38 Payable Dec  12  for shareholders of record Nov  13  ex div Nov  10 Now read ,2017-10-24,Seeking Alpha,https://www.investing.com/news/stock-market-news/walgreens-boots-declares-040-dividend-546970,546970
179287,400803,WBA,FTC judge rules against 1 800 Contacts on antitrust charges,news,WASHINGTON  Reuters    A Federal Trade Commission judge has ruled against the online seller 1 800 Contacts  which the agency accused of hammering out deals with rivals that made it harder for consumers to comparison shop  the agency said on Monday  The FTC accused the company of reaching agreements with 14 other online contact lens retailers which required the companies to refrain from advertising to consumers who had searched online for 1 800 Contacts  1 800 Contacts  in exchange  agreed to not advertise to people who searched for the rivals  names  The agreements hampered price conscious consumers from finding rival contact lens sellers and checking their costs  the ruling said   The evidence in this case demonstrates that the advertising restraints imposed by the challenged agreements cause harm to consumers and competition in the market for the sale of contact lenses online   wrote Michael Chappell  the FTC administrative law judge who heard the case  The decision was reached on Oct  20 but withheld until Monday in order to make redactions  Chappell ordered 1 800 Contacts to end the practice of reaching agreements that limit the advertisements of rivals  1 800 Contacts General Counsel Cindy Williams said she was disappointed in the initial ruling and the company would appeal to the commission   Nothing in the initial ruling  however  changes our view that the settlement agreements are lawful and procompetitive and that the company will ultimately prevail once the administrative process runs its course   she said  The deals were reached with Vision Direct  which is owned by Walgreens Boots Alliance  NASDAQ WBA  Inc  Luxottica Group SpA  which owns LensCrafters and Pearle Vision  and National Vision  among others  according to Chappell s initial decision  AEA Investors LP is a major owner of 1 800 Contacts   The online retailer is the world s largest contact lens store  according to its website  It also has about 50 percent of the market for online sales of contact lenses  according to the FTC complaint filed in the case ,2017-10-30,Reuters,https://www.investing.com/news/stock-market-news/ftc-judge-rules-against-1800-contacts-on-antitrust-charges-760347,760347
179304,400820,WBA,ADP Brings 250K New Jobs  Better Than Expected,opinion,"Thursday  January 4  2018The first U S  labor market data of 2018 has hit the tape before the opening bell this morning  with the ADP   NASDAQ ADP   private sector payroll read for December reaching 250K new jobs  This is well beyond the 195K analysts were expecting  November s tally was revised down  but only a tad   5K to 185K  We remain consistent with a very strong employment environment Unsurprisingly  Services easily outpaced Goods producing jobs   222K to 28K  respectively  Medium sized businesses  50 499 employees  brought in the most jobs at 100K  followed by 96K from Small companies  with Large corporations picking up the rear with 56K  Likely we re seeing a lot of seasonal employment in these numbers from December s holiday shopping season  but even still  strength all around Education Healthcare grew by 50K new jobs  followed by Trade Transportation at 45K and Leisure Hospitality at 28K  Even the long dormant Construction and Manufacturing brought in relatively healthy numbers with 16K and 9K  respectively Looking at holiday shopping totals  we see stronger than expected results from both Macy s   NYSE M    up 1 1  in holiday sales comps  and J C  Penney   NYSE JCP    up 3 4   For both companies  these sorts of positive comps are rare  and with new tax cuts for the big box retailers  both are cranking up earnings estimates for next fiscal year Walgreens Boots Alliance   NASDAQ WBA   reported top  and bottom line beats on its Q1 2018 estimates in today s pre market  as well  Earnings topped expectations by a penny to  1 28 per share  up 16 4  year over year  Revenues grew to  30 74 billion  hotter than the  30 33 billion anticipated and up 7 9  year over year  Finally  fresh Initial Jobless Claims numbers hit the early morning tape today  and these numbers were higher than expected   250K new claims were up 3 000 from the previous week s slightly upwardly revised total of 245K  This is at the top of our non hurricane related jobless claims range we ve seen over the past dozen quarters or more  Continuing claims  however  fell lower again from 1 951 million two weeks ago to 1 914 million last week  We remain under the psychologically satisfying 2 million jobless claims figure Mark VickerySenior EditorZacks  Best Private Investment Ideas
While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public 
Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2018-01-03,Zacks Investment Research,https://www.investing.com/analysis/adp-brings-250k-new-jobs-better-than-expected-200277661,200277661
179305,400821,WBA,ADP ADP Private Sector Payroll Read For December At 250K,opinion,The first U S  labor market data of 2018 has hit the tape before the opening bell this morning  with the ADP   NASDAQ ADP   private sector payroll read for December reaching 250K new jobs  This is well beyond the 195K analysts were expecting  November s tally was revised down  but only a tad   5K to 185K  We remain consistent with a very strong employment environment Unsurprisingly  Services easily outpaced Goods producing jobs   222K to 28K  respectively  Medium sized businesses  50 499 employees  brought in the most jobs at 100K  followed by 96K from Small companies  with Large corporations picking up the rear with 56K  Likely we re seeing a lot of seasonal employment in these numbers from December s holiday shopping season  but even still  strength all around Education Healthcare grew by 50K new jobs  followed by Trade Transportation at 45K and Leisure Hospitality at 28K  Even the long dormant Construction and Manufacturing brought in relatively healthy numbers with 16K and 9K  respectively Looking at holiday shopping totals  we see stronger than expected results from both Macy s   NYSE M    up 1 1  in holiday sales comps  and J C  Penney   NYSE JCP    up 3 4   For both companies  these sorts of positive comps are rare  and with new tax cuts for the big box retailers  both are cranking up earnings estimates for next fiscal year Walgreens Boots Alliance   NASDAQ WBA   reported top  and bottom line beats on its Q1 2018 estimates in today s pre market  as well  Earnings topped expectations by a penny to  1 28 per share  up 16 4  year over year  Revenues grew to  30 74 billion  hotter than the  30 33 billion anticipated and up 7 9  year over year  Finally  fresh Initial Jobless Claims numbers hit the early morning tape today  and these numbers were higher than expected   250K new claims were up 3 000 from the previous week s slightly upwardly revised total of 245K  This is at the top of our non hurricane related jobless claims range we ve seen over the past dozen quarters or more  Continuing claims  however  fell lower again from 1 951 million two weeks ago to 1 914 million last week  We remain under the psychologically satisfying 2 million jobless claims figure ,2018-01-03,Zacks Investment Research,https://www.investing.com/analysis/adp-adp-private-sector-payroll-read-for-december-at-250k-200277653,200277653
179306,400822,WBA,3 Earnings Reports to Watch Today  MON  WBA  SONC,opinion,"Later today we get three big earnings reports to start the New Year and the fourth quarter reporting season  which roughly reflects company performance from October   December 2017  varies by company  
1  Monsanto  NYSE MON  
Materials   Chemicals   Reports January 4  before the open 
The Estimize consensus on  calls for EPS of  0 42  four cents higher than the Wall Street consensus  and is suggesting YoY growth of 81   Revenues are also expected to beat  with the Estimize community looking for  2 88B vs  the Street s  2 72B  
What to Watch  Solid growth expectations appear to be back for Monsanto after a hiccup in FQ3 2017  Analysts on Estimize increased their EPS estimates for the quarter reporting today by 75  in the last 3 months   from  0 24 on October 4  to the current expectation of  0 42  Demand for crop yield enhancing products such as Roundup Ready Xtend Crop System and specialized herbicides like XtendiMax has remained strong  Last quarter s growth was lead by the Seeds and Genomics segment due to the adoption of newer soybean and cotton technologies  While the company pointed out adoption for their latest corn hybrids was picking up  sales of corn seed and traits were a weak spot in 2017  The  66B buyout from Bayer  DE BAYGN  should close early on this year 
2  Walgreens Boots Alliance  NASDAQ WBA 
Consumer Staples   Food   Staples Retailing   Reports January 4  before the open 
The Estimize consensus on  calls for EPS of  1 30  three cents higher than the Wall Street consensus  with revenues nearly in line at  30 3B 

What to Watch  All eyes will be on sales at Walgreens Retail Pharmacy USA division today  Last quarter pharmacy sales increased nearly 13  YoY due to higher prescription volumes  Despite the fact that comparable pharmacy sales increased 5 6   they were negatively impacted by reimbursement pressure and generics which will likely resurface again in this report  While the Rite Aid  NYSE RAD  deal announced in September will have no impact on this quarter s results  investors will be looking for an update on Walgreen s agreement to purchase 1 932 Rite Aid stores over the next 3 years  an arrangement that should be beneficial to both company s bottom lines 
3  Sonic Corp   NASDAQ SONC 
Consumer Discretionary   Hotels  Restaurants   Leisure   Reports January 4  after the close 
The Estimize consensus calls on   NASDAQ SONC  is for EPS of  0 26  one cent higher than the Wall Street consensus  with revenues nearly in line at  106M 

What to Watch  Sonic s expectations have come down considerably in the last quarter  with EPS estimates retreating 10   and revenues decreasing by 3  over that time  likely due to poor results reported for FQ4 2017  During that quarter same store sales slipped 3 3   the fifth consecutive quarterly decline  due to weak customer traffic which fell by over 3  due to an increasingly competitive environment where McDonald s  NYSE MCD  saw traffic increase by 2 1   Unfavorable weather and ill received menu additions and summer promotions also played a large role  The company s 2018 guidance calls for same store sales in the range of 0    2   which could mean a slight improvement in today s numbers ",2018-01-04,Estimize,https://www.investing.com/analysis/3-earnings-reports-to-watch-tomorrow-mon-wba-sonc-200277449,200277449
179307,400823,WBA,Company News For January 5  2018,opinion,Rite Aid Corporation s   NYSE RAD   shares decreased 1 4  after reporting fiscal third quarter revenues of  5 353 2 million  falling short of the Zacks Consensus mark of  7 736 4 millionShares of Walgreens Boots Alliance  Inc    NASDAQ WBA   declined 5 2  after posting fiscal first quarter net earnings of  821 million  reflecting a decrease of 22 1  from the prior year quarterCVS Health Corporation s   NYSE CVS   shares increased 2 6  after projecting that fiscal 2018 cash flow to rise by  1 2 billion following the recent tax overhaulShares of L Brands  Inc    NYSE LB   slumped 12 3  after forecasting fourth quarter earnings per share of  2 00  lower than the mid point of the previous guidance range of  1 95 to  2 10,2018-01-04,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-january-5-2018-200277896,200277896
179308,400824,WBA,Penumbra  PEN  Forms JV On Virtual Reality In Health Space,opinion,"Penumbra  Inc    NYSE PEN   has recently made a major investment in the field of healthcare applications through virtual reality technology  The company has partnered with Sixense Entierprises to form a joint venture  JV  called MVI Health Inc Sixense Entierprises is a leading provider of VR AR  Virtual and augmented reality  enterprise solutions  The company with its full presence platform delivers a more natural and intuitive way to interact in the virtual world 
MVI Health is expected to bring together Sixense Enterprises  unique immersive computing platform in virtual reality technology with Penumbra s focus on developing and commercializing advanced medical therapies  This combination indicates to form a leading digital health platform in MVI Health MVI Health will be headquartered in Alameda with the support of Penumbra s investments and contributions drawn from license  intellectual property plus other resources of Sixense Enterprises  However  financial terms of the deal have been kept under wraps Notably  Penumbra continues to demonstrate a strong momentum in its overall business  courtesy of its consistent investment in cutting edge product innovations  We also remain encouraged about the company s long term prospects and its strategic positioning within both its major markets namely  neuro and peripheral vascular Last quarter  the company saw a continued strength in neuro  driven by ischemic stroke procedural volumes  While in peripheral vascular franchise  the company is making strong inroads  both in embolization and thrombectomy businesses Share Price Performance
Over the past three months  the company s share price has underperformed the broader    The stock has declined 2 1  as compared to the 7 8  gain of the broader industry  However  with the positive developments we expect Penumbra to gradually gain investor confidence Zacks Rank and Key PicksPenumbra carries a Zacks Rank  3  Hold   Some better ranked stocks from the broader medical space are Akari Therapeutics PLC    NASDAQ AKTX    Protagonist Therapeutics Inc    NASDAQ PTGX   and Walgreens Boots Alliance  Inc    NASDAQ WBA    While Akari and Protagonist sport a Zacks Rank  1  Strong Buy   Walgreens carries a Zacks Rank  2  Buy   You can see Akari has a projected growth rate of 88 89  for the next quarter  The earnings surprises delivered by the company have been positive in the last three quarters with an average beat of 88 6  Protagonist has an expected earnings growth rate of 36 9  in 2017  The stock has surged an impressive 80 6  in the last six months Walgreens Boots has a long term expected earnings growth rate of 10 1   The stock has risen 3 2  year to date Zacks Editor in Chief Goes  All In  on This Stock Full disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ",2018-01-05,Zacks Investment Research,https://www.investing.com/analysis/penumbra-pen-forms-jv-on-virtual-reality-in-health-space-200278068,200278068
179309,400825,WBA,U S  FTC signs off on Walgreens Rite Aid deal,news,"The U S  Federal Trade Commission  FTC  has finally OK d Walgreens Boots Alliance s  NASDAQ WBA  purchase of a number of Rite Aid  NYSE RAD  stores  Under the terms of the deal  WBA will buy 1 932 RAD stores and related assets for  4 375B in cash  Store purchases will commence next month and should be completed in Spring 2018  Most are located in the Northeast and Southern U S   including three distribution centers in Connecticut  Pennsylvania and South Carolina 
RAD has the option of joining WBA s group purchasing organization  exercisable through May 2019 
Now read ",2017-09-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/us-ftc-signs-off-on-walgreensrite-aid-deal-530408,530408
179310,400826,WBA,Walgreens gets regulatory nod for slimmed down Rite Aid deal,news," Reuters    U S  antitrust regulators have allowed a slimmed down deal for drugstore chain Walgreens Boots Alliance Inc  O WBA  to buy about 42 percent of Rite Aid Corp s  N RAD  U S  stores for  4 38 billion  Walgreens said on Tuesday  Walgreens will acquire 1 932 Rite Aid stores  254 fewer than it announced in July  in areas where competition between the two chains is not significant  Rite Aid shares slid 9 3 percent at  2 48 while Walgreens was down 1 8 percent to  81 11  One member of the Federal Trade Commission was concerned that a smaller Rite Aid may be unable to compete against its larger rivals  The deal  which widens Walgreens  footprint in the United States  began as an offer made in October 2015 to buy all of Rite Aid s 4 600 stores  But Walgreens failed to win approval for that  9 4 billion deal and rejigged it  Walgreens operates stores under its own name as well as Boots stores in Britain and Duane Reade stores in the United States  Under the deal  Rite Aid has the option of joining Walgreens  group purchasing agreement to negotiate discounts on generic drug prices  Walgreens said it will also buy Rite Aid s three distribution centers in Connecticut  Pennsylvania and South Carolina  Republican Maureen Ohlhausen  the acting chairman of the Federal Trade Commission which approved the deal  said a sharply smaller Rite Aid will still be able to effectively compete against Walgreens and the other big U S  chain  CVS Health Corp  N CVS    Walgreens  acquisition of Rite Aid stores in the revised transaction is limited to areas where competition between the two firms is not significant   she said  Kroger  N KR  and Wal Mart  N WMT  and other big supermarket chains and retailers also offer significant pharmacy services  she added   Commissioner Terrell McSweeny  a Democrat and the only other member of what should be a five member commission  said she feared the deal  continues to raise significant competition issues    In particular  I am concerned that the transaction could reduce Rite Aid s long term ability to obtain low generic drug prices   she said  Leerink analyst David Larsen said in a research note he was  pleasantly surprised  the deal was approved without lengthy scrutiny  One antitrust expert  Andre Barlow of law firm Doyle  Barlow and Mazard PLLC  noted that Rite Aid was a smaller  No  3 behind two behemoths   Clearly a smaller chain doesn t have the same leverage as a larger chain  But there is probably a legitimate concern that Rite Aid wasn t an effective competitor prior to the acquisition   he said  Walgreens said it does not expect the deal to have a significant impact on its adjusted earnings for the fiscal year ending Aug  31  2018  
Store purchases would begin in October and are expected to be completed in spring 2018 ",2017-09-19,Reuters,https://www.investing.com/news/stock-market-news/walgreens-gets-regulators-nod-to-buy-rite-aid-stores-530435,530435
179311,400827,WBA,Fourth Time is a Charm for Walgreens  Purchase of Rite Aid ,news,"Investing com   Rite Aid Corporation s  NYSE RAD  shares plunged almost 10  on Tuesday after news broke that the company will be bought up by Walgreens Boots Alliance Inc  NASDAQ WBA  as the company s fourth attempt to appease regulators was successful  
This fourth attempt comes after Walgreens took further strides to satisfy regulator concerns  specifically  significantly reducing the number of stores it will purchase  To gain approval  Walgreens plans to buy 254 fewer Rite Aid stores than under a previous proposal in June  June s proposal was to buy 2 186 stores for  5 18 billion  which was  in turn  a sharply reduced offer compared to Walgreens  original October 2015 offer to buy 4 600 stores for  9 4 billion  The total deal value including debt was  17 billion 
The acquisition will start in October and will be completed in the spring of 2018  Walgreens expects cost synergies from the deal of  300 million  which will be fully realized within four years of closing 
While Rite Aid s shares crashed  Walgreens   shares were down just 1  ",2017-09-19,Investing.com,https://www.investing.com/news/stock-market-news/fourth-time-is-a-charm-for-walgreens-purchase-of-riteaid-530574,530574
179330,400846,WBA,Is A Beat In Store For Walgreens Boots  WBA  In Q1 Earnings ,opinion,"Walgreens Boots Alliance  Inc    NASDAQ WBA   is slated to release first quarter fiscal 2018 results before the market opens on Jan 4 Last quarter  the company had delivered a positive earnings surprise of 7 38   It is noteworthy that Walgreens Boots has outperformed the Zacks Consensus Estimate in three of the preceding four quarters with an average positive earnings surprise of 2 46   Let s take a look at how things are shaping up prior to this announcement Why a Likely Positive Surprise   Our proven model shows that Walgreens Boots is likely to beat on earnings in the fiscal first quarter riding on the right combination of the following two key ingredients  Zacks ESP   which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  3 97   This indicates a likely positive earnings surprise for the stock Zacks Rank  Walgreens carries a Zacks Rank  2  Buy   which increases the predictive power of ESP  Note that stocks with a favorable Zacks Rank  1  Strong Buy   2 and 3  Hold  have a significantly higher chance of beating estimates  Further coupled with a positive ESP  the combination makes us confident of an expected positive surprise We caution against the sell rated stocks   4 and 5  going into an earnings announcement   Key CatalystsNotably  Walgreens Boots  entire business has been posed with tough challenges during the fourth quarter of fiscal 2017 due to the devastating hurricane activity witnessed in the latter half of 2017  The company anticipates this lean patch to continue even in the first quarter of fiscal 2018 as the catastrophic event might adversely impact its overall business in Puerto Rico  where Walgreens Boost leads as the largest pharmacy chain  Walgreens Boots Alliance  Inc  Price and EPS Surprise
     Per Walgreens  the damages occurred to Puerto Rico s infrastructure  which grossly impacted trading on its stores so far  is expected to affected the adjusted earnings per share by a few cents in the first quarter of fiscal 2018  On the whole  the company expects adjusted net earnings per share in the range of  5 40  5 70 in fiscal 2018 Walgreens Boots  Retail Pharmacy USA division continued to witness comparable prescription growth as well as strength in retail prescription market  Several planned developments  early benefits of new pharmacy contracts as well as a volume increase from previously announced strategic pharmacy partnerships have been driving growth in this space over the past few quarters  We expect this growth momentum to continue in the fiscal first quarter as well However  the sales performance of the Retail Pharmacy international division continued to disappoint due to various factors including a decline across multiple product categories with beauty being hampered by the timing of product launches  Also  total retail sales were down on the impact of the previously announced closure of certain e commerce operations Amid this drag in retail pharmacy business  we are looking forward to the company s agreement to purchase a limited number of Rite Aid stores  which might boost its business  While the transition process of these stores is underway  we believe this integration to help Walgreens Boots expand and optimize its retail pharmacy network in the key U S  markets including the Northeast  However  we expect no material benefit to realize from this development till the first quarter closes Meanwhile  strong market growth is expected in certain emerging markets backed by the timing of price rise  Also  in order to expand footprint in Asia  the company launched its first Boots franchise store in South Korea earlier in 2017  This development is likely to contribute to the top line in the fiscal first quarter Other Stocks Worth a LookHere are a few other medical stocks worth considering as they too have the right combination of elements to deliver an earnings beat this quarter Zynex  Inc   has an Earnings ESP of  5 88  and a Zacks Rank of 2  You can see  Merit Medical Systems  Inc    NASDAQ MMSI   has an Earnings ESP of  1 59  and a Zacks Rank of 1 ICON Public Limited Company   NASDAQ ICLR   has an Earnings ESP of  0 07  and is a Zacks  2 Ranked player Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-12-27,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-store-for-walgreens-boots-wba-in-q1-earnings-200276310,200276310
179331,400847,WBA,Rite Aid looks to next phase,news,The FTC is still likely to get involved in the reworked deal between Walgreen Boots Alliance  WBA  0 2   and Rite Aid  RAD  2 9    according to a D C  antitrust attorney   They can t create a situation where the remaining Rite Aid stores  whatever that looks like  are not going to be competitively significant   says Andrea Agathoklis Murino  Working in Rite Aid s favor is the huge cash stack that it will bring in from the sale of 2 186 stores    an amount that it can be argued will help reposition its as a competitive chain  It really gives them a lifeline whereas there probably wasn t one if they had just gotten the deal scuttled and there was no transaction   notes Bloomberg Intelligence s Jonathan Palmer Now read ,2017-06-30,Seeking Alpha,https://www.investing.com/news/stock-market-news/rite-aid-looks-to-next-phase-501151,501151
179332,400848,WBA,CVS Health Q2 revenues up 5   non GAAP EPS up 1   revises guidance,news,CVS Health  CVS  Q2 results  Revenues   45 685M   4 5    Operating Income   2 117M   10 2    Net Income   1 097M   18 7    EPS   1 07   24 4    Non GAAP EPS   1 33   0 8    Quick Assets   2 169M   37 3    CF Ops   5 532M   35 4   Q3 Guidance  GAAP EPS   1 20   1 23  Non GAAP EPS   1 47   1 50 2017 Guidance  GAAP EPS   4 92   5 02 from  5 02   5 18  Non GAAP EPS   5 83   5 93 from  5 77   5 93  CF Ops   7 7B   8 6B  FCF   6 0B   6 4B Shares are down 1  premarket Now read ,2017-08-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/cvs-health-q2-revenues-up-5-nongaap-eps-up-1-revises-guidance-515857,515857
179333,400849,WBA,Walgreens to revise Rite Aid stores deal for antitrust approval  Bloomberg,news," Reuters    Walgreens Boots Alliance Inc  O WBA  is set to revise its agreement to buy some  Rite Aid Corp   N RAD  stores  a move that may be enough for the drugstore chain operator to resolve outstanding antitrust concerns  Bloomberg reported  Rite Aid s shares were up 8 4 percent at  2 85 before the bell on Monday  Walgreens is in final stage of negotiations with the Federal Trade Commission for its plan to buy more than 2 000 Rite Aid stores and is set to propose a modified deal  Bloomberg reported  citing people familiar with the matter     In June  Walgreens  the No 1 U S  drugstore chain operator  said it would buy nearly half of the smaller rival s stores for  5 18 billion  after it failed to win approval to take over the company  
Both Walgreens and Rite Aid declined to comment ",2017-09-18,Reuters,https://www.investing.com/news/stock-market-news/walgreens-to-revise-rite-aid-stores-deal-for-antitrust-approval-bloomberg-529863,529863
179351,400867,WBA,Rite Aid  RAD  Soars  Stock Adds 14 3  In Session,opinion,Rite Aid Corporation   NYSE RAD   was a big mover last session  as the company saw its shares rise more than 14  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  1 43 to  1 89 in the past one month time frame The upside was driven after the company witnessed volume growth for the second consecutive session  following its announcement of the completion of pilot closing of its amended asset purchase agreement with Walgreens Boots Alliance  NASDAQ WBA   Inc The company has not seen any estimate revisions in the past one month  while the Zacks Consensus Estimate for the current quarter has also remained unchanged  The recent price action is encouraging though  so make sure to keep a close watch on this firm in the near future Rite Aid currently has a Zacks Rank  3  Hold   while its  is 0 00  Rite Aid Corporation Price   A better ranked stock in the Retail   Pharmacies and Drug Stores industry is Diplomat Pharmacy  Inc    NYSE DPLO    which currently carries a Zacks Rank  2  Buy   You can see  Is RAD going up  Or down  Predict to see what others think   or The Hottest Tech Mega Trend of All Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2017-11-29,Zacks Investment Research,https://www.investing.com/analysis/rite-aid-rad-soars-stock-adds-143-in-session-200269510,200269510
179352,400868,WBA,Declining Comps Likely To Hurt Fred s  FRED  In Q3 Earnings,opinion,Fred s Inc   NASDAQ FRED   is slated to report third quarter fiscal 2017 results on Dec 6  before the opening bell We note that Fred s delivered losses in the past five quarters  Further  the company has been struggling with murky comparable store sales  comps  While the company has a mixed record of bottom line surprises in the trailing four quarters  let s look into how things are shaping up for the upcoming announcement What to Expect  The Zacks Consensus Estimate for the third quarter of fiscal 2017 is pegged at a loss of 15 cents  which has widened by a penny over the past 30 days  However  estimated loss for the quarter under review is lower than the prior year adjusted loss of 27 cents Also  analysts polled by Zacks expect revenues of  500 5 million  down 3 1  from the year ago period Fred s  Inc  Price  Consensus and EPS Surprise   Factors Impacting the Quarter Fred s has been delivering dismal comps since past many quarters  owing to declining traffic trends  sale of low productive discontinued inventory and rise in generic dispensing rate  Additionally  the company s store expansion plans were gravely impacted by the cancelled Walgreens Boots Alliance   NASDAQ WBA   and Rite Aid Corporation   NYSE RAD   merger in June 2017  Had the deal materialized  Fred s would have emerged as the third largest drugstore chain in the nation after Walgreens and CVS Health Corporation   NYSE CVS   We note that comparable store sales dipped 1 2  and 0 3  during the first and second quarters of fiscal 2017  The company s weak comps trend is likely to continue in the third quarter as well Nevertheless  Fred s has been advancing with initiatives to reduce selling  general and administrative expenses and boost free cash flow  Further  the company has been trying to organize pharmacy business to drive scripts into the stores and improve service to its patients  Although such efforts seem promising  they are yet to bear significant impacts upon the company s performance What Does the Zacks Model Unveil  Our proven model does not conclusively show that Fred s is likely to beat earnings estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  You may uncover the best stocks to buy or sell before they re reported with our  Although Fred s carries a Zacks Rank  3  its Earnings ESP of 0 00  makes surprise prediction difficult  You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2017-11-29,Zacks Investment Research,https://www.investing.com/analysis/declining-comps-likely-to-hurt-freds-fred-in-q3-earnings-200269475,200269475
179353,400869,WBA,Walgreens seen taking Rite Aid fight to court,news,Walgreens Boots Alliance  NASDAQ WBA  is likely to take the FTC to court if the proposed merger with Rite Aid  NYSE RAD  is blocked  according to Cowen and Company  The investment firm works out the math on Outperform rated Rite Aid to derive a  9 21 valuation off of synergies of  7 65 per share and a  2 standalone value subtracted by  0 44 in divestitures  Source  Bloomberg In premarket action  WBA is up 0 10  and RAD is 1 16  higher to  3 50  Keep an eye on Fred s  NASDAQ FRED  as well to move off the latest drugstore sector news  Now read ,2017-05-31,Seeking Alpha,https://www.investing.com/news/stock-market-news/walgreens-seen-taking-rite-aid-fight-to-court-490135,490135
179354,400870,WBA,Walgreens is buying Rite Aid s assets for  5 18bn,news,"Walgreens Boots Alliance  NASDAQ WBA  announced on Thursday that it entered into an agreement to acquire 2 186 Rite Aid stores and related assets for  5 18 billion in cash 
It s the latest twist in the ongoing saga between the two companies  which drew scrutiny from US antitrust regulators earlier this year after announcing a merger valued at  17 2 billion back in October 2015  The deal would ve seen Walgreens acquire all outstanding shares of Rite Aid  The new deal will replace the original merger agreement 
As part of the termination  Walgreens will pay Rite Aid a fee of  325 million in cash 
Rite Aid s stock plunged by 20  in premarket trading following the announcement after spiking by as much as 23  earlier  Walgreens saw shares climb by 4 2  
The asset sale will reposition Rite Aid as an independent  multiregional drugstore chain and pharmacy benefits manager  according to a press release from the company  Rite Aid will also have the option to buy generic drugs from an affiliate of Walgreens 
Further  Rite Aid is expected to use the proceeds from the deal to  significantly  reduce debt and strengthen its balance sheet  the release said 
 While we believe that pursuing the merger with WBA was the right thing to do for our investors and customers  this new agreement provides a clear path forward   Rite Aid chairman and CEO John Standley said in a statement   The transaction offers clear solutions to assist us in addressing our pharmacy margin challenges and allows us to significantly reduce debt  
The deal also terminates a divestiture agreement that Rite Aid had previously made with Fred s that would have seen the Tennessee based pharmacy chain acquire 865 Rite Aid stores for  950 million in cash  but only after merger with Walgreens closed 
The board at Fred s sensed something was amiss with the original merger on Wednesday following some  increased trading activity   and elected to adopt a short term shareholder rights plan  or  poison pill   The company s stock plummeted by 18  in premarket trading 
The new deal overshadowed Rite Aid s first quarter 2018 earnings report  which saw both revenue and adjusted EBITDA miss consensus analyst estimates  The results also came in below the most bearish forecast for either measure ",2017-06-29,Business Insider,"https://www.investing.com/news/economy-news/walgreens-is-buying-rite-aid-039;s-assets-for-$5.18-billion-after-the-2-sides-terminate-their-merger-(wba,-rad)-500540",500540
179355,400871,WBA,U S  stocks sell off as banks  upbeat GDP unable to support gains,news,"Investing com   Wall Street traded lower on Thursday as investors took profit from the prior session s gains and buying enthusiasm in banks and a positive read on growth were unable to support the wider market 
At 11 11AM ET  15 11GMT   the Dow Jones fell 56 points  or 0 26   the S P 500 lost 14 points  or 0 58   while the Nasdaq Composite traded down 85 points  or 1 36  
Tech was once again leading the losses Wednesday   nearly erasing what had been the Nasdaq s largest one day rise since last November in the prior session 
Financial institutions celebrated the fact that the Federal Reserve  Fed  did not object to any of the capital plans of the 34 banks it reviewed in the second part of the annual stress tests implemented in the wake of the financial crisis 
Several big Wall Street banks announced significant increases in their plans to return capital to shareholders after getting the green light from the U S  central bank 
The KBW bank index  known as the BKX  jumped nearly 2   with Goldman Sachs  NYSE GS  and JPMorgan Chase  NYSE JPM  leading the advancers on the Dow 
In other company news  Staples  NASDAQ SPLS  jumped 2  after the retailer confirmed a definitive agreement to be acquired by Sycamore Partners for  10 25 a share 
On the downside  Rite Aid  NYSE RAD  tumbled 25  as Walgreens Boots Alliance  NASDAQ WBA  opted to abandon the merger offer due to concerns over anti trust and instead decided to buy nearly half of the smaller rival s U S  stores for  5 18 billion 
Positive news came from the economic front  as first quarter growth was surprisingly revised up to 1 4  
Although weekly jobless claims came in above forecasts  the data confirmed the continuation of the solid U S  labor market 
Still ahead  St  Louis Fed president James Bullard was scheduled to give a presentation on the U S  monetary policy and the economy at 1 00PM ET  17 00GMT  
Meanwhile  oil prices extended gains into a sixth session to hit the strongest level in two weeks in North American trade on Thursday  after U S  government data revealed the biggest weekly decline in domestic crude production in almost a year 
Data from the U S  Energy Information Administration on Wednesday showed that total domestic crude production fell by 100 000 barrels a day to 9 25 million barrels  the biggest decline in weekly output since July 2016 
U S  crude futures gained 1 43  to  45 38 by 11 14AM ET  15 14GMT   while Brent oil traded up 1 43  to  48 22 ",2017-06-29,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-stocks-sell-off-as-banks,-upbeat-gdp-unable-to-support-gains-500607",500607
179356,400872,WBA,Fitch Ratings weighs in on Walgreens after Rite Aid decision,news,Fitch Ratings affirms a BBB default credit rating on Walgreen Boots Alliance  WBA  1 2   after factoring in the company s decision to buy 2 186 Rite Aid stores  instead of the entire company  The ratings agency says the move is neutral to its credit profile on Walgreens  but is seen as a strategic positive for the drug store operator   Given the significantly reduced purchase price  pro forma adjusted debt EBITDAR is expected to remain around 3 3x  similar to latest 12 month levels  excluding funded debt associated with the proposed Rite Aid acquisition   Fitch expects adjusted leverage to remain near these levels over the next 24 36 months  absent further investment opportunities   Full Fitch Ratings report on WBA Now read ,2017-06-29,Seeking Alpha,https://www.investing.com/news/stock-market-news/fitch-ratings-weighs-in-on-walgreens-after-rite-aid-decision-500715,500715
179357,400873,WBA,Walgreens scraps Rite Aid merger  will instead buy half its stores,news,"By Siddharth Cavale and Diane Bartz  Reuters    Drugstore chain Walgreens Boots Alliance Inc  O WBA  scrapped its deal to buy  Rite Aid Corp   N RAD  after failing to win antitrust approval  but said it would instead buy nearly half of the smaller rival s U S  stores for  5 18 billion  Rite Aid s shares plunged about 28 percent to  2 85  while Walgreens shares were up 1 percent at  77 97  Walgreens also ended a related deal to sell as many as 1 200 Rite Aid stores to Fred s Inc  O FRED   sending Fred s shares down 19 percent  Walgreens  the biggest U S  drugstore chain  will likely have an easier time winning antitrust approval to buy 2 186 Rite Aid stores after it failed to win approval to take over the nearly 4 600 store chain   Walgreens and Rite Aid have taken a pragmatic approach   said Neil Saunders  managing director of market research firm GlobalData Retail  The revised deal could offer many of the same benefits as a whole sale take out of the company  but on a smaller scale  Walgreens said it expects about  400 million of cost savings from its new agreement  down from around  1 billion expected from the original deal   That could help offset challenges it faced in recent years hitting targets for sales growth  which has been weighed on in part by disappointing growth in its retail segment   Walgreens also invited Rite Aid to join its group purchasing agreement  which aims to leverage the combined heft of its members to negotiate discounts on generic drug prices   The decision to sell so many stores will weaken Rite Aid and could still be controversial  said David Balto  an antitrust lawyer who had worked with groups opposing Walgreens  takeover of Rite Aid   Rite Aid s future is going to be bleak after they sell these stores  This is still going to raise some serious questions  It s still taking out a major competitor   Balto said  In fact  Walgreens  plan to buy 2 186 Rite Aid stores accomplishes many of the same goals as the merger   including eliminating Rite Aid as a rival   but does so in a way that makes it harder for the FTC to take the companies to court to stop the transaction  antitrust experts said   Obviously no victory dance for the FTC today  This was a big stick it to you  They re  the FTC  getting a worse outcome than they would before   said Andre Barlow of the law firm Doyle  Barlow and Mazard PLLC   Clearly they  the companies  know what the FTC concerns are  They have likely worked around those issues  which has to be very frustrating for the FTC   The FTC sued to stop two separate deals last week  suggesting that former administration s tough antitrust approach will continue under President Donald Trump  The agency is being run by Acting Chairwoman Maureen Ohlhausen and three commissioner slots are vacant  The FTC said on Thursday it would review the new proposal  WALGREENS TO PAY MORE PER STORE Rite Aid said the stores to be sold are mainly in the Northeast  Mid Atlantic and Southeast  The deal also includes distribution centers in Connecticut  Pennsylvania and South Carolina   Leerink Partners analyst David Larsen estimated that under the new deal  Walgreens would be paying  2 4 million per Rite Aid store  higher than what it would have paid under a previous agreement  where it would have paid  2 04 million to  2 06 million per store   Walgreens said on Thursday it expects the new deal to close within six months   Walgreens also reported better than expected profit and sales for the third quarter  helped by a rise in prescription volumes in its U S  pharmacy business   The company also authorized a  5 billion buyback program and raised the lower end of its full year profit forecast by 8 cents per share to a range of  4 98 to  5 08  Analysts on average were expecting full year profit of  4 96 per share  according to Thomson Reuters I B E S   The new agreement will assist Rite Aid in addressing pharmacy margin challenges and in significantly reducing debt  the company s CEO John Standley said in a statement   
Walgreens said it would pay Rite Aid a  325 million termination fee  In October 2015  Walgreens said it would buy No  3 Rite Aid for  9 5 billion ",2017-06-29,Reuters,"https://www.investing.com/news/stock-market-news/walgreens-scraps-rite-aid-takeover,-to-buy-half-its-stores-500493",500493
179369,400885,WBA,Can Fred s Strategies Help It Counter Slow Comps   Traffic ,opinion,The retail segment has been witnessing increased competition owing to technological upgradations and continuous expansion efforts by large retailers  Consumers are increasingly shifting toward online shopping  thereby hurting store traffic  As a result  smaller firms in the segment  who are incapable of adapting with such changing trends  have resorted to store closures as consumer footfall continues to decline Fred s  Inc   NASDAQ FRED   is one such company that has resorted to store closures amid such challenging retail scenario  Let s now delve into some of the aspects that have led to the dismal performance of the company Declining Comps and Store Closure Fred s has been witnessing sluggish comps  lately  owing to declining store traffic and sale of discontinued inventory  A glance at the comps  performance over the past four months reveals that  while comps were up 0 8  for during May  the same declined 1 6   0 1  and 0 5  during June  July and August  respectively  In fact  the decline in store traffic led to the closure of 39 stores during the first quarter of 2017  Persisting challenges in the Front Store business and competitive consumable categories had also affected the company s overall sales figures Cancelled Walgreens Rite Aid Merger Fred s strategic plans for store expansion were gravely impacted by the cancelled Walgreens Boots Alliance  Inc   NASDAQ WBA   and Rite Aid Corporation   NYSE RAD   merger on June 30  If the deal was to materialize  it would have positioned Fred s as the third largest drugstore chain in the nation after Walgreens and CVS Health Corporation   NYSE CVS    The professional  legal  banking and integration planning fees iincurred in connection with this deal  have become unyielding and hurt the company s profit reserves Lack of International Exposure Since the developed markets of Europe  America and Canada are already saturated  most retail companies are looking toward expanding themselves in developing nations such as China  Brazil  India  Mexico and Russia  amongst others  These nations offer great growth opportunity owing to rising population and an affluent middle class  Fred s  however  is yet to strengthen footprint in these markets Final Thoughts Such ongoing challenges have led Fred s to deliver weak bottom line performance over the past five quarters  posting a loss in each of them Nevertheless  the company has been making significant advancement with its turnaround strategies that aims at reducing selling  general and administrative expenses and driving free cash flow  The turnaround plans also includes focusing on organization of its pharmacy business  to drive scripts into the stores and improve service to its patients  The company has also been emphasizing on internal reorganization and geographic expansion  However  such efforts are yet to bear significant impacts upon the company s top line performance Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-09-29,Zacks Investment Research,https://www.investing.com/analysis/can-freds-strategies-help-it-counter-slow-comps--traffic-200216226,200216226
179370,400886,WBA,Walgreens working to finalize Rite Aid deal  clear antitrust hurdles,news,"WASHINGTON  Reuters    The chief executive of Walgreens Boots Alliance Inc  O WBA  said Thursday that the biggest U S  drug store chain was pressing on with its purchase of smaller  Rite Aid Corp   N RAD   which was announced in October 2015 and has not closed  Rite Aid Corp said on Dec  20 that it would sell 865 stores to Fred s Inc  O FRED  for  950 million to satisfy antitrust concerns on the deal  which was valued at  9 4 billion when it was announced in October 2015   The Federal Trade Commission is assessing the proposed merger to ensure it complies with antitrust law   During the year  we also continued in our effort to get regulatory approval for our acquisition   said Stefano Pessina  Walgreens Boots Alliance chief executive  at an annual shareholders meeting in New York City  Pessina declined to detail issues raised in the review   The only thing I can repeat is that we are actively engaged in dialogue with the FTC and we are doing everything we can to support their work   he said  Pessina said Walgreens was also talking to Rite Aid   These discussions include taking into account anything required to gain approval for the transaction   he said  It could take two months for the agency to assess a proposed divestiture of that size since it would look at the proposed sales  store by store  and in detail  said David Balto  a former FTC official now in private practice   Retail market divestitures are very complex  It s unrealistic to assume that they could get through a divestiture that s this significant in a few weeks   said Balto  The purchase is a big expansion for Fred s  The chain has more than 650 discount stores in the southeastern United States with 350 pharmacies  according to its website  Walgreens has 13 200 stores  nearly 60 percent of which are in the United States  while Rite Aid has 4 570 stores in the United States  The FTC may be doubly careful after it was stung by the failure of an earlier retail divestiture  It allowed regional grocer Haggen to buy 146 stores as part of a deal to allow Albertsons to buy Safeway in early 2015  only to have Haggen file for bankruptcy that same year  Albertsons bought dozens of the stores  
The FTC is also in transition  President Donald Trump named Commissioner Maureen Ohlhausen the acting chair on Wednesday  Another commissioner  former Chairwoman Edith Ramirez  leaves early next month ",2017-01-26,Reuters,"https://www.investing.com/news/stock-market-news/walgreens-working-to-finalize-rite-aid-deal,-clear-antitrust-hurdles-455957",455957
179371,400887,WBA,CVS Health s profit beats as pharmacy margins rise,news," Reuters    CVS Health Corp  N CVS  reported a bigger than expected quarterly profit as higher margins in its pharmacy business helped offset the loss of major contracts last year  Same store prescription volumes fell 460 basis points in the first quarter due to the loss of contracts to fill prescriptions for Tricare  a U S  Department of Defense health care program  and for customers of pharmacy benefits manager Prime Therapeutics  to rival Walgreens Boots Alliance Inc  O WBA   However  higher generic drug dispensing rate and a cut back on promotions at the front end of the store lifted gross margin in the pharmacy business by about 35 basis points to 29 4 percent  Front end same store sales fell 4 9 percent in the first three months ended March 31  The company sells beauty products  snacks and over the counter drugs at the front end of its nearly 9 700 stores   Front end same store sales slipped for the fourth straight quarter and the company has been investing to turn around sales by improving the store layout and product assortment  CVS reiterated its 2017 profit forecast and estimated second quarter adjusted earnings largely below analysts  average estimate of  1 33 per share  The company s shares were down 2 percent at  80 23 in morning trading on Tuesday  Through Monday s close  they had gained 5 4 percent since Walgreens reported a surprise drop in sales last month   Revenue in CVS s bigger pharmacy services business rose 8 5 percent to  31 2 billion as claims increased across its network and on strong demand for its specialty pharmacy service  The specialty pharmacy service provides expensive drugs to people with chronic conditions such as rheumatoid arthritis  Net income attributable to CVS fell to  952 million  or 92 cents per share  in the first quarter  from  1 15 billion  or  1 04 per share  a year earlier  Interest expenses declined 11 percent to  252 million  while the company also got  19 million in tax benefits from the adoption of new accounting guidance for share based compensation  Excluding items  the company earned  1 17 per share  Revenue rose 3 percent to  44 51 billion  
Analysts on average had expected earnings of  1 10 per share on revenue of  44 20 billion  according to Thomson Reuters I B E S ",2017-05-02,Reuters,https://www.investing.com/news/stock-market-news/drugstore-chain-cvs-reports-better-than-expected-profit-479280,479280
179373,400889,WBA,Rite Aid talks Walgreens scenarios,news,Rite Aid  NYSE RAD  expects shareholders to receive  6 50 per share if a deal with Walgreens Boots Alliance  NASDAQ WBA  is finalized  The disclosure was made in the company s 10 K  and is based on conversations with the FTC on divesting 1 200 stores  The final amount could be higher or lower as described below by the company  Rite Aid   The exact per share merger consideration will be determined based on the number of retail stores that WBA agrees to divest in connection with the parties  efforts to obtain the required regulatory approvals for the Merger  with the price set at  7 00 per share if 1 000 stores or fewer retail stores are required to be divested and at  6 50 per share if 1 200 retail stores are required to be divested  or more  if WBA agrees to sell more   If the required divestitures fall between 1 000 and 1 200 stores  then there will be a pro rata adjustment of the price per share  SEC Form 10 K Rite Aid is up 0 49  premarket to  4 08  WBA  0 06  to  85 74  FRED inactive  Now read  Quarterly Review Of DivGro  Q1 2017,2017-05-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/rite-aid-talks-walgreens-scenarios-480177,480177
179379,400895,WBA,Tobacco Stocks In Focus As Cigarette Prices Rise In New York,opinion,"It seems that the leaders of New York City have been striving hard to make the city smoke free  In fact  the Mayor Bill de Blasio of New York has reportedly issued a series of laws in April to reduce the number of smokers in the city over the next three years 
Per the Aug 28 bill  the minimum price for a pack of cigarettes will now be  13 in New York  Notably  a packet of cigarettes currently costs  10 50  The latest price hike has made New York the most expensive city in the U S  for cigarettes  as declared by some officials in the Health Department stated in sources  In the past too  the mayor has resorted to price hike as a tool to restrict smokers  Smoking rate in the city has declined from 21 5  in 2002 to about 14 3  in 2015  The rate is expected to decline to 12  by 2020 due to this price hike  as anticipated by some city health officials 
The law was introduced in anticipation of making almost 900 000 smokers quit smoking as well as to reduce the number of retailers licensed to sell tobacco products in the city  Currently  about 8 300 retailers have a license to sell cigarettes 
The mayor is also seeking to ban the sale of all tobacco products in pharmacies  as a result of which pharmacy chains like Walgreens Boots Alliance Inc  s   NASDAQ WBA   Duane Reade and CVS Health Corporation   NYSE CVS   will have to take cigarettes off their shelves  The new legislation also requires licensing of e cigarette retailers and will force all residential buildings to have smoking policies  including banning cigarettes in common areas like hallways 
We note that these measures will severely dent businesses of tobacco majors including Philip Morris International Inc    NYSE PM    Altria Group Inc    NYSE MO    British American Tobacco  LON BATS  p l c    NYSE BTI   and Vector Group Ltd    NYSE VGR    which are already plagued by ongoing government restrictions related to selling and packaging 
If we look into the share price performance of these tobacco stocks in comparison with the   we note that except Philip Morris  all the other stocks have underperformed the industry that declined 5 6  in the past six months  While Philip Morris gained 5 5  and British American declined 4 3   Vector Group and Altria declined 7 8  and 15 4   respectively  in the same time frame 


Recently  the state government in India s capital directed Philip Morris and other tobacco companies to remove all advertisements in the city  warning them of legal action if they do not comply  Last month  the U S  Food and Drug Administration  FDA  proposed to lower nicotine levels in cigarettes  as it is responsible for a number of health issues 
Governments around the world are imposing restrictions on tobacco companies which  in turn  are lowering cigarette consumption  The FDA has made it mandatory for tobacco companies to use precautionary labels on cigarette packets to dissuade customers from smoking  The European Union and the FDA have proposed a ban on menthol in accordance with the Tobacco Control Act  Per the act  menthol has an adverse effect on health and thus should not be used in any product 
Amid increasing government restrictions and declining smoking rates  the tobacco giants have introduced e cigarettes and Reduced Risk Products to mitigate losses  Altria is expanding presence in the e cigarette market steadily with its MarkTen and Green Smoke brands 
On the other hand  Philip Morris has been gaining from its iQOS smokeless cigarettes since its launch in November 2014  The marketing and technology sharing agreement between Philip Morris and its peer Altria Group is also boosting the business of both the companies amid declining tobacco volumes 
However  the FDA also imposed several restrictions on e cigarettes  The FDA made it mandatory for all tobacco makers to seek marketing authorization for any tobacco product introduced after Feb 15  2007  The law was extended to include e cigarettes  pipe tobacco  cigars and hookah  The FDA has currently deferred its reviews for products like cigars and hookah tobacco until 2021 and e cigarettes until 2022 
Bottom Line
While price hike and lower availability of cigarettes do help smokers to quit smoking  as seen in the past  the ban also creates a serious black market for these products  which can be detrimental to all tobacco companies 
4 Surprising Tech Stocks to Keep an Eye On 
Tech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really take off ",2017-08-30,Zacks Investment Research,https://www.investing.com/analysis/tobacco-stocks-in-focus-as-cigarette-prices-rise-in-new-york-200210562,200210562
179380,400896,WBA,Why Did Rite Aid  RAD  Stock Crash Today ,opinion,"Shares of Rite Aid   NYSE RAD   fell more than 10  on Tuesday after Walgreens Boots   NASDAQ WBA   received government approval to buy fewer Rite Aid stores than had initially been proposed 
In order to clear a regulatory hurdle presented by the Federal Trade Commission  Walgreens Boots said it would only buy 1 932 stores from Rite Aid  The deal is still worth a whopping  4 38 billion  but that total is a full 254 fewer stores than the companies agreed to in June 
Walgreens Boots also said that it intends to acquire three Rite Aid distribution centers located in Connecticut  Pennsylvania  and South Carolina  The exchange and transition of these distribution centers will not begin for at least another year  however 
Today s approval looks to be the final chapter in what has been a lengthy saga involving Walgreens and Rite Aid  Earlier this year  Walgreens said it was calling off its nearly two year operation to acquire its rival pharmacy company after numerous antitrust cases halted the deal 
Instead  Walgreens would settle for acquiring just under half of Rite Aid s domestic stores a figure that has obviously since been reduced  Still  the store purchase plan should help widen Walgreens Boots  foothold in the U S   where it also competes with the likes of CVS Health Corp    NYSE CVS   
 With this process taking close to two years to come to a conclusion  we think the final outcome and the structure of the transaction were well anticipated   an analyst at Pivotal Research Group told    However  with each recent iteration of the transaction  the economics appear to be shifting more and more in Walgreens  favor  
The store purchases will begin in October and will be completed in spring 2018  Walgreens said  The company also noted that the acquisitions will not have a significant impact on the company s earnings for the fiscal year ending Aug  31  2018  although it expects annual synergies to reach  300 million eventually 
 We are confident in the path ahead and look forward to working together to shape the future of health care and deliver on the full potential these stores bring to our network   Walgreens CEO Stefano Pessina said in a press release 
Want more stock market analysis from this author  Make sure to follow   on Twitter 
4 Promising Stock Picks to Keep an Eye On 
With news stories about computer hacking and identity theft becoming increasingly commonplace  the cybersecurity industry looks like a promising investment opportunity  But which stocks should you buy  Zacks just released Cybersecurity  An Investor s Guide to Locking Down Profits to help answer this question 
This new Special Report gives you the information you need to make well informed investment choices in this space  More importantly  it also highlights 4 cybersecurity picks with strong profit potential ",2017-09-19,Zacks Investment Research,https://www.investing.com/analysis/why-did-rite-aid-rad-stock-crash-today-200214232,200214232
179387,400903,WBA,Walgreens sues Theranos for breach of contract  seeks  140 million,news,"By Nate Raymond  Reuters    Walgreens Boots Alliance  NASDAQ WBA  Inc sued Theranos Inc on Tuesday  seeking  140 million in damages while accusing its onetime lab testing partner of breaching a contract  according to court records  The company s  Walgreen Co  unit filed the lawsuit in federal court in Wilmington  Delaware  five months after the drugstore chain announced it was ending its relationship with Theranos  Details of the lawsuit were unclear  as Walgreens filed it under seal  citing a confidentiality agreement between the two companies  A Walgreens spokesman declined to comment  In a statement  Theranos said it was  disappointed  Walgreens filed the lawsuit  Theranos claimed Walgreens has  consistently failed to meet its commitments to Theranos  and mishandled the companies  partnership   We will respond vigorously to Walgreens  unfounded allegations  and will seek to hold Walgreens responsible for the damage it has caused to Theranos and its investors   Theranos said  Theranos was founded by CEO Elizabeth Holmes in 2003 to develop a blood testing device that would deliver quicker results using only a drop of blood  The Palo Alto  California based company ran into trouble after the Wall Street Journal published a series of articles beginning in October 2015 suggesting its blood testing devices were flawed and inaccurate  In June  Walgreens announced that it was terminating its relationship with Theranos and closing operations at 40 blood draw sites that the Silicon Valley company ran in Arizona at Walgreens  stores  The decision came after Walgreens in January decided to halt Theranos laboratory testing services at its Palo Alto location   
The case is Walgreen Co v  Theranos Inc  U S  District Court  District of Delaware  No  16 01040 ",2016-11-08,Reuters,"https://www.investing.com/news/stock-market-news/walgreens-sues-theranos-for-breach-of-contract,-seeks-$140-million-438922",438922
179389,400905,WBA,Report  Albertsons  Kroger may buy some Rite Aid and Walgreens stores,news,Albertsons and Kroger  NYSE KR  have emerged  as key prospective suitors for Walgreens  NASDAQ WBA  in its attempts to find a way to satisfy the FTC s review of the company s proposed acquisition of Rite Aid  NYSE RAD   while CVS  NYSE CVS  seems to have withdrawn interest  CTFN reports Walgreens  has not yet  freshened up the package  of store selloffs that it plans to present to the FTC  according to the report  which cites an antitrust attorney  who also says that  Albertsons and Kroger are established retail players with experience in pharmacies  and that the assets they are eyeing represent  key geographic expansion for both  ,2016-11-11,Seeking Alpha,"https://www.investing.com/news/stock-market-news/report:-albertsons,-kroger-may-buy-some-rite-aid-and-walgreens-stores-440139",440139
179390,400906,WBA,Walgreens Theranos battle heats up,news,Theranos  Private THERA  allegedly voided 11 3  of all blood test reports that it provided to customers of Walgreens  NASDAQ WBA  stores through a yearslong partnership between the two companies When news broke last week that Walgreens had filed a  140M suit against Elizabeth Holmes  now hobbled unicorn for breach of contact   details were sparse   but a public version of the complaint against Theranos has now been released ,2016-11-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/walgreens-theranos-battle-heats-up-441193,441193
179391,400907,WBA,Rite Aid to sell 865 stores to Fred s,news," Reuters    Rite Aid Corp said it would sell 865 stores to Fred s Inc for  950 million to satisfy antitrust concerns over its proposed takeover by Walgreens Boots Alliance  NASDAQ WBA  Inc  Fred s shares jumped 73 pct to  19 34 in morning trading on Tuesday  while Rite Aid shares were up 5 6 pct at  8 63  Rite Aid and Walgreens were widely expected to divest stores in states where the combined company would have a particularly strong position  Walgreens has 13 200 stores  nearly 60 percent of which are in the United States  while Rite Aid has 4 570 stores in the United States  Walgreens said in October 2015 it would buy smaller peer Rite Aid for  9 4 billion to widen its U S  footprint  Fred s will continue to operate the acquired stores under the Rite Aid banner during the transition period  the companies said on Tuesday  Walgreens said it continues to expect the acquisition to realize savings of over  1 billion within three to four years after the closing of the deal  which is expected in early 2017  Fred s said BofA Merrill Lynch and Regions Bank will provide financing for store acquisitions   
Fred s was advised by A T  Kearney  BofA Merrill Lynch was the financial adviser for Walgreens Boots Alliance  while Citi advised Rite Aid ",2016-12-20,Reuters,https://www.investing.com/news/stock-market-news/rite-aid-to-sell-865-stores-to-fred's-448902,448902
179393,400909,WBA,Walgreens profit beats estimates on PBM partnerships,news," Reuters    Walgreens Boots Alliance Inc  O WBA  reported a better than expected quarterly profit as recent partnerships with pharmacy benefit managers  PBMs  and insurance companies helped boost sales of prescription drugs as well as non drug items  The largest U S  drugstore chain also raised the lower end of its adjusted profit forecast for the year ending August 2017  Walgreens  which is awaiting regulatory approval for its  9 5 billion takeover of smaller rival  Rite Aid Corp   N RAD   said it expects to close the deal early this year  It had previously extended the merger agreement till Jan  27  Walgreens entered partnerships last year with PBMs such as Express Scripts Holding Co  O ESRX  and OptumRx and insurer UnitedHealthcare  N UNH  which helped boost sales in the first quarter  Net income attributable to Walgreens fell to  1 05 billion  or 97 cents per share  in the first quarter ended Nov  30  from  1 11 billion  or  1 01 per share  a year earlier   Excluding items  the company earned  1 10 per share  beating the average analysts  estimate of  1 09  according to Thomson Reuters I B E S  
Sales fell to  28 50 billion from  29 03 billion  falling for the first time in four years and missing the analyst estimate of  29 23 billion ",2017-01-05,Reuters,https://www.investing.com/news/stock-market-news/walgreens-reports-surprise-drop-in-quarterly-sales-451294,451294
179394,400910,WBA,Walgreens to pay  50 million to resolve U S  prescription kickback case,news,By Nate Raymond and Brendan Pierson NEW YORK  Reuters    Walgreens Boots Alliance Inc  O WBA  will pay  50 million to resolve a U S  lawsuit accusing it of violating federal law by providing beneficiaries of government healthcare programs discounts and other incentives to fill their prescriptions at its pharmacies  The settlement  announced by Manhattan U S Attorney Preet Bharara on Thursday  resolves a whistleblower lawsuit that the government joined related to the national pharmacy chain s Prescription Savings Club program  Bharara said Walgreens allowed beneficiaries of Medicare and Medicaid to take part in the Savings Club program even though doing so violated a federal law against paying those beneficiaries kickbacks so they would choose Walgreens  Walgreens  written materials about the Savings Club program  and its own internal policy  stated that beneficiaries of government health insurance programs were not eligible to participate  according to court filings related to the settlement  Nonetheless  the company offered employees bonuses for enrolling people in the program without checking whether they were eligible  Bharara said  As a result  he said  hundreds of thousands of beneficiaries were enrolled in the program  Walgreens acknowledged as part of its settlement that government beneficiaries were improperly enrolled in its savings program  About  46 million of the settlement will resolve claims by the federal government and the rest will go to states  which help administer Medicaid  The former Walgreens pharmacy manager who filed the whistleblower lawsuit  Marc Baker  will get about  9 7 million of the federal government s portion of the settlement   We entered into this agreement to avoid the delay  expense  and uncertainty of litigation  and did so without any admission of legal liability   Walgreens spokesman Jim Cohn said in an email  He said the company still offers discounts to customers who are not government beneficiaries through the Savings Club program ,2017-01-19,Reuters,https://www.investing.com/news/stock-market-news/walgreens-to-pay-$50-million-to-resolve-u.s.-prescription-kickback-case-454428,454428
179395,400911,WBA,FTC not sold on Walgreens  plan to win nod for Rite Aid deal  Bloomberg,news," Reuters    The U S  Federal Trade Commission is not satisfied with Walgreens Boots Alliance Inc s  O WBA  plan to divest stores to win antitrust clearance for its acquisition of  Rite Aid Corp   N RAD   Bloomberg reported  citing people familiar with the matter 
The FTC isn t convinced that Walgreen s proposal to sell 865 drugstores to Fred s Inc  O FRED  would do enough to preserve competition that would be lost in the  9 4 billion tie up  Bloomberg reported on Friday    
The FTC is also unlikely to complete its review of the deal before the deadline of Jan  27 to close the transaction  Bloomberg reported 
Walgreens will have to pay Rite Aid a termination fee of  325 million if the FTC blocks the deal 
Walgreens declined to comment  Rite Aid  Fred s and the FTC could not be immediately reached for comment 
Walgreens shares were down 2 percent in heavy trading  Rite Aid shares tumbled about 14 percent and Fred s shares fell 5 8 percent ",2017-01-20,Reuters,https://www.investing.com/news/stock-market-news/ftc-not-sold-on-walgreens'-plan-to-win-nod-for-rite-aid-deal:-bloomberg-454672,454672
179396,400912,WBA,Fred s Posts Dismal Comparable June Store Sales  Stock Down,opinion,Fred s  Inc    NASDAQ FRED    which has been struggling to recover from the blow of a failed merger between Rite Aid Corporation   NYSE RAD   and Walgreens Boots Alliance  Inc    NASDAQ WBA    recently announced soft June comparable store sales  comps   This extinguished hopes of a comeback  dampening investor spirits which is evident from the 13 2  decline in the stock s value We observed that Fred s shares have underperformed the Zacks categorized  industry over the past three months  During the said time frame  shares of this Zacks Rank  4  Sell  company plunged 58 7  compared with the industry s decline of 6 4  You can see Dismal Comps PerformanceTotal comparable store sales  comps  for June declined 1 6  compared with a 1 3  decrease recorded in the year ago period  The decline came after posting an increase of 0 8  and 1 2  in May and April  respectively  Fred s has not been able to continue with the positive comps trend for the reported month  Lower sales led to discontinuation of inventory productivity and adversely impacted comps for the month under review by approximately 0 9  Fred s  which shares space with CVS Health Corporation   NYSE CVS    hinted that comps for the month of June were lower than what they had previously anticipated  Sustained headwinds in consumables categories impacted Front Store sales  The same was also affected by lower seasonal sales during summer  primarily due to cooler than average temperatures  The favorable results in Retail and Specialty Pharmacy businesses  which delivered an increase of 3 5   raised investor s confidence   The company remains optimistic about the recent introduction of beer and wine in select stores  based on their early results Fred s reported a year over year decline of 2 7   3  and 3 1  in net sales during March  April and May  respectively  The company s total sales for June declined 5 3  to  197 5 million  The fall in sales can be attributed to the closure of 39 underperforming stores in the first quarter of 2017  Continued challenges in the Front Store business also impacted sales Bottom LineGoing forward  management stated that it no longer expects sequential improvement from the first quarter  Current headwinds combined with lower than expected sales in June would impact the second quarter results  Nevertheless  the management would continue to execute their transformation strategies  which includes optimizing supply chain and store fleet and improving their pharmacy business  to drive scripts Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-07-06,Zacks Investment Research,"https://www.investing.com/analysis/fred's-posts-dismal-comparable-june-store-sales,-stock-down-200199753",200199753
179397,400913,WBA,What You Should Know About Fred s Apart From Dismal Comps,opinion,Fred s  Inc    NASDAQ FRED   has been in the red for quite some time now due to sluggish comps  The company has been struggling with declining sales that has been impacting its profits as well as overall growth  Also  it seems that the company is yet to recover from the cancelled Walgreens Boots Alliance  Inc    NASDAQ WBA   and Rite Aid Corporation   NYSE RAD   merger  Such factors have hurt the performance of the company in the last reported first quarter fiscal 2017 results Let s now delve deeper into some of the factors that has been pulling down Fred s performance Dismal Comps Trend and Declining Sales Fred s has been posting dismal comps since past many quarters  as a result of the sale of low productive discontinued inventory  Declining traffic trends are also hurting comps  We note that the company s July comp sales declined 0 1   after posting a decrease of 1 6  in June and 0 8  in May Sales were also affected by the closure of 39 underperforming stores in the first quarter of 2017  Continued challenges in the Front Store business and competitive consumable categories also affected the top line  We note that Fred s reported a year over year decline of 2 7   3   3 1  and 5 3  during March  April  May and June  respectively  The company s total sales for July declined 3 5  to  150 5 million Cancelled Merger   A Grave Disappointment Owing to various antitrust issues and unlikely FTC  Federal Trade Commission  clearance  Walgreens Boots Alliance decided not to proceed with its planned takeover of rival drugstore  Rite Aid Corporation  The cancelled Walgreens Rite Aid merger also closed doors for Fred s  which had inked a deal in Dec 2016 to buy 865 Rite Aid stores  The acquisition of these stores would have positioned Fred s Pharmacy as the third largest drugstore chain in the nation after Walgreens and CVS Health Corporation   NYSE CVS    Fred s was left disappointed after the cancelled merger  which would have given the company greater negotiating power and would have also improved its healthcare growth strategy   Moreover  the professional  legal  banking and integration planning fees incurred in connection with this deal  have also become unyielding and have hurt the company s profits Less International Exposure Fred s does not have any presence in the developing markets which deprives it of the benefits of high growth opportunities in the developing nations like China  Brazil  India  Mexico  Russia and Southeast Asia  Since the developed markets of Europe  America and Canada are already saturated  most of the U S  companies are looking toward the emerging ones  which offer great growth opportunity owing to the growing population and affluent middle class Bottom Line In an effort to revamp its performance  the company has shifted focus to its pharmacy organization to drive scripts into the stores and improve service to its patients  Growth strategies of the company also include internal reorganization and geographic expansion Although such efforts have improved Fred s specialty business  they are yet to bear a significant impact upon the company s top line  Moreover  the management expects that the current headwinds combined with lower than expected sales trend would impact second quarter results  Such weak fundamentals indicate that Fred s is not a favorable stock currently Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ,2017-08-14,Zacks Investment Research,https://www.investing.com/analysis/what-you-should-know-about-freds-apart-from-dismal-comps-200207333,200207333
179406,400922,WBA,Drugstore operator Walgreens Boots Alliance appoints co COOs,news," Reuters    Drugstore operator Walgreens Boots Alliance Inc  O WBA  said on Thursday it named two executive vice presidents to the role of co chief operating officers  Alex Gourlay  executive vice president of Walgreens Boots Alliance and President of Walgreens  will oversee Walgreens and Boots in his new role  Ornella Barra  executive vice president of Walgreens Boots Alliance and president and chief executive of global wholesale and international retail  will supervise global brands  human resources and other business services  the company said   Simon Roberts  executive vice president of Walgreens Boots Alliance and president of Boots  is leaving in July to pursue new opportunities  the company said  
 Walgreen Co  and Alliance Boots GmbH completed their merger to form Walgreens Boots Alliance Inc in December 2014  finalizing a two step merger launched in 2012 ",2016-06-09,Reuters,https://www.investing.com/news/stock-market-news/drugstore-operator-walgreens-boots-alliance-appoints-co-coos-407451,407451
179407,400923,WBA, What Will Rite Aid Walgreens Merger Mean To Fred s  FRED   ,opinion,Shares of Fred s  Inc    NASDAQ FRED    popularly known as Fred s Pharmacy  rallied nearly 23  on Jun 26  on rumors about the Federal Trade Commission s  FTC  approval of the much awaited acquisition of Rite Aid Corporation   NYSE RAD   by Walgreens Boots Alliance  Inc    NASDAQ WBA    However  we await FTC s final decision on the merger slated for Jul 7 The possible nod of FTC on Rite Aid Walgreens merger has also paved way for Fred s  The company had inked a deal in Dec 2016 with Rite Aid and Walgreens to buy 865 stores located in the eastern and western U S   along with certain assets for a total cash outlay of  950 million  Additionally  Fred s Pharmacy announced that it might buy additional assets  including up to 1 200 Rite Aid stores  in order to obtain the FTC s approval for the transaction How the Deal Would Benefit Fred The acquisition of these pharmacy stores is very crucial for Fred s as it will place the company as the third largest drugstore chain in the U S  after Walgreens and CVS Health Corporation   NYSE CVS    At present  the company operates 601 pharmacy and general merchandise outlets  along with three specialty pharmacy only locations  comprising 14 franchised locations as of Jun 26  2017  In addition  it possesses two distribution centers  each in Memphis  TN and Dublin  GA  The buyout of Rite Aid stores will more than double the company s store count and would boost its network We note that Fred s witnessed a slowdown in traffic in the last few quarters  This is evident from its sales that have been declining due to the fall in comparable store sales  Furthermore  the company has been reporting loss in the last four quarters In fact  the sluggishness is well reflected in the stock price performance of the company  Shares of Fred s have declined over 14  in the past one year compared with the Zacks categorized  industry s decline of 8 2  The deal is expected to aid this Zacks Rank  4  Sell  company spark a turnaround  Additionally  the acquisitions will complement Fred s strategy of focusing on the pharmacy department and contributing significantly to its overall performance  We believe that it will also improve the company s healthcare growth strategy and would largely benefit its customers  patients  supplier partners and other stakeholders  going forward You can see  Today s Stocks from Zacks  Hottest Strategies   It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively   And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-06-27,Zacks Investment Research,https://www.investing.com/analysis/what-will-rite-aid-walgreens-merger-mean-to-fred's-(fred)-200198104,200198104
179409,400925,WBA,Wall Street edges up as investors digest comments on Brexit,news,"By Marcus E  Howard  Reuters    Wall Street stocks rose Wednesday afternoon as officials sought to reassure investors of limited impact from Britain s decision to leave the European Union and as healthcare shares gained   German Chancellor Angela Merkel said Britain s June 23 vote would have limited impact on the country s economy  while Federal Reserve Governor Daniel Tarullo said world financial markets are well prepared for it  Minutes from the U S  central bank s June policy meeting showed policymakers decided in June that interest rate hikes should stay on hold until they have a handle on the consequences of the  Brexit  vote   A recovery in oil prices and strong U S  services data also helped alleviate some concerns about a potential global economic slowdown  The S P energy index  SPNY  was up 0 1 percent  U S  services industry activity hit a seven month high in June as new orders surged and companies hired more workers  suggesting the economy regained speed in the second quarter    In the morning sector there was certainly a lot of stress due to Europe and you saw that flight to safety very apparent in record low yields   said Ryan Larson  head of U S  equity trading at RBC Global Asset Management in Chicago   So Europe closes out the lows and we ve been able to build off that here in the U S   simply off of short covering and some rebounds in the commodities  WTI specifically   Stocks have been volatile following the June 23 Brexit decision  while investors have driven up safe haven assets such as gold   Most of the major S P indexes were higher  led by a 0 9 percent rise in healthcare  SPXHC   Celgene s  O CELG  4 percent rise to  104 33 was its biggest boost   At 2 26 p m   1826 GMT   the Dow Jones industrial average  DJI  was up 31 67 points  or 0 18 percent  to 17 872 29  the S P 500  SPX  had gained 4 89 points  or 0 23 percent  to 2 093 44 and the Nasdaq Composite  IXIC  had added 21 66 points  or 0 45 percent  to 4 844 56   Larson said he expected the U S  central bank to take a gradual approach  noting the uncertainties related to Brexit  The Fed s next two day policy meeting is July 26 27    It s very more likely the Fed will cut rates before they raise rates according to how futures are pricing this   said Larson  Facebook  O FB  rose 1 6 percent to  115 83 and provided the biggest boost to the Nasdaq and the S P 500  Among the day s decliners  Walgreens Boots Alliance  O WBA  fell 2 5 percent following results and comments from its CEO that it is bracing for a long period of volatility following the Brexit vote  Advancing issues outnumbered declining ones on the NYSE by 1 761 to 1 219  for a 1 44 to 1 ratio on the upside  on the Nasdaq  1 633 issues rose and 1 166 fell for a 1 40 to 1 ratio favoring advancers  
The S P 500 posted 54 new 52 week highs and three new lows  the Nasdaq recorded 58 new highs and 47 new lows ",2016-07-06,Reuters,https://www.investing.com/news/stock-market-news/stock-futures-fall-for-second-day-as-uncertainty-weighs-in-412695,412695
179410,400926,WBA,Have You Noticed Potential In Herbalife  Stock Adds 48  YTD,opinion,"Shares of Herbalife Ltd    NYSE HLF   have exhibited a bullish run on the index  This Zacks Rank  1  Strong Buy  stock has surged 48 4  year to date  outperforming the Zacks categorized  industry and the broader sector  Meanwhile  the industry declined 3 8  and the Zacks categorized  sector gained 13 6   Notably  the current share price is also hovering to its 52 week high of  74 49 Herbalife looks promising on its impressive earnings history  strong growth potential in China and solid brand portfolio of personal care and nutritional supplements  Let s delve deep to explore more about this attractive stock What s Leading Herbalife Higher Recently  Herbalife informed that 90  of the U S  sales were documented purchases by consumers in May  which consisted of over three million receipted retail transactions because of its distributors  commitment  Further  management said it outpaced the key threshold of 80  under its agreement with the U S  Federal Trade Commission As a result  the company raised its earnings guidance for the second quarter and full year 2017  Herbalife now expects its adjusted earnings in the band of 95 cents  1 15 for the second quarter that ends on Jun 30  Earlier  it had projected the same in the range of 85 cents  1 05 and delivered  1 29 in the year ago quarter  We note that one estimate has moved north for the upcoming second quarter of 2017 over the last 30 days  The Zacks Consensus Estimate has been favorable for the said quarter as the same increased 10 cents to  1 10 For 2017  Herbalife estimates its adjusted earnings in the band of  4 10  4 50 per share versus  4 05  4 45  guided previously  In 2016  the company had posted adjusted earnings of  4 85  Currently  the Zacks Consensus Estimate is pegged at the higher end of the current guided range However  the company expects sales decline in the range of 2 6  from 0 5 4 5   guided previously  Also  volumes are expected to decrease 4 8  compared with previous range of 1 5  for the second quarter  For 2017  Herbalife s projected sales growth is 2 2  Impressive Earnings StreakThis leading nutrition company  which shares space with Walgreens Boots Alliance  Inc    NASDAQ WBA    Rite Aid Corporation   NYSE RAD   and CVS Health Corporation   NYSE CVS    has reported better than expected earnings for 10 straight quarters of late  In the trailing four quarters  the company s earnings have surpassed the Zacks Consensus Estimate with an average of 18 4  Herbalife Vs IndustryOther DevelopmentsHerbalife has solid growth potential in China  where there is higher demand for nutritional products  Moving ahead  management remains optimistic on the volume growth in the respective market  Evidently  sales and volumes in China significantly exceeded expectations primarily owing to the positive timing of sales and volume resulting from an increase in price announced in Mar 2017 In fact  China recorded volume growth of 17  in the first quarter  Additionally  this weight management company is witnessing volume improvement in key markets like the EMEA  Asia Pacific and Mexico  primarily backed by its marketing plan changes that were implemented in 2015 
You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-06-28,Zacks Investment Research,https://www.investing.com/analysis/have-you-noticed-potential-in-herbalife-stock-adds-48-ytd-200198358,200198358
179413,400929,WBA,Theranos CEO Holmes barred from operating lab for two years,news,"By Ankur Banerjee and Natalie Grover  Reuters    Theranos Inc founder and CEO Elizabeth Holmes  once touted as the Steve Jobs of biotech for her company s innovative blood testing technology  has been barred by a U S  regulator from owning or operating a lab for at least two years  Dealing the biggest blow yet to the privately held company  the Centers for Medicare   Medicaid Services revoked a key certificate for its California lab and terminated the facility s approval to receive government payments  Medicare is the government s medical insurance program for the elderly  while Medicaid is for the poor  The sanctions  which also include an unspecified monetary penalty  come six months after the regulator sent a scathing letter to the company  saying its practices were jeopardizing patient health and safety  Theranos said late on Thursday that it would continue to service its customers through its Arizona lab  The company  once valued at  9 billion  was founded by Holmes in 2003 to develop an innovative blood testing device that would give quicker results using just one drop of blood  However  its fortunes waned after the Wall Street Journal published a series of articles starting in October last year that suggested the devices were flawed and inaccurate  Forbes magazine said last month that the company s value had fallen to about  800 million  while Holmes  own net worth had shrunk to zero from about  4 5 billion   a figure the magazine had said had made her the richest self made woman in America   Everyone wanted her to succeed   Steve Brozak  president of WBB Securities  told Reuters  noting that the basic blood diagnostics sector has not had a significant advance in technology in 90 years  Walgreens Boots Alliance  O WBA  terminated its relationship with the company last month and closed operations at all 40 Theranos Wellness Centers at its drug stores in Arizona  Theranos is also facing a class action lawsuit filed in May accusing it of endangering customer health through  massive failures  that misrepresented test results  
The Palo Alto  California based company is also being investigated by other federal and state agencies  including the U S  Securities and Exchange Commission and the State Department of Health in Arizona ",2016-07-08,Reuters,https://www.investing.com/news/economy-news/theranos-ceo-holmes-barred-from-operating-lab-for-two-years-413247,413247
179414,400930,WBA,Walgreens profit beats  Rite Aid deal seen closing in 2017,news,"By Sruthi Ramakrishnan  Reuters    Drugstore operator Walgreens Boots Alliance Inc  O WBA  reported a better than expected quarterly profit  helped by cost cutting  and said it now expected its acquisition of  Rite Aid Corp   N RAD  to close on Jan  27  three months later than planned  Walgreens said in September it would likely have to divest between 500 and 1 000 stores to get regulatory clearance for the  9 4 billion deal  Walgreens  the No  1 U S  drugstore operator by store count  had previously said it expected it would need to divest not more than 500 stores and that the deal would close on Oct  27  The company said it expected to divest stores to win approval for the deal by the end of 2016  Supermarket chain  Kroger Co   N KR  is questioning whether to proceed with buying divested stores from Walgreens  a source familiar with the situation said on Wednesday  casting doubts on the future of the Walgreens Rite Aid deal  Kroger and Walgreens representatives declined to comment  Walgreens wants to buy Rite Aid to widen its footprint in the United States and negotiate for lower drug costs  Walgreens  shares were up 1 7 percent at  78 50 in premarket trading after closing at their lowest in five months on Wednesday  Rite Aid s shares were up about 4 4 percent at  6 95   The longer the  merger  process takes the more likely it is to close as it signals a delay in sorting out the divestiture package vs  a true blockage by FTC   Evercore ISI analyst Ross Muken wrote in a client note  Walgreens said on Thursday its net income attributable to the company rose to  1 03 billion  or 95 cents per share  in the fourth quarter ended Aug  31  from  26 million  or 2 cents per share  a year earlier  The company had recorded a loss of  143 million on a previously held equity interest and  479 million in other expenses in the year ago quarter  Walgreens said it met its goal of achieving  1 billion in synergies in June from its Boots Alliance acquisition  It is also working on cutting  1 5 billion in costs by the end of its fiscal year ending in August 2017  including by closing about 200 stores and reorganizing operations  among other measures  Excluding items  the company earned  1 07 per share in the quarter  beating the average analyst estimate of 99 cents per share  according to Thomson Reuters I B E S  
Sales rose marginally to  28 64 billion  missing the average estimate of  29 06 billion ",2016-10-20,Reuters,"https://www.investing.com/news/stock-market-news/walgreens-profit-jumps,-rite-aid-deal-seen-closing-in-2017-433599",433599
179415,400931,WBA,Walgreens sues Theranos  alleging breach of contract,news,Walgreens Boots Alliance  NASDAQ WBA  files a lawsuit against former lab tersting partner Theranos  alleging breach of contract and demanding a jury trial  WBA s Walgreens drug store unit is seeking  140M in damages  according to court records  which repreents the amount it invested in Theranos  Dow Jones  reports  Walgreens alleges Theranos misled it about the state of its technology when the two firms initially forged their agreement  and perhaps continued to do so ,2016-11-08,Seeking Alpha,"https://www.investing.com/news/stock-market-news/walgreens-sues-theranos,-alleging-breach-of-contract-438905",438905
179416,400932,WBA,Walgreens  Rite Aid Ditch Long Suffering Drugstore Merger,opinion,"On Thursday  Walgreens Boots Alliance   NASDAQ WBA    that it has abandoned efforts to merge with fellow drugstore chain Rite Aid   NYSE RAD    Instead  Walgreens will purchase almost half if its rivals stores after the deal passes U S  regulatory scrutiny from the Federal Trade Commission 
In premarket trading  shares of Walgreens were up about 3 7   though it has settled a bit  and is currently down 0 60  in late morning trading  Rite Aid shares were down over 4  in premarket trading  and have now plunged over 26  in light of the news 
Under the terms of the new deal  Walgreens will acquire 2 186 Rite Aid stores and related assets for  5 175 billion  Rite Aid will remain a  multi regional  drugstore chain  and the store locations being acquired are primarily in the Northeast  Mid Atlantic  and Southeastern regions of the U S 
 It will allow us to expand and optimize our retail pharmacy network in key markets in the U S   including the Northeast  and provide customers and patients with greater access to convenient  affordable care   Walgreens CEO Stefano Pessina said   We believe this new transaction addresses competitive concerns previously raised with respect to the prior transaction  
For Walgreens  the new transaction will be significantly less expensive  The original deal between the drugstore giant and its smaller competitor came in at about  9 4 billion  though the price range was lowered between  6 8 billion to  7 4 billion in January  The new deal stays  true to our original strategic aim   Pessina said   Overall I view this deal as being more attractive than the transaction it replaces  
For Rite Aid  the company said it will use the proceeds to pay down debt  and the bonds gained on that news   that the company s  6 75 percent unsecured notes due in 2021 rose as much as 4 cents on the dollar to 102 875   while the 7 7 percent notes due in 2027 were trading as high as 102 75 Thursday morning in New York  
 While we believe that pursuing the merger with WBA was the right thing to do for our investors and customers  this new agreement provides a clear path forward and positions Rite Aid as a strong  independent  multi regional drugstore chain and pharmacy benefits manager with a compelling footprint in key markets   Rite Aid CEO John Standley said in a statement 
This new deal also means that pharmacy chain Fred s Inc    NASDAQ FRED   will no longer be a buyer of Rite Aid stores  Last December  the company announced it would purchase 865 stores for  950 million in cash  Shares of Fred s are down about 19  in late morning trading  The pharmacy operates stores in 16 Southeastern states
Walgreens said it will begin taking over the Rite Aid stores over a period of about six months  and intends to covert the stores to the Walgreens name brand over time 
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2   respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-06-29,Zacks Investment Research,"https://www.investing.com/analysis/walgreens,-rite-aid-ditch-long-suffering-drugstore-merger-200198352",200198352
179417,400933,WBA,Fred s Stock Falls  Walgreens   Rite Aid Merger Deal Revised,opinion,"Fred s  Inc    NASDAQ FRED   or Fred s Pharmacy lost over 20  yesterday after Walgreens Boots Alliance  Inc    NASDAQ WBA   decided not to proceed with its planned takeover of the rival drugstore Rite Aid Corporation   NYSE RAD   due to various antitrust issues  as per Bloomberg  The cancelled merger significantly hurt Rite Aid s stock too  which fell 26 46  yesterday amid Federal Trade Commission  FTC  pushback 
What Led to the Revision of the Deal 
Walgreen Boots Alliance had agreed to acquire Rite Aid in Oct 2015 for about  9 4 billion  In order to obtain FTC s approval for the transaction  Fred s inked a deal in Dec 2016 with Rite Aid and Walgreens to buy 865 stores located in the eastern and western U S   along with certain assets for a total cash outlay of  950 million Fred s also announced plans to buy additional assets  including up to 1 200 Rite Aid stores  Notably  Fred s could also forge ahead with the deal only after the proposed merger of Rite Aid and Walgreens received clearance from FTC 
FTC was slated to announce its decision on the Walgreens Rite Aid merger on Jul 7  Though the deal was anticipated to hurt competition  there were indications earlier this week that the  
However  Walgreens was unlikely to get a FTC clearance and thus considered a revision of the previously announced merger deal 
Revised Deal   A Boon for Rite Aid  A Curse for Fred s
Under the terms of the revised deal  Walgreens  the pharmacy giant  agreed to acquire 2 186 stores and related assets from Rite Aid for  5 175 billion  Walgreens  shares closed 1 66  higher yesterday after the announcement of the new deal 
This new downsized deal  if it gets FTC nod  would offer enough cash to Rite Aid to pay down its huge debt  It will transform Rite Aid into a smaller but a strong  independent  multi regional drugstore chain and pharmacy benefits manager with a compelling footprint in key markets 
However  it did not do any good to Fred s  as this new deal means that the company will no longer be a buyer of Rite Aid stores  Fred s was left disappointed after the cancelled merger  which would have given the company greater negotiating power and as many as 1 200 stores beyond small rural towns  It would have also improved the company s healthcare growth strategy and benefit customers  patients  payors  supplier partners  team members and shareholders 
The busted Walgreens Rite Aid pact was very crucial for Fred s as it would have positioned this regional pharmacy chain as the third largest drugstore chain in the U S  after Walgreens and CVS Health Corporation   NYSE CVS   
We note that Fred s has been disappointing investors of late  Fred s posted weaker than expected sales in the first quarter of fiscal 2017  wherein losses were in line with the Zacks Consensus Estimate  Adjusted quarterly loss of 6 cents per share was also unfavorable compared with the year ago quarter figure 3 cents  Decline in sales along with lower comps and gross margin contraction led to the decline  First quarter sales slipped 3 1  year over year to  532 2 million  while comparable store sales dipped 1 2   as a result of the sale of low productive discontinued inventory  The company is also facing headwinds in the competitive consumable categories Fred s  Inc  Price  Consensus and EPS Surprise
    Price Performance
If we look into the past six months performance of Fred s  we note that the Zacks Rank  4  Sell  stock has significantly underperformed the Zacks categorized  industry 
The stock lost around 48 8  in the past six months  as compared to the industry s decline of 8 6  over the same time frame  You can see  

5 Trades Could Profit   Big League   from Trump Policies 
If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course 
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-06-29,Zacks Investment Research,"https://www.investing.com/analysis/fred's-stock-falls,-walgreens---rite-aid-merger-deal-revised-200198541",200198541
179425,400941,WBA,Stocks Mixed After Tech Troubles,opinion,"U S  equities finished a volatile session mixed as strength in financial and energy issues was countered by a tumble in technology stocks  which led the Nasdaq sharply lower on heavy volume  The U S  dollar gained ground  gold was lower and crude oil prices were slightly to the upside  Treasuries continued a recent move lower  while a light domestic docket showed that wholesale inventories declined more than expected 
The Dow Jones Industrial Average increased 89 points  0 4   to 21 272  the S P 500 Index lost 2 points  0 1   to 2 432  and the Nasdaq Composite tumbled 114 points  1 8   to 6 208  In heavy volume  984 million shares were traded on the NYSE and 3 1 billion shares changed hands on the Nasdaq  WTI crude oil increased  0 19 to  45 83 per barrel and wholesale gasoline was  0 01 higher at  1 50 per gallon  Elsewhere  the Bloomberg gold spot price decreased  7 10 to  1 272 90 per ounce  and the US Dollar Index a comparison of the U S  dollar to six major world currencies was 0 3  higher at 97 28  Markets were mixed for the week  as the DJIA advanced 0 3   the S P 500 Index declined 0 3   and the Nasdaq Composite fell 1 6  
VeriFone Systems  NYSE PAY  Inc  reported a fiscal Q2 loss of  0 80 per share  or earnings per share  EPS  of  0 30 ex items  versus the FactSet estimate of a  0 29 per share profit  as revenues declined 10 0  year over year  y y  to  474 million  above the projected  472 million  The payments and commerce solutions company issued Q3 guidance that missed expectations  while lowering its full year outlook  Separately  PAY announced that it is divesting three non strategic businesses to reallocate resources and capital to its core payments and commerce platform  Shares traded solidly lower 
DuPont  NYSE DD  Fabros Technology Inc  and Digital Realty Trust Inc  NYSE DLR  announced an all stock merger agreement with a total enterprise value of  7 6 billion  Under the terms of the deal  DuPont Fabros shareholders will receive a fixed exchange ratio of 0 545 Digital Realty shares for each share they own  DFT rallied  while DLR declined 
Pandora Media Inc   NYSE P  finished higher after announcing Sirius XM Holding Inc  NASDAQ SIRI  made a  480 million investment in the company and an agreement to sell its Ticketfly business to Eventbrite for  200 million 
Rite Aid Corporation  NYSE RAD  fell sharply amid a report from Capitol Forum saying Federal Trade Commission  FTC  staff are preparing a recommendation to sue to block the takeover of the company by Walgreens Boots Alliance  NASDAQ WBA  Inc  Neither entity mentioned commented on the story 
Wholesale inventories revised lower
Wholesale inventories were revised down to a 0 5  month over month  m m  decline for April  versus the Bloomberg forecast of an unrevised preliminary 0 3  decrease  and following March s unrevised 0 1  rise  Sales were 0 4  lower m m  after March s negatively revised 0 2  decline  The inventory to sales ratio the amount of time it would take to deplete inventories at the current sales pace remained at March s 1 28 months level 
Treasuries finished lower with the yields on the 2 year and 10 year notes rising 2 basis points  bps  to 1 34  and 2 21   respectively  while the 30 year bond rate gained 1 bp to 2 86  
Europe gains as markets react to U K  election  Asia also ticks higher
European equities finished higher  with the markets digesting yesterday s U K  election results that showed Prime Minister Theresa May s Party lost a majority  resulting in a hung parliament  The British pound dropped sharply versus the U S  dollar  providing some support to U K  stocks  as the outcome fostered Brexit uncertainty regarding the timing of negotiations and whether it will result in a hard of softer exit terms 
Stocks in Asia finished mostly to the upside  with the global markets taking yesterday s vote that led to a hung parliament in the U K   the ECB s changed language and outlook  and fired FBI Director Comey s testimony in the U S  in stride  Japanese equities gained ground  with the yen giving back some recent gains  while South Korean shares also advanced  Mainland Chinese stocks rose  but those traded in Hong Kong dipped on the heels of a report that showed consumer price inflation rose in line with forecasts  while wholesale price increases slowed more than expected for May  Australian securities finished flat and Indian equities moved higher 
Stocks mixed as technology sees late week stumble
Stocks finished mixed  with a late week pullback in technology issues from a decisive rally as of late weighing on the markets  Stocks showed little reaction to some highly anticipated events such as the relatively surprising U K  election  the European Central Bank s mixed outlook and apparent dovish tone by President Mario Draghi and former FBI Director Comey s testimony on Capitol Hill  Financials led the charge  with Treasury yields and the U S  dollar rebounding from a recent drop  Energy stocks also showed some resiliency  gaining ground despite pressure on crude oil prices that has persisted since last month s disappointing extension of OPEC production cuts  exacerbated by this week s unexpected jump in U S  oil inventories  Economic data was relatively light  though the ISM non Manufacturing Index showed growth continued for the all important services sector and the JOLTS Job Openings report hit a record high 
The markets are looking to this week s fully loaded economic calendar  highlighted by the Consumer and Producer Price Indexes  CPI   PPI   NFIB Small Business Optimism  retail sales  industrial production and capacity utilization  the NAHB Housing Market Index  housing starts and building permits  and the preliminary University of Michigan Consumer Sentiment Index  However  the headlining event will likely be the Federal Open Market Committee s  FOMC  monetary policy decision  A 25 bp hike to the target fed funds rate is highly expected  but the accompanying statement  updated economic projections and subsequent press conference by Chairwoman Janet Yellen are poised to garner heavy attention 
International reports due out next week that deserve a mention include  Australia consumer confidence and employment change  China lending statistics  retail sales and industrial production  India CPI  industrial production and trade balance  Japan Bank of Japan monetary policy decision  machine orders and industrial production  Eurozone industrial production  Q1 employment  trade balance and CPI  along with German investor confidence  U K  Bank of England monetary policy decision  CPI  retail sales and employment change ",2017-06-11,Marvin Clark,https://www.investing.com/analysis/stocks-mixed-after-tech-troubles-200194346,200194346
179430,400946,WBA,Walgreens threatens to pull out of Theranos partnership  WSJ,news," Reuters    Walgreens Boots Alliance Inc  O WBA   the largest U S  drugstore chain  threatened to terminate its relationship with Theranos Inc unless the blood testing company quickly fixes the problems found by federal inspectors at its laboratory in California  the Wall Street Journal reported  The drugstore chain gave the warning in a letter to Theranos late last month  the Journal said  citing people familiar with the matter   A spokesman for Walgreens declined to comment  Walgreen had suspended laboratory services by Theranos on Jan  28 after the U S  Centers for Medicare   Medicaid Services said that Theranos  deficient practices at its Newark lab posed  immediate jeopardy to patient health and safety   Theranos has been in the spotlight after reports in the Wall Street Journal suggested that its blood testing devices were flawed and had problems with accuracy  The 40 Theranos  wellness centers  at Walgreens stores in Arizona are the primary source of revenue for the blood testing company and its conduit to consumers  the newspaper said  
Theranos was unavailable for comment outside regular U S  business hours ",2016-02-10,Reuters,https://www.investing.com/news/stock-market-news/walgreens-threatens-to-pull-out-of-theranos-partnership:-wsj-384207,384207
179431,400947,WBA,Fred s  FRED  To Get Additional Funds For Rite Aid Stores,opinion,"Fred s  Inc    NASDAQ FRED   or Fred s Pharmacy has entered into a second amended and restated commitment letter with a number of banks on Jun 9  2017  The agreement pertains to the company s debt financing plans as well as the proposed acquisition of 865 stores  certain intellectual property and certain other tangible assets of Rite Aid Corporation   NYSE RAD    announced in Dec 2016 
Notably  Fred s can forge ahead with the  950 million deal only after the proposed merger of Rite Aid and Walgreens Boots Alliance  Inc    NASDAQ WBA   materializes post the Federal Trade Commission   FTC   clearance 
Fred s is working in collaboration with Walgreens Boots Alliance  Rite Aid and the FTC to obtain the approval of Walgreen Boots Alliance s pending acquisition of Rite Aid  announced in Oct 2015  and the divestiture of certain Rite Aid assets  Fred s also announced that it might buy additional assets  including up to 1 200 Rite Aid stores  in order to obtain the FTC s approval of the transaction 
According to 8 K SEC filing  Fred s has received increased committed financing for the deal from  1 2 billion to  1 65 billion on Jun 9 and extended the commitment date to July 31  Fred s could extend the outside commitment date further to Oct 31 
In addition to the financing  the letter included provisions for a senior asset based term loan secured by certain acquired intellectual property and for real estate financings and sale leaseback transactions  Per the letter  Fred s has received increased financing  contemplated thereunder  by  100 million  from  450 million to  550 million 
Hence  the available finances will be used to fund the company s proposed acquisition from Rite Aid of assets  including up to 1 200 retail stores  certain intellectual property  corporate infrastructure and distribution centers  The acquisition of these stores will position Fred s as the third largest drugstore chain in the nation  It will also improve the company s healthcare growth strategy and would largely benefit customers  patients  payors  supplier partners  team members and shareholders 
However  the company has been disappointing investors of late 
Disappointing Q1
Fred s posted weaker than expected sales in the first quarter of fiscal 2017  wherein losses were in line with the Zacks Consensus Estimate  Adjusted quarterly loss of 6 cents per share was also unfavorable compared with the year ago quarter figure 3 cents  Decline in sales along with lower comps and gross margin contraction led to the decline 
First quarter sales slipped 3 1  year over year to  532 2 million  while comparable store sales dipped 1 2   as a result of the sale of low productive discontinued inventory  The company is also facing headwinds in the competitive consumable categories 
Estimates Moving South
Estimates for the company for fiscal 2017 and fiscal 2018  have moved south in the past 30 days  reflecting the negative outlook of analysts  While estimates for fiscal 2017 dropped 86 4  from earnings of 22 cents to just 3 cents  for fiscal 2018  the same declined 32 3  to 65 cents per share Fred s  Inc  Price  Consensus and EPS Surprise
    Price Performance
Fred s stock has lost around 28 3  in the past three months  underperforming the Zacks categorized  industry s gain of 1 7  

Fred s currently carries a Zacks Rank  4  Sell  
Key Pick from the Sector
Investors interested in the broader retail space may consider Burlington Stores Inc    NYSE BURL    which carries a Zacks Rank  2  Buy  and has long term earnings growth of 15 85   You can see  
Zacks  2017 IPO Watch List
Before looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time 
One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-06-12,Zacks Investment Research,https://www.investing.com/analysis/fred's-(fred)-to-get-additional-funds-for-rite-aid-stores-200194852,200194852
179435,400951,WBA,Walgreens beats earnings expectations  revenues whiff ,news,"Walgreens  NASDAQ WBA  reported second quarter earnings that were better than expected on Tuesday  helped by cost reductions 
The retailer said it earned  1 31 in adjusted earnings per share  topping the forecast for  1 28 according to Bloomberg 
Its revenues for the period totaled  30 2 billion  below the estimate for  30 7 billion 
Its shares were little changed in premarket trading  They re also flat for the last 12 months 
 We continued to make good progress in the quarter in reducing costs and establishing more efficient working practices  which contributed to overall adjusted earnings growth   CEO Stefano Pessina said in the  
The company said its acquisition of Rite Aid announced last October is expected to close in the second half of this year 
It raised the low end of its guidance for fiscal 2016 adjusted net earnings by five cents per share  to a range of  4 35 to  4 55 ",2016-04-05,Business Insider,"https://www.investing.com/news/stock-market-news/walgreens-beats-earnings-expectations,-revenues-whiff-393585",393585
179445,400961,WBA,Plenty To Look Forward To,opinion,Monday  April 3  2017On this first trading day for the month of April  certain aspects of the market feel like the beginning of something  along with the hopes of warmer weather and the crack of the baseball bat sounding in parks all across the country  we are anticipating another strong quarter of growth as Q1 earnings season starts in the next couple weeks  At the end of this week  we ll see the latest non farm payroll report from the Bureau of Labor Statistics  BLS  Before this  however  we ll see the latest private sector payroll reports from ADP   NASDAQ ADP   released before the opening bell this Wednesday  Last month  ADP posted nearly 300K private sector jobs  which was much higher than analysts had expected  Growth in Construction and Manufacturing surprised to the upside  with Goods employment up triple digits for the first time in a very long time  We shall see if this continues as the Trump Era moves along in its still early stages This week also brings along some early Q1 earnings reports  including Monsanto   NYSE MON   and Walgreens Boots Alliance   NASDAQ WBA   on Wednesday  Monsanto is currently a Zacks Rank  2  Buy  stock with a Zacks Style Score  Value  Growth  Momentum  of B  Walgreens also has a Zacks Style Score of B  with a Zacks Rank  3  Hold  For comprehensive coverage of earnings season both in its current nascent stages as well as when reporting heats up  we d all do well to follow what Zacks Director of Research Sheraz Mian has to say about it  For his latest Earnings Preview  click here  Handicapping Q1 Earnings Season   VickerySenior Editor,2017-04-02,Zacks Investment Research,https://www.investing.com/analysis/plenty-to-look-forward-to-200181064,200181064
179446,400962,WBA,Earnings Season In Focus,opinion,On this first trading day for the month of April  certain aspects of the market feel like the beginning of something  along with the hopes of warmer weather and the crack of the baseball bat sounding in parks all across the country  we are anticipating another strong quarter of growth as Q1 earnings season starts in the next couple weeks  At the end of this week  we ll see the latest non farm payroll report from the Bureau of Labor Statistics  BLS  Before this  however  we ll see the latest private sector payroll reports from ADP   NASDAQ ADP  released before the opening bell this Wednesday  Last month  ADP posted nearly 300K private sector jobs  which was much higher than analysts had expected  Growth in Construction and Manufacturing surprised to the upside  with Goods employment up triple digits for the first time in a very long time  We shall see if this continues as the Trump Era moves along in its still early stages This week also brings along some early Q1 earnings reports  including Monsanto   NYSE MON  and Walgreens Boots Alliance   NASDAQ WBA  on Wednesday  Monsanto is currently a Zacks Rank  2  Buy  stock with a Zacks Style Score  Value  Growth  Momentum  of B  Walgreens also has a Zacks Style Score of B  with a Zacks Rank  3  Hold  ,2017-04-02,Zacks Investment Research,https://www.investing.com/analysis/earnings-season-in-focus-200181182,200181182
179447,400963,WBA,Fred s  FRED  Q4 Loss Narrower Than Expected  Shares Up,opinion,"Fred s  Inc    NASDAQ FRED   posted narrower than expected losses in fourth quarter fiscal 2016  However  sales lagged the Zacks Consensus Estimate  Nevertheless  the company has witnessed improvement in bottom line on the back of  sequential growth in Retail Pharmacy adjusted script comps  sequential progress in sales trends in Specialty Pharmacy business  Front Store margin expansion and strong holiday seasonal category sales  As a result  its share price rose13 86  after market closing on Apr 6 
In fact  we note that in the past six months  the company s shares gained momentum  due to the positive impact of the initiatives initiated in 2016  Shares rallied 50 7  outperforming the Zacks categorized  industry which dipped 0 3  in the same time frame  Further  we believe there is room for further upside which is also evident from its  score of  A  and long term earnings growth rate of 8 00  

Quarterly Results
The discount retailer posted adjusted quarterly loss of 11 cents per share which was narrower than the Zacks Consensus Loss Estimate of 19 cents  The figure  however  was in line with the year ago loss of 11 cents  Improvement in gross margins was offset by lower comps Fred s  Inc  Price and Consensus   Revenues   Margins
Fourth quarter sales slipped 4 5  year over year to  529 7 million and lagged the Zacks Consensus Estimate of  531 million by 0 24  
Comparable store sales dipped 3 6   narrower than a 3 8  decline recorded in the preceding quarter  However  results compared unfavorably with 1 7  gain reported a year ago 
Gross profits slumped 2 5  year over year to  129 6 million  while gross margins increased 50 basis points  bps  to 24 5   driven by the successful and profitable sale of discontinued inventory  We note that this gross margin increase was significantly better than the 480 bps decline in gross margins in the preceding quarter  which was due to soft sales and continued reimbursement pressure in the pharmacy category 
In the fourth quarter  Fred s incurred an operating loss of  22 2 million  compared to a loss of  5 1 million incurred a year ago  Losses increased due to higher selling  general and administrative expenses 
Selling  general and administrative expenses  including depreciation and amortization  expanded 380 bps to 28 7  of sales mainly due to higher professional  legal  banking and integration planning fees incurred in connection with the  
The Rite Aid transaction
On Dec 20  discount retailer Fred s entered into an agreement with Rite Aid Corp    NYSE RAD   and Walgreens Boots Alliance  Inc    NASDAQ WBA   to buy 865 stores located in the Eastern and Western U S  and certain assets that are required for store operations  The deal is worth  950 million and was paid in cash 
Fred s Pharmacy is working collaboratively with Walgreens Boots Alliance  Rite Aid and the Federal Trade Commission  FTC  to obtain the approval of Walgreen Boots Alliance s pending acquisition of Rite Aid  announced in Oct 2015  and the divestiture of certain Rite Aid assets  Recently  Fred s Pharmacy announced that it might buy additional assets  including up to 1 200 Rite Aid stores  in order to obtain the FTC s approval of the transaction  However  the completion of the transaction is still subject to approval by the FTC and requires other customary regulatory approvals and closing conditions 
The acquisition of these stores will position Fred s Pharmacy as the third largest drugstore chain in the nation  It will also improve the company s healthcare growth strategy and would largely benefit its customers  patients  payors  supplier partners  team members and shareholders 
Fiscal 2016 Results
In fiscal 2016  adjusted losses were 52 cents  narrower than the Zacks Consensus Loss Estimate of 59 cents  It was however wider than the year ago loss of 20 cents per share 
Net sales in fiscal 2016 were in line with the Zacks Consensus Estimate but decreased 1 2  year over year to  2 13 billion  due to a 2 2  fall in comp sales 
March Sales
In the five week period ended April 1  2017  sales dipped 2 7  to  208 6 million  due to the decline of comps of 0 5  against an increase of 1 8  in Mar 2016  A delayed Easter  from March last year to April this year  and a shift in holiday sales into April more than offset the benefit of tax refunds  which were delayed from February to March  
Store Update
As of Jan 28  2017  Fred s operates 601 pharmacy and general merchandise stores and three specialty pharmacy only locations  including 14 franchised Fred s Pharmacy locations 
Looking Ahead
The company is witnessing consistently favorable sequential growth in Retail Pharmacy adjusted script comps along with sequential progress in sales trends in Specialty Pharmacy business  The company expects the sequential improvement to continue throughout 2017 
Fred s currently carries a Zacks Rank  3  Hold  
Key Pick from the Sector
Investors interested in the broader retail space may consider Burlington Stores Inc    NYSE BURL    which sports a Zacks Rank  1  Strong Buy  and has long term earnings growth of 15 85   You can see  
Zacks  Best Private Investment Ideas
While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public 
Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-04-07,Zacks Investment Research,"https://www.investing.com/analysis/fred's-(fred)-q4-loss-narrower-than-expected,-shares-up-200181739",200181739
179452,400968,WBA,Walgreens Boots  WBA  Up 5 4  Since Earnings Report  Can It Continue ,opinion,"It has been about a month since the last earnings report for Walgreens Boots Alliance  Inc    NASDAQ WBA    Shares have added about 5 4  in that time frame  outperforming the market 
Will the recent positive trend continue leading up to the stock s next earnings release  or is it due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts 
Recent EarningsWalgreens Boots Alliance  Inc   WBA  reported adjusted earnings per share  EPS  of  1 36 in second quarter fiscal 2017  up 6 1  year over year  Adjusted EPS was in line with the Zacks Consensus Estimate On a reported basis  net earnings came in at  1 06 billion  reflecting an increase of 13 9  from the prior year quarter  Reported earnings came in at  0 98  reflecting an improvement of 15 3  on a year over year basis Total SalesWalgreens Boots recorded total sales of  29 44 billion in the fiscal second quarter  down 2 4  year over year and up 0 9  at constant exchange rate  CER   The top line missed the Zacks Consensus Estimate of  30 56 billion Following the earnings release  the company s share price dropped 0 90  during pre market trading session Segments in DetailWalgreens Boots currently reports under three operating segments  Retail Pharmacy USA  Retail Pharmacy International and Pharmaceutical Wholesale The Retail Pharmacy USA division delivered sales of  21 81 billion in the reported quarter  reflecting an increase of 1 5  on a year over year basis  Within this segment  total sales at comparable drugstores rose 2 4   while prescriptions filled in comparable stores grew 7 9  on account of Medicare Part D growth and volume growth from previously announced strategic pharmacy collaborations  On the other hand  comparable retail stores edged down 0 8  due to lower sales of consumables and general merchandise category and at the personal care category  partially offset by higher sales in the health and wellness and beauty categories Pharmacy sales  which accounted for 66 5  of the division s sales in the quarter  increased 3 7  from the year ago period  while pharmacy sales at comparable stores increased 4 2  on higher volumes Revenues at the Retail Pharmacy International division declined 14 5  on a year over year basis  down 1 9  at CER  to  3 10 billion  on account of currency fluctuations  At CER  comparable store sales in the second quarter increased 0 6  year over year  while comparable pharmacy sales fell 3 7  due to a reduction in government pharmacy funding in the U K The Pharmaceutical Wholesale division recorded quarterly sales of  5 03 billion  down 10 6  year over year  At CER  excluding acquisitions and dispositions  comparable store sales rose 5 2  MarginsGross profit decreased 3 8  year over year to  7 56 billion  Reported gross margin contracted 39 basis points  bps  to  25 67 million Selling  general and administrative  SG A  expenses inched up 1 9  to  6 12 billion  Adjusted operating income decreased 22 7  to  1 43 billion owing to significantly lower gross profits  Accordingly  adjusted operating margin contracted 128 bps to 4 8  Financial ConditionWalgreens Boots ended the second quarter of 2017 with cash and cash equivalents of  11 82 billion  compared with  9 56 billion at the end of first quarter fiscal 2017  Long term debt was  17 75 billion at the end of the reported quarter  compared with  12 97 billion at the end of the second quarter of fiscal 2016 Moreover  over the last six months the company generated operating cash flow of  3 38 billion  as compared to  525 million in the first quarter fiscal 2017  The resultant free cash flow was  2 74 billion in the reported quarter as compared with  147 million in the first quarter GuidanceWalgreens Boots maintained its guidance for fiscal 2017 and continues to expect adjusted earnings per share in the range of  4 90 to  5 08 The Zacks Consensus Estimate of  5 00 is within the guided range As announced on Jan 30  2017  the company no longer expects any material accretion from Rite Aid in fiscal 2017  Additionally  this guidance assumes current exchange rates for the rest of the fiscal 
How Have Estimates Been Moving Since Then 
Following the release  investors have witnessed a downward trend in fresh estimates  There have been two revisions lower for the current quarter Walgreens Boots Alliance  Inc  Price and Consensus
    VGM Scores
At this time  Walgreens Boots  stock has a great Growth Score of  A   though it is lagging a lot on the momentum front with a  F   However  the stock was allocated a grade of  B  on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of  B   If you aren t focused on one strategy  this score is the one you should be interested in 
Our style scores indicate that the stock is more suitable for growth investors than value investors 
Outlook
Estimates have been broadly trending downward for the stock  The magnitude of these revisions also indicates a downward shift  Interestingly  the stock has a Zacks Rank  3  Hold   We are looking for an inline return from the stock in the next few months ",2017-05-08,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-(wba)-up-5.4-since-earnings-report:-can-it-continue-200187656,200187656
179453,400969,WBA, Fred s  FRED  Up 4 3  Since Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Fred s  Inc    NASDAQ FRED    Shares have added about 4 3  in that time frame  outperforming the market 
Will the recent positive trend continue leading up to the stock s next earnings release  or is it due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers Fred s Fourth Quarter Loss Narrower than Expected  Sales In LineFred s posted narrower than expected losses in fourth quarter fiscal 2016  However  sales lagged the Zacks Consensus Estimate  Nevertheless  the company has witnessed improvement in bottom line driven by sequential growth in retail pharmacy adjusted script comps  sequential progress in sales trends in the Specialty Pharmacy business  Front Store margin expansion and strong holiday seasonal category sales  Quarterly ResultsThe discount retailer posted adjusted quarterly loss of  0 11 per share  which was narrower than the Zacks Consensus Loss Estimate of  0 19 per share  The figure  however  was in line with the year ago loss of  0 11  Improvement in gross margins was offset by lower comps Revenues   MarginsFourth quarter sales slipped 4 5  year over year to  529 7 million and also lagged the Zacks Consensus Estimate of  531 million by 0 2  Comparable store sales dipped 3 6   narrower than a 3 8  decline recorded in the preceding quarter  However  results compared unfavorably with a gain of 1 7  reported a year ago  Comps declined as a result of the sale of low productive discontinued inventory versus the fourth quarter of 2015 Gross profits slumped 2 5  year over year to  129 6 million  while gross margins increased 50 basis points  bps  to 24 5   driven by the successful and profitable sale of discontinued inventory  We note that this gross margin increase was significantly better than the 480 bps decline in gross margins in the preceding quarter  which was due to soft sales and continued reimbursement pressure in the pharmacy category In the fourth quarter  Fred s incurred an operating loss of  22 2 million  compared to a loss of  5 1 million incurred a year ago  Losses increased due to higher selling  general and administrative expenses Selling  general and administrative expenses  including depreciation and amortization  expanded 380 bps to 28 7  of sales mainly due to higher professional  legal  banking and integration planning fees incurred in connection with the announced agreement to acquire Rite Aid stores The Rite Aid transactionOn Dec 20  Fred s entered into an agreement with Rite Aid Corporation and Walgreens Boots Alliance  NASDAQ WBA  to buy 865 stores located in the Eastern and Western Unites States and certain assets that are required for store operations  The deal is worth  950 million and was paid in cash Fred s Pharmacy is working collaboratively with Walgreens Boots Alliance  Rite Aid and the Federal Trade Commission  FTC  to help obtain the approval of Walgreen Boots Alliance s pending acquisition of Rite Aid  announced in Oct 2015  and the divestiture of certain Rite Aid assets to Fred s  Recently  Fred s Pharmacy announced that it might buy additional assets  including up to 1 200 Rite Aid stores  in order to obtain the FTC s approval of the transaction  However  the completion of the transaction is still subject to approval by the FTC  and requires other customary regulatory approvals and closing conditions The acquisition of these stores will give scale to the company and will position Fred s Pharmacy as the third largest drugstore chain in the nation  It will also improve the company s healthcare growth strategy and would largely benefit its customers  patients  payors  supplier partners  team members and shareholders Fiscal 2016 ResultsIn fiscal 2016  adjusted losses were  0 52 per share  narrower than the Zacks Consensus Loss Estimate of  0 59 per share  It was however wider than the year ago loss of  0 20 per share  Net sales in fiscal 2016 were in line with the Zacks Consensus Estimate but decreased 1 2  year over year to  2 13 billion  due to a 2 2  decline in comp sales March SalesIn the five week period ended April 1  2017  sales dipped 2 7  to  208 6 million  due to comps decline of 0 5  against an increase of 1 8  in Mar 2016  A delayed Easter  from March last year to April this year  and a shift in holiday sales into April more than offset the benefit of tax refunds  which were delayed from February to March  Store UpdateAs of Jan 28  2017  Fred s operates 601 pharmacy and general merchandise stores and three specialty pharmacy only locations  including 14 franchised Fred s Pharmacy locations Looking AheadThe company is witnessing consistently favorable sequential growth in Retail Pharmacy adjusted script comps along with sequential progress in sales trends in its Specialty Pharmacy business  The company expects the sequential improvement to continue throughout 2017  The company also remains focused on health care services  improving trends in Front Store and reducing inventory and expenses throughout the business  which will improve cash flow 
How Have Estimates Been Moving Since Then 
It turns out  fresh estimate flatlined during the past month  There has been one revision higher for the current quarter compared to one lower  In the past month  the consensus estimate has shifted lower by 142 9  due to these changes Fred s  Inc  Price and Consensus
    VGM Scores
At this time  Fred s stock has a poor Growth Score of  F   however its Momentum is doing a lot better with an  B   However  the stock was allocated a grade of  D  on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of  F   If you aren t focused on one strategy  this score is the one you should be interested in 
The company s stock is suitable solely for momentum based on our styles scores 
Outlook
The stock has a Zacks Rank  3  Hold   We are expecting an inline return from the stock in the next few months ",2017-05-08,Zacks Investment Research,https://www.investing.com/analysis/fred's-(fred)-up-4.3-since-earnings-report:-can-it-continue-200187692,200187692
179456,400972,WBA,Senators call for scrutiny of Walgreens Rite Aid deal,news,"By Sruthi Ramakrishnan and Diane Bartz  Reuters    Two influential U S  senators called for close scrutiny of Walgreens Boots Alliance Inc s  O WBA  plan to buy  Rite Aid Corp   N RAD  for  9 4 billion  a deal that would unite two of the three biggest U S  drugstore chains  Walgreens Chief Executive Stefano Pessina said the company had analyzed the antitrust aspect of the deal but would not speculate on the number of drugstores it might need to divest in order to win regulatory approval  Walgreens ranks first and Rite Aid third by number of stores  either side of CVS Health Corp  N CVS   The top two antitrust lawmakers in the U S  Senate on Wednesday urged antitrust enforcers to give the plan careful scrutiny because of the importance of healthcare in the U S  economy   I have fought tirelessly to promote competition in the health sector and I believe the proposed merger of two of the three largest drug store chains in the country raises serious issues   Senator Amy Klobuchar  the top Democrat on the Senate Judiciary Committee s antitrust subcommittee  said in a statement  The subcommittee s chair  Republican Senator Mike Lee  said he hoped antitrust agencies would  closely scrutinize  the deal  Several analysts and antitrust lawyers said the deal would probably pass regulatory muster provided some stores were divested  especially in the northeastern United States  where Walgreens and Rite Aid stores overlap by more than 25 percent  Walgreens shares closed down 10 7 percent on Wednesday  They had risen 7 percent on Tuesday after reports emerged that a deal was imminent  Rite Aid shares  which rose 40 percent on Tuesday  fell 7 0 percent to  8 06   We have done significant analysis on how we can bring the two companies together  including the antitrust analysis   Pessina said on a conference call with analysts on Wednesday  He said the deal made sense as the company was facing  tough challenges  in all its markets  either from competitors or from the government s  relentless  drive to manage healthcare costs  Walgreens offered to buy Rite Aid to gain scale in the retail pharmacy industry and not to increase its negotiating power with insurers and pharmacy benefit managers  he added  President Barack Obama s national healthcare reform law  which seeks to limit spending by cutting payments in government insurance programs  has been a contributory factor to a recent spurt in consolidation across the healthcare industry  Healthcare deal making hit a record of  392 4 billion in 2014 and has already surpassed that this year  reaching  447 5 billion as of Sept  10  according to Thomson Reuters data  Walgreens  which also reported better than expected quarterly profit and sales on Wednesday  said it expects to save more than  1 billion from the Rite Aid deal  
But the company said it would suspend share repurchases under its  3 billion program to fund the deal ",2015-10-28,Reuters,https://www.investing.com/news/stock-market-news/drugstore-operator-walgreens'-quarterly-sales-beat-estimates-368430,368430
179457,400973,WBA,Fred s  FRED  Q1 Loss In Line  Sales Weaker Than Expected,opinion,"Fred s  Inc    NASDAQ FRED   or Fred s Pharmacy posted weaker than expected sales in the first quarter of fiscal 2017  while losses were in line with the Zacks Consensus Estimate  The company s share price slumped 11 99  after market closing on Jun 6  2017 
Quarterly Results
The discount retailer posted adjusted quarterly loss of 6 cents per share  which was in line with the Zacks Consensus Estimate  It was unfavorable compared with the year ago quarter figure 3 cents  Decline in sales along with lower comps and gross margin contraction led to the decline 
Revenues   Margins
First quarter sales slipped 3 1  year over year to  532 2 million and also marginally lagged the Zacks Consensus Estimate of  533 million by 0 2   Comparable store sales dipped 1 2   narrower than a 3 6  decline recorded in the preceding quarter  However  results compared unfavorably with a gain of 1 0  reported a year ago  Comps declined as a result of the sale of low productive discontinued inventory  The company is also facing headwinds in the competitive consumable categories
Gross profits declined 5 9  year over year to  132 9 million  while gross margins declined 70 basis points  bps  to 25 0   due to the closure of 39 underperforming stores  In the first quarter  Fred s incurred an operating loss of  34 2 million  compared with an income of  2 4 million incurred a year ago  Losses were due to higher selling  general and administrative expensesmainly due to higher professional  legal  banking and integration planning fees incurred in connection with the  and the development and implementation of the company s growth strategy 
In fact  we note that in the past six months  the company s shares have been gaining momentum significantly  The company started to recognize the positive impact of the initiatives it began implementing in 2016  Shares have increased 10 3  outperforming the Zacks categorized  industry which declined 4 2  over the same time frame  Further  we believe there is room for further upside which is also evident from its Momentum Score of  A  and long term earnings growth rate of 8 00  

We note that despite dismal first quarter results  the company has witnessed improved growth in Retail Pharmacy adjusted script comps and year over year progress in sales trends in the Specialty Pharmacy business  as the company continues to execute the Fred s Pharmacy healthcare transformation  The company has announced new board members and closed underperforming stores  Fred s has been upgrading technical know how  improving supply chain and is focusing on its health care strategy in relation to execution of the Fred s Pharmacy transformation 
The Rite Aid Transaction
On Dec 20  discount retailer Fred s entered into an agreement with Rite Aid Corp    NYSE RAD   and Walgreens Boots Alliance  Inc    NASDAQ WBA   to buy 865 stores located in the Eastern and Western Unites States and certain assets that are required for store operations  The deal is worth  950 million and was paid in cash 
Fred s Pharmacy is working collaboratively with Walgreens Boots Alliance  Rite Aid and the Federal Trade Commission   FTC   to help obtain the FTC s approval of Walgreen Boots Alliance s pending acquisition of Rite Aid  announced in Oct 2015  and the divestiture of certain Rite Aid assets to Fred s Pharmacy  Fred s Pharmacy announced that it might buy additional assets  including up to 1 200 Rite Aid stores  in order to obtain the FTC s approval of the transaction  However  the completion of the transaction is still subject to approval by the FTC  and requires other customary regulatory approvals and closing conditions 
The acquisition of these stores will boost company s network and will position Fred s Pharmacy as the third largest drugstore chain in the nation  It will also improve the company s healthcare growth strategy and would largely benefit its customers  patients  payors  supplier partners  team members and shareholders Fred s  Inc  Price  Consensus and EPS Surprise
    Store Update
As of Apr 28  2017  Fred s operates 601 pharmacy and general merchandise stores and three specialty pharmacy only locations  including 14 franchised Fred s Pharmacy locations  and 3 specialty pharmacy only locations 
Looking Ahead
The company s Retail and Specialty Pharmacy businesses are improving significantly and driving momentum  The company expects the trend to continue throughout 2017  The remodel program in the Front Store is expected to accelerate in the back half of 2017  which will further boost sales 
Fred s currently carries a Zacks Rank  4  Sell  
Key Pick from the Sector
Investors interested in the broader retail space may consider Burlington Stores Inc    NYSE BURL    which carries a Zacks Rank  2  Buy  and has long term earnings growth of 15 85   You can see  
3 Stocks to Ride a 588  Revenue Explosion
At Zacks  we re mostly focused on short term profit cycles  but the hottest of all technology mega trends is starting to take hold   
By last year  it was already generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ",2017-06-07,Zacks Investment Research,"https://www.investing.com/analysis/fred's-(fred)-q1-loss-in-line,-sales-weaker-than-expected-200193830",200193830
179470,400986,WBA,Walgreen to pay  22 4 million in N Y  Medicaid improper billing case,news,"NEW YORK  Reuters     Walgreen Co   NYSE WBA  has reached a  22 4 million settlement with the New York attorney general resolving claims that a unit improperly billed the government for reimbursement for a pediatric drug  The settlement  disclosed in court papers filed in Manhattan federal court on Thursday  resolves claims first asserted in 2009 by a whistleblower in a lawsuit against Trinity Homecare LLC  a pharmacy primarily owned by Walgreen  The settlement marked the second in less than two weeks by the New York attorney general and Walgreen over improper conduct and billings by Trinity  after an earlier  2 55 million accord on June 29  Walgreen agreed to the settlement to avoid delay and expense and did so without any admission of liability  said spokesman James Cohn   The latest settlement concerned an injectable respiratory drug called Synagis  a brand name drug sold by AstraZeneca Plc that is intended for at risk premature infants  According to the whistleblower lawsuit filed by a hospital physician  Susan Vierczhalek  Trinity promoted the off label use of the drug and caused false claims to be submitted to the government  In a statement  New York Attorney General Eric Schneiderman said the pharmacy  did not always have a prescription for that drug  but billed Medicaid for it anyway    Of greater concern than the improper billing  is the possibility that infants could have received injections which were not properly prescribed to them   he said  The federal government will receive some of the settlement  while New York will receive  12 23 million  Schneiderman s office said  New York in turn will pay Vierczhalek  4 million as her share of the settlement  according to court papers  Barbara Hart  Vierczhalek s lawyer  called the settlement  a great fraud recovery for Medicaid and gratifying in all respects   Representatives for Walgreen did not respond to requests for comment  
Walgreen is part of Walgreens Boots Alliance Inc  and this year sold a majority stake in Trinity s parent Walgreens Infusion Services to private equity firm Madison Dearborn Partners  That business is now known as Option Care ",2015-07-09,Reuters,https://www.investing.com/news/stock-market-news/walgreen-to-pay-$22.4-million-in-n.y.-medicaid-improper-billing-case-350523,350523
179471,400987,WBA,Walgreen deceives shoppers with stale price tags  Missouri AG,news,"By Jonathan Stempel  Reuters     Walgreen Co  should be held in contempt and fined for its persistent failure to remove expired price tags from store shelves  a practice that deceives consumers  causes overcharges and violates a 2014 settlement  Missouri s attorney general said  Attorney General Chris Koster on Tuesday filed papers in a Kansas City  Missouri state court seeking civil fines of up to  5 000 per tag against the Walgreens Boots Alliance Inc  O WBA  unit  and additional penalties if the tags are not removed  Koster said inspectors from his consumer protection unit found 1 306 expired tags at 49 of the 50 Walgreens stores they visited in Missouri from July 26 to Sept  1  including two tags that expired in 2013  He said this violated a June 2014 agreement and permanent injunction under which the largest U S  drugstore chain  which is based in Deerfield  Illinois  agreed to remove stale tags within 12 hours of their expiration  That agreement also called for periodic  independent audits of Walgreen stores   Consumers should not have to dig through outdated and incorrect information to find out the true price of any item   Koster said in a statement  Walgreen in a statement said the settlement was  in our customers  best interests   and that it will continue working with Koster to ensure pricing accuracy   We are committed to continuing to earn our customers  trust and loyalty   it said   
The case is Missouri ex rel  Koster v Walgreen Co  Circuit Court of Jackson County  Missouri  No  1316 cv 21688 ",2015-09-22,Reuters,"https://www.investing.com/news/stock-market-news/walgreen-deceives-shoppers-with-stale-tags,-deserves-fines:-missouri-ag-362858",362858
179474,400990,WBA,Here s Why I Like CVS Health Corporation,opinion,"Introduction
Investing in great companies sits at the core of my investment philosophy  In this regard  I reject the idea that I invest in the stock market  To me  the stock market is simply the store I shop in to purchase interests in fine businesses  In the final analysis  my investment objective is to become a long term shareholder partner in a business that I believe can make me money over time 
On the other hand  no matter how great I think the business is  I am also very focused on only investing in it at a fair price  When looking for great businesses  this can at times be a problem  Great businesses attract investors  and since stocks are liquid instruments  the forces of supply and demand can have a significant impact on valuation over the short run  In other words  the demand for great businesses is typically high 
Nevertheless  time is the equalizer where in the long run a company s stock price will be driven by its business success  When dealing with stocks  the common measuring sticks are earnings  cash flows and dividends   if a company pays one  Consequently  because of the supply demand dynamics over the short run  a company s valuation can be temporarily out of sync with its business success 
Therefore  to my way of thinking  the trick to long term investment success is to identify a great business and then invest in it only when the market offers it at a fair or attractive valuation  You can overpay for even the greatest company  and if you re diligent you can also find times when it is fairly valued or even undervalued  I am content to buy a great business at fair value  and I get quite excited when given the opportunity to invest at a low valuation  I have recently become interested in CVS Health Corporation  NYSE CVS  because I believe the market has recently provided an opportunity to invest in it at a fair price 
CVS Health Corporation a Great Business at a Fair Price
Before I delve into CVS Health Corporation s valuation  I would like to establish why I consider it a great business from a shareholder s perspective  For starters  I really admire the consistency of operating results that the company has generated  The following F A S T  Graph plots the company s earnings and dividends since 2000 through 2015  Note that I chose this timeframe because it includes both of our most recent recessions  It is very rare to find a company that has so consistently grown its earnings and dividends over time  Moreover  in addition to consistent growth  CVS s growth rate has also been significantly above average 
CVS has grown earnings at the compound annual rate of 12 5  since 2000 versus the S P 500 which has only grown earnings at the rate of 5 4   As I will later illustrate  CVS s stronger earnings and dividend growth has led to significantly higher returns than the market over this timeframe  Importantly  both capital appreciation and cumulative total dividend income have been superior with CVS  This illustrates my basic definition of a great business  A great business is one that has proven itself to grow faster and more consistently than the average company  CVS represents a quintessential example of that standard  as illustrated by the following earnings and dividend graph 

To further clarify this distinction  I also offer a similar graph on the S P 500 plotting earnings and dividends over the time frame 2000 2015  Not only have the S P 500 s earnings grown at less than half the rate of CVS s earnings  the overall market s earnings has also been significantly more cyclical  The market s dividend record is a little better  but dividends were cut in 2009  When stacked up against the average company  I consider CVS a great business 

As I indicated in the introduction  in addition to identifying a great business  I also want to see it at an attractive price  On these next two graphs I bring in monthly closing stock prices for both CVS and the S P 500  It s important that the reader recognizes that both CVS and the S P 500 were overvalued in 2000  For those that recall  calendar year 2000 represented the coming to the end of what was dubbed the  irrational exuberant period  in the stock market  Consequently  I would ve had no interest in investing in either at this time 
Furthermore  the reader should also note that both of these entities were also overvalued at the end of calendar year 2015  Consequently  I had no interest in investing in either of these entities during calendar year 2015  CVS continued to perform strongly on an operating basis  but stock price was so disconnected from fair value  the orange line on the graph  that I had no interest in spite of its impeccable operating record 


The following performance report compares CVS versus the S P 500 over this time frame  What I found interesting is how both CVS and the S P 500 produced capital appreciation returns that were lower than their respective earnings growth achievements  This is the effect that overvaluation had on both 
On the other hand  the great business CVS was still able to produce very attractive double digit total returns thanks for the most part to its high and consistent growth  In contrast  the S P 500 produced positive results but they pale in comparison to CVS  The simple lesson here is that valuation matters  and it matters a lot 

Now let s fast forward to current time and evaluate what CVS looks like today from a valuation perspective  Since the summer of 2015  and for most of 2016  CVS s stock price has been in a free fall  The net result is an approximately 23  drop off from its 2015 summer high  Investors hate it when a stock s price drops  and as a result it typically conjures up a lot of negativity 
In doing my research on CVS I have come across several recent articles on the company  most of them positive  However  some of the comments made in these articles illustrate my previous point about negative investor sentiment  Reasonable questions start to be asked such as   if the stock is so good  why does it keep dropping  But more importantly  answers to those questions are also offered  Some of those answers are relevant  some are rationalizations   and some even cynical laments with political overtones 
I support the proposition that everyone is entitled to their own opinions and views  However  to me  the answer to the question of why is the stock dropping seems quite obvious  It is quite clear to me that starting in the fall of 2014 the company s stock price began separating from its fundamental value and support  In my experience  when valuation gets extreme  a company s stock price becomes highly vulnerable to even a whiff of bad news  Furthermore  the more overvalued a stock is  the more vulnerable 
For example  in the case of retail pharmacy chain and pharmacy benefit management businesses such as CVS Health Corporation and Walgreens Boots Alliance  Inc   NASDAQ WBA  the threat of rising pressure to reduce reimbursement fees for generic drugs is seen as a potential threat to future profitability  Additionally  stiff competition is also a challenge that must be met  Nevertheless  demographics suggest a bright future for well managed companies within this sector  Consequently  expectations for continued growth remain strong 
With all that said  I contend that the biggest headwind that CVS has faced in recent years has been significant overvaluation  A quick glance at the following graph makes it clear to me that the biggest reason that the stock price has dropped is because it was ridiculously overvalued  And as the title of this article suggested  the fact that it has now moved down to a fair valuation level is precisely why I have become interested in it at this time 

CVS Health Corporation  Attractive Dividend Growth and Total Return Opportunity
Since CVS has recently moved into fair valuation territory  I have become interested in conducting a comprehensive research and due diligence process  That is not the same as saying I am recommending it as a strong buy  On the other hand  I am reasonably confident that a purchase made today would generate attractive long term future returns  It is possible that the stock could drop further based on negative investor sentiment  But  it is also possible that the price has bottomed out 
As investors  we must accept the reality that finding perfect tops or bottoms is rarely possible notwithstanding luck  But more importantly  you don t have to find the perfect bottom in order to make attractive long term returns  Potential short term pain can easily lead to exceptional long term gain as long as your original purchase is made at a sound valuation  Personally  I believe that CVS s stock price is currently at a sound level 
As a result  I have started a comprehensive research and due diligence process and so far I like what I see  With the remainder of this article  I will share much of what I found thus far  but also caution that this is still a work in progress  However  before I attempt to dig too deep into the workings of the company  I like to review important financial metrics such as the balance sheet  cash flow statement  profitability  and income statement 
The Balance Sheet
I believe that CVS s balance sheet is strong and healthy  Assets per share  atps  and book value or common equity per share  ceps  are both steadily increasing  Long term debt per share  dltps  and total debt per share  dtps  are at reasonable levels  Furthermore  the company s increase in debt in 2015 is primarily attributable to their acquisitions of Omnicare and Target s pharmacy and clinical businesses  Both of these acquisitions hold the promise to expand CVS s customer base and retail channels going forward 

Cash Flow Statement
Since dividends represent an important component of the allure for investing in CVS  I was gratified to see that cash flow per share  cflps  more than adequately covers their dividends 

Profitability
The retail pharmacy chain and pharmacy benefit management businesses do not produce exceptionally high gross profit margins  gpm  or net profit margins  npm   However  the consistency and predictability of these businesses still allows for high rates of bottom line growth  Gross profit margins for CVS have weakened slightly in recent years  but net profit margins have remained consistent  Moreover  I consider these reasonable margins a plausible defense against political onslaught considering the important nature of the business 

On the other hand  return on equity  roe  and return on invested capital  roi  have been improving in recent years 

The Income Statement
From the income statement perspective  I have previously covered CVS s consistent and high earnings growth  Additionally  cost of goods sold  cogsps  has also been rising  but revenue growth  revps  has been following suit 

Shareholder Friendly Management
Generally speaking  I consider the CVS management team as very shareholder friendly  Since fiscal year 2000  the company s dividend has grown at an average rate of 17 8  translating to a compound annual growth rate of 16 9   However  the dividend was frozen from fiscal year 2000 through 2003    which included the recession of 2001  On the other hand  the company did raise their dividend throughout the Great Recession at double digit rates 
In addition to increasing their dividend  the company has also been buying back their shares since 2007  On this count I would give them a B  grade because I do not consider share buybacks in 2014  2015 and 2016 as an especially good use of shareholder capital  On the other hand  now that the stock is reasonably valued I would favor a continuation of share buybacks 

CVS Health Corporation  The Businesses
The following short business description provided courtesy of S P Capital IQ 
 CVS Health Corporation  together with its subsidiaries  provides integrated pharmacy health care services  It operates through Pharmacy Services and Retail LTC segments 
The Pharmacy Services segment offers pharmacy benefit management solutions  such as plan design and administration  formulary management  Medicare Part D services  mail order and specialty pharmacy services  retail pharmacy network management services  prescription management systems  clinical services  disease management programs  and medical pharmacy management services  This segment serves employers  insurance companies  unions  government employee groups  health plans  managed Medicaid plans and plans offered on public and private exchanges  other sponsors of health benefit plans  and individuals under the CVS Caremark Pharmacy Services  Caremark  CVS Caremark  CarePlus CVS Pharmacy  CVS Specialty  Accordant  SilverScript  NovoLogix  Coram  Navarro Health Services  and Advanced Care Scripts names 
As of December 31  2015  it operated 24 retail specialty pharmacy stores  11 specialty mail order pharmacies and 5 mail order dispensing pharmacies  and 83 branches for infusion and enteral services 
The Retail LTC segment sells prescription drugs  over the counter drugs  beauty products and cosmetics  personal care products  convenience foods  seasonal merchandise  and greeting cards  as well as provides photo finishing services 
It operates 9 655 retail stores in 49 states  the District of Columbia  Puerto Rico  and Brazil primarily under the CVS Pharmacy  CVS  Longs Drugs  Navarro Discount Pharmacy  and Drogaria Onofre names  online retail pharmacy Websites  and 32 onsite pharmacy stores  long term care pharmacy operations  and retail health care clinics 
The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014  CVS Health Corporation was founded in 1892 and is headquartered in Woonsocket  Rhode Island  
CVS Health Corporation  Thesis for Growth
The consensus of 25 analysts reporting to S P Capital IQ expect CVS to grow earnings by 13 57  for this fiscal year end followed by an 11 77  for fiscal year ending December 31  2017  and 18 analysts expect earnings to grow 10 84  for fiscal year end December 31  2018  If these analysts are correct  that would suggest double digit rates of return over the next couple of years  Additionally  these analysts  earnings estimates are consistent with CVS management s guidance range for adjusted earnings of  5 81 to  5 89 for this fiscal year end 

I have a reasonably high level of confidence in those forecasts based on the excellent historical track record of analyst estimates when made one year and two years forward as evidenced by the following Analyst Scorecard 


Additionally  Morningstar believes that CVS possesses a wide economic moat and that their large claim volume affords them the opportunity to take advantage of two key industry drivers   supplier pricing leverage and centralized cost scale  
The following excerpt from their analyst report speaks to CVS s strong returns on invested capital and their long term growth opportunity 
 CVS Health has pursued a vertically integrated strategy to try and capture as much value as possible from the retail pharmacy industry  The firm has established itself as a top tier pharmacy benefit manager and one of the largest U S  pharmacy retailers  Its stalwart competitive advantages have churned out outstanding returns on invested capital and have given it a wide economic moat  We anticipate robust growth for the pharmaceutical industry over the long term  which should provide CVS with a solid platform for continued success  
In the most recent report provided by Zacks they highlight the recent Omnicare acquisition and suggest that it will contribute to future growth opportunities  They also believe that the recent Target Pharmacy purchase represents a strategic fit  and reports a positive view that the PBM business is gaining traction  Zacks also considers CVS s specialty pharmacy business to be a high growth driver  And they cite the opportunity regarding domestic demographic trends as a result of our aging population 
On the other hand  Zacks also points out CVS s vulnerability to federal and state reimbursement laws due to their high dependence on Medicare  Medicaid and other government sponsored health programs  They also address the potential competitive threat from the Walgreens Boots Alliance and Rite Aid pending merger  However  that merger is currently facing FTC scrutiny  Personally  I believe that there is room for both powerhouses to flourish in the future  Moreover  although I consider both WBA and CVS to be excellent businesses  I currently favor CVS based on a more attractive current valuation  For perspective  here is the earnings and price correlated F A S T  Graph on WBA 

Summary and Conclusions
I suggest that CVS Health Corporation currently provides the opportunity for above average long term total returns over the next several years  I base my position on the company s exceptional historical operating results  its growing dividend  and most importantly its current attractive valuation  In my opinion  the company s recent stock price weakness is primarily attributed to the past overvaluation  Consequently  now that the company s price has returned to fair value  I have become interested in learning more about this great business  Moreover  I would consider any further price weakness an opportunity to invest in a great business at a very attractive valuation 
Disclosure  Long CVS
Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation ",2016-10-14,Chuck Carnevale,https://www.investing.com/analysis/why-i-am-now-interested-in-cvs-health-corporation-200158755,200158755
179475,400991,WBA,Walgreens Boots  WBA  Earnings Top  Margins Slide In Q4,opinion,"Walgreens Boots Alliance  Inc    NASDAQ WBA   reported adjusted earnings per share  EPS  of  1 07 in the fourth quarter of fiscal 2016  up 21 6  from the year ago quarter  Adjusted EPS also beat the Zacks Consensus Estimate by 8 1  
Single digit growth observed in the company s top line primarily drove the adjusted earnings 
On a reported basis  net earnings came in at  1 0 billion  a significant improvement from  26 million in the year ago quarter  Reported earnings per share came in at 95 cents  reflecting a rise of 97 8  year over year WALGREENS BAI Price  Consensus and EPS Surprise

   For full year 2016  adjusted EPS came in at  4 59  up 18 3  compared from the year ago quarter  The figure also surpassed the Zacks Consensus Estimate of  4 51 
Total Sales
Walgreens Boots recorded total sales of  28 6 billion in the fiscal fourth quarter  up 0 4  year over year or 2 5  at constant exchange rate  CER   However  the top line missed the Zacks Consensus Estimate of  29 2 billion 
Fiscal 2016 total sales totaled  117 4 billion  up 13 4  from the year ago comparable period  However  it missed the Zacks Consensus Estimate of  117 9 billion by a slight margin 
Segments in Detail
Walgreens Boots currently reports under three operating segments  Retail Pharmacy USA  Retail Pharmacy International and Pharmaceutical Wholesale 
The Retail Pharmacy USA division delivered sales of  20 7 billion in the reported quarter  reflecting an increase of 4  on a year over year basis  Within this segment  total sales in comparable drugstores increased 3 2   while prescriptions filled in comparable stores grew 3 7  on account of continued growth in Medicare Part D volumes  On the other hand  comparable retail stores dropped 0 3  due to lower sales of certain consumables and seasonal items  partially offset by higher sales in the health and wellness and beauty categories 
Pharmacy sales  which accounted for 69  of the division s sales in the quarter  increased 6 2  from the year ago quarter  while pharmacy sales in comparable stores increased 5  
Revenues from the Retail Pharmacy International division dropped 10 9  on a year over year basis  up 1 4  at CER  to  3 2 billion  on account of currency fluctuations  At CER  comparable store sales in the fourth quarter decreased 0 6  year over year  while comparable pharmacy sales were flat as the loss of certain institutional sales contracts in Chile was offset by growth in other markets 
The Pharmaceutical Wholesale division recorded quarterly sales of  5 4 billion  down 6 2   At CER  excluding acquisitions and dispositions  comparable store sales improved 2 9  
Margins
Gross profit decreased 87 1  year over year to  7 1 billion  Reported gross margin contracted a stupendous 16899 basis points  bps  
Selling  general and administrative  SG A  expenses contracted 4 9  to  6 billion  However  adjusted operating income decreased 97 7  to  1 1 billion owing to significantly lower gross profits  Accordingly  adjusted operating margin contracted a massive 16782 bps to 3 9  
Financial Condition
Walgreens Boots exited fiscal 2016 with cash and cash equivalents of  9 8 billion  compared with  3 billion at the end of fiscal 2015  Long term debt was  18 7 billion  compared with  13 3 billion at the end of the prior fiscal year 
Moreover  the company generated operating cash flow of  7 8 billion in 2016 compared with  5 6 billion a year ago  The resultant free cash flow was  6 5 billion in 2016 
Guidance
Walgreens Boots has issued its fiscal 2017 guidance  The company expects adjusted EPS in the  4 85  5 20 range for the fiscal  The current Zacks Consensus Estimate for fiscal 2017 earnings is  5 08  within the company s guided range 
This guidance assumes 5 to 12 cents of accretion from the impending Rite Aid Corporation  RAD  acquisition and is also based on the expected store divestitures and timing of closing of the acquisition  
Progress on Rite Aid Acquisition
In a separate press release  Walgreens Boots announced that the closing date of the impending acquisition of Rite Aid has been extended from Oct 27  2016 to Jan 27  2017 
Notably  in Oct 2015  Walgreens Boots announced an agreement to acquire U S  based retail pharmacy chain Rite Aid for a total enterprise value of  17 2 billion  including acquired net debt 
Our Take
Walgreens Boots reported a mixed fourth quarter fiscal 2016 with earnings comfortably beating the Zacks Consensus Estimate and sales missing the mark  We note that the reported results are reflective of the trend exhibited by the company in the preceding five quarters  On a brighter note  the company has a strong cash position as is evident from the rise in cash flow reserve in the reported quarter  However  the company s postponement of the Rite Aid buyout adds to our concerns 
Nevertheless  Walgreens Boots was successful in achieving its earlier set target of achieving combined net synergies of at least  1 billion  on account of the merger with Alliance Boots 
Zacks Rank   Key Picks
Walgreens Boots currently has a Zacks Rank  3  Hold   Better ranked stocks in the medical product sector include GW Pharmaceuticals plc   NASDAQ GWPH    Quidel Corp    NASDAQ QDEL   and NuVasive  Inc    NASDAQ NUVA    Both GW Pharmaceuticals and Quidel sport a Zacks Rank  1  Strong Buy   while NuVasive carries a Zacks Rank  2  Buy   You can see 
GW Pharmaceuticals surged 75 4  year to date compared to the S P 500 s 4 91  over the same period  The company s four quarter average earnings surprise is 41 6  
Quidel rallied 16 6  in the past one year  higher than the S P 500 s 6 2  gain  Over the next five years  the stock is estimated to record earnings growth rate of 20   higher than the industry average of 14 8  
NuVasive s shares soared 39  over the past one year  compared to the S P 500 s 6 2   Over the next five years  the stock is expected to see 16 7  earnings growth  compared to the industry average of 14 8   It has a trailing four quarter average earnings surprise of 19  
Confidential from Zacks 
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-20,Zacks Investment Research,"https://www.investing.com/analysis/walgreens-boots-(wba)-earnings-top,-margins-slide-in-q4-200159881",200159881
179476,400992,WBA,Stock Market News For October 21  2016,opinion,"Benchmarks finished in the red on Thursday following slump in oil prices and decline in telecom stocks  Continued crude oversupply concerns and stronger dollar had a negative impact on oil prices  which in turn weighed on energy stocks  Additionally  decline in shares of Verizon following its mixed third quarter results pulled telecom stocks downward  Moreover  European Central Bank s  ECB  decision to keep interest rates unchanged boosted dollar 

	For a look at the issues currently facing the markets  make sure to read today s  article 

	The Dow Jones Industrial Average  DJI  decreased 0 2   to close at 18 162 35  The S P 500 fell 0 1  to close at 2 141 34  The tech laden Nasdaq Composite Index closed at 5 241 83  also losing 0 1   The fear gauge CBOE Volatility Index  VIX  decreased 4 6  to settle at 13 75  A total of around 6 19 billion shares were traded on Thursday  lower than the last 20 session average of 6 42 billion shares  Decliners outpaced advancing stocks on the NYSE  For 55  stocks that declined  40  advanced 

What Weighed On the Benchmarks 

	After reaching its best level in 15 months on Wednesday following a decline in domestic crude inventories  oil prices fell yesterday  Total U S  crude inventories of 468 7 million barrels for the week ended October 14  was 5 4  more than the year over year figure  Moreover  doubts persist over the production cut deal between the OPEC nations mainly because of the continuous internal problems between its members 

	Also  the U S  dollar index  DXY touched 98 32  its highest level in seven months following surge in domestic existing home sales and ECB s decision to keep rates unchanged  Jump in dollar also weighed on oil prices  WTI crude fell 2 3  to  50 43 per barrel  Brent crude declined 2 5  to  51 38 a barrel  Decrease in oil prices led the Energy Select Sector SPDR  XLE  NYSE XLE   to fall 0 1   The Dow component  Chevron Corporation  NYSE CVX      lost 0 4  

	Moreover  Verizon Communications  NYSE VZ  Inc s    shares fell 2 5  after the company s third quarter revenues missed the Zacks Consensus Estimate  Its subscribers for wireless postpaid phone fell 36 000 in contrast to an increase of 430 000 year over year  However  its earnings per share beat the Zacks Consensus Estimate   Read More    

	Declines in Verizon led the telecom sector in the S P 500 to fall 2   its largest decline in last five weeks  Some of its key holdings including AT T  NYSE T   Inc     and Level 3 Communications  Inc      lost 1 9  and 0 2   respectively  Both the two companies possess a Zacks Rank  3  Hold   You can see   

	Further  ECB kept rates unchanged as expected  but President Mario Draghi s comments resulted in an uncertainty in the markets  Draghi said that the policy makers  didn t discuss tapering or the intended horizon of our asset purchase program  

Economic Data on Focus

	In economic news  initial claims increased last week by 13 000 to 260 000  matching the highest level in six week and was also higher than the consensus estimate of 254 000  However  sales of existing homes rose 3 2  in September from August to a seasonally adjusted rate of 5 47 million  according to the National Association of Realtors 

Stocks That Made Headlines 



	After witnessing a negative earnings surprise of 5 9  in the second quarter  Skechers USA Inc     again missed the Zacks Consensus Estimate in the third quarter     



	Schlumberger Ltd     reported third quarter earnings which beat the Zacks Consensus Estimate  but revenues missed the same    



	Crown Castle International Corp     reported mixed financial numbers in the third quarter of 2016  wherein the top line outpaced the Zacks Consensus Estimate while the bottom line fell short of the same     



	Rite Aid Corporation    and Walgreens Boots Alliance  NASDAQ WBA   Inc      have jointly agreed to postpone the deadline for the mega merger to Jan 27  2017  three months later than the planned deadline of Oct 27  2016     



	AT T Inc     is currently engaged in informal talks with media giant Time Warner Inc  NYSE TWX      to evaluate various business strategies including a possible merger     

Confidential  Zacks  Best Investment Ideas

	Would you like to see a hand picked  all star  selection of investment ideas from the man who heads up Zacks  trading and investing services  Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-20,Zacks Investment Research,"https://www.investing.com/analysis/stock-market-news-for-october-21,-2016-200160021",200160021
179485,401001,WBA,Walgreens profit beats expectations  more cost cuts planned,news,"By Nandita Bose and Shailaja Sharma  Reuters    Drugstore operator Walgreens Boots Alliance Inc  O WBA  on Thursday reported a higher than expected quarterly profit and said it would widen its cost cutting program  sending its shares higher  The company  formed by the December acquisition of Europe s Alliance Boots by  Walgreen Co   said it would reorganize corporate and field operations  streamline information technology functions and close 200 U S  stores while opening 200 others   This really is just getting the right stores in the right place   Executive Vice President Alex Gourlay said on a conference call  In August  Walgreen Co announced a  1 billion cost cutting program over three years  Walgreens said on Thursday that it had identified ways to increase the program to a projected  1 5 billion by the August year end of fiscal 2017  The company said it would take pretax restructuring charges of  1 6 billion to  1 8 billion over time  Shares of the largest U S  drugstore chain operator  which is reporting its first results since the merger  were up 2 8 percent at  90 17  Walgreens said combined net savings for the first half of fiscal 2015 were  310 million and that it was on track to reach at least  650 million for the full year and  1 0 billion in fiscal 2016  The company reported a 35 5 percent rise in net sales to  26 6 billion for the second quarter ended Feb  28  mainly due to the addition of Boots  Analysts on average had expected sales of  27 77 billion  according to Thomson Reuters I B E S  Sales at U S  Walgreens and Duane Reade stores open at least a year rose 6 9 percent  benefiting from a strong cough  cold and flu season and continued growth in Medicare Part D prescriptions  The U S  drugstore business generated about 79 percent  or  21 billion  of total sales  Pharmacy sales accounted for 64 4 percent of U S  sales  Comparable store sales in the international retail pharmacy division rose 2 9 percent in January and February  Net income attributable to Walgreens Boots was  2 04 billion  or  1 93 per share  Walgreen alone earned  716 million  or 74 cents per share  in the year earlier period  Excluding special items  Walgreens Boots earned  1 18 per share  beating the analysts  average estimate of 95 cents  
The company forecast full year earnings of  3 45 to  3 65 per share  excluding items  Analysts were expecting  3 61 ",2015-04-09,Reuters,"https://www.investing.com/news/stock-market-news/walgreens-profit-beats-street,-drug-chain-to-close-200-u.s.-stores-336285",336285
179497,401013,WBA,Stocks Finish Strong After Slow Start ,opinion,"U S  stocks overcame some early weakness and finished higher in the wake of some upbeat services sector reports and as the Fed released the minutes from its June monetary policy meeting  Domestic equities climbed into positive territory on the heels of an upside reversal for crude oil prices  while the U S  dollar dipped slightly and Treasury yields were mixed  Overseas  stocks were mostly lower amid uneasy global sentiment and exacerbated global growth concerns  Gold continued to move higher 
The Dow Jones Industrial Average  DJIA  gained 78 points  0 4   to 17 919  the S P 500 Index increased 11 points  0 5   to 2 100  and the Nasdaq Composite added 36 points  0 8   to 4 859  In moderately heavy volume  1 0 billion shares were traded on the NYSE and 1 9 billion shares changed hands on the Nasdaq  WTI crude oil was  0 83 higher at  47 43 per barrel  wholesale gasoline was unchanged at  1 43 per gallon and the Bloomberg gold spot price increased  7 70 to  1 364 15 per ounce  Elsewhere  the US Dollar Index a comparison of the U S  dollar to six major world currencies was nearly 0 1  lower at 96 08 
Walgreens Boots Alliance  NASDAQ WBA  Inc   WBA  82  reported fiscal 3Q earnings per share  EPS  ex items of  1 18  above the FactSet estimate of  1 14  as revenues rose 2 4  year over year  y y  to  29 5 billion  compared to the forecasted  29 7 billion  WBA raised the low end of its full year profit outlook  Shares closed to the downside 
Nortek Inc  NASDAQ NTK   NTK  87  surged after the industrial company announced an agreement to be acquired by Melrose Industries PLC  LON MRON  for  86 00 per share in cash  in a transaction with an estimated enterprise value of about  2 8 billion 
Fed releases June meeting minutes  while services sector activity accelerates  At 2 00 p m  ET the Federal Open Market Committee  FOMC  released the minutes from its June monetary policy meeting  The report showed that a number of participants in the Committee judged after assessing the outlook and associated uncertainties for economic activity  the labor market  and inflation that the target range for the federal funds rate should remain at 0 25 0 50   Members also generally agreed that the British referendum  commonly known as Brexit  could affect economic performance by creating turbulence in financial markets  while some also noted that  continued uncertainty regarding the outlook for China s foreign exchange policy and the relatively high levels of debt in China and some other emerging market economies represented appreciable risks to global financial stability and economic performance   The minutes reiterated that in determining the timing and size of future adjustments to the target range  the Committee would assess realized and expected economic conditions relative to its dual mandate  The Committee members voted unanimously in favor of leaving policy unchanged 
The Institute for Supply Management  ISM  non Manufacturing Index    showed growth  a reading above 50  accelerated more than expected  rising to 56 5 in June the highest since November 2015 from 52 9 in May  and compared to the Bloomberg forecast of a gain to 53 3  New orders and business activity both showed solid growth  while employment moved back into expansion territory  The ISM said the report reflects a strong rebound from the cooling off of the previous month for the non manufacturing sector  Non manufacturing activity dwarfs manufacturing in terms of U S  economic output  driven by the consumer  that the U S  economy is hanging in there  with the all important U S  consumer being bolstered by higher wages due to the apparent tightening of the labor market  However  should the impact from the British vote become harsher than currently expected  we may be forced to downgrade our longer term view of both the U S  economy and equities 
The final Markit U S  Services PMI Index was revised to 51 4 in June from the preliminary level of 51 3  which matched May s figure and was expected to remain  The release is independent and differs from ISM s report  as it has less historic value and Markit weights its index components differently 
The trade balance    showed that the deficit came in at  41 1 billion in May  compared to the  40 0 billion Bloomberg estimate  April s deficit was unrevised at  37 4 billion  Exports dipped 0 2  month over month  m m  to  182 4 billion  and imports rose 1 6  m m to  223 5 billion 
The MBA Mortgage Application Index jumped 14 2  last week  after decreasing 2 6  in the previous week  The solid gain came as a 20 8  surge for the Refinance Index coupled with a 4 3  rise for the Purchase Index  The average 30 year mortgage rate fell 9 basis points  bps  to 3 66  
Treasuries were mixed  with the yield on the 2 Year note rising 3 bps to 0 58   the yield on the 10 Yearnote was flat at 1 37  and the 30 Year bond rate dipped 2 bps to 2 14  
Tomorrow  the domestic economic calendar will offer weekly initial jobless claims  forecasted to show a slight uptick to a level of 269 000  as well as the ADP Employment Change Report  with economists anticipating a 160 000 increase in private sector jobs during June following the 173 000 rise in May 
Europe extends selloff  Asia mostly lower  European equities were decisively lower for a third straight session  with the U K  Brexit fallout persisting and fueling continued risk aversion and global growth concerns  Also  uneasiness toward the Italian banking sector festered to exacerbate the selloff in the region  Moreover  the British pound remained under pressure  touching a 31 year low versus the U S  dollar  The economic front likely did not help sentiment in the region  as German factory orders for May came in flat m m  versus projections of a 1 0  gain  and following the favorably revised 1 9  drop in April  The euro was little changed versus the U S  dollar  while bond yields in the region finished mixed 
Stocks in Asia finished mostly to the downside  with the global markets remaining hamstrung by the festering U K  Brexit vote fallout  which exacerbated global growth sentiment  The ensuing flight to safety is amplifying the pressure on global bond yields and is boosting the yen  which continued to gain ground to foster a drop for Japanese equities  Also  securities trading in Australia  Hong Kong  and South Korea fell  However  mainland Chinese listings rose  buoyed by growing expectations of further stimulus measures from the nation s central bank  Finally  markets in India were closed for a holiday 
The international economic docket for tomorrow will include the Leading Index from Japan  industrial production from Germany  trade data from France and industrial and manufacturing production from the U K ",2016-07-07,Marvin Clark,https://www.investing.com/analysis/stocks-finish-strong-after-slow-start-200140438,200140438
179498,401014,WBA,Walgreen Boots  Q3 A Mixed Bag  Achieves  1B In Synergy,opinion,On Jul 8  we issued an updated research report on Deerfield  IL based Walgreens Boots Alliance  Inc    NASDAQ WBA     the world s first pharmacy led  health and wellbeing enterprise  The company currently carries a Zacks Rank  3  Hold  Walgreens Boots reported a mixed third quarter fiscal 2016 results with earnings comfortably beating the Zacks Consensus Estimate but revenues falling just shy of the mark  On the brighter side  the company continues to hold a strong cash balance position  which is evident from its increased cash flow reserve in the quarter So far  the legacy Walgreens  partnership with Alliance Boots has yielded positive results  with combined synergies of  330 million in third quarter  totaling  947 million in fiscal 2016 so far   Encouragingly  in Jun 2016  the company was successful in achieving its target of at least  1 billion in combined net synergies from this deal in fiscal 2016 Currently  Walgreens Boots continues to expect to realize synergies in excess of  1 billion from the Rite Aid deal  In late Oct 2015  the company announced its plan to acquire U S  retail pharmacy chain   Rite Aid   for a total enterprise value of  17 2 billion  including acquired net debt  As of now  the acquisition process is progressing at a healthy pace and is expected to close in the second half of calendar year 2016 Earlier  Walgreens Boots had identified additional opportunities for cost savings  which increased the total expected cost savings program by  500 million to a projected  1 5 billion by the end of fiscal 2017  The company is currently on track to achieve this target within the projected time frame On the flip side  fewer generic drug introductions and the ongoing generic drug inflation has been hindering Walgreens Boots  pharmacy margin  In the fiscal third quarter as well  the company s pharmacy gross margin figures contracted  in line with management s expectation  on account of ongoing reimbursement pressure and changes in the mix Besides  the recent UK referendum and the subsequent exit of Britain from the EU have paved the way for volatility in the market  which in turn might hamper Walgreens Boots  business in the region  Further  the public bond offering worth  6 billion  which Walgreens Boots issued in Jun 2016 to fund the Rite Aid deal  is sure to increase the company s long term liability Other Stocks to ConsiderSome better ranked stocks in the medical sector are GW Pharmaceuticals plc   NASDAQ GWPH    NuVasive  Inc    NASDAQ NUVA   and ICU Medical  Inc    NASDAQ ICUI     While GW Pharmaceuticals and NuVasive sport a Zacks Rank  1  Strong Buy   ICU Medical holds a Zacks Rank  2  Buy  ,2016-07-10,Zacks Investment Research,"https://www.investing.com/analysis/walgreen-boots:-q3-a-mixed-bag,-achieves-$1b-in-synergy-200141155",200141155
179499,401015,WBA,Walgreens Partners EnvisionRx On 90 day Health Program,opinion,Leading drugstore chain Walgreens  a part of the first global pharmacy led  health and well being enterprise Walgreens Boots Alliance  Inc    NASDAQ WBA    announced a 90 day pharmacy program in collaboration with EnvisionRx  the pharmacy benefit management  PBM  division of EnvisionRxOptions  This health program called Rx90 emphasizes on changing behaviors and improving health conditions in a rising number of patients with chronic conditions   The health program offers patients the option to fill 90 day prescriptions at any of the nearly 8 200 Walgreens pharmacies nationwide for the same price as home delivery through EnvisionPharmacies  mail service  The program intends to offer patients with total clinical care and health advice from EnvisionRx and Walgreens pharmacists and to curb down medical expenses related to clinical visits and hospitalizations Walgreens has always focused on offering better pharmacy solutions to its customers and patients  Management of Walgreens is positive on working with EnvisionRx to create a new solution  which can benefit patients  health plans and employers WALGREENS BAI Price    This latest alliance is expected to prove beneficial for Walgreens  business as cooperation with PBMs and health plans are important in today s healthcare setting to ensure the availability of medications at affordable prices along with efficient pharmacy support According to a Ken Research report  future growth of pharmacy retail market is expected to be led by acceleration in over the counter drugs segment and online pharmacies  With a number of drugs  worth  150 billion as per a global generic drugs market 2016 report  waiting to lose their patent by 2020  this is a lucrative opportunity for both drug retailers and PBM companies to reap profits Walgreen s retail pharmacy segment recorded positive numbers in the recently concluded third quarter  The company is confident about the success of its ongoing pharmacy programs aimed at offering affordable medications Other recent developments include the company s partnership with the U S  Department of Health and Human Services  HHS  for a free flu vaccination program  The company has also made an effort to fight prescription drug abuse through collaboration with American Pharmacists Association  APhA  Zacks Rank   Key PicksWalgreens currently has a Zacks Rank  3  Hold   Better ranked stocks in the medical product sector are GW Pharmaceuticals plc   NASDAQ GWPH    NuVasive  Inc    NASDAQ NUVA   and Quidel Corp    NASDAQ QDEL    All these stocks sport a Zacks Rank  1  Strong Buy   You can see  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand    ,2016-09-18,Zacks Investment Research,https://www.investing.com/analysis/walgreens-partners-envisionrx-on-90-day-health-program-200154336,200154336
179500,401016,WBA,Where Does Rite Aid  RAD  Stand After Mixed Q2 Results ,opinion,Drugstore retailer  Rite Aid Corporation   NYSE RAD   has been a mixed bag for quite some time now as its stock price has been unstable  However  the stock has managed to gain over 3  year to date and has surged nearly 19  in the past year The primary reason for the not so good performance of this Camp Hill  PA based retailer is the dismal quarterly results over the past two quarters  The company s otherwise strong surprise trend has turned negative due to the earnings miss in the first quarter of fiscal 2017 followed by in line results in the second quarter  Evidently  the company has recorded an average negative surprise of 10 8  in the trailing four quarters RITE AID CORP Price and Consensus   The recent negative earnings trend is mainly attributed to pharmacy reimbursement rate pressures  as drug purchasing efficiencies fell short of expectations  This offset the company s otherwise encouraging performances at its Pharmacy Services segment and its front end business  Moreover  the company s results benefited from an improvement in prescription drug costs However  the company stated that challenges relating to the pharmacy reimbursement rate are expected to continue through the rest of the fiscal year  These factors make us somewhat cautious of the company s performance in the near term Consequently  the Zacks Consensus Estimates trended downward  In the last 7 days  the Zacks Consensus Estimate for the third quarter plunged 16 7  to 5 cents per share while the estimate for fiscal 2017 is down 7 1  to 13 cents Further  this Zacks Rank  4  Sell  company s top line results were also mixed as total revenue rose 4 8  year over year but missed our estimate mainly due to lower Retail Pharmacy segment revenues  Additionally  the company s comps trend continued to be negative owing to a fall in pharmacy comps neutralized by a marginal rise in front end comps However  Rite Aid s stringent focus on cost management and strengthening its portfolio of health along with wellness services remains impressive  Its constant endeavors to enhance pharmacy and clinical services also bode well  Moreover  the company remains positioned to gain from its merger with Walgreens Boots Alliance Inc    NASDAQ WBA    which is anticipated to close in the second half of calendar 2016 Stocks to ConsiderA better ranked stocks in the retail drugstore industry is Herbalife Ltd    NYSE HLF    with a Zacks Rank  2  Buy   Herbalife looks like a promising investment  with a positive surprise trend over the last four quarters  The average beat for the trailing four quarters is 21 6   You can see  Investors may also consider the one of the largest stock in the retail drugstore industry by size  CVS Health Corporation   NYSE CVS    which sports a Zacks Rank  3  Hold   The company has witnessed positive estimate revisions in the last 60 days and has to its credit a favorable surprise trend  with an average beat of 0 6  in the trailing four quarters Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-09-25,Zacks Investment Research,https://www.investing.com/analysis/where-does-rite-aid-(rad)-stand-after-mixed-q2-results-200155599,200155599
179507,401023,WBA,Senators urge Burger King to ditch move to Canada,news,"By Emily Stephenson  WASHINGTON  Reuters    A group of U S  senators wants Burger King Worldwide  N BKW  to scrap its plans to invert  or move its tax domicile to Canada  as part of a deal to buy coffee and donut chain Tim Hortons Inc  TO THI    Burger King announced in August plans to buy the Canadian restaurant chain for  11 5 billion  Canada has a lower corporate tax rate than the United States  and it does not require companies based there to pay extra taxes on income earned abroad  so the deal was expected to yield tax savings   Dick Durbin  the No  2 Senate Democrat  and four other lawmakers argue that move is unfair because many Burger King workers count on programs such as Medicaid and food stamps that rely on taxpayer funding   They also said  in a letter to Burger King Chief Executive Officer Daniel Schwartz that was dated Thursday  that the burger chain uses taxpayer supported roads  food safety inspectors and other perks of doing business in the United States    Now  after profiting from these taxpayer funded benefits  Burger King intends to move its tax address overseas to avoid paying its fair share for these benefits   the group said in the letter  which was viewed by Reuters    Many of your loyal customers may choose to spend their hard earned money at one of your many competitors  instead of supporting a company that wants all the benefits of America but refuses to pay its fair share to support our nation   they said   In addition to Durbin  Senate Democrats Jack Reed  Sherrod Brown  Carl Levin  and Independent Bernie Sanders signed on   At least nine U S  companies are in the final stages of inversions  which involve buying a competitor in a lower tax country and basing the combined business there   Democrats  worried the moves will erode the U S  corporate tax base  have called the deals  unpatriotic  and floated a number of proposals to crack down on them   Drug store chain Walgreen Co  N WAG   which is based in Durbin s state of Illinois  considered inverting as part of its purchase of European retailer Alliance Boots Holdings  After Durbin and others slammed the move  Walgreen said last month that it would not move overseas after all   Burger King has said that its deal is largely about opportunities for growth and that its headquarters would remain in Miami   
But Durbin and the other senators urged Burger King not to move its tax domicile either  saying its workers and the people who run the chain s franchises would likely suffer if it did     Reporting by Emily Stephenson  Editing by Lisa Shumaker ",2014-09-11,Reuters,https://www.investing.com/news/politics-news/senators-urge-burger-king-to-ditch-move-to-canada-309080,309080
179508,401024,WBA,Labor pension adviser CtW seeks details from Walgreen,news,"BOSTON  Reuters    CtW Investment Group  an adviser to union pension funds  called on Walgreen Co  N WAG  to provide more details about a change in projected earnings and questioned the U S  drugstore chain operator s appointment of an activist investor to its board 
Walgreen has faced pressure from many sides and last month scrapped a plan to move its tax domicile to Europe to save money 
It also replaced its chief financial officer in August  two days before it lowered an earnings projection 
In a Sept  11 letter to Walgreen s audit committee chair  CtW asked for more details such as when committee members learned the company s performance was not on track 
The group also asked the board for changes that could make it easier for shareholders to elect certain directors  They cited the recent naming to the Walgreen board of Barry Rosenstein  who founded activist hedge fund Jana Partners  CtW said Jana s presence could  further dilute the voice of long term shareholders  
CtW said it advises funds that own about 2 5 million Walgreen shares  less than 1 percent of those outstanding 
Walgreen spokesman James Graham said in an email that the company will share the letter with its board and respond appropriately   In accordance with our normal practice and our commitment to engage with our shareholders  
Regarding the director election changes  Graham noted a shareholder proposal calling for so called  proxy access  did not pass at the company s annual meeting in January 

A Jana spokesman was not available to comment 
 Reporting by Ross Kerber  Editing by Andre Grenon and Lisa Shumaker ",2014-09-12,Reuters,https://www.investing.com/news/stock-market-news/labor-pension-adviser-ctw-seeks-details-from-walgreen-309300,309300
179509,401025,WBA,Drugstore chain Walgreen s quarterly sales rise 6 2 percent,news," Reuters    U S  drugstore chain operator Walgreen Co reported a 6 2 percent rise in quarterly sales  helped by higher prescription sales  sending its shares up more than 3 percent in premarket trading 
Prescription sales  which made up nearly two thirds of the company s total sales  rose 9 3 percent in the fourth quarter ended Aug  31 
Total revenue rose to  19 06 billion in the quarter from  17 94 billion a year earlier 
The net loss attributable to the company was  239 million  or 25 cents per share  in the quarter  and included an  866 million non cash loss due to the amendment and exercise of its Alliance Boots call option 
Walgreen posted a profit of  657 million  or 69 cents per share  a year earlier 
Excluding items  the company earned 74 cents per share in the latest quarter 

The company s shares rose 3 2 percent to  61 50 in trading before the bell on Tuesday 
 Reporting by Nandita Bose in Chicago and Sruthi Ramakrishnan in Bangalore  Editing by Savio D Souza ",2014-09-30,Reuters,https://www.investing.com/news/stock-market-news/drugstore-chain-walgreen's-quarterly-sales-rise-6.2-percent-311298,311298
179510,401026,WBA,Strong prescription sales help Walgreen top profit estimates,news," Reuters    U S  drugstore chain operator Walgreen Co  N WAG  reported a better than expected quarterly profit  helped by a record number of prescriptions filled  sending its shares up 3 6 percent   Cost savings resulting from its acquisition of the remaining stake in Alliance Boots Holdings Ltd  ABN UL   Europe s biggest pharmacy chain  also boosted first quarter results   The largest U S  drug retailer also said it was on track to reach its target of  650 million in savings from the Alliance Boots deal in the fiscal year ending August 2015   The company s margins  however  continue to remain under pressure due to lower insurer payments for prescriptions amid increased competition and a rise in generic drug prices   Gross margins decreased 1 percentage point to 27 1 percent in the first quarter ended Nov  30  marking the fifth straight quarter of decline   The combined cost savings for Walgreen and Alliance Boots in the quarter were about  140 million   The company said in August it would acquire the 55 percent it did not already own in Alliance Boots in a deal valued at  15 billion   The company said it filled a record 222 million prescriptions in the quarter ended Nov  30  up 4 3 percent from a year ago   Smaller rival Rite Aid Corp  N RAD  also reported higher quarterly sales and profit and lifted its full year earnings forecast last week  helped by strong prescription sales   Net income attributable to Walgreen rose 16 percent to  809 million  or 85 cents per share  Excluding items  earnings were 81 cents per share in the first quarter   Net sales rose 6 7 percent to  19 55 billion  with same store sales rising 5 7 percent   Analysts on average had expected a profit of 75 cents per share on sales of  19 5 billion  according to Thomson Reuters I B E S   
Walgreen s shares were trading at  76 90 before the bell on Tuesday     Reporting by Sruthi Ramakrishnan in Bengaluru and Nandita Bose in Chicago  Editing by Ted Kerr and Saumyadeb Chakrabarty ",2014-12-23,Reuters,https://www.investing.com/news/stock-market-news/strong-prescription-sales-help-walgreen-top-profit-estimates-321305,321305
179511,401027,WBA,Walgreen Shareholders Approve Alliance Boots Deal,news,"By    

Walgreen Co  shareholders approved the final acquisition of the European pharmacy chain Alliance Boots GmbH in a near unanimous decision Monday  The Deerfield  Illinois  company announced that about 97 percent of shareholders cast votes in support of the plan  which will create a new holding company called Walgreens Boots Alliance Inc  The cross Atlantic chain will operate drugstores in all 50 states and across Europe and be the world s largest prescription drug buyer  with trading on Nasdaq under the ticker symbol WBA expected to begin Wednesday   The transaction will fully combine the two companies to form the first global pharmacy led  health and well being enterprise   Walgreen said in a Monday statement announcing the development  Walgreen is the largest U S  pharmacy chain  with 8 200 stores and fiscal 2014 sales of  76 billion  With the acquisition of U K  based Alliance Boots  the new company will have more than 11 000 shops spread over more than 10 countries and will have access to much of the lucrative European drug market  Walgreens Boots Alliance Inc  will be headquartered in Deerfield  Walgreen said in the statement  reflecting its decision in August to not pursue a  tax inversion   a controversial move that would have moved the company s headquarters to Europe and saved the company hundreds of millions of dollars on taxes  Tax inversions came under fire this year as a number of prominent companies considered the idea  Anger over the practice peaked in August  when Burger King Worldwide Inc  announced it was acquiring about 51 percent of Tim Hortons Inc  and moving its headquarters to Canada  In September  the Obama administration spoke out against U S  corporations employing the tactic and the U S  Treasury Department introduced new restrictions on its use  About 50 U S  companies have undertaken tax inversions over the past 10 years  The backlash against tax inversions contributed to Walgreen s decision to withdraw its plan to move its headquarters to Ireland after it acquired Alliance Boots  Walgreen s acquisition of its European counterpart began with the launch of a strategic partnership in June 2012 with the acquisition of 45 percent equity ownership of Alliance Boots with an option to purchase the remaining 55 percent of the company  Walgreen exercised that option in August 2014  and Monday s development approves the final phase of the process that will see the two come together as Walgreens Boots Alliance Inc  The announcement of the deal saw Walgreen shares rise 0 43 in Monday trading to close at  76 79  The company s stock has risen by about a third on the year  The move was seen as overwhelmingly positive by the vast majority of Walgreen shareholders  as shown by the near unanimous vote Monday  But some observers  like Dieter Waizenegger  executive director of the CtW Investment Group  criticized the deal   Shareholders are left with too many unanswered questions about how the combined company will meet optimistic performance goals and how it will correct governance failures that became painfully obvious in the past year   Waizenegger told USA Today ",2014-12-29,International Business Times,https://www.investing.com/news/stock-market-news/walgreen-shareholders-approve-alliance-boots-deal-321661,321661
179522,401038,WBA,Rite Aid  RAD  Stock Suffers Downside  Will It Turn Around ,opinion,The stock of Rite Aid Corporation   NYSE RAD    the third largest retail drugstore in the U S  based on revenues and the number of stores  has currently turned into a roller coaster ride as evident from its year to date price graph  The stock witnessed considerable upside in April on the back of its fourth quarter fiscal 2016 results  but has been on a decline since May and going down further following the recently released first quarter fiscal 2017 results The stock is down about 1 2  year to date and has lost nearly 3  in 3 months  time  In the past one year  the stock has slumped nearly 11  RITE AID CORP Price  Consensus and EPS Surprise   The primary reason for the recent slump in the stock price is the Camp Hill  PA based drugstore retailer s dismal performance in the first quarter of fiscal 2017  Rite Aid s first quarter fiscal 2017 results were a letdown as the company failed to live up to its its robust earnings surprise history  The company s first quarter earnings missed estimates after seven quarters of consecutive beats  mainly due to a fall in adjusted EBITDA  offset by lower taxes and interest expense Though the quarter gained from solid performance of its Pharmacy Services segment and front end business  along with efficient expense control  the miss was due to pharmacy reimbursement rate pressures as drug purchasing efficiencies were short of expectations Looking ahead  the company expects drug cost reductions to remain below expectations in the near term  with improvement likely in the second half of fiscal 2017  These factors make us somewhat cautious of the company s performance in the near term Consequently  the Zacks Consensus Estimates trended downward  In the last 7 days  the Zacks Consensus Estimate for fiscal 2017 has fallen 11 5  to 23 cents while the estimate for fiscal 2018 is down 21 9  to 25 cents The company s top line performance was the saving grace in the quarter as sales beat estimates and grew year over year  This was backed by strength in both Retail Pharmacy and Pharmacy Services segments  as well as comparable sales growth   Additionally  Rite Aid s stringent focus on cost management and strengthening its portfolio of health and wellness services have been impressive  Its constant endeavors to enhance pharmacy and clinical services also bode well  The company remains positioned to gain from its merger deal with Walgreens Boots Alliance Inc    NASDAQ WBA    which is anticipated to close in the second half of calendar 2016 That said  how far the company s strategic initiatives will help overcome the current slowdown in share price remains a wait and watch story  Rite Aid currently holds a Zacks Rank  4  Sell  Stocks to ConsiderA couple of better ranked stocks in the retail sector are Herbalife Ltd    NYSE HLF   and Wal Mart Stores Inc    NYSE WMT    both carrying a Zacks Rank  2  Buy  ,2016-06-20,Zacks Investment Research,https://www.investing.com/analysis/rite-aid-(rad)-stock-suffers-downside:-will-it-turn-around-200137328,200137328
179523,401039,WBA,Walgreens Boots Tops Q3 Earnings  Rite Aid Deal On Track,opinion,"Walgreens Boots Alliance  Inc   NASDAQ WBA   reported adjusted earnings per share  EPS  of  1 18 in the third quarter of fiscal 2016  up 15 7  from the year ago adjusted number  Adjusted EPS also beat the Zacks Consensus Estimate by 3 5  
A single digit growth observed in the company s top line number primarily drove the improvement in adjusted earnings 
On a reported basis  net earnings came in at  1 1 billion or  1 01 per share  reflecting a decline of 15 3  or 14 4  respectively  from the year ago quarter 
Total Sales
Walgreens Boots recorded total sales of  29 5 billion in the fiscal third quarter  up 2 4  year over year or 3 3  at constant exchange rate  CER   However  the top line missed the Zacks Consensus Estimate of  29 9 billion 
Segments in Detail
Walgreens Boots currently reports under three operating segments  Retail Pharmacy USA  Retail Pharmacy International and Pharmaceutical Wholesale 
The Retail Pharmacy USA division delivered sales of  21 2 billion in the reported quarter  reflecting an increase of 3 7  on a year over year basis  Within this segment  total sales in comparable drugstores increased 3 9   while prescriptions filled in comparable stores grew 4 5  on account of continued growth in Medicare Part D volume  On the other hand  comparable retail stores grew 0 1   driven by higher sales in the health and wellness and photo categories 
Pharmacy sales  which accounted for 67 4  of the division s sales in the quarter  increased 5 8  from the year ago quarter  while pharmacy sales in comparable stores climbed 6  
Revenues from the Retail Pharmacy International division dropped 2 3  on a year over year basis  up 3 4  at CER  to  3 2 billion  on account of currency fluctuations  At CER  comparable store sales in the third quarter increased 0 2  year over year  while comparable pharmacy sales dropped 0 7    partly driven by expected reduction in the U K  s pharmacy funding and the loss of certain institutional sales contracts in Chile 
The Pharmaceutical Wholesale division recorded quarterly sales of  5 7 billion  up 0 7  At CER  excluding acquisitions and dispositions  comparable store sales improved 6 3 
Margins
Gross profit improved 0 2  year over year to  7 5 billion and adjusted gross profit improved 0 5  to  7 6 billion  However  reported gross margin dropped 60 basis points  bps   while adjusted gross margin declined 50 bps in the fiscal third quarter 
Adjusted selling  general and administrative  SG A  expenses dropped 0 3  to  5 8 billion  Consequently  adjusted operating income increased 3 3  to  1 8 billion owing to higher gross profit and lower operating expense  However  adjusted operating margin remained approximately flat at 6 1  
Financial Condition
Walgreens Boots exited the reported quarter with cash and cash equivalents of  3 3 billion  compared to  3 6 billion in the second quarter of fiscal 2016  Long term debt was  13 2 billion  compared with  13 billion in the prior quarter 
Moreover  the company generated operating cash flow of  5 2 billion in the reported quarter compared with  4 2 billion a year ago  The resultant free cash flow was  1 9 billion 
Guidance
Walgreens Boots has once again raised the lower end of its EPS guidance for fiscal 2016  The company currently expects adjusted EPS in the  4 45  4 55 range for the full fiscal  as against the earlier guided  4 35  4 55  The current Zacks Consensus Estimate for fiscal 2016 earnings is  4 49  within the company s guidance range 
This guidance assumes no impact from the proposed acquisition of Rite Aid and related financing and assumes current exchange rates for the rest of fiscal 2016 
Progress on Rite Aid Acquisition
In Oct 2015  Walgreens Boots announced that it has agreed to acquire U S  based retail pharmacy chain   Rite Aid Corporation  RAD   for a total enterprise value of  17 2 billion  including acquired net debt  Management continues to expect the transaction to close in the second half of calendar year 2016 
Currently  this acquisition is progressing as per Walgreen Boots  plans  following Rite Aid s shareholders approving the transaction on Feb 4  2016  However  the transaction is still subject to the expiration or termination of applicable waiting periods under the Hart Scott Rodino Antitrust Improvements Act of 1976  as amended  and other customary closing conditions 
On Jun 1  2016  in order to partially fund this deal  Walgreens Boots completed a public offering of  6 billion aggregate principal amount of unsecured  unsubordinated notes with varying maturities and interest rates  Management expects this transaction to be accretive to its adjusted EPS in its first full year after completion 
Our Take
Walgreens Boots reported a mixed third quarter fiscal 2016 with earnings comfortably beating the Zacks Consensus Estimate  while the top line closely missed the mark  We note that the reported results echo the trend exhibited by the company in the preceding four quarters as well  On a brighter note  the company continues to hold a strong cash balance position as is evident from its increased cash flow reserve in the reported quarter  while its proposed on track buyout of Rite Aid is expected to expand its business realm in the U S  over the long term 
However  the recently completed public offering of notes  in order to fund the Rite Aid deal  will increase the company s long term liabilities 
Nevertheless  Walgreens Boots was successful in achieving its earlier set target of achieving combined net synergies of at least  1 billion  on account of the legacy Walgreens  merger with Alliance Boots  in June 2016 
 Zacks Rank
Walgreens Boots currently has a Zacks Rank  3  Hold   Some other well ranked stocks in the medical sector are GW Pharmaceuticals plc   NASDAQ GWPH    ICU Medical  Inc    NASDAQ ICUI   and TG Therapeutics  Inc    NASDAQ TGTX    All these stocks sport a Zacks Rank  1  Strong Buy  ",2016-07-05,Zacks Investment Research,"https://www.investing.com/analysis/walgreens-boots-tops-q3-earnings,-rite-aid-deal-on-track-200140313",200140313
179524,401040,WBA,Walgreens Boots  WBA  Tops Q3 Earnings  Misses On Revenues,opinion,Are you a frequent visitor to retail drugstores  Then you must have come across at least one of the 13 100 drugstores operated by Walgreens Boots Alliance  Inc    NASDAQ WBA    This Illinois based company is the first global pharmacy led  health and wellbeing enterprise Currently  Walgreens Boots has a Zacks Rank  3  Hold  but that could change following its mixed third quarter fiscal 2016 earnings report which has just released  We have highlighted some of the key details from the just released announcement below Earnings The Zacks Consensus Estimate remained steady at  1 14 per share over the last 60 days  Walgreens Boots  adjusted earnings per share of  1 18 beat this estimate by 3 5  Revenues Walgreens posted revenues of  29 5 billion and slightly missed the Zacks Consensus Estimate for revenues of  29 9 billion Key Stats  Revenue from the Retail Pharmacy USA division increased 3 7  to  21 2 billion  while revenues from the Pharmaceutical Wholesale division grew 0 7  to  5 7 billion  However  revenues from the Retail Pharmacy International division dropped 2 3  to  3 2 billion  Moreover  Walgreens Boots filled 235 million prescriptions  including immunizations  on a 30 day adjusted basis in the quarter  reflecting an increase of 3 9   over third quarter of fiscal 2015 Major Factors  Per management  Walgreens Boots delivered solid results  on a year over year basis in the fiscal third quarter  while continuing to make progress in several key areas  including development in the company s long term strategic relationships and pursuing partnership opportunities  With respect to the impending Rite Aid takeover  the company is continuing its integration planning and continues to expect the transaction to close in the second half of calendar 2016   The company has once again raised the low end of its fiscal 2016 adjusted EPS guidance by 10 cents Stock Price  Following the earnings release  share prices did not show any movement in the pre market trading session Check back later for our full write up on this Walgreens Boots earnings report later ,2016-07-06,Zacks Investment Research,"https://www.investing.com/analysis/walgreens-boots-(wba)-tops-q3-earnings,-misses-on-revenues-200140242",200140242
179525,401041,WBA,Company News For July 07  2016,opinion,"  Walgreens Boots Alliance  NASDAQ WBA   Inc s    shares fell 2 4  after reporting fiscal third quarter revenues of  29 5 billion  lower than the Zacks Consensus Estimate of  29 9 billion


	  Shares of MSC Industrial Direct Co  Inc     increased 2 4  after posting fiscal third quarter diluted earnings of  1 05 per share  beating the Zacks Consensus Estimate of  1


	  Greenbrier Companies  Inc s    shares slumped 9 2  after reporting fiscal third quarter revenues of  612 9 million  missing the Zacks Consensus Estimate of  614 million 


	  Shares of Nortek Inc     jumped 38 4  after the company received a takeover offer of  2 81 billion from Melrose Industries",2016-07-06,Zacks Investment Research,"https://www.investing.com/analysis/company-news-for-july-07,-2016-200140520",200140520
179533,401049,WBA,Walgreen CFO s departure due to  1 billion forecasting error   WSJ,news," Reuters    Drugstore retailer Walgreen Co s  N WAG  Chief Financial Officer  Wade Miquelon  and another top executive lost their jobs after a  1 billion forecasting error in the company s Medicare related business  the Wall Street Journal reported 
Walgreen named Kraft Foods Group Inc s  O KRFT  former CFO  Timothy McLevish  to replace Miquelon   its CFO of six years   on Aug  4 
Miquelon last month cut by  1 1 billion a forecast of  8 5 billion in pharmacy unit earnings for the year ending August 2016 that he had made at an April board meeting  the journal said    
Miquelon s departure was due to his transitioning to newer opportunities  Walgreen told Reuters in an email 
The company had earlier said Miquelon would continue as advisor to assist it with a strategic partnership with Alliance Boots Holding Ltd  ABN UL  
The newspaper report said the forecast error also led to the departure of Kermit Crawford  Walgreen s president of pharmacy  health and wellness 
Crawford announced his retirement last month after 31 years with the company 
He will continue as an advisor  and moves forward to pursue new opportunities outside  Walgreen said 
The forecasting error was based partly on contracts to sell drugs under Medicare  WSJ said 
Walgreen  which gets 25 30 percent of its prescriptions from Medicare Part D plans  had not factored in a spike in the price of some generic drugs that it sells as part of annual contracts  the paper said 
The company said it did not break down its pharmacy business revenue by segment 
Medicare Part D subsidizes the cost of prescription drugs and prescription drug insurance premiums for Medicare benefits in the United States 
Walgreen would pay Miquelon severance of  3 2 million and a performance bonus of about  1 2 million  and pay  3 3 million to Crawford as severance and consultation fees  the company said in a regulatory filing this month 
Miquelon  49  joined Walgreen in June 2008 as senior vice president and CFO  In 2012  he was promoted as executive vice president  CFO and president  international  and joined the board of Alliance Boots 
Miquelon is also credited with playing a central role in launching the Walgreens Alliance Boots deal 

Walgreen said earlier this month it would buy the 55 percent it does not already own of Alliance Boots for 3 13 billion pounds   5 3 billion  in cash and 144 3 million shares  giving a total deal of about  15 billion 
 Reporting by Shailaja Sharma in Bangalore  Editing by Joyjeet Das ",2014-08-20,Reuters,https://www.investing.com/news/stock-market-news/walgreen-cfo's-departure-due-to-$1-billion-forecasting-error-:-wsj-304533,304533
179548,401064,WBA,CVS Looks Poised To Deliver Strong Q1 Earnings  Here s What To Expect,opinion,"CVS Health Corp  NYSE CVS 
Consumer Staples   Food   Staples Retailing   Reports May 3  Before Market Opens
Key Takeaways
The Estimize consensus is calling for  1 17 on  43 02 billion in revenue  1 cent higher than Wall Street on the bottom line and  50 million in sales
Acquisitions of Omnicare and Target Pharmacy reflects CVS s commitment to the fast growing specialty care market
Despite robust earnings growth   stock has been relatively flat and typically doesn t move around earnings season
Retailer and health care services company  CVS  is scheduled to report first quarter earnings Tuesday  before the market opens  The last two years were favorable for CVS as both revenue and earnings per share steadily increased  Last quarter featured double digit gains on both the top and bottom line with this quarter expected to be just as good  The Estimize consensus is calling for  1 17 on  43 02 billion in revenue  1 cent higher than Wall Street on the bottom line and  50 million higher on sales  Compared to a year earlier  profits are expected to increase 3  while revenue could rise as much as 18   Despite CVS s recent gain  the stock has been relatively flat and typically doesn t change during earnings season 

Lately a majority of CVS s growth has come from strength in its specialty and retail pharmacy segments  Last quarter  revenue in pharmacy services increased 11 1  primarily driven by growth in specialty pharmacy  The company s  12 7 billion acquisition of Omnicare reflects the company s focus on the fast growing specialty care market  Meanwhile  CVS also plans to expands its retail pharmacy to Target stores nationwide  In a  1 9 billion deal  the buyout will expand CVS Health s customer base and add a new retail channel for its products  Topping it all off  CVS maintains a strong balance sheet which allows them to issue generous capital return programs 
Still  CVS operates in a competitive landscape and must deal with poor economic conditions  Major competitors including  Walgreens Boots Alliance Inc  NASDAQ WBA  and Walmart  NYSE WMT  are expanding their pharmacy businesses to tap the high growth specialty avenue ",2016-05-03,Estimize,https://www.investing.com/analysis/cvs-looks-poised-to-deliver-strong-q1-earnings.-heres-what-to-expect-200127430,200127430
179549,401065,WBA,In A Struggling Economy Are Hold N Hope  Portfolios Valid ,opinion,"Some analysts may dismiss 115 years of economic data  I do not  In particular  if one averages the results of four respected stock valuation methodologies  one finds that stocks are wildly expensive  Greater irrationality in stock price exuberance only existed during conditions prior to the Great Depression circa 1929 and the tech wreck of 2000 
Consider the chart below  Based on the analysis by Doug Short  the widely cited Vice President of Research at Advisor Perspectives  the U S  stock market is overvalued by 76   It is worth noting that on all three occasions when the aggregate average approached two standard deviations above a geometric mean   1929  1999  2007   U S  stocks collapsed by 50  or more  In addition  current valuation extremes surpass those reached in 2007 

Investors should be mindful of the fact that Mr  Short does not typically offer  bearish  or  bullish  commentary  He usually provides investment and economic research  allowing others to draw their own conclusions  That said  he has served up bullet points on the high probability that market returns will be low over the next 7 10 years  Mr  Short has also mentioned that  will be more important in the coming decade  as holding the S P 500 for the next 7 10 years is likely to be  disappointing  
Keep in mind  elevated valuations in and of themselves may not provide much insight with respect to reducing risk in one s portfolio  Years of valuation extremes can persist when other factors are at play   Think central bank interest rate and balance sheet shenanigans   Nevertheless  an economy that shows signs of stagnation coupled with signs of  risk off  positioning can break the back of a stock market bull  particularly when interest rate manipulating  balance sheet expanding central banks are only running on fumes 
I mentioned that the economy is stagnating and that signs of  risk off  positioning are evident  Let me first address the economy  Corporations are not increasing their profits  as corporate earnings per share have declined for four consecutive quarters  Business revenue is even more abysmal  Companies have fallen back to 2012 levels with respect to revenue generation  and that does not even adjust for inflation 

Traditional retailers are struggling and some are disappearing  e g   Wal Mart  NYSE WMT   J C  Penney  NYSE JCP   Sears  NASDAQ SHLD   Macy s  NYSE M   Office Depot  NASDAQ ODP   Walgreens  NASDAQ WBA   Sports Authority  Sports Chalet  which announced in April that it was closing all its stores  Aeropostale  NYSE ARO   etc    
Oil and gas companies  Yikes  According to reports on a Deloitte study  one third of oil corporations may go belly up in 2016  The study focused on some 175 plus companies with more than  150 billion in debt 
What about gross domestic product  GDP   At a pace of 1  over the last six months  it is hardly expanding at all  Even the bright spot of job growth is deteriorating  Consider the Federal Reserve s own Labor Market Condition s Index  LMCI  which evaluates 19 unique indicators of labor market health  The LMCI peaked in April of 2014  its intermediate moving average  6 months  peaked in August of 2014   Note  S P 500 earnings per share hit its all time top in September of 2014  representing Q3 on 9 30 2014  

The 6 month moving average on the LMCI has not rolled into negative territory since the Great Recession  2007 2009   Before that  you d need to look at the NASDAQ s tech wreck and 2001 recession  2000 2002  for significant troubles in the well being of the labor market 
Does this mean that a recession is imminent  No  But it sure as heck means that labor market conditions are weakening  With  job growth  having been the one supposed saving grace in a slow growing economy that required near 0  interest policy for seven plus years  it seems optimism for a turnaround prior to a sell off in risky assets would be misplaced 
Of course  there are those that are keeping the faith with respect to stocks rallying well into the end of 2016 without a correction or bear  The thinking  As long as the economy muddles through  the Federal Reserve won t be able to raise rates  and the dollar will move lower in the absence of tightening  and the lower dollar will help businesses increase their overseas sales and profitability  In other words  bad news will be good news for never say die hold n hopers 
Unfortunately  there are a number of problems with the muddle through scenario  Problemo numero uno  Household debt exceeds disposable personal income  Granted  Americans have been spending more than their take home pay after taxes since 2001  Yet the modest deleveraging that occurred after the Great Recession has passed us by  Sooner or later  as families continue to accumulate increasing amounts of debt to spend more than they clear via disposable personal income  a retrenchment period comes to pass  Either households will be challenged in accessing credit  involuntary deleveraging  or they themselves will choose to borrow less in spite of ultra low rates  voluntary deleveraging  

Economic data on consumption shows that the consumer has been softening  Bring disposable personal income into the picture  and the consumer is likely to weaken even more 
The second problem for the muddle through economy dream is the reality that  risk off  investing has been outperforming the U S  market for 18 months already  18 months  Consider the fact that three of the best performing assets in the 2008 systemic financial meltdown were the yen  the dollar and long maturity Treasury bonds  You could have invested in each via CurencyShares Yen Trust  NYSE FXY   PowerShares Dollar Bullish  NYSE UUP  and iShares 20  Treasury Bond  NYSE TLT   Over the last year and a half  all three of these  risk off  assets have beaten the SPDR S P 500 Trust  NYSE SPY  

In sum  stock valuations are exorbitant  business sales are soft  consumption is strained  the labor market is weakening and  risk off  assets are outperforming  Add it all up  There is limited upside reward for the risk one takes by remaining overexposed to equities and higher yielding vehicles 
If you normally leave 65  70  in a diversified basket of stock  e g   large cap  mid cap  small cap  foreign  emerging  etc    downshift to 45  50  high quality larger caps only  If you typically allot 30  35  to diversified income  e g   investment grade  cross over corporate  high yield  convertible  foreign  etc    dial it back to 20  25  investment grade only  The 25  30  35  that you raise in cash or cash equivalents by selling riskier assets at relatively higher prices will minimize portfolio volatility  More importantly  it will be the  dry powder  you require to buy  risk on  assets at more attractive prices in the future 
Disclosure  Gary Gordon  MS  CFP is the president of Pacific Park Financial  Inc   a Registered Investment Adviser with the SEC  Gary Gordon  Pacific Park Financial  Inc  and or its clients may hold positions in the ETFs  mutual funds  and or any investment asset mentioned above  The commentary does not constitute individualized investment advice  The opinions offered herein are not personalized recommendations to buy  sell or hold securities  At times  issuers of exchange traded products compensate Pacific Park Financial  Inc  or its subsidiaries for advertising at the ETF Expert web site  ETF Expert content is created independently of any advertising relationships ",2016-05-11,Gary Gordon,https://www.investing.com/analysis/what-happens-to-hold-n-hope-portfolios-when-an-economy-struggles-to-ex-200129211,200129211
179550,401066,WBA,US STOCKS Europe sparks third day of gains for Wall Street,news,"  S P 500 index rises 4 1 pct over three sessions
   Portfolio rebalancing gives market an extra boost
   U S  listed shares of RIM rally on talk of Icahn stake
   Dow up 1 3 pct  S P 500 up 1 1 pct  Nasdaq up 1 2 pct
   For up to the minute market news see  STXNEWS US 
  Updates to close 
 By Ryan Vlastelica
 NEW YORK  Sept 27  Reuters    U S  stocks rose for a third
day on Tuesday on efforts by euro zone officials to solidify
the region s rescue fund and alleviate a sovereign debt crisis 
boosting optimism 
 Nevertheless  equities ended off their highs for the day
after a report suggested cracks were emerging in a previously
agreed deal to tackle the crisis 
 A successful solution to Europe s sovereign debt crisis
would take the pressure off banks worried about funding and
remove a threat to economic growth  Rising hopes for an
agreement have helped push the S P 500  up more
than 4 percent since Thursday s close 
 That s the biggest three day percentage gain by the S P 500
 since mid August  So far this week  the CBOE volatility index
 is down more than 10 percent 
  It s great to see some steps toward resolution  Shoring up
banks and dealing with the region s fiscal issues is a real
positive for equities   said Malcolm Polley  president and
chief investment officer of Stewart Capital Advisors in
Indiana  Pennsylvania 
 The Dow Jones industrial average  finished up 146 83
points  or 1 33 percent  at 11 190 69  The Standard   Poor s
500 Index  was up 12 44 points  or 1 07 percent  at
1 175 39  The Nasdaq Composite Index  was up 30 14
points  or 1 20 percent  at 2 546 83 
 The S P materials index  was up 2 1 percent and an
S P index of energy stocks  added 1 5 percent as
commodity prices rallied on hopes of a solution in Europe 
Mining and energy shares were the top performers among
large cap stocks 
 While European officials have considered various approaches
to maximize the bailout fund and to recapitalize banks 
substantial political hurdles to sealing the deal remain  For
details  see  ID nL5E7KR1CV   ID nL5E7KR0T5 
 The Financial Times reported a split was developing in the
euro zone over the terms of the next bailout for Greece 
However  this had been reported earlier in the day 
 German and French government economic advisers urged in a
joint article on Tuesday that Greece be allowed to write off
around 50 percent of its debt and called for support for banks
with large Greek holdings   nL5E7KR0JX 
 Market volatility could remain high as traders react to
headlines and attempt to gauge the commitment of governments
and institutions as they work to prevent a Greek default  U S 
equities have been highly sensitive to Europe s debt issues in
recent weeks 
  If there was no resolution  that would create a capital
hole which would put more pressure on the global financial
system and make things worse here   Polley said 
 The S P has gained 3 4 percent so far this week  after
losing 6 5 percent on European led fears the previous week 
That week was also the Dow s worst since October 2008 during
the thick of the financial crisis 
 Stocks also got a boost as investors rebalanced their
portfolios in the last days of the quarter  The wide gap in
performance between equities and bonds  favoring government
debt so far this quarter  may partly reverse   ID nS1E78P1Q8 
  All these end of quarter issues are amplifying the moves
that we ve been seeing in stocks   said Paul Simon  chief
investment officer at Tactical Allocation Group in Birmingham 
Michigan   I don t have a lot of faith in the moves we ve been
seeing  
 U S  listed shares of Research in Motion 
surged on market speculation that investor Carl Icahn had taken
a stake in the BlackBerry maker  The stock was one of the top
gainers in the Nasdaq 100   climbing 4 5 percent to
 22 65   ID nS1E78Q0NL 
 Walgreen Co  fell 6 3 percent to  33 77 after it
signaled that it wouldn t budge in its battle with Express
Scripts Inc  over what the pharmacy benefits manager
will pay for prescriptions  Express Scripts rose 0 9 percent to
 39 68   ID nS1E78K1SC 
 Almost five stocks rose for every one that fell on the New
York Stock Exchange  while about 73 percent of Nasdaq issues
ended in positive territory  About 9 04 billion shares traded
on the New York Stock Exchange  the American Stock Exchange and
Nasdaq  above last year s daily average of 8 47 billion 
  Reporting by Ryan Vlastelica  Editing by Kenneth Barry ",2011-09-27,Reuters,https://www.investing.com/news/stock-market-news/us-stocks-europe-sparks-third-day-of-gains-for-wall-street-224526,224526
179551,401067,WBA,U S  stocks higher on Greek talk progress  Dow up 0 26 ,news,Investing com    U S  stocks traded higher at the close Tuesday  as Greece made progress on obtaining a European Union bailout package    Near the close of U S  trade  the Dow gained 0 26   the S P 500 advanced 0 20  and the Nasdaq Composite climbed 0 07     Stocks rallied on reports that Greek officials were working on the final draft of a bailout agreement in front of a meeting between Greek Prime Minister Lucas Papademos and coalition leaders today    This agreement is critical for Greece to avoid default on March 20 by obtaining its next tranche of bailout funds    Eurogroup President Jean Claude Juncker stated earlier that he is confident Greece will remain in the euro zone  provided the island nation fulfilled its obligations to other euro zone nations    However the Greek prime minister delayed a meeting with heads of the political parties supporting his government for a second time as the government and international creditors negotiated over terms to secure the second EU bailout package    Papademos plans to meet with the leaders in Athens on Wednesday  instead of this evening as previously scheduled    Earnings season is in full swing with 68  of the 280 companies in the S P 500 reporting since January 9 beating estimates    Burger kingpin McDonald s gained 1 4  on word that it will announce tomorrow a strong gain in global sales for units open at least 13 months    Yum climbed 2 7  after reporting a 21  sales increase in stores open at least 12 months in China    Strong Asian sales lifted Coca Cola 1 2  after the soft drink maker reported fourth quarter profits topping analysts  estimates    In bearish news  retailer Walgreen Co  gave back 2 2  after Citigroup cut its shares to neutral    After the close of European trade  the EURO STOXX 50 gained 0 25   France s CAC 40 advanced 0 18   while Germany s DAX slipped 0 16   Meanwhile  in the U K  the FTSE 100 dropped 0 03     Investors are awaiting Australian consumer sentiment  New Zealand employment  Canadian housing starts  as well as U S  crude oil inventories on Wednesday ,2012-02-07,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-stocks-higher-on-greek-talk-progress;-dow-up-0.26-230039,230039
179565,401081,WBA,Swing Trades  MDLZ  SM  LXK  AMZN  WBA,opinion,"Here s today s swing trading watch list
Long Mondelez International  O MDLZ 

Long SM Energy Company  N SM 

Long Lexmark International  N LXK 

Long Amazon com  O AMZN 

Short Walgreens Boots Alliance Inc  O WBA ",2015-10-15,Ryan Mallory,"https://www.investing.com/analysis/swing-trading-mdlz,-sm,-lxk,-amzn,-wba-268275",268275
179566,401082,WBA,Based On Great Equities October  4th Quarter Off To Great Start,opinion,"As the end of fall inches closer and closer  the lovely mornings more frequently get replaced by a cold chill  When you go outside to start the car  now you have to wipe a bit of ice off the windshields  The little changes of your daily routine become more complicated by the additional variable of a less friendly working environment  Just as the weather changes  so does the business cycle  Over the course of the last week  we learned third quarter GDP growth came in at a meandering 1 5   and personal consumption was  1  for September  below the  2  expected level   In case you were more concerned with making arrangements for tonight s Halloween party or deciding what candy to put out for trick or treaters  let me remind you the third quarter is when summer takes place  It is when people generally  as they say in California  chill out  A lower GDP number should be expected  or to put it more formally  factored into your model  You could make a different argument about personal consumption as you would expect it to increase  but reality is often different than theory  Deal with it 
When the Federal Reserve Board released their monthly policy statement this past Wednesday  interest rates were not changed  and the same objectives of employment and inflation levels were reiterated  Market participants expectations about when lift off will take place is pretty much 50 50 for a rate hike in December or moved back to January  You can get some indication by looking at Fed Funds futures  At some point  in any endeavor  following through on your intentions is required for credibility  It does not matter whether it is warning a child  or preparing the markets  credibility is earned depending on action  The bottom line is  I suspect December is when rates rise  provided global markets don t fall out of bed in the meantime 
Based on what took place in October  the best month for equities in nearly four years  the fourth quarter is off to a fabulous start  Early in the week  Walgreen s  O WBA  announced its intention to purchase Rite Aid  N RAD  for  17 2 billion  Later on  it was confirmed Pfizer  N PFE  is communicating with Allergan  N AGN pa  about a combination of the two huge pharmaceutical companies  Big oil reported drastically reduced profits this week and the largest integrated oil groups all pretty much had the same kinds of results  A tough environment in upstream was balanced by strong refining and trading numbers in downstream  Nearly all said to expect the same for 2016 with oil prices gradually moving up throughout the year  The big concern is the sustainability of their big dividend payouts  but all are reducing capital expenditures based on their operating results  Chevron  N CVX  announced a further cut of 7 000 jobs as well  Been through this before  thank you 
In technology  LinkedIn  N LNKD  posted a blowout number  and Twitter  N TWTR  as well  but disappointed on guidance and monthly active users  Mr  Dorsey is the founder and showed how motivated he is to change the perception of tweety bird  He is doling out  200 million of his own stock  1  of the company  to help incentivize the employees left at the company after announcing an 8  workforce reduction  Many in the market see an interesting comparison between Facebook  O FB  and Twitter in terms of a potential comeback  Not out of the realm  but certainly not a layup either  Don t you just love the intrigue of markets 
A couple of other pastings in the market included GoPro  O GPRO  and Buffalo Wild Wings  O BWLD   Both have long been market darlings  as who doesn t love a good chicken wing and a self video of skydiving or surfing  or gosh knows what else   Apparently  not investors  as each got beat up this week  In fact  GoPro is now down over 50  for the year  Wall Street is not for the faint of heart  as you well know 
As for the little debate the other night  it was not nearly as watched as the first two  but what transpired may have been far more significant regarding the future  Republican National Committee chairman Royce Priebus described it as a  crap sandwich   delivered by the CNBC moderators  regarding the tone and kind of questions asked during a wild affair  The RNC subsequently suspended an upcoming February debate on NBC  I suspect things will get worked out  but clearly  the recurring issue of the quality of the moderators and the substance and neutrality of the questions means the whole design and structure of these events has to be reconsidered 
In terms of the outcome  like the rolling in of a new season  we may have seen a changing of the guard regarding who the Republican establishment will back for it s leading candidate  After three very poor debate efforts  Jeb Bush  even with his  100 million war chest  is not gaining traction among voters  His fellow Floridian  Marco Rubio  undressed him pretty severely and has now received the support of Paul Singer  a billionaire  and major Republican rainmaker on many different levels  primarily fund raising  Ted Cruz and Chris Christie also had strong showings  Rubio downplayed his prospects after the debate  noting it is a long process  Agreed  Still  change is always healthy  especially when you go younger and positive  as Willie so eloquently illustrated 
Disclaimer  Y H   C Investments  Yale Bock  and the family of Yale Bock own positions in securities mentioned in the blog post  Investing in stocks can lead to the complete loss of your capital  As always  on any company mentioned here  past performance is not a guarantee of future returns  Investing involves risk of losses on invested capital  One should research any investment and make sure it is suitable with your objectives  risk tolerance  risk profile liquidity considerations  tax situation  and anything else pertinent to your financial situation  Also  the CFA credential in no way implies investment returns will be superior for any charter holder ",2015-11-01,Yale Bock,"https://www.investing.com/analysis/once-you-replace-negative-thoughts-with-positive-ones,-you'll-start-havi-269835",269835
179567,401083,WBA,US STOCKS Wall St slightly lower after mixed data,news,"  Consumer confidence data falls unexpectedly in Sept
   Strong home prices index boost home construction stocks
   For up to the minute market news  click  STXNEWS US 
 Updates with consumer confidence data 
 By Angela Moon
 NEW YORK  Sept 29  Reuters    U S  stocks traded slightly
lower on Tuesday after mixed economic data on consumer
confidence and home prices 
 Stocks  which had opened in positive territory  briefly
turned negative after the Conference Board s Consumer
Confidence Index fell short of Wall Street expectations  For
details   ID nN29135785 
 But the major indexes regained ground  led by home
construction shares that got a boost from
stronger than expected readings on home prices for July
  Now it seems like expectations have gotten ahead of where
the economy is at  so we are starting to see     certainly a
majority of data that are beneath expectations  That s going to
weigh on the market   said Stephen Massocca  managing director
at Wedbush Morgan in San Francisco 
 The Dow Jones US Home Construction Index  gained
1 4 percent on an improved S P Case Shiller home price index
reading  suggesting the domestic housing market was bottoming
out   ID nNYS005445 
 D R  Horton Inc  rose 1 6 percent to  11 96  while
Toll Brothers Inc  gained 1 4 percent to  20 24  Beazer
Homes USA Inc  gained 1 2 percent to  5 96 
 The Dow Jones industrial average  was down 6 95
points  or 0 07 percent  at 9 782 41  The Standard   Poor s 500
Index  was up 0 71 points  or 0 07 percent  at 1 063 69 
The Nasdaq Composite Index  was down 1 40 points  or
0 07 percent  at 2 129 34 
 Walgreen Co   which reported quarterly results
before the bell  rose 11 percent at  38 02   ID  nN29508139 
 U S  stocks rallied on Monday  snapping a three day losing
streak  as a spurt of corporate takeovers in the technology and
health care sectors fueled optimism about share values 
 The Dow Jones industrial average marked its biggest one day
point and percent gain since August 21 and held an advance of
about 16 percent in the quarter so far  its best such period
since the fourth quarter of 1998 
 But the end of the third quarter on Wednesday may spur
volatility as fund managers engage in what is known as  window
dressing     the sale of laggard stocks in favor of
outperformers to spruce up portfolios at quarter s end 
 CIT Group Inc  shares rose 13 percent  1 89 on a
report that hedge fund manager John Paulson was considering
merging the troubled U S  finance company with failed mortgage
lender IndyMac Federal Bank    ID nBNG500407 
 Editing by Padraic Cassidy ",2009-09-29,Reuters,https://www.investing.com/news/equities-news/us-stocks-wall-st-slightly-lower-after-mixed-data-90752,90752
179568,401084,WBA,US STOCKS SNAPSHOT Consumer confidence sends Wall St lower,news,"NEW YORK  Sept 29  Reuters    U S  stocks fell on Tuesday
as a surprise drop in a gauge of consumer confidence
overshadowed signs of stabilization in housing and solid
earnings from Walgreen Co 
   The Dow Jones industrial average unofficially dropped
46 25 points  or 0 47 percent  to 9 743 11  The Standard  
Poor s 500 Index fell 2 40 points  or 0 23 percent  to
1 060 58  The Nasdaq Composite Index  shed 6 70 points  or 0 31
percent  to 2 124 04 
  Reporting by Chuck Mikolajczak  Editing by Kenneth Barry ",2009-09-29,Reuters,https://www.investing.com/news/equities-news/us-stocks-snapshot-consumer-confidence-sends-wall-st-lower-90867,90867
179569,401085,WBA,U S  chains  sales seen down but not dead in March,news,"  U S  March same store sales expected to fall 0 7 pct	
   Late Easter  inflation likely trimmed sales	
 
 CHICAGO  April 7  Reuters    March is not looking to be as
bad as expected for U S  retailers  at least as far as initial
sales reports show 	
 U S  retailers are likely to show a drop in March same store
sales  hurt by Easter falling three weeks later than last year 
which delays some spring clothing purchases  	
 Chilly weather and rising inflation were also expected to
hurt discretionary purchases 	
 But retailers that report their monthly sales earlier than
most  including drugstore operator Walgreen Co and teen
apparel retailers Hot Topic Inc and Zumiez Inc
   reported better than expected sales for the month 
 ID nL3E7F634W  	
 Sales at stores open at least a year  or same store sales 
are expected to fall 0 7 percent when tallying results from 25
retailers  according to Thomson Reuters 	
 
 
 
 With Easter falling on April 24 this year  20 days later
than in 2010  the bulk of sales of spring clothing  candy and
other goods are expected to be delayed until April 
 ID nN05116416 	
 At the same time  shoppers have already started to pay more
for groceries and gasoline  reducing the amount left for
discretionary purchases  	
 Craig Johnson  president of Customer Growth Partners  said
visits to stores showed the  first major impact of inflation on
retail spending  particularly discretionary spend  in many
years  	
 While unemployment remains high  it has edged down in recent
months 	
  This March I spent more than last March because I was
searching for a job last March   said Jane Marcinkiewicz  a
37 year old mother of two from New York s Harlem neighborhood 
who works part time at a department store 	
 Figures being released by companies this week will not paint
the full picture of the consumer economy as the retailers that
still issue monthly sales figures account for only 10 percent of
total U S  retail sales  Johnson noted 	
 Major retailers such as Wal Mart Stores Inc   Home
Depot Inc and large grocers do not issue monthly sales
reports and several apparel chains recently abandoned the
practice as well 	
 Walgreen Co  one of the largest companies that still issues
monthly sales reports  said on Tuesday that its March same store
sales rose 3 percent  with sales of general merchandise beating
expectations 	
  Reporting by Jessica Wohl and Brad Dorfman in Chicago and
Dhanya Skariachan in New York  Editing by Phil Berlowitz ",2011-04-07,Reuters,https://www.investing.com/news/stock-market-news/u.s.-chains'-sales-seen-down-but-not-dead-in-march-206541,206541
179570,401086,WBA,US STOCKS Futures gain on optimism over Greek confidence vote,news,"  Greek govt confidence vote later in the day
   Existing home sales on tap
   Futures up  S P 6 9 pts  Dow 62 pts  Nasdaq 12 25 pts
   For up to the minute market news see  STXNEWS US 
   Adds quote  updates prices 
 By Angela Moon
 NEW YORK  June 21  Reuters    U S  stock index futures rose
on Tuesday as expectations grew that a solution will be found
for Greece to avoid a default and a short term contagion risk
to other euro zone countries could be contained 
 Euro zone finance ministers said the Greek government had
until July 3 to approve new steps to get the next installment
of 110 billion euros in European Union and International
Monetary Fund aid 
 The market expected a vote of confidence in Greek Prime
Minister George Papandreou new cabinet to pass on Tuesday   
the first of three hurdles the government must clear to avert
the euro zone s first sovereign debt default  The vote is due
around 5 p m  EDT  2100 GMT  For details  see  ID nL3E7HL0BG 
  There is hope that at the end some positive decision will
come out of EU  IMF     A lot of worries in the market for the
most part have been discounted and any good news coming out of
Greece will be a relief to investors  concern  and the market
will see some technical balance in the next couple of days  
said Peter Cardillo  chief market economist at Avalon Partners
in New York 
 S P 500 futures  gained 6 9 points and were above
fair value  a formula that evaluates pricing by taking into
account interest rates  dividends and time to expiration of the
contract  Dow Jones industrial average futures  advanced
62 points  and Nasdaq 100 futures  rose 12 25 points 
 The Federal Reserve Open Market Committee  FOMC  begins a
two day meeting later Tuesday  The Fed is expected to cut its
growth forecast for 2011  but the central bank and its
chairman  Ben Bernanke  will likely continue to argue the
slowdown is temporary and the economy will pick in the second
half of the year   FED AHEAD 
 U S  home sales data for May is due at 10 a m  EDT  1400
GMT   Analysts in a Reuters survey expected sales to drop to
about 4 8 million  compared with 5 05 million the month
before 
 In company news  Walgreen Co  shares fell 5 percent
to  42 90 in premarket trade after the drugstore chain said
efforts to renew an agreement with pharmacy benefits manager
Express Scripts Inc  failed  It also reported higher
quarterly earnings   ID nN1E75K038 
 Adobe Systems Inc  is set to release results after
the bell  with analysts looking for a 20 percent increase in
earnings per share from 44 cents a year ago 
 Research In Motion Ltd  lost a second
marketing executive  and its shares dropped 7 percent Monday in
the latest bit bad news that has cut the BlackBerry maker s
market value in half this year   ID nN1E75J1N9  The stock rose
0 7 percent at  26 06 in premarket trade 
 U S  lawmakers working to rein in the country s rising debt
said they will have to make substantial progress this week to
ensure the country retains its top notch credit rating 
 ID nN1E75J23Y 
 Rating agency Fitch said it would place the credit rating
of the United States on watch negative if the debt ceiling is
not raised by Aug  2  when the government has warned it may not
be able to borrow more   ID nL3E7HL063 
 On Monday  stocks erased early losses as the S P 500 dipped
toward 1 259 78  its 200 day moving average  which is often
viewed as a pivotal point in determining market direction 
   Reporting by Angela Moon  editing by Jeffrey Benkoe ",2011-06-21,Reuters,https://www.investing.com/news/stock-market-news/us-stocks-futures-gain-on-optimism-over-greek-confidence-vote-217744,217744
179585,401101,WBA,Retail Sector In The Spotlight,opinion,"The only remaining point of interest in the Q1 earnings season is the Retail sector  which is the only one that has any meaningful number of reports still awaited  Beyond Retail  the Q1 earnings season has actually ended for 10 of the 16 sectors in the S P 500 index and effectively ended for the others 
The Retail sector had a good run this earnings season  with growth rates and surprises not only coming in better other recent periods  but also better than most of the other sectors  But the Macy s Inc  NYSE M  report indicates that the going will be tougher for department stores and others whose reports are still to come  The retail environment is no doubt difficult  with consumers hesitant to spend their energy savings  The government s April Retail Sales report showed  headline  sales flat or down in three of the last four months 
 Including today s Retail sector earnings reports  we now have Q1 results from 23 of the 41 retailers in the S P 500 index  Total earnings for these retailers are  6 9  on  11 2  higher revenues  with 87 0  beating EPS estimates and 52 2  coming ahead of revenue estimates   Please note that the sector s earnings beat ratio is the highest in the S P 500 index  while the revenue beat ratio is the third highest in the index  The side by side comparison charts below show how the sector s results are tracking notably better relative to other recent periods 
 The sector s strong results notwithstanding  the double digit revenue growth rate is a bit misleading as it reflects easy comparisons at Walgreens Boots Alliance Inc  NASDAQ WBA  and the outsized gains at Amazon  NASDAQ AMZN   Take these two companies out of the results thus far and the sector s revenue growth rate drops to  6 3    still reasonably good  We will see in the coming days if this momentum can be maintained or not  but Macy s report likely shows that we should temper our expectations  particularly from the department stores Q1 Scorecard  as of May 13th  2015  Total earnings for the 458 S P 500 members that have reported results already are up  2 4  on  3 8  revenues  with 65 4  beating EPS estimates and only 43 7  coming ahead of top line expectations  As we have stated repeatedly in this space since the start of this reporting cycle  this is weak performance compared to what we have seen from the same group of 458 S P 500 members in other recent periods   Please note that we provide the scorecard for the Russell 2000 index on page 16 of the detailed report   The two side by side charts below give a historical context to the results thus far   by comparing the Q1 earnings   revenue growth rates  left hand side chart  and earnings   revenue beat ratios  right hand side chart  with what these same companies achieved in the preceding quarter as well as the 4 quarter average 

Three things stand out as we look at the results thus far
First  the revenue weakness is very notable  We knew that growth will be problematic in Q1  so the weak revenue growth rate of  3 8  compared to other recent periods isn t that surprising  But the very low proportion of companies beating revenue estimates is surprising and likely indicative that the growth backdrop has been even weaker than what was reflected in consensus estimates Second  the earnings growth rate   2 4   is also weak relative to what we saw from the same group of companies in 2014 Q4 and the 4 quarter average  While the Finance sector has been a positive growth contributor  the Energy sector s impact has been in the opposite direction  Excluding contribution of these two sectors  the Q1 growth picture still compares to unfavorably other recent periods  as the right hand side chart below shows 
Third  as has been the norm in recent quarters  management teams continue to guide lower for the current and following quarters  As a result  estimates for the current quarter  which had fallen quite a bit already in solidarity with the Q1 estimate cuts  have started coming down even more  The chart below shows how earnings growth estimates for Q2 have evolved since the beginning of the year 

The dollar issue has added to the Energy sector s woes and some concerns about the U S  economic picture in bringing down this year s estimates  Current consensus estimates show earnings growth for the S P 500 to be in the negative for the first three quarters of the year  with the growth rate for the full year now modestly in the negative  The expectation is that the growth picture starts improving in the last quarter of the year  with the growth pace ramping up to double digit rates in 2016 ",2015-05-14,Zacks Investment Research,https://www.investing.com/analysis/retail-sector-in-the-spotlight-251694,251694
179586,401102,WBA,5 Monthly Dividend Stocks To Help Pay Your Bills,opinion,"Part of my job as an advisor is helping my clients sort out their finances  But even though I do this professionally  I sometimes have a hard time sorting out my own finances because my expenses are out of sync with my income  My regular expenses tend to be monthly  whereas my income is mostly paid quarterly 
That s always been a major source of frustration to me  and it is no doubt a major source of frustration to millions of retirees living off of their investments  Bonds generally pay interest just twice per year  and most companies pay dividends quarterly  But our home mortgages  car loans  and credit card bills are due monthly 
Well  I have a solution to this problem  monthly dividend stocks  Today  I m going to share five monthly paying dividend stocks that you can bank on to pay your monthly bills 
We should never buy a stock purely because its dividend is paid monthly  Dividend safety and growth are far more important considerations  and the following list has plenty of both 
LTC Properties Inc
I ll start with LTC Properties Inc  NYSE LTC   one of my favorite plays on the aging of the Baby Boomers 
If you want to know what LTC does  just look at its name   LTC  is short for  long term care   something that millions of Baby Boomers will be needing in the years ahead   turn 65 years old with every passing day  making this one of the most powerful trends in the world today 
LTC Properties invests in properties for providers or skilled nursing  assisted living  independent living and memory care  It also invests in mortgages secured by long term care properties 
Roughly four fifths of LTC s portfolio is invested in properties  with the remainder in mortgages 
LTC currently yields 4 9  in dividends  which is very competitive among medical REITs  And importantly  if you want to make sure your monthly income continues to match your monthly expenses  LTC is a serial dividend raiser  LTC has hiked its dividend at a 5 5  annual clip over the past five years 
A monthly dividend payer with a track record of raising its dividends that also happens to be invested in one of the most powerful macro trends in the world  If you can think of a better stock to include in a retirement portfolio  let me know  I d love to hear it 
Realty Income 
No list of monthly dividend stocks can be complete without the company that calls itself  the monthly dividend company    Blue chip retail REIT Realty Income  NYSE O 
I write about Realty Income quite regularly  and there is a reason for that  I consider it one of the very best dividend stocks a retiree can own  It s about as stable and conservative as a stock can be  while still offering regular dividend growth  Realty Income has paid 538 consecutive monthly dividends  and has raised its dividend for 70 consecutive quarters  Not every dividend hike is a large one  but the stock has managed 5  compound annualized dividend growth for 20 years and running  That s well ahead of inflation 
How can I be so confident in Realty Income s stability 
To start  Realty Income isn t really a  company   It s a mostly passive landlord with a portfolio of more than 4 300 properties  most of which are high quality  high traffic retail sites  A Walgreens  NYSE WBA  or CVS  NYSE CVS  pharmacy is a  typical  property for Realty Income 
Furthermore  Realty Income s properties are leased on a triple net basis  meaning that the tenants are responsible for paying all maintenance  taxes and insurance 
Realty Income s stock price has taken a beating in 2015  down nearly 20  from its recent fears due to investor concerns about rising bond yields  Use this as a buying opportunity in one of America s finest divided payers 
American Realty Capital Properties Preferred Stock
Next up is actually not a common stock but a preferred stock  I m recommending American Realty Capital Properties 6 7  Cumulative Preferred Shares  NASDAQ ARCPP  
This might take a little explaining   Preferred stock  is actually more similar to a bond that to common stock  Shareholders have no voting rights and buy these primarily for income  And while dividend payments are not guaranteed in the sense that bond interest is  it takes priority over common stock dividends  Furthermore  some preferred stock including this one have provisions that make them cumulative  In other words  if the company skips a preferred dividend for any reason  they have to play  catch up  and pay the preferred stockholders their cumulative past dividends before they can offer a dividend to common shareholders 
So  why am I recommending the preferred shares of American Realty Capital and not its regular common stock 
There are a couple reasons  To start  American Realty Capital Properties common stock  NASDAQ ARCP  does not currently pay a dividend  It was suspended last year due to an accounting snafu  I expect that the dividend will be reinstated this year  but as of this writing ARCP does not pay a dividend 
Meanwhile  ARCPP pays a massive 6 7  coupon  At current prices  that amounts to a yield of almost 7  
Will you get dividend growth here  No  you won t  That coupon payment won t change  But with a yield of almost 7   I m OK with that 
Prospect Capital
I may get hate mail for the next recommendation  but here me out  For a slightly riskier monthly payer  I recommend you consider shares of Prospect Capital  NASDAQ PSEC  
Earlier this week  I wrote that Prospect Capital is  the most hated stock on Wall Street   As a value investor  that should get your blood pumping  but as a conservative income investor that might cause you to take a step back  Let me explain 
Prospect Capital is a business development company   BDC   that primarily makes loans to small and medium sized businesses  It essentially does what banks used to do back when banks actually lent money  Prospect lowered its risk profile last year  not wanting to  reach for yield   so to speak  But less risk also meant less return  so Prospect had to cut its dividend 
I m normally reluctant to recommend a company that has recently cut its dividend because  like cock roaches  there is never just one  But in Prospect s case  the dividend cut made sense to me  and our risk is mitigated in my view by two things  Firstly  the stock is insanely cheap  trading at just 70  of book value  And secondly  Prospect Capital s executives have been buying the stock on the open market hand over fist  see insider trading table at the bottom of the article link  above  for the full list  
At current prices  Prospect yields nearly 14   Yes  this is a riskier play that  say  Realty Income  But I also expect it to be a fantastic performer over the next 6 12 months 
Main Street Capital
And finally  I d like to recommend Main Street Capital  NYSE MAIN   Like Prospect Capital  Main Street is a business development company  Main Street provides debt and equity financing to small and medium sized businesses  Think of it as a publically traded private equity company 
Main Street pays a modest monthly dividend of  0 175 per month  but twice per year it also generally pays a larger dividend based on its operating results  This allows Main Street to keep its base dividend stable  which is exactly what you want with a stock you re using to fund your monthly expenses  Based on its regular dividend  Main Street yields about 6 6  at current prices  But including the irregular dividends gets you to a yield of about 8 4   Not too shabby 
Main Street had to cut its dividend during the pits of the financial crisis  But it has been growing it steadily since 2011 
Disclosure  Charles Lewis Sizemore  CFA  is chief investment officer of the investment firm Sizemore Capital Management and the author of the  blog  As of this writing  he was long ARCP  LTC  O and PSEC ",2015-06-15,Charles Sizemore,https://www.investing.com/analysis/5-monthly-dividend-stocks-to-pay-your-bills-254999,254999
179587,401103,WBA,Walgreens Looks To Blow Away Earnings Expectations This Thursday,opinion,"Walgreens Boots Alliance  NYSE WBA  is scheduled to report FQ3 15 earnings before the market opens this Thursday  The Estimize consensus is set at  0 88  only 1 cent higher than the Wall Street consensus  In terms of revenue forecasts  the Estimize consensus is marginally lower than Wall Street s at  30 27M  Last quarter company EPS and revenue numbers shocked both the Estimize community and the Street  coming in at nearly 14 7  and 4 27  lower than expected  respectively 

Walgreens  the largest drug retailing chain the United States  merged with Switzerland based Alliance Boots in 2014 to form Walgreens Boots Alliance  The stock has been trading on the NASDAQ since  switching from the ticker WAG to WBA as it has soared to new highs  Year to date  the stock has risen 12 72   The S P 500 has paled in comparison year to date  returning a negative  32  

At its last quarterly earnings release  Walgreens released revenue numbers of  26 57M  up nearly 35 5  from the same quarter in the previous year  The company has also experienced a massive increase in its Earnings Before Interest and Tax  EBIT  from  1 16M in 2014 to  2 59M in 2015  an increase of roughly 123   Further bolstering the company s bullish performance  member of the board of directors John Anthony Lederer purchased 10 000 shares of the company s stock as filed with the SEC on April 20th of this year 
The company has been growing rapidly since its acquisition of Boots Alliance  and it is expected to continue throughout this fiscal year  Both Citi and Deutsche Bank have both recently rated the stock as a  buy   and the stock paid a quarterly dividend of  0 33 on June 12th  Be sure to keep an eye out for Walgreens as it looks to post increased earnings at the beginning of the season this Thursday ",2015-07-09,Estimize,https://www.investing.com/analysis/walgreens-looks-to-blow-away-earnings-expectations-this-thursday-257705,257705
179588,401104,WBA,Global Indices Advance As Chinese Stocks Increase,opinion,"Global indices advanced yesterday  as Chinese stocks increased 6   The trend continues this morning  Shanghai Composite has added 10 3  for 2 days  recording the best 2 day result since September 2008  It happened because the government introduced a number of market regulations that cut commissions and banned some holders from selling stocks  No important macroeconomic news was released yesterday in the USA  but we would like to point out that the weekly unemployment rate appeared to be a bit worse than expected  Corporate news and other statistics were generally neutral  The largest pharmacy network  Walgreens Boots Alliance  NASDAQ WBA   raised this year s income forecast  so its shares gained 4 2   Coty Cosmetics  NYSE COTY  reported buying P G beauty business for  12 5 billion and lost 4 5   Yesterday  the American stocks turnover was 7  below the weekly average  making 6 6bln shares  Janet Yellen will speak today at 18 00 CET  which is considered the most significant event this week  Market participants are looking forward to know about the rate hike  Besides  wholesale inventories in May will be published at 16 00 CET  the tentative outlook is moderately negative 
Dow Jones Weekly Chart
European stocks and the EUR USD have been growing today  due to concessions made by the Greek government  It intends to acquire  53 5bln in exchange for tax reforms aimed to increase budget income and pay off debts  As far as particular stocks are concerned  United Internet AG  XETRA UTDI   Germany  added 4 5   French AXA  PARIS AXAF  edged higher 4 3   and the largest Norwegian bank DNB  OSLO DNB  inched 4 2   Greek stocks are closed until July 13th  Eurozone leaders will hold a special meeting July 12th to discuss the Greek proposal  No important economic data are expected today in the EU 
Nikkei has been expanding for two consequent days with other global indices  Before  it nearly witnessed the strongest 9 month fall  However  at the moment  we see that the overall drop will be less dramatic because of the rebound  Expectations of Chinese stock stabilization weighed on the demand for the yen  driving it down  It is worth mentioning that Machinery Orders growth clearly outstripped forecasts  We believe that this factor  together with the cheap yen  produced additional support for Japanese stocks  Bank and Food market sectors scored the best results 
International Monetary Fund slightly lowered the economic outlook for 2015  from 3 5  to 3 3   and left unchanged the forecast for 2016   3 8    It cut US and Japan growth forecast as well  The analysts expect that oil will cost on average  59 per barrel this year  While the situation in Greece and China becomes stable  global oil prices and other commodities advance  According to International Energy Agency  the global oil demand will expand next year 1 2mln barrels daily   less than in 2015  1 4mln barrels increase   The agency highlights oil oversupply on the world market 
Wheat Weekly Chart
American National Weather Service said there is 90  chance of El Nino continuing through the winter  There is 80  chance it will last through the spring  Japan Weather Bureau also expects El Nino this winter  We remind that this natural phenomenon causes drought and floods in pacific Region and makes agricultural futures more expensive ",2015-07-10,IFC Markets,https://www.investing.com/analysis/the-speech-of-the-fed-chairman-is-expected-today-257942,257942
179589,401105,WBA,Swing Trading Watch List  MDLZ  SM  LXK  AMZN  WBA,opinion,"Here s today s swing trading watch list 
Long  Mondelez Int l  O MDLZ 

Long  SM Energy  N SM 

Long  Lexmark Int l  N LXK 

Long  Amazon com  O AMZN 

Short  Walgreens Boots Alliance  O WBA ",2015-10-15,Ryan Mallory,"https://www.investing.com/analysis/swing-trading-watch-list:-mdlz,-sm,-lxk,-amzn,-wba-268241",268241
179590,401106,WBA,US STOCKS Wall St drops on economic worries  commodities weigh,news,"  Fears over economy resurface
   Lower commodity prices sink natural resource stocks
   Dow off 1 9 pct  S P off 2 4 pct  Nasdaq off 2 7 pct
  Updates to midday 
 NEW YORK  June 22  Reuters    U S  stocks slid on Monday as
investors fretted about the strength of an economic recovery 
and falling commodity prices hit shares of energy and other
natural resource companies 
  Weighing on sentiment  the World Bank said prospects for
the global economy remain  unusually uncertain  as it cut 2009
growth forecasts for most economies 
 Adding to a glum economic outlook  Walgreen Co posted weak
quarterly results as U S shoppers focused on buying only
necessities  Shares in the drugstore chain fell more than 5 2
percent to  29 79 
 The Dow Jones industrial average dropped 165 51 points  or
1 94 percent  to 8 374 22  The Standard   Poor s 500 Index fell
21 89 points  or 2 38 percent  to 899 34  The Nasdaq Composite
Index slid 49 39 points  or 2 70 percent  to 1 778 08 
  When you hear the comments come out this morning
downgrading global economic growth  and then some comments from
Walgreen about what they are seeing on the retail side    and
they are one of the bigger drug retailers as well    I think it
gave investors a good reason to step back   said Paul Nolte 
director of investments at Hinsdale Associates in Hinsdale 
Illinois 
 Shares of energy companies were among the biggest decliners
as the front month price of crude fell nearly 4 percent to
 66 87 a barrel  Exxon Corp was down 2 2 percent to  69 48 
while Chevron Corp fell 3 percent to  66 03 
 Metal prices slid across the board  Shares in
Freeport McMoRan Copper   Gold Inc  which often mirror the
price of gold  dropped nearly 9 4 percent to  46 15 as the
precious metal hit its lowest level since mid May 
 After a sharp three month rally  indexes have eased as
traders increasingly questioned if stocks were due for a
correction  Worries that the economic recovery could be tepid
have wilted the optimism that drove up the S P 500 by as much
as 40 percent from the 12 year low in March  Indexes have
fallen 4 percent to 5 percent since an intraday high on June
11 
 On the Nasdaq  big cap technology stocks led the decline 
with Qualcomm Inc down 3 3 percent to  44 49  while Apple Inc
fell nearly 2 percent to  136 81 
 Apple said it had sold more than 1 million of its newest
iPhone in the first three days of launch  beating expectations 
The company statement also quoted Chief Executive Steve Jobs 
leading at least one analyst to speculate he was back from
medical leave ",2009-06-22,Reuters,https://www.investing.com/news/equities-news/us-stocks-wall-st-drops-on-economic-worries;-commodities-weigh-64980,64980
179591,401107,WBA,RPT US STOCKS Wall St drops with energy shares  economic worries,news,"  Global forecast deepens economic worries
   Lower oil prices hit energy shares
   Dow off 2 2 pct  S P off 2 8 pct  Nasdaq off 3 2 pct
  Updates to early afternoon  adds byline 
 By Caroline Valetkevitch
 NEW YORK  June 22  Reuters    U S  stocks fell on Monday
as a sharp drop in oil prices weighed on energy company
shares  while a global forecast fueled worries about an
economic recovery 
 The Dow slid 2 percent while the S P 500 index lost 2 8
percent and the Nasdaq fell as much as 3 2 percent 
 Shares of energy companies were among the biggest
decliners as the front month price of crude fell  2 77 to
 66 78 a barrel  Exxon Mobil Corp lost 2 7 percent to  69 13 
while Chevron Corp sank 3 2 percent to  65 88 
 Also weighing on stocks  the World Bank said prospects for
the global economy remain  unusually uncertain  as it cut 2009
growth forecasts for most economies 
  Oil has kind of been leading us up  so you re seeing
those stocks come off   said Todd Leone  head of listed
trading  Cowen   Co  in New York 
 On the Nasdaq  big cap technology stocks led the decline 
 The Dow Jones industrial average shed 188 86 points  or
2 21 percent  to 8 350 87  The Standard   Poor s 500 Index
dropped 25 67 points  or 2 79 percent  to 895 56  The Nasdaq
Composite Index declined 58 15 points  or 3 18 percent  at
1 769 32 
 Apple s stock tumbled 2 percent to  136 70 even as it said
it had sold more than 1 million of its newest iPhone in the
first three days of its launch  beating expectations  The
company statement also quoted Chief Executive Steve Jobs 
leading at least one analyst to speculate he was back from
medical leave 
 Leone said the S P 500 s break below the 900 level    and
its recent trading range    also was a psychologically bearish
factor for some investors 
 Adding to a glum economic outlook  Walgreen Co posted weak
quarterly results as U S shoppers focused on buying only
necessities  The drugstore chain s stock fell 6 1 percent to
 29 53 
 Metal prices also slid  dragging down shares of resource
companies  Freeport McMoRan Copper   Gold Inc dropped 10 4
percent to  45 64 
 After a sharp three month rally  the major U S  indexes
have eased as traders increasingly questioned if stocks were
due for a correction 
  Editing by Jan Paschal ",2009-06-22,Reuters,"https://www.investing.com/news/equities-news/rpt-us-stocks-wall-st-drops-with-energy-shares,-economic-worries-65004",65004
179592,401108,WBA,US STOCKS Wall St drops with energy companies  economic worries,news,"  Oil prices slide  taking energy shares lower
   Global forecast deepens economic worries
   Dow off 2 pct  S P off 2 6 pct  Nasdaq off 2 8 pct
  Updates to late afternoon 
 By Caroline Valetkevitch
 NEW YORK  June 22  Reuters    U S  stocks fell on Monday
as a sharp drop in oil prices prompted investors to sell some
energy companies  shares  while a global forecast fueled
worries about the sustainability of an economic recovery 
 The World Bank said prospects for the global economy
remain  unusually uncertain  as it cut 2009 growth forecasts
for most economies 
 While lower crude oil prices tend to be a positive for the
broader stock market  they tend to hurt shares of energy
companies by giving investors a reason to unload some holdings
in that sector  The front month price of crude fell  2 62  or
almost 4 percent  to settle at  66 93 a barrel  Exxon Mobil
Corp lost 2 5 percent to  69 27  while Chevron Corp sank 3
percent to  66 05 
 Monday s pullback follows losses last week for the three
major indexes and investors speculating about more obstacles
for the stock market after its three month rally 
  There are traders desiring to take some profits at these
levels if indeed the market is headed for a correction   said
Tim Ghriskey  chief investment officer of Solaris Asset
Management in Bedford Hills  New York 
  Crude oil was down from the get go and that is a weak
sector here   he said 
 The Dow Jones industrial average dropped 168 53 points  or
1 97 percent  at 8 370 82  The Standard   Poor s 500 Index
shed 23 47 points  or 2 55 percent  to 897 76  The Nasdaq
Composite Index slid 51 95 points  or 2 84 percent  to
1 775 52 
 On the Nasdaq  big cap technology stocks led the decline 
 Apple s stock fell 1 5 percent to  137 42 even as it said
it had sold more than 1 million of its newest iPhone in the
first three days of its launch  beating expectations  The
company statement also quoted Chief Executive Steve Jobs 
leading at least one analyst to speculate he was back from
medical leave 
 Adding to a glum economic outlook  Walgreen Co posted weak
quarterly results as U S shoppers focused on buying only
necessities  The drugstore chain s stock fell 5 4 percent to
 29 72 
 Metal prices also slid  dragging down shares of resource
companies  Freeport McMoRan Copper   Gold Inc dropped 9 7
percent to  45 96 
  Editing by Jan Paschal ",2009-06-22,Reuters,"https://www.investing.com/news/equities-news/us-stocks-wall-st-drops-with-energy-companies,-economic-worries-65033",65033
179593,401109,WBA,US STOCKS Sell off leaves S P in negative terrory for year,news,"  S P falls back into negative territory for year
   Financials  energy and materials lead losses
   Dow off 2 4 pct  S P off 3 1 pct  Nasdaq off 3 4 pct
  Updates to close 
 By Caroline Valetkevitch
 NEW YORK  June 22  Reuters    U S  stocks suffered their
worst one day loss in two months  dropping the S P 500 back
into negative territory for the year on Monday in a
broad based sell off  as investors reconsidered the health of
the economy 
 Shares of economically sensitive sectors such as
financials  energy and materials led the S P 500 s decline  A
sharp drop in U S  crude oil futures and other commodities hit
shares of companies sensitive to those prices  including Exxon
Mobil Corp  which lost 3 1 percent to  68 84 
 Analysts said investors were keen to sell shares that led
the market up in its rally since early March  Major averages
have largely been trading sideways in recent weeks and many
investors have speculated that more obstacles were in store
for stocks 
  The recovery is likely to be anemic by post war
standards  said Hugh Johnson  chief investment officer of
Johnson Illington Advisors  in Albany  New York   The recovery
in the economy and earnings is unlikely to be as strong as the
rise in stock prices since early March has implied  
 The Dow Jones industrial average dropped 200 72 points  or
2 35 percent  to end at 8 339 01  The Standard   Poor s 500
Index was down 28 19 points  or 3 06 percent  at 893 04  The
Nasdaq Composite Index was down 61 28 points  or 3 35 percent 
at 1 766 19 
 The S P financial index fell 6 2 percent  while the energy
sector dropped 4 6 percent  The financial sector had the
biggest gains since the S P 500 hit a 12 year closing low in
early March 
  Some people are skeptical of how the summer is going to
play out and may be taking some profits   said John O Brien 
senior vice president at MKM Partners LLC in Cleveland 
 Underscoring worries about the economy s outlook  the
World Bank said prospects for the global economy remain
 unusually uncertain  as it cut 2009 growth forecasts for most
economies 
 While lower crude oil prices tend to be a positive for the
broader stock market  they tend to hurt shares of energy
companies by giving investors a reason to unload some holdings
in that sector 
 Crude oil prices fell  2 62  or almost 4 percent  to
settle at  66 93 a barrel  Chevron Corp sank 3 4 percent to
 65 76 
 Metal prices also slid  dragging down shares of resource
companies  Freeport McMoRan Copper   Gold Inc dropped 11 3
percent to  45 18 
 On the Nasdaq  big cap technology stocks led the decline 
 Apple s stock fell 1 5 percent to  137 37 even as it said
it had sold more than 1 million of its newest iPhone in the
first three days of its launch  beating expectations  The
company statement also quoted Chief Executive Steve Jobs 
leading at least one analyst to speculate he was back from
medical leave 
 Adding to a glum economic outlook  Walgreen Co posted weak
quarterly results as U S shoppers focused on buying only
necessities  The drugstore chain s stock fell 5 7 percent to
 29 64 
  Additional reporting by Edward Krudy  Editing by Jan
Paschal ",2009-06-22,Reuters,https://www.investing.com/news/equities-news/us-stocks-sell-off-leaves-s-p-in-negative-terrory-for-year-65057,65057
179594,401110,WBA,US STOCKS Futures dip after previous rally  data eyed,news,"  Home price  consumer confidence data on tap
   Futures off  S P 2 3 pts  Dow 5 pts  Nasdaq 4 3 pts
   For up to the minute market news  click  STXNEWS US 
 Updates with quote  adds byline 
 By Angela Moon
 NEW YORK  Sept 29  Reuters    U S  stock index futures were
little changed on Tuesday following solid gains in the previous
session as investors awaited data on home prices and consumer
confidence 
 Economists expect the Conference Board s Consumer
Confidence Index to rise to 57 0 for September  up from
August s 54 1  according to a Reuters survey  Despite an
improvement  the reading would still be considered far from
healthy  suggesting consumers are worried about more economic
woes ahead  The data is due at 10 a m   1400 GMT  
  With yesterday s roaring stock market rally on the heels
of the deal announcements  investors are now asking  is M A
activity a precursor to a good market or does it follow an
already buoyant one   said Peter Boockvar  equity strategist at
Miller Tabak   Co in New York 
 U S  stocks rallied on Monday  snapping a three day losing
streak  as a spurt of corporate takeovers in the technology and
health care sectors fueled optimism about share values  The Dow
Jones industrial average marked its biggest one day point and
percent gain since August 21  and its 4th highest close this
year 
 The S P Case Shiller U S  home price indexes for July are
due at 9 a m   1300 GMT   Economists look for prices in the
20 city index to rise 0 5 percent in July from a 1 4 percent
increase in the previous month 
 S P 500 futures  fell 2 3 points and were below fair
value  a formula that evaluates pricing by taking into account
interest rates  dividends and time to expiration on the
contract  Dow Jones industrial average futures  lost 5
points and Nasdaq 100 futures  fell 6 25 points 
 Energy shares are likely to come under pressure  following
a drop in crude oil futures  A weak demand outlook expected to
be reinforced by weekly inventory data from the United States
pushed down crude futures  by 0 5 percent 
 Walgreen Co  shares rose 6 8 percent at  36 40 in
premarket trade after the company reported its quarterly
results   For details  see ID  nN29508139 
 Nike Inc   Micron Technology Inc  and Jabil
Circuit Inc   are set to report quarterly results later
in the day 
 European shares advanced on Tuesday  led by French bank BNP
Paribas   which launched a 4 3 billion euro capital
increase as it seeks to pay back government aid  For details 
see  ID nLT458563 
 Editing by Padraic Cassidy ",2009-09-29,Reuters,https://www.investing.com/news/equities-news/us-stocks-futures-dip-after-previous-rally;-data-eyed-90693,90693
179611,401127,WBA,Walgreens to Complete Acquisition Of Alliance Boots,opinion,"Walgreen  NYSE WAG  reported its first quarter FY2015 results on December 23rd  which also confirmed the imminent retirement of CEO Greg Wasson  The report beat analyst estimates and highlighted the pending transaction with Alliance Boots The pharmaceutical retailer posted GAAP earnings per diluted share of  0 85  an 18  year over year increase and above the analyst estimate of  0 72  Sales increased 6 7  to a record  19 6 billion  Adjusted gross profit increased 2 3  year over year  though profit from pharmaceuticals was negatively impacted by  lower third party reimbursement and generic drug price inflation   This did not come as a surprise and was slightly offset by  an increase in the brand to generic drug conversions  The report confirmed that CEO Greg Wasson will be retiring after 35 years with Walgreen once the merger with Alliance Boots is completed  which is expected to close on December 31st  Walgreen spent  6 7 billion in June of 2012 to purchase 45  of Alliance Boots  a European drugstore chain  The deal was the largest purchase ever made by Walgreen  Walgreens plans to buy the remaining 55  of Alliance Boots pending shareholder approval  The transaction will create a new holding under the name of Walgreen Boots Alliance Inc   operating under the NASDAQ ticker WBA According to the Q1 FY2015 report  Alliance Boots already contributed  0 11 per diluted share to Walgreen in the quarter s adjusted earnings per share  The report added   The combined synergies for Walgreen and Alliance Boots in the first quarter were approximately  140 million and remain on track to reach at least  650 million in fiscal 2015  On December 23rd  analyst  of Deutsche Bank maintained a Buy rating on and raised his price target from  69 to  82  Hill commented that  gross margins came in weaker than expected on continued pharmacy reimbursement pressure  but  Walgreen is expecting to see some relief from payers with respect to generic inflation  Management also remains focused on targeting discretionary costs at the corporate level   The analyst added   We see potential for earnings estimates to increase if management has overestimated the long term margin pressure or increases cost savings  Hill has a 79  overall success rate recommending stocks with a  7 9  average return per recommendation Separately  on December 23  analyst of Bank of America Merrill Lynch maintained a Neutral rating on Walgreen and raised his price target to  75  Willoughby is apprehensive about the Alliance Boots acquisition  noting that the buyout may result in slow growing profits  He is uncertain about the merger s  capital efficiency  because it is a  vastly  complex strategy   Willby concluded   We re less convinced of the sustainable competitive advantage it creates  particularly in the U S  Willoughby has an 83  overall success rate recommending stocks with an average return of  17 4  per recommendation 
Disclosure  All recommendations for WAG sourced from TipRanks ",2014-12-24,Uri Gruenbaum,https://www.investing.com/analysis/walgreens-to-complete-acquisition-of-alliance-boots-236784,236784
179612,401128,WBA,Standout Sectors Of Q1 Earnings Season,opinion,"It isn t news anymore that the earnings picture emerging from the Q1 earnings season has been very bad   there is not much growth  with revenue gains particularly hard to come by and many companies unable to meet even the lowered top line estimates  The outlook is no better for the current period either  with Q2 estimates following the by now familiar downtrend that we have been seeing for the last many quarters 
 While there is no question about the overall soft earnings landscape  but is the underperformance widespread and present in all sectors or do some pockets of strength exist  The answer to that is yes  some sectors have done better  But the better performance is relative   relative to pre season expectations and relative to the very weak performance of other sectors this earnings season  I will spotlight three sectors here that have done reasonably better this earnings season   Retail  Medical and Energy  The reference to the Energy sector will likely surprise many given how much of a drag the sector has been on the aggregate growth picture  But the Energy sector s results have nevertheless been better than expected  with a bigger proportion of companies beating estimates and the growth rates aren t as bad as initially feared Is the Retail Turnaround for Real  One could dispute putting the Energy sector results in a favorable light  but it s hard to characterize the Retail sector s performance thus far as anything but very good  Not only is a bigger proportion of retailers beating estimates compared to other sectors  but the sector s Q1 growth rates also represent an improvement over other recent reporting cycles  We should keep in mind  however  that while the Q1 earnings season is winding down for most of the other sectors  we are only about half way through for the retailers  For the 22 retailers in the S P 500 index that have reported Q1 results  out of a total 44   total earnings are up  7 5  on  11 7  higher revenues  with 90 9  beating EPS estimates and 50  coming ahead of revenue estimates   Please note that the sector s earnings beat ratio is the highest in the S P 500 index  while the revenue beat ratio is the fourth highest  The side by side comparison charts below show how the sector s results are tracking notably better relative to other recent periods 
 The sector s strong results notwithstanding  the double digit revenue growth rate is a bit misleading as it reflects easy comparisons at Walgreens Boots Alliance Inc  NASDAQ WBA  and the outsized gains at Amazon  NASDAQ AMZN   Take these two companies out of the results thus far and the sector s revenue growth rate drops to  6 7    still reasonably good  but no longer the best in the S P 500  No doubt  the retail sector stock prices have risen the most of all the sectors in the index in response to earnings releases  The Retail sector s positive momentum in the Q1 earnings season could change in the coming days as more companies report results  But at this stage in the reporting cycle  it remains a standout performer  Results have been fairly strong in the Medical sector as well  with total earnings for the 88 5  of the sector s companies that have reported results up  17 6  on  8 8  higher revenues  with 80 4  beating EPS estimates and 56 5  coming ahead of top line expectations  Strong growth at Gilead Sciences  NASDAQ GILD    Gilead s earnings are up  2 1 billion from the same period last year on  2 6 billion higher revenues   are a big contributor to the Medical sector s growth numbers  But the sector s earnings would still be up double digits without Gilead  Q1 Scorecard  as of May 7th  2015  We now have Q1 results from 436 S P 500 members that combined account for 90 3  of the index s total market capitalization  Total earnings for these 436 companies are up  2 0  on  4 1  revenues  with 66 7  beating EPS estimates and only 42 7  coming ahead of top line expectations  This is weak performance compared to what we have seen from the same group of 436 S P 500 members in other recent periods   Please note that we provide the scorecard for the Russell 2000 index on page 16 of the detailed report  The two side by side charts below give a historical context to the results thus far   by comparing the Q1 earnings   revenue growth rates  left hand side chart  and earnings   revenue beat ratios  right hand side chart  with what these same companies achieved in the preceding quarter as well as the 4 quarter average 
 Three things stand out as we look at the results thus farFirst  the revenue weakness is very notable  We knew that growth will be problematic in Q1  so the weak revenue growth rate of  4 1  compared to other recent periods isn t that surprising  But the very low proportion of companies beating revenue estimates is surprising and likely indicative that the growth backdrop has been even weaker than what was reflected in consensus estimates Second  the earnings growth rate   2 0   is also weak relative to what we saw from the same group of companies in 2014 Q4 and the 4 quarter average  While the Finance sector has been a positive growth contributor  the Energy sector s impact has been in the opposite direction  Excluding contribution of these two sectors  the Q1 earnings growth still compares to unfavorably other recent periods  as the right hand side chart below shows 
Third  as has been the norm in recent quarters  management teams continue to guide lower for the current and following quarters  As a result  estimates for the current quarter  which had fallen quite a bit already in solidarity with the Q1 estimate cuts  have started coming down even more  The chart below shows how earnings growth estimates for Q2 have evolved since the beginning of the year 

The dollar issue has added to the Energy sector s woes and some concerns about the U S  economic picture in bringing down this year s estimates  Current consensus estimates show earnings growth for the S P 500 to be in the negative for the first three quarters of the year  with the growth rate for the full year now modestly in the negative  The expectation is that the growth picture starts improving in the last quarter of the year  with the growth pace ramping up to double digit rates in 2016 ",2015-05-08,Zacks Investment Research,https://www.investing.com/analysis/standout-sectors-of-q1-earnings-season-251054,251054
179613,401129,WBA,RPT Wall St Week Ahead  Stock investors hope Santa touches down,news," Repeating column initially transmitted late Friday 
 By Leah Schnurr
 NEW YORK  Dec 21  Reuters    Investors could do their
holiday shopping on Wall Street this week as bargain basement
prices for stocks and optimism over efforts to fight the
year long recession may prompt a year end rally 
 But not even a Santa Claus rally to end the year can rescue
2008 from going into the books as the worst for stocks since
the Great Depression  thanks to the body blow delivered by the
housing market slump  credit crisis and  finally  recession 
 With just seven trading days left  the benchmark S P 500
index is down 39 5 percent for the year  on pace perhaps to
match Wall Street s second worst year ever  1937  when the S P
also plummeted nearly 39 percent  Should no rally develop next
week  2008 could well challenge 1931    when the S P crashed 46
percent    for the mantle of Wall Street s worst ever year 
 That said  the slump in stocks has left them relatively
cheap  And analysts are now more optimistic that unconventional
recession fighting efforts such as the Federal Reserve s big
interest rate cuts may soon gain traction 
  You re getting a lot of people picking through the
wreckage of this year and doing some selective buying   said 
Paul Nolte  director of investments at Hinsdale Associates  in
Hinsdale  Illinois 
  There are some good bargains out there and there is a fair
amount of buying in the marketplace  
 This week  market watchers will look at fresh data on the
housing market for any sign that the sector is getting closer
to a bottom 
 HUNTING FOR HOLIDAY BARGAINS
 Volume is expected to be light in a week shortened by the
Christmas holiday and an early close on Christmas Eve 
 The buying spirit tends to visit Wall Street nearly every
year   bringing a short  sweet  respectable rally within the
last five days of the year and the first two in January  
according to the Stock Trader s Almanac 
 Santa s appearance on Wall Street has been good for an
average 1 5 percent gain since 1969  according to the Almanac 
while the absence of such a rally tends to precede times when
stocks can be bought at much lower prices 
 As of Friday s close  the broad S P 500 was off about 40
percent from where it started the year  and was down about 44
percent from the all time high it reached in October 2007 
 But the S P has recovered about 20 percent since hitting an
11 year intraday low in late November  prompting some to
speculate that the worst may be over 
  A lot of people are wondering whether they ll get a Santa
Claus rally   said Michael Sheldon  chief market strategist at
RDM Financial in Westport  Connecticut 
  Clearly  this is not a normal year  but just the fact that
you have history on your side around the New Year s holidays
can only be called a positive  
 Analysts said sentiment over the outlook for the battered
U S  economy has shifted to a more positive tone as investors
were cheered by the Fed s move last week to cut the benchmark
fed funds rate to as low as zero and pledge further measures to
shore up credit markets 
 Optimism over President elect Barack Obama s proposed
stimulus plan has added to the more positive tone  helping the
market rally in the face of an onslaught of dire economic and
corporate outlooks 
  No one is very good at dealing with economic Armageddon 
but we have dealt with recessions in the past   Sheldon said 
 He noted that more investors are coming around to  the
opinion the economy is going through a severe recession  but
we ve been here before  and we ll get through this at some
point  We re starting to see a little more positive
sentiment  
 WATCHING HOME SALES AND CASH REGISTERS
 Among economic indicators due this week are new home sales
and existing home sales for November  the final look at gross
domestic product for the third quarter  and the final December
reading on consumer sentiment from the Reuters University of
Michigan Surveys of Consumers 
 The home sales figures are not likely to bring much relief 
with current forecasts pointing to an 18 year low for new home
sales and a nearly 10 year low for sales of existing houses 
Meanwhile  the GDP data should confirm the economy  which has
been in recession since December 2007  contracted at an annual
rate of 0 5 percent in the third quarter 
 Weekly jobless claims will come out a day early on
Wednesday because of Thursday s Christmas holiday 
 Analysts also will look for anecdotal signs of how
retailers fare over the last shopping weekend before the
holidays 
 Over the weekend  retailers made a last ditch effort to
lure cash strapped consumers to spend  But Friday s big
snowstorm that has blanketed much of the northern half of the
country threatened to hold down shopper traffic 
 Quarterly results are light  Pharmacy chain Walgreen Co and
memory chip manufacturer Micron Technology Inc are among those
expected to report 
  Editing by Jan Paschal 
  Wall St Week Ahead runs weekly  Questions or comments on this
column can be e mailed to  leah schnurr at reuters com ",2008-12-21,Reuters,https://www.investing.com/news/forex-news/rpt-wall-st-week-ahead:-stock-investors-hope-santa-touches-down-15845,15845
179614,401130,WBA,US STOCKS Wall St set to slip on economic malaise  oil,news,"  Stocks set to extend last week s pullback
   Energy shares could be pressured by lower oil
   Futures down  S P 10 pts  Dow 79 pts  Nasdaq 13 pts
  Adds details  stock prices 
 By Leah Schnurr
 NEW YORK  June 22  Reuters    Wall Street was poised for a
lower open on Monday as investors assessed the potential
strength of an economic recovery  while energy shares could be
pressured by lower oil prices 
 After a sharp three month rally  indexes eased last week as
traders increasingly questioned if stocks are due for a
correction  Worries the economic recovery could be tepid have
dented optimism that drove the S P 500 up by as much as 40
percent from March s 12 year low 
 Investors were cautious ahead of a Federal Reserve meeting
that starts on Tuesday  bracing for Fed guidance on growth and
any hints on expanding the central bank s  300 billion program
of Treasuries purchases  Housing and gross domestic product
data are also expected this week 
 Investors are also watching the Treasury s record  104
billion worth of bond auctions scheduled this week to finance
massive spending aimed at reviving the world s biggest economy 
There is a growing worry about the escalating budget deficit
and the threat of inflation related to government fund
raising 
 S P 500 futures fell 10 points and were below fair value  a
formula that evaluates pricing by taking into account interest
rates  dividends and time to expiration on the contract  Dow
Jones industrial average futures slid 79 points  and Nasdaq 100
futures lost 13 points 
  The enthusiasm for a  V shaped  recovery has been tempered
by the realization that there remains systemic risk in the
economy   said Andre Bakhos  president of Princeton Financial
Group in Princeton  New Jersey 
 Energy shares could come under pressure as oil fell below
 69 a barrel as the dollar strengthened  Exxon Mobil Corp was
off 1 percent to  70 35 in premarket trading  While higher oil
prices can be a boon for energy companies  rising prices can
lead consumers to further curb spending 
 Adding to the caution  the World Bank said Monday that
prospects for the global economy remain  unusually uncertain 
as it cut 2009 growth forecasts for most economies 
 Walgreen Co fell 6 percent to  29 53 in premarket trading
after the drugstore chain posted slightly lower third quarter
profit as shoppers stuck to the necessities 
 Apple Inc climbed before the open after initially
retreating  adding 0 6 percent to  140 30  Over the weekend 
there was a report that Chief Executive Steve Jobs had a liver
transplant about two months ago but is expected to return to
work later this month  On Monday  Apple reported that it sold
more than 1 million units of its newest iPhone in the first
three days of the launch 
 On Friday  the S P 500 and Nasdaq rose as positive broker
comments on Microsoft lifted tech shares  but the major indexes
lost ground for the week for the first time in five weeks ",2009-06-22,Reuters,"https://www.investing.com/news/equities-news/us-stocks-wall-st-set-to-slip-on-economic-malaise,-oil-64911",64911
179630,401146,WBA,Will Walgreen Benefit As CVS Drops Cigarettes ,opinion,"Walgreen Co   NYSE WAG  is set to report FQ3 2014 earnings before the market opens on Tuesday  June 24th  Walgreen is the largest pharmacy chain in the United States  In February Walgreen s biggest competitor CVS Corporation  NYSE CVS  announced that it will become the first major pharmacy chain in the US to voluntarily give up cigarette and tobacco sales  Despite mounting pressure from many state attorney generals  Walgreen s has refused to fold on tobacco and could stand to add billions in sales from cigarette shoppers after CVS stops selling tobacco products in October  For now  Wall Street expects continued modest growth from Walgreens  This quarter sales are expected to increase about 5  compared to the same quarter of last year while earnings increase by 9c per share  Here s what investors are expecting from Walgreen on Tuesday 
The information below is derived from data submitted to the Estimize com platform by a set of Buy Side and Independent analyst contributors 

The current Wall Street consensus expectation is for Walgreens to report 94c EPS and  19 341B revenue while the current Estimize com consensus from 15 Buy Side and Independent contributing analysts is 95c EPS and  19 275B in revenue  This quarter the buy side as represented by the Estimize com community is expecting Walgreens to beat the Wall Street earnings consensus by 1c per share while coming up short on revenue 
By tapping into a wider range of contributors including hedge fund analysts  asset managers  independent research shops  students  and non professional investors Estimize has created a data set that is more accurate than Wall Street up to 69 5  of the time 
More importantly it does a better job of representing the market s actual expectations  It has been confirmed by Deutsche Bank Quant  Research and an independent academic study from Rice University that stock prices tend to react with a more strongly associated degree to the expectation benchmark from Estimize than from the Wall Street consensus 
The magnitude of the difference between the Wall Street and Estimize consensus numbers often identifies opportunities to take advantage of expectations that may not have been priced into the market  Here we are seeing an average sized differential between the two groups  expectations  

The distribution of earnings estimates published by analysts on the Estimize com platform range from 86c to 99c per share and from  19 100B to  19 476B in revenues  This quarter we re seeing a moderate range of estimates on Walgreens earnings 
The size of the distribution of estimates relative to previous quarters often signals whether or not the market is confident that it has priced in the expected earnings already  A wide range of earnings estimates signals less agreement in the market  which could mean greater volatility post earnings 

Over the past 3 months the Wall Street consensus bounced around but both started and ended the period at 94c while the Estimize consensus edged higher from 94c to 95c  Meanwhile the Wall Street revenue forecast spiked from  19 194B to  19 341B while the Estimize sales consensus shot up from  19 137B to  19 275B  Timeliness is correlated with accuracy and upward analyst revisions going into an earnings are often a bullish indicator 

The analyst with the highest estimate confidence rating this quarter is turbinecity who projects 96c EPS and  19 217B in revenue  turbinecity was our Winter 2014 season winner and is  overall among over 4 500 contributing analysts  This season turbinecity has been more accurate than Wall Street in forecasting EPS and revenue 60  and 51  of the time respectively throughout a massive 1169 estimates 
Estimate confidence ratings are calculated through algorithms developed by deep quantitative research which looks at correlations between analyst track records and tendencies as they relate to future accuracy  In this case turbinecity is expecting Walgreens to report slightly higher earnings than the Wall Street consensus  but less revenue 
This quarter the Estimize community is expecting Walgreen s to edge past the Wall Street consensus by 1c per share while missing revenue estimates by  66 million  Walgreens may have a growth opportunity later this year if a significant portion of CVS shoppers switch over to Walgreens to satisfy their cigarette buying habits  For now more modest gains are expected  Over the previous 4 quarters Walgreens has increased revenue on a year over year basis between 3  and 6  each period and contributing analysts on the Estimize com platform are expecting another quarter of 5  sales growth on Tuesday ",2014-06-23,Estimize,https://www.investing.com/analysis/will-walgreen-benefit-as-cvs-drops-cigarettes-217061,217061
179631,401147,WBA,Realty Income  Another BORING And Solid Quarter,opinion,"It was another  for Realty Income Corporation  NYSE O    one of my very favorite long term dividend machines 
Revenues jumped 22 6  on the back of new property investments and a 1 4  increase in same store rents   During the quarter  Realty Income raised  528 million in a secondary share offering and ploughed  405 million of it into new properties and development projects while managing to modestly increase its occupancy rate from 98 2  to 98 3    The new properties have a weighted average lease maturity of 10 6 years and a lease yield of 7 3   meaning that these should be nice income generators for a long time to come 
Funds from operations  FFO    the most common metric of profitability for REITs   increased 21 1  and 6 7  per share   For the uninitiated   FFO is a measure of net income that adds back non cash charges like depreciation and backs out gains on the sale of properties   The idea is to give a more accurate measure of real operating performance and of the cold  hard cash being generated for the payment of dividends 
And speaking of dividends  Realty Income increased its monthly dividend in June for the 76th time in its history and for the 67th consecutive quarter  see  5 Monthly Dividend Stocks     Since going public in 1994  Realty Income has churned out 527 dividend checks  making it one of the most dependable income payers to ever be traded publically 
This gets to the crux of why I love Realty Income and why I consider it far better than a bond for your retirement income needs   Right now  Realty Income pays an annualized dividend of  2 19   Ten years ago  it paid an annualized dividend of  1 22   So  if you had retired in 2004  using your Realty Income dividends to pay your bills  you would have seen your income rise by fully 80   far outpacing inflation   And this says nothing at all about capital gains  which were substantial 
Had you instead purchased a 10 year bond  your income would not have changed  the coupon payment you received in 2014 would be the same as the first one you received in 2004   And looking at current bond yields  your income would actually fall significantly if you were to reinvest the proceeds in today s market 
Rather than think of Realty Income as a stock  I prefer to think of it as a perpetual bond with a rising  inflation beating payout   Yes  it is  riskier  than your average corporate bond in that its stock price is more prone to fluctuation than that of a bond   As a case in point  O stock lost a third of its value during last year s  taper tantrum  
But if you re buying it as an income generator  price fluctuations really don t matter   so long as the business remains strong and the dividend remains intact   And on that count  Realty Income passes the test with flying colors  Its portfolio is full of high quality  recession resistant properties  its  typical  property is a pharmacy run by Walgreen Co   NYSE WAG  or CVS Corporation  NYSE CVS  
Realty Income continued to pay and raise its dividend throughout the crisis years   and in my book  that qualifies O stock as a viable income substitute for bonds 
The question simply becomes one of price   Realty Income currently yields 4 9    In a world in which the 10 year Treasury yields 2 5   that s attractive   I would consider Realty Income a buy at a yield of 4 5  or higher 
If you are still years away from retirement  consider instructing your broker to automatically reinvest the monthly dividends   I personally own shares  and that is exactly what I do   I hope to leave these shares to my children decades from now  and if they are smart they will hold on to them and pass them on to their own children 
This post first appeared on  
Charles Lewis Sizemore  CFA  is the editor of Macro Trend Investor and chief investment officer of the investment firm Sizemore Capital Management ",2014-07-24,Charles Sizemore,https://www.investing.com/analysis/realty-income:-another-boring-and-solid-quarter-220560,220560
179632,401148,WBA,A Graphic Look At The  Inversion  Boom,opinion,"Walgreen s  NYSE WAG  decision to go ahead an buy the 55  of Alliance Boosts that it does not own  but not move their headquarters may mark the beginning of the end of the so called inversion boom   Inversion is simply when a US businesses buys a foreign company in a lower tax country and moves its headquarters there 

 
As this Great Graphic  from Goldman Sachs and published on Business Insider by Joe Wesienthal  illustrates there has been an explosion in such deals this year   The latest legislation was in 2004 that seemed to prevent or deter inter company inversions  requiring actual transactions to accomplish this   There is a push for new legislation to close this loophole and there is some idea that the legislation could be retroactive  
 
While there is genuine concern  perhaps it is not too cynical to suggest that it also makes good copy for some candidates ahead of the November elections   The counter argument is two fold   First  that addressing the perverse incentive structure should be part of the a larger tax reform effort   Second  in some quarters the tax avoidance strategy is condoned as part of a criticism of the double taxation on corporate profits  
 
One of the big arguments is that the 35  top US federal corporate tax rate is among the highest in the world   It is little wonder then that corporations seek to minimize their tax burden  with inversions being simply one of the ways   Yet  we think the debate is all too often based on tax scheduled rates and not actual rates   What is the average rate that the large US multinational companies  who are doing these inversions to reduce their taxes  actually paying 
 

 
Large companies operating in other countries have to file special tax forms  M 3    According to the Government Accounting Office the effective tax rate that is actually being paid is 22 7  in 2013     If only profitable companies are included  the effective tax rate is 17  
 
This helps explain why corporate tax collection is relatively low   It is low on two counts   First  it is low relative to what the federal government has historically collected    This Great Graphic  posted by Danielle Kurtzleben on Vox depicts the falling share of Federal corporate tax revenues compared with size of the economy and other taxes and revenues 
 
In 1952  corporate taxes revenue accounted for nearly a third of the federal revenue   By 2013  it had fallen below 10   
 

 
Second  the taxes actually collected a relatively low as a percentage of GDP compared with what other OECD countries  This final chart   was also posted on Vox by Kurtzleben  It shows that  on average  OECD countries collected 3  of GDP in corporate taxes   The US stood at 2 3  in 2011   Several countries  like Ireland and Luxembourg that are tax havens  corporate tax revenues are larger as a percentage of GDP than in the US   
 
We remarked recently that several major central banks  including the Federal Reserve  the Bundesbank  the Bank of Japan and the Bank of England all want to see an increase in wages   Higher wages are seen as either a signal that their economies have recovered sufficiently to normalize monetary policy  US and UK  or to ensure the economic recovery is not derailed  Japan and Germany    
 
If the problem is understood as insufficient aggregate demand  then boosting taxes on consumption  demand  as Japan did on April was is counter productive   Businesses  on the other hand  in the US  Europe and Japan are flush with cash and savings   Yet  despite low interest rates  net new capital investment  net of depreciation  remains meager at best   Besides  it has been several business cycles since investment led a recovery    Recent earnings data confirm that  generally speaking  profit margins remain fat    Cutting corporate taxes  as Japan plans and other countries consider  also seems counter productive 
 
While some observers have attributed the financial crisis to global imbalances  perhaps there is an other imbalance that contributed   Retained earnings that are not reinvested in plant and equipment have to be invested into something   If not real assets  the money is invested in paper assets   In addition to the large pools of capital by reserve managers  central banks and sovereign wealth funds  and large asset managers  pension funds  life insurers and mutual funds unit trusts   corporate balance sheets should be included when analyzing why interest rates remain low   
 
Conventional wisdom holds that core bonds yields are low because of QE in both the US and Japan   That is the low long term interest rates are artificial and a function of manipulation by central banks   One implication of the analysis here is that perhaps what is happening is a return of the Greenspan Conundrum   
 
The Greenspan Conundrum refers to the question the former Federal Reserve Chairman asked in early 2000s   Why were long terms rates falling even though the Fed was raising short term interest rates    Summer s resurrection of the secular stagnation hypothesis is a similar but different answer than Bernanke s answer to the conundrum      
 
Bernanke argued that the key was that after the Asian financial crisis  many countries in the region shifted from current account deficits to surpluses  yet did not have the capacity to absorb the new savings   They chose to export it and often bought US bonds   Bernanke also attributed a role to oil exporters as well  and recognized s role for demographics   The vast retained earnings of corporations in the high income countries maybe should be added to such surplus savings ",2014-08-06,Doug Short,https://www.investing.com/analysis/a-graphic-look-at-the-'inversion'-boom-221868,221868
179633,401149,WBA,5 Dividend Raising REITs,opinion,"Over the course of his hockey career  Wayne Gretzky repeated several variations of a truly fantastic quote   I skate where the puck is going to be  not where it has been  
Gretzky attributed the quote to his father  and he credits the advice with making him the hockey legend we remember today 
Not all of us can have Gretzky s instincts or athletic prowess  of course   But the same insights apply to the more mundane world of dividend investing   In you want to fund your retirement with a steady stream of dividends that will keep pace with inflation  you have to look beyond the current dividend yield to what the payout will be in 5 or 10 years  time 
Inflation    even the modest variety we have today    is death to long term bond returns   Your semiannual coupon payments do not change in dollar terms over the life of the bond  even as the value of those dollars declines every year   At the Fed s target 2  inflation rate  your income would effectively shrink by nearly 22  after 10 years due to the compounding effects of inflation 
The same holds true of other income paying securities  such as dividend paying stocks  REITs  and Master Limited Partnerships   Current dividend income is an important part of your total return  but the rate at which the company boosts the payout over time will be what determines the sort of lifestyle you ll be able to afford in retirement 
Today  we re going to take a look at five safe  reliable REITs with a long history of raising their dividends 
Realty Income
I ll start with a REIT that I own personally and that in the interests of full disclosure    I intend never to sell in my personal account   If my children take my advice  they will gift my shares to their own children someday   Realty Income Corporation  NYSE O  is a  triple net  retail REIT  meaning that its tenants are responsible for paying all taxes  insurance and maintenance  Realty Income only responsibility is to collect the rent    and to acquire new properties  of course 

Realty Income is known as the Monthly Dividend Company  and for good reason  At current prices  it yields an attractive 5 3   It has paid 530 uninterrupted monthly dividends and has raised its dividend 77 times since 1994   It s grown its dividend at a  over the past three years  and its 10 year  yield on cost    i e  the current payout divided by a hypothetical purchase price ten years ago  is a whopping 8 6  
Realty Income s track record has proven it to be a reliable payer with a long history of keeping pace with inflation  The fact that the REIT pays its dividend monthly rather than quarterly is a nice bonus as well  as most of our living expenses in retirement will come on a monthly schedule 
National Retail Properties
Next on the list of retirement REITs is a close competitor of Realty Income  National Retail Properties  NYSE NNN   Like Realty Income  National Retail is a triple net retail REIT  hence its ticker symbol   NNN  represents  triple net  

Also like Realty Income  NNN has been a serial dividend raiser over the years  The REIT has raised its dividend for 24 consecutive years and counting    the 4th longest run among public REITs  NNN sports a current dividend yield of 4 7   and its payout is plenty safe   Its five year annualized dividend growth rate is modest  at 1 6    But remember  that time period includes the aftermath of the 2008 2009 meltdown  a period in which a lot of REITs actually cut their dividends 
National Retail Properties and Realty Income invest in the same basic types of properties  Your local Walgreen  NYSE WAG  pharmacy is a perfect example  a free standing building in a high traffic area rented under a long term lease by a high quality tenant  These are properties that you can safely bet your retirement on 
LTC Properties
Next up  LTC Properties Inc  NYSE LTC   a REIT I highlighted in Retirement REITs Poised To Profit From The Graying Of America  is a real estate investment trust that invests primarily in the long term care sector of the health care industry  including long term care provider properties  skilled nursing properties  assisted living properties  independent living properties and memory care properties  LTC also invests in first lien mortgages secured by long term care properties 

LTC s monthly dividend works out to a current yield of 5 4   making it competitive with other medical REITs  LTC is also a relatively small REIT with a market cap of just  1 34 billion  I like that because smaller REITs can generally grow their portfolios    and their dividends    at a faster rate than their lumbering  large cap cohorts 
LTC has raised its dividend at an annualized 9 3  clip over the past five years  and its five year  
Retail Opportunity Investments
Another young REIT showing excellent dividend growth is Retail Opportunity Investments  NASDAQ ROIC  

ROIC has a simple enough business model  The company buys neighborhood shopping centers  generally anchored by a  necessity based  retailer such as a major grocery store  The REIT currently owns and operates fifty nine shopping centers encompassing approximately 6 9 million square feet 
ROIC has been a dividend raising monster over its short life   Since initiating a  0 06 quarterly dividend in 2010  ROIC has raised its dividend eight times to  0 16   Its three year annualized dividend growth rate is an incredible 49 4   and  is an almost too good to be true 14 0  
Digital Realty Trust
Finally  we come to datacenter REIT Digital Realty Trust  NYSE DLR   If you don t know what a  datacenter REIT  is  here is a nice  concise explanation  They charge rent to companies to house their servers   The popularity of smartphones and tablets and the rise of  the cloud  for data storage and processing will continue to boost demand for server resources  I am reluctant to recommend a long term position in Facebook  NASDAQ FB  or Twitter  NYSE TWTR  because social networking is changing quickly and it s impossible to know in advance who the ultimate winners will be  But with an investment in a datacenter REIT like Digital Realty  it doesn t matter  You stand to profit from the underlying trend    the increased need for remote computing power in the age of hyperconnectivity 

Digital Realty yields an attractive 5 2  and has been growing its payout at an annualized 20 6  clip over the past five years   Your yield on cost here would be 13 3  over the past five years and a mind blowing 61 9  over the past 10 
This article first appeared on  
Charles Lewis Sizemore  CFA  is the chief investment officer of the investment firm Sizemore Capital Management ",2014-09-24,Charles Sizemore,https://www.investing.com/analysis/5-dividend-raising-reits-226980,226980
179634,401150,WBA,Earnings Preview   Walgreens  CalAmp,opinion,With the New Year right around the corner  the last of the year s quarterly earnings reports are scheduled to be released in the next two weeks  What should investors expect Walgreens Walgreens  NYSE WAG  is set to announce its first quarter fiscal 2015 earnings report on Tuesday  The company is expected to post  0 74 earnings per share  up from the same quarter last year when they posted  0 72 earnings per share  In addition  Walgreens has seen a 17  increase in shares over the past 3 months Walgreens is currently in the process of acquiring the remaining shares of Alliance Boots  a European drugstore chain  Shareholders are slated to vote on its full acquisition of the company next week Once the merger is complete  Walgreens will no longer be traded on the New York Stock Exchange  but rather on the NASDAQ under its new ticker   WBA  A spokesman for Walgreens stated the new ticker symbol will be introduced when the deal closes  by the end of the first quarter of calendar 2015  In addition  Walgreens CEO Greg Wasson announced that he will retire after the company s merger with Alliance Boots is complete Wasson said in a statement   When I became CEO six years ago  I had three goals   to transform the front end of Walgreens drugstores  to advance the role that community pharmacy plays in health care and to find the right partner to take Walgreens global  With the creation of Walgreens Boots Alliance  it is now time for new leadership to move that vision forward building on the global platform we have created  Monaco tycoon Stefano Pessina is slated to take over as Chief Executive Officer once Wasson steps down The best performing analyst consensus on TipRanks for Walgreens is Moderate Buy CalAmp Corp CalAmp Corp  NASDAQ CAMP  is scheduled to announce its third quarter fiscal 2015 earnings report on Tuesday after market close  The company is expected to post  0 22 earnings per share  up from the same quarter last year when they posted  0 21 earnings per share CalAmp is best known for producing wireless communications software and hardware devices in the Internet of Things and Machine 2 Machine Space The company is forecast to see significant growth this quarter and next quarter from their Caterpillar OEM business beginning full production with deliveries higher than expected In addition  CalAmp s usage based insurance is beginning to normalize and is expected to bring in about  16 million in annual revenue  Investors should also look for the company s new display terminal and app store as they are quickly gaining momentum and adding to their cloud revenue On average  the best performing analyst consensus on TipRanks for CalAmp is Strong Buy Will these factors ultimately benefit Walgreens and CalAmp s earnings  or will they miss their estimates ,2014-12-22,Uri Gruenbaum,"https://www.investing.com/analysis/earnings-preview:--walgreens,-calamp-236551",236551
179651,401167,WBA,Will Walgreen Kick Its Smoking Habit Tuesday ,opinion,"Walgreen  Corp   NYSE WAG  is set to report FQ2 2014 earnings before the market opens on Tuesday  March 25th  Walgreen is the largest pharmacy chain in the United States  This quarter  Wall Street projects WAG s earnings per share to drop by 3  compared to FQ2 last year  Despite reduced profit  bolstered in store services such as screenings and vaccinations are expected to grow revenue by 5  on a year over year basis  In February rival CVS Caremark  CVS Corporation  NYSE CVS  announced it will stop selling cigarettes and tobacco products by October 1st  Larry J  Merlo  president and CEO of CVS announced   Ending the sale of cigarettes and tobacco products at CVS pharmacy is the right thing for us to do for our customers and our company to help people on their path to better health    CVS expects to lose over  2 billion in annual sales by kicking the habit  Going into Tuesday s earnings report there is mounting pressure on Walgreen to follow CVS and end its tobacco sales  Here is what investors are expecting from Walgreen 
The information below is derived from data submitted to the Estimize com platform by a set of Buy Side and Independent analyst contributors 
The current Wall Street consensus expectation is for Walgreen  to report 93c EPS and  19 557B revenue while the current Estimize com consensus from 16 Buy Side and Independent contributing analysts is 92c EPS and  19 587B in revenue  This quarter the buy side as represented by the Estimize com community is expecting Walgreen to miss the Wall Street consensus by 1c EPS and beat the Street s forecast on revenue by  30 million 
By tapping into a wider range of contributors including hedge fund analysts  asset managers  independent research shops  students  and non professional investors Estimize has created a data set that is more accurate than Wall Street up to 69 5  of the time  but more importantly it does a better job of representing the market s actual expectations  It has been confirmed by an independent academic study from Rice University that stock prices tend to react with a more strongly associated degree to the expectation benchmark from Estimize than from the Wall Street consensus 
The magnitude of the difference between the Wall Street and Estimize consensus numbers often identifies opportunities to take advantage of expectations that may not have been priced into the market  In this case we are only seeing a small difference between the 2 groups  expectations 

The distribution of estimates published by analysts on the Estimize com platform range from 85c to 98c EPS and from  19 400B to  20 112B in revenues  This quarter we re seeing a wide distribution of estimates on Walgreen  
The size of the distribution of estimates relative to previous quarters often signals whether or not the market is confident that it has priced in the expected earnings already  A wider distribution of estimates signaling less agreement in the market  which could mean greater volatility post earnings 
 
Over the past 4 months the Wall Street EPS consensus fell from  1 01 to 93c while the Estimize consensus also decreased from 99c to 92c  Meanwhile the Wall Street revenue forecast remained relatively flat slipping from  19 561B to  19 557B while the Estimize forecast advanced steadily from  19 471B to  19 587B  Timeliness is correlated with accuracy and upward analyst revisions towards the end of the quarter are often a bullish indicator 

The analyst with the highest estimate confidence rating this quarter is TheEmulator23 who projects 94c EPS and  19 576B in revenue  In the Winter 2014 season TheEmulator23 is rated as the 12th best analyst and is ranked 22nd overall among over 4 000 contributing analysts  This season TheEmulator23 has been more accurate than Wall Street in forecasting EPS and revenue 60  and 54  of the time respectively throughout 149 estimates  Estimate confidence ratings are calculated through algorithms developed by deep quantitative research which looks at correlations between analyst track records and tendencies as they relate to future accuracy  In this case TheEmulator23 is expecting Walgreen to beat the Estimize community s forecast on EPS but come up short on revenue 
This quarter the Estimize community is expecting Walgreen s to come up short of Wall Street s quarterly profit target  The harsh weather this winter has kept customers off the road and out of stores leading retailers to offer aggressive sales to get shoppers into stores which can have a cost on the bottom line  Although profit is expected to be lower  the community expects quarterly revenue to increase by  941 million compared to FQ2 last year  Investors will also be waiting to see if Tuesday s earnings report brings any announcement about Walgreen s decision to keep after tobacco sales or follow CVS and give them up completely ",2014-03-24,Estimize,https://www.investing.com/analysis/will-walgreen-kick-its-smoking-habit-tuesday-207157,207157
179652,401168,WBA,Pharmacies  Cigarettes  And Market Impact,opinion,"To sell smokes or not to tell smokes  that is the  2 billion question  In early February CVS Corporation  NYSE CVS  became the first national drugstore chain to voluntarily give up selling cigarettes and other tobacco products by October 1st  CVS was the first brick to fall due to mounting pressure coming from 28 state and territory attorney generals  These AGs have not yet threatened any legal action  but the case certainly brings the NYC sugary drinks ban to mind  In July a court judge struck down Mayor Bloomberg s proposed ban because of separation of powers  the mayor had no legal right to tell consumers what they could or could not buy 
Cigarettes are well documentated as being far more detrimental to health than soda  but they are also heavily regulated and come with clear warning labels  But regardless of whether or not the legislature has any actual power or not  the situation still levies immense pressure against the pharmacies   In addition to CVS the AGs have also targeted Wal Mart Stores Inc  NYSE WMT   Walgreen Co  NYSE WAG   Kroger Company  NYSE KR   Rite Aid Corporation  RAD   and Safeway Inc  NYSE SWY  which together represent the top 5 pharmaceutical retailers which also sell tobacco products  The purpose of this note is to discuss whether or not pharmacies should sell tobacco  so Kroger and Safeway which primarily operate as supermarkets will no longer be included in the discussion  Since Walmart sells just about everything in the observable Universe  we will be leaving them out of the conversation as well 

The numbers may have changed a bit since 2010 but for all intents and purposes Walgreen  CVS  and Rite Aid all have similar numbers of stores and otherwise equal branding  CVS jumped on the opportunity to become an industry leader by giving up its cigarette sales and is now benefiting from positive press coverage and generating goodwill from both smokers and nonsmokers alike  But that s not to say this decision doesn t come without a cost  CVS is expecting its forfeiture of tobacco sales to cost the company s top line about  2 billion per year  To put things in perspective  according to data from Estimize com CVS generated a total of  126 955B revenue in the last fiscal year  While  2billion is a lot of money  kicking the tobacco habit will only lower CVS s annual sales by only about 1 6  
CVS has taken the first mover advantage and given up a small   of its revenue in exchange for brand differentiation from 2 otherwise identical pharmacy chain commodities  And their move puts Walgreen and Rite Aid in what could be a state of decision making paralysis  From a game theory perspective  this move looks brilliant  If Rite Aid and Walgreen are the only other 2 large pharmacy chains  neither would be wise to be give up their tobacco sales after CVS made the first move  There are two problems with being the second mover to give up tobacco sales  The first is that much of the positive press and goodwill have already been taken by CVS  The second is that giving up tobacco sales would leave the third pharmacy with the distinct and significant advantage of being the only major pharmacy chain still selling tobacco products  CVS created a huge chicken game between its competitors  There is a subset of the pharmacy going population that always buys cigarettes at the pharmacy and all of these customers would flock to the last Marlboro Man standing  There isn t a strong incentive for either Walgreen or Rite Aid to be the second major pharmacy chain to give up its tobacco sales 
The third possibility is that  both Walgreen and Rite Aid agree to simultaneously surrender tobacco sales  In this situation  all three pharmacies lose  but no one company loses too badly  Rite Aid and Walgreen could understand the dilemma and collude to make this compromise and mitigate their risk  There is building political and legal pressure to force pharmacies to give up their cigarette sales and both of the remaining chains could lose brand power if they try to fight the forces that be  even if they win  in plain view 
Part of the beauty of our product at Estimize is that if we come together as a community and submit forward looking estimates for the pharmacies  we can get a consensus on how the market believes each of the 3 pharmacies will be affected  What are your thoughts  Will Walgreen and Rite Aid continue to sell cigarettes or will they give billions of dollars in sales  Will smokers ditch CVS to get a pack while picking up their prescription  Or on the other hand will the health conscious public rally around CVS Caremark  The beauty of having a public consensus openly available is that if you are confident in your own thesis and think the market s expectations are wrong about something  you can trade on it and potentially unlock alpha  Head over to  and submit estimates for CVS  WAG  and RAD to tell us what you think ",2014-03-26,Estimize,"https://www.investing.com/analysis/pharmacies,-cigarettes,-and-market-impact-207361",207361
179653,401169,WBA,What To Expect From Rite Aid s Earnings Report,opinion,"Rite Aid Corporation  RAD  is set to report FQ4 2014 earnings before the market opens on Thursday  April 10th  Rite Aid is one of the largest retail pharmacy chains in the country  In February competitor CVS Corporation  NYSE CVS  announced it would end all tobacco and cigarettes sells by October 1  Rite Aid and Walgreen Co  NYSE WAG  are yet to announce an end to tobacco sales  but there is mounting pressure for pharmacies to give up their tobacco sales and focus on the health of customers  CVS  WAG  and RAD all had great years in 2013 and Rite Aid s revenue is expected to continue growing  This quarter Wall Street is expecting Rite Aid to post year over year sales growth of 1 5  although EPS is predicted to fall by 8c per share  Here s what investors expect from RAD Thursday 

The current Wall Street consensus expectation is for Rite Aid to report 5c EPS and  6 550B revenue while the current Estimize com consensus from 14 Buy Side and Independent contributing analysts is 6c EPS and  6 544B in revenue  This quarter the buy side as represented by the Estimize com community is expecting Rite Aid  to beat the Wall Street consensus on EPS but come up a few million dollars short on revenue 
By tapping into a wider range of contributors including hedge fund analysts  asset managers  independent research shops  students  and non professional investors Estimize has created a data set that is more accurate than Wall Street up to 69 5  of the time  but more importantly it does a better job of representing the market s actual expectations  It has been confirmed by Deutsche Bank Quant  Research and an independent academic study from Rice University that stock prices tend to react with a more strongly associated degree to the expectation benchmark from Estimize than from the Wall Street consensus 
The magnitude of the difference between the Wall Street and Estimize consensus numbers often identifies opportunities to take advantage of expectations that may not have been priced into the market  In this case we are seeing a small difference between the two groups  expectations 

The distribution of estimates published by analysts on the Estimize com platform range from 5c to 7c EPS and from  6 492B to  6 600B in revenues  This quarter we re seeing a narrow distribution of estimates on EPS for Rite Aid and a wider distribution of estimates on revenue 
The size of the distribution of estimates relative to previous quarters often signals whether or not the market is confident that it has priced in the expected earnings already  A narrow distribution of EPS estimates signaling more agreement in the market  which could mean less volatility post earnings  In this case we are seeing a tight range of profit expectations with much more uncertainty around sales 

Over the past 4 months the Wall Street EPS consensus fell from 6c to 5c while the Estimize consensus both started and ended the period at 6c  Meanwhile the Wall Street revenue consensus climbed from  6 495B to  6 550B while the Estimize forecast also increased from  6 532B to  6 544B  Timeliness is correlated with accuracy and upward analyst revenue revisions at the end of the quarter are often a bullish indicator 

The analyst with the highest estimate confidence rating this quarter is BradHewitt91 who projects 6c EPS and  6 540B in revenue  BradHewitt91 is ranked 13th overall among over 4 000 contributing analysts  Over the past year BradHewitt91 has been more accurate than Wall Street in forecasting EPS and revenue 53  and 49  of the time respectively throughout 655 estimates  Estimate confidence ratings are calculated through algorithms developed by deep quantitative research which looks at correlations between analyst track records and tendencies as they relate to future accuracy  In this case BradHewitt91 is expecting Rite Aid to report in line with the Estimize consensus on EPS but come up slightly short of the community s expectations on revenue 
Rite Aid stock had a great year in 2013 returning 254   Shares were beaten down to prices as low as  1 43 at the start of last year but 4 consecutive quarters of beating Wall Street expectations on both the top and bottom line gave RAD a considerable boost  This quarter contributing analysts on the Estimize com platform have lower expectations than the Street and are projecting yoy revenue growth of 1 4  compared to 0  yoy revenue growth reported in FQ4 of last year 
Get access to estimates for Rite Aid published by your Buy Side and Independent analyst peers and follow the rest of earnings season by heading over to Estimize com  Register for free to create your own estimates and see how you stack up to Wall Street ",2014-04-10,Estimize,https://www.investing.com/analysis/what-to-expect-from-rite-aid's-earnings-report-209191,209191
179688,401204,WBA,Stocks Churn Lower Ahead Of April Jobs Report  Markets Retreat After Weak Service Sector Report,opinion,After Hours  Closing Update  Stocks Churn Lower Ahead of April Jobs Report  Markets Retreat After Weak Service Sector Report4 10 PM  May 3  2012    U S  stocks finished lower for a second session after a new report said service industries expanded less than expected last month  stalling an early rally that followed initial jobless claims last week falling by the largest amount in nearly one year  All 10 industry sectors in the S P 500 finished in the red  with energy and material stocks posting the steepest declines as commodity prices also tumbled The Institute for Supply Management this morning reported a 2 5 point decline in its non manufacturing business purchasing managers index  falling to a 53 5  reading in April  Reading above 50  indicate expansion but the fall was much sharper than the 0 5 point decline in the Marketwatch analyst consensus Stocks turned lower after the report  giving back moderate gains that followed the Labor Department reporting that the number of Americans filing first time claims for unemployment insurance fell to 365 000 during the week ended April 28  The 27 000 person decline was the largest weekly drop since early May 2011 and carried the weekly total analyst expectations for 380 000 new claims The government tomorrow reports monthly job hiring and the overall unemployment rate for April with consensus opinion expecting no change from the 8 2  rate reported in March  Employers are seen adding 167 000 jobs  according to the Briefing com consensus  up from the 121 000 workers hired in March Non farm productivity and costs fell 0 5  in Q1  matching forecasts  according to preliminary figures also released today by the Labor Department  Unit labor costs rose 2 0   down from a 2 8  rise in the prior quarter  Initial response to the report was positive  with experts saying the drop in productivity    the largest decline since Q2 of 2011    points to the need for companies to bring on more new hires  Productivity rose 0 9  in Q4 April chain store sales offered a mixed picture  with shares of Target  TGT   Walgreen Co  WAG  and the Gap  GPS  all retreating today after each reported weaker than expected same store sales  Costco Wholesale Corp  COST  also missed Wall Street estimates for the second month in a row  But April comps for The TJX Companies Inc  TJX   whose brands include T J  Maxx  Marshalls and HomeGoods  rose 6   beating a 4 1  estimated increase and prompting the company to raise its Q1 EPS guidance  Several other clothing retailers  including Limited Brands Inc  LTD  and Zumiez Inc  ZUMZ   also posted better than expected sales last month Overall  the 19 chains tracked by Thomson Reuters reported a 0 8  increase overall during April    missing the 1 5  gain analysts had forecast In other corporate news  General Motors  GM  shares were down today despite Q1 profits for the automaker topping estimates  Excluding one time items  GM earned  0 93 a share on  37 8 billion in Q1 sales  up from 4 4  from the  36 2 billion in year ago sales  Analysts had been expecting an  0 85 a share profit on  37 9 billion in revenues  according to FactSet Green Mountain Coffee Roasters  GMCR  tumbled nearly 48   establishing a new 52 week low  after the company reduced its current year financial targets because of difficulty predicting demand for its Keurig single serve coffee brewers and packs  GMCR is now guiding for FY12 sales in a range of  3 8 billion to  4 0 billion and per share earnings of  2 40 to  2 50  The Street is at earnings of  2 67 per share and  4 27 billion in revenues  Fiscal Q2 revenues also missed forecasts by nearly 10  Kensey Nash  KNSY  leapt 32  after the medical device manufacturer agreed to be acquired by Dutch life sciences company Royal DSM for about  337 million in cash Crude oil for June delivery settled  2 68 lower at  102 54 a barrel  June gold fell  20 10 to finish at  1634 30 an ounce while July silver fell 58 cents to finish at  30 05 an ounce  July copper finished 5 cents lower at  3 73 a pound  June natural gas rallied 8 7 cents to settle at  2 34 per 1 million BTU following a bullish inventory report this morning Here s where the markets stand at an end of day Dow Jones Industrial Average down 61 98   0 47   to 13 206 59S P 500 down 10 74   0 77   to 1 391 57NASDAQ Composite Index down 35 55   1 16   to 3 024 30GLOBAL SENTIMENTHang Seng down 0 3 Shanghai Composite up 0 1 FTSE 100 up 0 06 UPSIDE MOVERS    AVNW  Surprises with Q3 EPS of  0 05 vs   0 01 net loss forecast by analysts     WWE  Q1 earnings body slam Wall Street expectations     WFM  Q2 earnings beat by  0 05 a share  revises Q3 EPS range 6 5  above prior guidance     ALL  Q1 profit of  1 53 a share tops consensus view by  0 43  revenues in line DOWNSIDE MOVERS    VCLK  Q1 revenues 3  below Street view  guides Q2 EPS  revenues under consensus     WTW  36  bulge in Q1 ad spending fails to boost sales  EPS slims 26  from year ago     MITK  Fiscal Q2 earnings swing to  0 09 a share net loss  revenues slide 58      PRU  Adjusted Q1 earnings of  1 56 a share lags consensus by  0 15 ,2012-05-04,Midnight Trader,"https://www.investing.com/analysis/stocks-churn-lower-ahead-of-april-jobs-report,-markets-retreat-after-weak-service-sector-report-122144",122144
179689,401205,WBA,Walgreen  WAG    Vol Hits Multi Year Lows Following Dispute Settlement ,opinion,Walgreen Co   Walgreen   together with its subsidiaries  operates a drugstore chain in the United States  The Company provides its customers with multichannel access to consumer goods and services  and pharmacy  health and wellness services in communities across America I know I don t normally write about 19 vol stocks  but this one caught my attention in an otherwise slow day  Let s start with the Charts Tab  six months   below  The top portion is the stock price  the bottom is the vol  IV30    red vs HV20    blue vs HV180    pink   On the stock side  we can see how volatile the ride has been  Here are the three moves I ve highlighted  4 17 2012  Stock went from  33 30 to  35 07  up 5 3   6 18 2012     6 20 2012  Stock went down from  31 96 to  29 21  down 8 6  on earnings  7 19 2012  Stock went up from  30 97 to  34 62  up 11 8   Here s a news snippet from that day  LOS ANGELES  MarketWatch    Shares of Walgreen Co  made double digit percentage gains Thursday after the drug retailer announced it had ended a seven month dispute with Express Scripts Holding Co  and will now start to take the pharmacy benefit manager s customers  Investors bid the shares nearly 12  higher in recent action to  34 62  rallying as Walgreen  US WAG  brought the feud to a halt  Express Scripts  US ESRX  also climbed  adding nearly 2  to  58 76  But the peacemaking had a detrimental effect on shares of CVS Caremark Corp   US CVS  and Rite Aid Corp   US RAD   Walgreen s rivals  Rite Aid tumbled by more than 6  to  1 20  while CVS Caremark also dropped more than 6  to  45 43  The two companies had been taking Express Scripts customers away from Walgreen  Source  Marketwatch via Yahoo  Finance    written by Russ Britt  So  in totality  the stock has had some volatile days  Looking to the vol portion of the Charts Tab  though  we can see how depressed the implied is to both the short term and long term historical realized vols  Before today  the 52 wk range in IV30  was  19 09   46 38    so the level today is a new annual low  In fact  it s at least a two year low  Granted  the Express Scripts dispute ended n  stuff  but still  a multi year vol low right now    It makes sense  yet is noteworthy  if that makes any sense  Let s turn to the Skew Tab to examine the line by line and month to month vols  The skew is normal  with the back two expiries demonstrating a normal skew shape and the front showing a parabolic shape  which isn t uncommon three and a half trading days from expo Finally  let s turn to the Options Tab for completeness We can see the monthly vols across the top are priced to 18 24   19 00  and 23 52   respectively for Aug  Sep and Oct  An interesting set up could be to follow the trend with low vols and fund an earnings month long option position with front month sales and then rolling them after each expo  I m not saying this is a good trade  I m just trying to add some color This is trade analysis  not a recommendation ,2012-08-15,Ophir Gottlieb,https://www.investing.com/analysis/walgreen-(wag)---vol-hits-multi-year-lows-following-dispute-settlement-133040,133040
179690,401206,WBA,Graham Value Portfolio Update,opinion,In January I announced a   a Benjamin Graham  inspired  value stock portfolio  The purpose of the hypothetical portfolio is to track returns for a portfolio of 15 stocks selected based on a variety of valuation metrics  I originally intended to update the portfolio monthly  however  in the spirit of creating a lower turnover  value driven portfolio it is now updated approximately once per quarter  I have also added an additional criteria to limit turnover in the portfolio  see below   The Graham portfolio is an attempt to add a value strategy to   which is otherwise focused on momentum  trend  income and market timing strategies  There are numerous ways to add market timing or hedging techniques to any stock portfolio  such as shorting the S P 500 when it trades below a long term moving average while simultaneously holding a portfolio of long stock positions  However  for the purposes of this portfolio there will be no additional timing or hedging techniques  The criteria used to select the stocks are listed below  The tools used to perform the screen and backtests are courtesy of    SS123   and    P123    The actual screen factors are below Liquidity filter  No OTC StocksEliminate companies classified in the Miscellaneous Financial Services Industry  most of which are investment companies and funds and not the kind of stocks this all star tended to seekCurrent ratio must be at least 1 5Long term debt must be no higher than 10  above working capitalEPS must be above breakeven in each of the last four quarters and in each of the last five annual periodsTrailing 12 month EPS most be above EPS in the latest annual periodEPS in the latest annual period must be above EPS in the prior year and five years agoThe company must have paid common dividends in the last 12 monthsThe ranking system used as a basis for selecting the top 15 based among those stocks that pass the Graham screen are below Valuation   60  of totalTrailing 12 month P E  15  of this category Price to Book  15  of this category Price to Tangible Book Value  35  of this category Operating P E  defined as Market Capitalization divided by Business Income  which is Sales minus Cost of Goods sold minus Selling  General   Administrative Expense and omits unusual items  35  of this category Earnings   40  of total5 year EPS Growth Rate  50  of this category EPS Stability  defined as the standard deviation of EPS over the past 16 quarters  lower being better  50  of this category I began tracking this portfolio real time on January 13th  2012  As of this writing  the portfolio is down 2 11  including dividends compared to a positive return of 11 63   excluding dividends  for SPY over the same period and 10 5  for Vanguard Small Cap Value ETF  VBR  over the same time period The portfolio has been hampered by big drawdowns in a handful of names  which the quantitative rules continue to define as undervalued  These are excellent examples of the challenges in value investing   a stock could be defined as under valued for a good reason  and may remain so for a significant period of time  perhaps years or forever if the company has experienced a permanent and material change in operations  a  value trap    On the other hand  under valued stocks may lag longer than investors wish  but patient  longer term investors who aptly select value stocks can be rewarded in the long run A real world application of this portfolio could also utilize stop losses in order to prevent large drawdowns in single positions  However  for the purposes of tracking the portfolio results  all positions are bought and held until rebalancing In July a rule was added to help limit portfolio turnover   stocks will only be sold when they drop out of the top 20 in Graham Value screen  Thus  a stock could theoretically drop to the 20th ranking but remain in the 15 stock portfolio if it is a current holding An interesting early trend in live tracking is that of smaller  less liquid equities appearing frequently on the list  This makes for a potentially more volatile  higher beta list of equities  This could also be of concern for those nervous about equity markets  As mentioned earlier one potential strategy for hedging equity positions would be to short the overall equity market when an index such as the S P 500 drops below a long term moving average Another filter worth consideration is one based on market capitalization  Given my personal level of discomfort with stocks with ultra low market capitalizations  and especially those based overseas  going forward any new additions to the portfolio will be required to have a market cap greater than  100 million  Three stocks remain in the portfolio with market caps below  100 million but no new stocks will be added with market caps below  100 million The top 20 stocks based on the screen criteria  no market cap requirement  are listed below Below are 3  5  and 10 year backtest results for this screen  with no market cap requirement  using a quarterly rebalance and  5  slippage to help account for bid ask spreads and commission costs The 10 year results with the added  100 million market cap criteria is below Three stocks were sold at today s close   Formula Systems  FORTY   Walgreen  WAG  and Deer Consumer Products  DEER   The proceeds were used to purchase Schweitzer Mauduit Intl Inc  SWM   ADTRAN Inc  ADTN   and CARBO Ceramics Inc   CRR   Current holdings are below Disclaimer  Stock Loon LLC  Scott s Investments and its author is not a financial adviser  Stock Loon LLC  Scott s Investments and its author does not offer recommendations or personal investment advice to any specific person for any particular purpose  Please consult your own investment adviser and do your own due diligence before making any investment decisions ,2012-10-17,Scott's Investments,https://www.investing.com/analysis/graham-value-portfolio-update-140069,140069
179707,401223,WBA,Newsflash  Dividend Aristocrats Found The Lost Decade ,opinion,Introduction   There are many people who continue to hold a jaundiced view of stocks because they were traumatized by the last two recessions  Precipitous drops in equity prices drove them to distrust stocks and stock markets  However  I believe that most of the negative sentiment is a function of what I would describe as vague ideas about what really happened  A lot has to do with many investors failing to recognize  or make the important distinctions  that were the true causes of our last two market crashes    The first market collapse  late summer 2000  was first a function of significant overvaluation  especially regarding the technology sector  followed by the mild recession of 2001  The second market collapse was the result of a greedy and fraudulently induced  and consequently  more serious recession dubbed the great recession of 2008  Therefore  at least in my opinion  the two huge drops in stock values were not really the result of a weak economy  as many people think  The first was the result of an extremely inefficiently behaving stock market  and the second  the result of a greedy financial sector induced by poor government policy    Nevertheless  these two major catastrophic events have shaken the confidence of many investors  What bothers me about this is how it is driving people away from investing in our country s finest companies at precisely the time when I believe that it makes more sense to do so than it has in many years  Most importantly  the conditions that existed when these two market collapses occurred no longer exist  Nevertheless  investors and pundits alike  continue to look for reasons why a market collapse will soon reoccur  Their views are based on a pessimistic view of equities  and I believe an exaggerated view of the risk profile of stocks that was caused by the trauma    Personally  I abhor pessimism  because I believe it is both an erroneous and dangerous mindset for investors to possess  In a recent article  I mistakenly titled my introduction  pessimism is for losers  and therefore  inadvertently offended many readers  Although I accept the responsibility that it was my fault for penning such a provocative statement  the offended readers misunderstood my intent  I was not calling pessimistic people losers  I was attempting to articulate that a pessimistic attitude can create unnecessary losses    Furthermore  many readers also mistook my words to mean that I was a  perma Bull  that was in denial that a future market collapse could even occur  That is not what an optimistic attitude is actually about  An optimistic attitude is about understanding and believing that even though a recession or market collapse can occur  both will inevitably end  Therefore  both our equity markets and our economy will prosper and grow once again  it s only a matter of time    But the real problem is that pessimists are most likely to sell at the bottom of the market and as a result realize unnecessary losses  Market bottoms have always represented great buying opportunities  that only an optimist is capable of exploiting  More simply stated  people usually sell their equities when the risk of owning them is the lowest and the opportunity for gain the highest  In other words  selling into the bottom of the market instead of buying into it as the optimist does    Since 2000  Dividend Aristocrats Outperformed the S P 500   I have come to learn that Dividend Growth investors  which have also been disparagingly referred to as Dividend Zealots  are among the most optimistic investors in the universe  And in many ways  perhaps the most misunderstood  Dividend Growth investors often state that they are not concerned with drops in the price of their stocks  but only that their dividends grow  For some reason  this offends certain people who apparently feel that this makes Dividend Growth investors arrogant and or even ignorant    What these detractors misunderstand in my judgment  is that the average Dividend Growth investor does not worry about short term volatility because they do not intend to sell  Dividend Growth investors buy in order to hold quality dividend paying companies for the long run  that have long histories of increasing their dividends every year  There are two popular sources of identifying the consistent dividend achiever  They are the lists of Dividend Champions  Contenders and Challengers provided by David Fish found   and perhaps the more widely known Standard   Poor s Corp s Dividend Aristocrats  Both the Dividend Champions and Dividend Aristocrats are comprised of companies that have increased their dividends for at least 25 consecutive years    Since there are fewer names on the Dividend Aristocrats than there are the Dividend Champions  51 versus 103   I took the easy route and calculated the returns of the Dividend Aristocrats since calendar year 2000  Although we are now into our 13th year  thus going three years beyond the so called  Lost Decade   the evidence of rebounding stock values is profoundly obvious  Not only did all but three of the Dividend Aristocrats dramatically outperform the S P 500  they also provided very strong returns  that on balance  out stripped inflation and even taxation    I was motivated to run this study because of a comment that one reader made on my article  link provided above  as follows     The average S P 500 index fund is down roughly 28  since 1 1 2000  after adjusting for inflation  Add in dividends and that gets investors to nearly the breakeven point  Subtract the funds taxes from Gains and dividends  and investors are back to a loss     The same commenter also expressed the same sentiment in another comment to another reader as follows     it is likely that nearly all the dividend buy  and  hold Bulls have lost money relative to year 2000  after adjusting for inflation and taxes     Although the first comment above is accurate regarding the S P 500 as inflation was approximately 28   by my calculation inflation was actually 32 3    his second comment is inaccurate where his view is biased by his first comment  In truth  at least regarding the Dividend Aristocrats who increased their dividend every year for 25 straight years  all the dividend buy and hold bulls that held them would have trounced the S P  inflation and taxes    The following tables generated by the  research tool reviews the performance of the Dividend Aristocrats since December 31  1999  Astoundingly  only 3 of the 51 Dividend Aristocrats underperformed the S P 500  Furthermore  only 7 of the 51 companies would have failed to generate the 3  compounded annual return necessary to combat inflation and taxes  Moreover  the majority of the Dividend Aristocrats have lavishly rewarded their dividend buy and hold bulls  optimists   As you review the list  note that every company from Procter   Gamble  PG  and above outperformed the S P 500  inflation and taxes    Table One  Top 15 Dividend Aristocrats Since 1999   Our first table lists the top 15 Dividend Aristocrats in order of highest performing to the lowest  Sherwin Williams  SHW   the best performer averaged over 16  returns per annum  with Becton Dickinson   Co   BDX  rounding out the top 15 by averaging a 10 1  compounded annual return    As you review the records of these first 15 Dividend Aristocrats  keep in mind that this is during one of the worst 13 year periods of price performance in stock market history  For added perspective and insight and just following this first table  I provide the complete earnings and price driven F A S T  Graphs   plus performance tables on these two Dividend Aristocrats Sherwin Williams Co There are at least two very interesting takeaways that the 13 year earnings and price correlated graph on Sherwin Williams reveals  First of all  Sherwin Williams was not overvalued at the beginning of calendar year 2000  This validates a point that I ve often written about that states that in every market  whether bull or bear  the scrutinizing investor can always find good stocks at fair value to invest in  Second  I would like to point out that I believe that Sherwin Williams is currently significantly overvalued  which greatly contributes to its outperformance There was no  Lost Decade  for shareholders of Sherwin Williams Company since 1999  Not only did they receive significant long term capital appreciation  they were rewarded by strong growth in their dividend income  Finally  what follows is a napkin calculation of Sherwin Williams  return after inflation and taxes  576 154 38 capital appreciation   33  inflation    386 203    56 287 of total dividends paid   15  tax    47 844    329 916 total cash return  The figure needed to beat inflation is approximately  133 000  Becton Dickinson   Co   BDX Becton Dickinson is also interesting in at least two ways  First  it represents another example of a company that was fairly valued at the beginning of calendar year 2000  However  it was overvalued in 2008  which contributed to their large drop in stock price during the great recession  But even though they have not returned to their previous high price of  93 24 in 2008  fair value at that time was approximately somewhere between  65  70 per share  In other words  Becton Dickinson s stock price should never have been that high in the first place  As an aside  even the optimistic investor should have  or could have  realistically sold or lightened up on their position at that time The scrutinizing reader might notice that Becton Dickinson shareholders enjoyed a total rate of return  10 1   that was very close to its operating earnings growth rate of 10 4   At the end of the day  fundamentals matter  Also  note that dividends increased in close correlation with earnings growth Table Two  Top Performing Dividend Aristocrats 16   30Our second top 15 best performing Dividend Aristocrats also soundly outperformed the S P 500  inflation and taxes Table Three  Top Performing Dividend Aristocrats 31   45On this list of Dividend Aristocrats  only one company  Walgreen Co   WAG  did not outperform the S P 500  inflation and taxes Table Four  Final Six Lowest Performing Dividend AristocratsOnly 3 of our final 6 of 51 Dividend Aristocrats failed to outperform the S P 500 since December 31  1999  Technically  none of these final six would have outstripped inflation or taxes either  However  only two of the six would have actually generated a real loss  excluding inflation and taxes  However  the reasons why are fascinating  and are reviewed in detail following the table Wal Mart Stores Inc   WMT Our next to last worst performing Dividend Aristocrat was Wal Mart  which tells a very interesting story about stock market inefficiency  Clearly  the company was significantly overvalued at the beginning of calendar year 2000  However  the reader should also note that this company grew earnings at above average rates through both the recession of 2001 and the great recession of 2008  It was an inefficient stock market  not poor operating results  or even weak economies  that hurt the performance of this company Even though Wal Mart s earnings growth averaged better than 11  per annum since calendar year 2000  the shares were not able to overcome the headwinds of excessive overvaluation  Consequently  shareholders lost money  but not because the company was poorly managed or because the economy went through two recessions  Shareholders lost money because Mr  Market overpriced their shares in a very inefficient manner during the irrational exuberant period which ended in calendar year 2000 Pitney Bowes Inc   PBI Our worst performing Dividend Aristocrat  Pitney Bowes  is one of the few Dividend Aristocrats that actually experienced an earnings drop off since calendar year 2000  However  all of it occurred since the great recession of 2008  Therefore  this company had two strikes going against it  Strike one  was massive overvaluation at the beginning of the timeframe  and strike two  falling earnings since the great recession However  in spite of falling earnings  Pitney Bowes managed to raise their dividends every year since calendar year 2000  Nevertheless  shareholders lost a considerable portion of their initial investment even when dividends are added in  But most importantly  Pitney Bowes  problems were all company specific  rather than a function of a bad market Summary and ConclusionsThere are numerous lessons that I believe can be learned by a careful analysis of the above tables and individual earnings and price correlated company specific F A S T  Graphs   First of all  it should be recognized that Dividend Aristocrats  almost by definition  are above average quality operating enterprises  A company cannot increase its dividend every year for 25 or more years without having a good operating history that includes strong balance sheets  and healthy earnings and cash flow generation  Second  the results that these quality companies produced validate my thesis that it is more appropriate to think of a market of individual stocks in contrast to a stock market But perhaps one of the most important lessons of all is the validation of the benefits of taking an optimistic view of stocks  Business cycles  which include recessions and sometimes unforeseen catastrophic events such as 911 should be expected  However  we should all realize that so far none has ever been severe enough to completely destroy our economy  And  God forbid  if one ever does  there is absolutely nothing anyone could do to protect themselves anyway  As I like to say  you can t manage portfolios based on Armageddon  Therefore  I strongly believe that the optimistic approach is the superior and most profitable one to take  Volatility can only hurt you if you react to it  And you should not react to it unless there is a real fundamental deterioration with the fundamentals of the businesses you own  If fundamentals are strong and price falls  then buy more if you can  or hold if you can t buy more  Note that as three of the four specific examples that were cited in this article illustrate  the very best companies can remain profitable even during our most severe economic challenges  Consequently  when you can find these companies on sale  regardless of what caused it  I believe you should consider optimistically investing in them  It sure beats taking losses that you don t need to absorb Disclosure   Long CLX  VFC  WAG  MKC  BCR  ADP  MDT  T  XOM  MCD  KO  PG  GPC  KMB  ITW  MHP  SYY  CL  JNJ  AFL  ABT  PEP at the time of writing Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation ,2012-05-02,Chuck Carnevale,https://www.investing.com/analysis/newsflash:-dividend-aristocrats-found-the-lost-decade-121876,121876
